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Abstract 
The flavonoids are a family of compounds with a C6-C3-C6 scaffold found 
ubiquitously in nature. They are well known for their various therapeutic effects, 
including antioxidant, anticancer, antidiabetic, and antihypertensive properties. The 
development of new synthetic methodologies, as well as the synthesis of a library of 
flavonoid compounds (including 2ʹ-hydroxychalcones, flavanones, flavones and 
flavonols) was investigated during this research project. Cytotoxicity evaluations of a 
series of 2ʹ-hydroxychalcones offered three non-cytotoxic compounds, which were 
submitted for further evaluation of their antibacterial, antidiabetic and anticancer 
properties. 
A focus of this flavonoid library was the incorporation of halogen atoms onto 
the flavonoid scaffold, as halogen bonding has been shown in medicinal chemistry to 
strengthen drug to molecular target binding. Halogenated flavonoids were also used as 
substrates in the Heck reaction, so as to further functionalise the flavonoid scaffolds. 
The synthesis of flavonoid-based Designed Multiple Ligands (DMLs) was then 
attempted, combining the antihypertensive flavonol 3ʹ,4ʹ-dihydroxyflavonol with 
various peptidomimetic and peptidic ACE inhibitors. Attempts were made to join 3ʹ,4ʹ-
dihydroxyflavonol to peptidomimetic enalapril analogues in a ‘conjugate’ fashion 
(through a linker group), through the use of four different linkers. 
The synthesis of ‘fused’ DMLs, joining 3ʹ,4ʹ-dihydroxyflavonol and di- and 
tripeptides directly through an ester successfully provided a total of five ‘fused’ DMLs. 
These included three with Fmoc-protected dipeptide ligands, and two with tripeptide 
ligands. These five DML compounds were submitted for biochemical evaluation of 
their antihypertensive properties, which is to be conducted in 2013. 
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Plain English Summary 
The flavonoids are a family of compounds found in nature, and are synonymous 
with therapeutic benefits. This thesis outlines attempts to synthesise a library of novel 
flavonoid compounds, such that new beneficial properties might result. A particular 
focus of this work was the attachment of a flavonoid with antioxidant and 
antihypertensive properties, 3ʹ,4ʹ-dihydroxyflavonol, to a number of known 
antihypertensive compounds, so as to provide Designed Multiple Ligands (DMLs), dual 
action compounds for the treatment of hypertension.  
 
 
 1 
 
Chapter One: 
Introduction 
1.1 Chapter Overview 
The flavonoids are a broad family of polyphenolic compounds found 
ubiquitously in nature. They are well known for their antioxidant and therapeutic 
effects, and are the subject of the synthetic efforts in this project. This research aims to 
further functionalise flavonoids for enhanced therapeutic activity against several 
afflictions including cardiovascular disease, and therefore, an introduction to the 
flavonoids, hypertension and ACE inhibition is provided.  
1.2 The Flavonoids 
1.2.1 Naming and Structure 
The flavonoids are a family of compounds with a C6-C3-C6 scaffold 
(Figure 1.1). This structural formula makes up three rings, labelled A, B and C, to give 
the ‘flavan’ scaffold 1 of the flavonoids (Figure 1.1). Rings A and B are those to the left 
and right of the structure respectively, and Ring C is the middle ring, as it is the last ring 
to be closed synthetically.1 The structure is numbered as shown in Figure 1.1, with 
Rings A and C numbered as single digits, and Ring B numbered using prime symbols. 
 
Figure 1.1. The ‘flavan’ scaffold 1 is made up of Rings A, C and B. 
There are three main classes of flavonoid compounds which depend on the 
positioning of Ring B; the flavonoids (or 2-phenylbenzopyrans) 1, the isoflavonoids 2, 
and the neoflavonoids 3 (Figure 1.2).1 Flavonoids incorporate their Ring B at the 2-
position of Ring C, isoflavonoids at the 3-position, and neoflavonoids at the 4-position.  
 
Figure 1.2. The three main classes of flavonoids differ by the position of Ring B. 
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The minor flavonoids, related compounds which also contain the C6-C3-C6 
backbone, include the chalcones 4 (which do not have a Ring C but are used 
synthetically to access numerous flavonoid structures) and the aurones 5 (Figure 1.3).1 
As this research focuses on compounds in the flavonoid class of structures 1, as well as 
the chalcones 4, the isoflavonoids and neoflavonoids will not be discussed further. 
 
Figure 1.3. The minor flavonoids, chalcones 4 and aurones 5, also contain the C6-C3-C6 backbone.  
 Within the flavonoid class, further structural subclasses exist. These subclasses 
are distinct from one another depending on the functionalities of the 2-, 3- and 4-
positions of Ring C. One such subclass are the flavanones 6 (Figure 1.4), which 
incorporate a single bond between the 2- and 3-positions (corresponding to the –an– of 
flavanone), and a ketone functionality at the 4-position (corresponding to the –one of 
flavanone). Similarly, flavones 7 incorporate an alkene at the 2-position and a ketone at 
the 4-position (–one), and flavonols 8 are flavones with an additional hydroxyl group at 
the 3-position (flavonol) (Figure 1.4). Not all flavonoids follow this somewhat 
systematic naming system; for example, the anthocyanins 9 are charged compounds 
with an alkene between positions 2 and 3, and a hydroxyl group at the 3-position 
(Figure 1.4).1 
 
Figure 1.4. Subclasses of flavonoids include the flavanones 6, flavones 7, flavonols 8, and anthocyanins 9. 
Many flavonols are fluorescent, often exhibiting orange or yellow fluorescence 
under UV light,2 and other flavonoids are brightly coloured due to their high degree of 
conjugation. Anthocyanins, including pelargonidin 10, cyanidin 11, and delphinidin 12, 
are plant pigments in flowers responsible for their orange, red, blue, and violet 
colouring.3-5 These flavonoids are important to plants as they assist in attracting insects 
to food, support pollination, and even protect against fungal parasites, pathogens, and 
oxidative cell injury.6  
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Figure 1.5. Anthocyanins are responsible for colouring in flowers. 
1.2.2 Natural Sources 
The flavonoids are plant-specific secondary metabolites, in that their production 
in plants is not vital to the survival of their cells.7, 8 They occur ubiquitously in plants, 
fruits and vegetables, with over 9000 structures discovered to date.8 Flavonoids exist in 
many of the foods and beverages we consume every day; from citrus fruits to licorice, 
onions to soy beans, and even red wine and chocolate.9-11 
The pathways through which flavonoids are synthesised in plants have been 
thoroughly examined (Scheme 1.1).8 There are numerous enzymes responsible for 
converting simple, hydroxylated starting materials into the various types of flavonoids, 
including flavanones 6, flavones 7 and flavonols 8, as well as the colourful 
anthocyanins 9. 
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Scheme 1.1. Different types of flavonoids are synthesised by various enzymes in plants.8 
Natural flavonoids are hydroxylated only at certain positions. These are the 5- 
and 7-positions of Ring A, and the 4ʹ- / 3ʹ-,4ʹ- / 3ʹ-,4ʹ-,5ʹ-positions of Ring B.12 
Quercetin 13, a flavonol (3-hydroxyl) with hydroxyl groups at the 5-, 7-, 3ʹ- and 4ʹ-
positions, is the most prevalent flavonoid in nature (Figure 1.6).13 Methoxyl, sulfoxyl, 
and malonyl substitutions are also common in natural flavonoids.1, 14 
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Figure 1.6. Hydroxyl groups in natural flavonoids are often found in certain positions, as shown in quercetin 13. 
Flavonoids are found in both their glycosidic (attached to a sugar molecule) and 
aglycone (non-sugar) forms in natural sources.14 Quercitrin 14 (3-O-rhamnose) and 
rutin 15 (3-O-rutinose disaccharide) are two naturally-occurring glycosides of the 
flavonol quercetin 13 (Figure 1.7).15, 16 
 
Figure 1.7. Quercitrin 14 and rutin 15 are glycosides (shown in blue) of the flavonol quercetin 13.  
1.2.3 Flavonoids Throughout History 
 Flavonoids have long been recognised for their therapeutic benefits. Propolis, a 
substance that bees extract from plants to use as a type of ‘glue’ in their hives, is a 
concentrated form of flavonoids17, 18 which has been used for centuries for its antiseptic, 
antimycotic, bacteriostatic, astringent, choleric, spasmolytic, anti-inflammatory, 
anaesthetic and antioxidant properties.2, 6, 17 The Old Testament (propolis was known as 
‘tzori’ in Old Hebrew) and the Koran have both referred to the use of propolis as a 
remedy, and it was also prescribed by Hippocrates (460-377 BC) to treat sores and 
ulcers.2, 19 The presence of flavonoids in many plants and foods used in traditional 
herbal remedies also demonstrates their capabilities as treatments for human ailments. 
These remedies include the use of licorice as a traditional Chinese medicine to treat 
tuberculosis,10 and Huangqin (a tree root rich in flavonoids) for the treatment of various 
inflammatory diseases, hepatitis, tumours and diarrhoea in East Asian countries.20 
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Between the 1920’s and 1950’s, an extract from lemon juice named ‘citrin’ 
which contained the flavanone glycoside hesperidin 16 gave rise to the proclamation 
that flavonoids were a vitamin (due to its treatment of scurvy), and flavonoids were 
given the title of ‘Vitamin P’ (Figure 1.8).21, 22 This title was later removed as 
researchers were unsure which polyphenol was responsible for the therapeutic effect, 
and because earlier claims of reduction in haemorrhage and scurvy could not be 
substantiated in later research.23, 24 
 
Figure 1.8. ‘Citrin’, a flavonoid extract from lemons which contained hesperidin 16, gave flavonoids the title of ‘Vitamin P’. 
While ‘vitamin’ status was taken from the flavonoids, they are often referred to 
as nutraceuticals, or ‘a food or parts of food that provide medical or health benefits, 
including the prevention and treatment of disease’.25 While the intake of flavonoids by 
humans has been researched, much is still unknown. 
1.2.4 Flavonoids in Food: Content and Intake 
Flavonoids are present in many plants and foods, although the types of 
flavonoid and their quantities vary considerably between sources. For example, 
soybeans contain the isoflavone genistein 17 in a concentration of approximately 
350 μg per gram of soybean.26 Meanwhile, onions contain up to 486 μg of quercetin 13 
per gram of fresh edible part, and mushrooms, cucumber and radish contain less than 
1 μg of quercetin per gram of vegetable (Figure 1.9).27 Flavonoid content in fruits and 
vegetables also differ between varieties; cherry tomatoes contain six times more 
quercetin than normal tomatoes,28, 29 and Granny Smith and Red Delicious contain more 
procyanidins than Golden Delicious apples.30 Concentrations even vary between 
seasons.27 These variations are the result of different flavonoid synthesis enzymes being 
available in different sources, and the storage of flavonoids in the skin of fruits and 
vegetables, leading to higher concentrations in smaller fruits like tomatoes.12 There are 
also discrepancies on the flavonoid content of foods between publications, due a lack of 
agreement on an appropriate analytical method.12 
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Figure 1.9. Genistein 17 and quercetin 13 are found in high concentrations in soybeans and onions respectively. 
The intake of flavonoids by humans is also subject to variance between 
publications, once again due to discrepancies between analytical methods. In 1976, 
Kühnau published that the average dietary flavonoid intake of people in the USA was 
approximately 1g per day.31 This data was based on the concentrations of flavonoids in 
foods as acquired using analytical methods of the time (ultraviolet and visible light 
spectroscopy, NMR spectroscopy, paper and thin layer chromatography, gas liquid 
chromatography),31 however such food analysis techniques are now obsolete.6  
In 1993, a study by Hertog utilised data on the flavonoid content of foods as 
determined by high-performance liquid chromatography, a far more reliable method.27, 
32 This research studied five particular flavonoids (the flavonols kaempferol 18, 
quercetin 13, and myricetin 19, and the flavones luteolin 20 and apigenin 21, Figure 
1.10), as these were most commonly investigated in anticarcinogenesis studies at the 
time.27, 33 It was determined that the average intake of these five flavonoids by people in 
the Netherlands was approximately 23 mg per day, a far cry from Kühnau’s 1g per day. 
 
Figure 1.10. Hertog found that the average daily intake of these five flavonoids by people of the Netherlands 
was 23 mg per day.27, 33 
The fact that flavonoids are present in many of the foods we eat daily establishes 
a good safety profile. However, chronic pharmacological doses (greater than those of 
the estimated dietary intake of 23-170 mg per day)31, 33 may cause side effects. 
Examples include cyanidanol 22 and sciadopitysin 23 (Figure 1.11), which cause acute 
renal failure (loss of kidney function),34 hepatitis (inflammation of the liver), fever, and 
skin reactions at extremely high doses (≥500 mg).35  
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Figure 1.11. Cyanidanol 22 and sciadopitysin 23 exhibit debilitating side effects when consumed in excessive doses. 
1.2.5 The Absorption and Bioavailability of Flavonoids 
Whilst humans consume flavonoids on a daily basis from food and beverages, 
there are numerous problems regarding the ability of the body to metabolise them, and 
they are generally poorly bioavailable.36 
The absorption of flavonoids was originally thought to occur only through the 
large intestine, however the discovery of quercetin 13 in plasma by researchers 
suggested absorption also from the small intestine.13 Knowing that flavonoids are often 
in their glycosidic forms in plants, the presence of glucosidases in the small intestine 
suggested that flavonoid glycosides are cleaved in the lumen and cells of the gut prior 
to absorption.36-39 Deglycosylated flavonoids from celery are absorbed better than their 
glycoside counterparts, suggesting that deglycosylation increases absorption.40 
However, anthocyanins and some quercetin glycosides have been found in their 
glycosidic forms when excreted in urine.16, 41, 42  
Following deglycosylation, flavonoids are often conjugated to form a more polar 
compound for rapid excretion: the formation of flavonoid glucuronides, sulfates, and 
even a mixture of the two (sulfoglucuronides) is common.36, 39, 41-43 Also, the 
methylation of hydroxyl groups in the liver and intestinal wall is possible, especially 
with quercetin 13.44 It is in these forms that flavonoids are often found in urine. 
Conflicting data is rife regarding the presence of flavonoids in plasma; quercetin 
13 is one such example. Hollman et. al. found quercetin aglycone in plasma samples in 
concentrations of approximately 64 mg after ingestion of fried onions,45 and analysis of 
absorption of quercetin from its glycosidic and aglycone forms relied on blood plasma 
concentrations to determine that the aglycone was more quickly absorbed.46, 47 
However, other studies have returned results whereby no quercetin aglycone could be 
found in plasma, even after consuming up to four grams of the pure flavonoid.48, 49 
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As only general, and often conflicting, data is available regarding the absorption 
and destination of flavonoids in the body, it is no surprise that a thorough review in 
2009 on the bioavailability of flavonoids stated that ‘much is still unknown about 
membrane transporters involved in the gastro-intestinal absorption and tissue 
distribution of flavonoids’.7 Nevertheless, research on the isotopic labelling of 
flavonoids has proven that structural differences and the different chemical properties 
of flavonoids (such as polarity) do have an effect on the route of their absorption.  
The isotopic labelling of flavonoids using 2H, 3H, 13C and 14C has been 
conducted in the interests of determining absorption and distribution routes in the body 
(Figure 1.12).50-52 While a comprehensive review of the isotopic labelling of flavonoids 
is outside the scope of this thesis, a thorough review by Barron is recommended.52 
Interestingly, when isotopically-labelled flavonoids were investigated in animal models, 
different flavonoids followed different routes of absorption, distribution and 
elimination, as well as different concentrations of uptake.52 This supports research 
suggesting that those flavonoids found most abundantly in food are not necessarily 
those found in the greatest concentration in the body.36  
 
Figure 1.12. 13C-labelled catechin 2451 and 13C-labelled quercetin 3-glycoside 2550 have been synthesised for transport and 
metabolism studies. 
 Research has also shown that flavonoid absorption varies between people. Two 
separate studies regarding the absorption and excretion of flavonoids from green tea 
showed interindividual differences, with some volunteers showing 100% 
absorption/excretion, and others less so.53, 54 
 One of the reasons for the low bioavailability of flavonoids is their lack of 
solubility in water.55-57 This is due to the planar conformation of flavonoids, which 
allows π-π stacking, an occurrence supported by crystal structures (Figure 1.13).58 This 
stacking has implications on flavonoid bioavailability; research regarding the 
accumulation of quercetin 13 in plasma after delivery in different solvent vehicles 
revealed reduced uptake when administered in water.57 
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Figure 1.13. The antiparallel and parallel π-π stacking configurations of quercetin 13.59  
This lack of solubility plagues the use of flavonoids as pharmaceuticals,13, 60 
however numerous methods have been discovered to circumvent the problem. 
Examples have included the formation of flavonoid salts,61, 62 complexation with 
cyclodextrin,63, 64 co-administration with lipids and emulsifiers,65 and the formation of 
semisynthetic analogues incorporating acetate, propionate, and palmitol side chains.55 
As the solubility issue can be addressed, there are no longer bioavailability issues 
regarding the use of flavonoids as therapeutic agents. 
1.2.4 Confirmed Therapeutic Properties  
 As outlined in Chapter 1.2.3, the flavonoids have long been associated with the 
treatment of disease. Recent scientific research has confirmed the therapeutic benefits 
of the flavonoids against numerous diseases.66 In fact, a study of the flavonoid intake 
and health of over 10,000 men and women in Finland verified that a decreased risk of 
chronic diseases including cancer, Type 2 Diabetes (T2D), mortality from ischemic 
heart disease and even asthma, is associated with increased dietary flavonoid intake.67 
For the sake of brevity, only four major therapeutic properties of the flavonoids will be 
discussed here; antioxidant, anticancer, antidiabetic, and cardiovascular activities. It is 
worth noting that flavonoids have also been associated with antiobesity,68-70 
antiallergic,71-73 asthma,67, 74 antimicrobial,19, 75-82 neuroprotective,83-85 and 
antialcoholism properties,86 amongst many others.87-93 
1.2.4.1 Antioxidant Properties 
Oxygen-centred free radicals, also known as reactive oxygen species (ROS), 
cause damage to cells in the body by attacking lipids in cell membranes, proteins in 
tissues of enzymes, carbohydrates, and DNA, causing membrane and DNA damage, 
and protein modification (including enzymes).94 This damage plays a causative role in 
aging and several degenerative diseases associated with it, such as heart disease, 
cataracts, and cancer.94, 95 ROS radicals include superoxide (O2•-), peroxyl (ROO•), 
alkoxyl (RO•), hydroxyl (HO•), and nitric oxide (NO•).94  
 12 
 
This oxidant damage can be avoided if other compounds are present to react 
with ROS, thereby terminating the radical process before it can affect the cells. The 
flavonoids are well known for their antioxidant properties,94, 96 and many foods and 
beverages containing flavonoids are associated with, and marketed for, their antioxidant 
potential, especially teas and wine.11, 30, 32, 97-100 This activity is strongly associated with 
the phenols present in natural flavonoids.101, 102 
Flavonoids provide this antioxidant activity through a number of pathways.94, 103 
Flavonoids inhibit enzymes that produce superoxide anions, such as xanthine oxidase 
and protein kinase,104, 105 and may also chelate to trace metals, preventing the metal’s 
ability to catalyse the formation of ROS such as the hydroxyl radical.106-109 As well as 
preventing the formation of ROS, flavonoids also scavenge ROS:11, 110, 111 flavonoids 
such as quercetin 13 rapidly react with peroxyl radicals, forming a flavonoid radical 26, 
which then reacts with other free radicals to form a quinone 27 and thus terminate the 
reaction (Scheme 1.2).6, 111 
 
Scheme 1.2. Hydroxylated flavonols, including quercetin 13, are efficient antioxidants which react rapidly with ROS (R•) to 
form quinones.94 
 The relationship between the structures of natural flavonoids and their 
antioxidant potential has been intensively studied,96, 102, 112 to the point where the free 
radical scavenging activity of flavonoids can be predicted.102 Generally, more hydroxyl 
groups on a flavonoid correlates with an increase in antioxidant activity.113 More 
specifically, there are three key structural features that increase radical scavenging 
ability of flavonoids (Figure 1.14): (i) an ortho-dihydroxy structure on Ring B, shown 
in blue, which scavenges reactive radical species and also chelates metals which 
promote oxidation; (ii) a 2,3-double bond with a hydroxyl at the 3-position and a ketone 
at the 4-position of Ring C, shown in green, which provides a more stable flavonoid 
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radical through conjugation and electron delocalisation, and (iii) hydroxyl groups at the 
5- and 7-positions of Ring A, shown in red, which also scavenge radical species and 
prevent lipid oxidation.11, 96, 102, 112, 114 The combination of these criteria, which result in 
the structure of quercetin 13, produce a Trolox Equivalent Antioxidant Capacity 
(TEAC)115 score almost five times greater than the antioxidant activity of Vitamin E.101 
It is noted that flavonoid glycosides do not portray the antioxidant activity of their 
aglycones.116 
 
Figure 1.14. Antioxidant activity of the flavonoids can be attributed to three structural criteria. 
Although it is mainly the natural flavonoids that have been examined for their 
antioxidant capacity, this does not mean that synthetic examples are unresearched;117-119 
the synthetic flavanone 3ʹ-hydroxyfarrerol (also known as IdB1031, Figure 1.15), which 
fulfils criteria i. and iii. for antioxidant activity of flavonoids, inhibits lipid peroxidation 
to approximately the same level as quercetin.105 
 
Figure 1.15. The synthetic flavanone 3ʹ-hydroxyfarrerol 28 has antioxidant properties.105 
1.2.4.2 Anticancer Properties 
Cancer, the unregulated growth of abnormal cells in the body, is the second 
leading cause of death (after cardiovascular disorders).120, 121 The flavonoids have been 
well documented in regards to anticancer activity. Treatment of many types of cancer 
(including colon, breast, and prostate cancers) has been undertaken, in vitro and in vivo, 
using pure flavonoids and foods high in flavonoid content, and for the treatment of both 
chemical- and UV-induced cancers.23, 122 
Kuo published a thorough review regarding the cancer preventative activity of 
dietary flavonoids,23 and recognised three possible results from the treatment of cancer 
with flavonoids:23 (i) a decrease in tumour incidence;123, 124 (ii) the inhibition of tumour 
progression;125, 126 and (iii) the enhancement of the antiproliferative activity of other 
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chemotherapeutic agents when administered in combination.127 However, extreme 
doses of flavonoids (far greater than those found in foods) have been linked to an 
increase in cancer incidence.23, 128, 129 
The link between intake of foods high in flavonoid content and anticancer 
activity has been well researched,27, 32, 33, 130 with low incidences of lung cancer131 and 
breast cancer132 associated with increased flavonoid intake. Isolated natural flavonoids 
have also been extensively studied,120, 133, 134 and genistein 17 has been noted for its 
antileukemic and antitumour (breast cancer) activity (Figure 1.16).132, 135 Quercetin 13 
in particular has undergone Phase I Clinical trials for in vivo tyrosine kinase inhibition 
(tyrosine kinases are known to cause unregulated cell growth).136, 137 
 
Figure 1.16. Genistein 17 and quercetin 13 exhibit anticancer activity. 
Synthetic flavonoids have also been studied for their anticancer activities,138-142 
however none to date have had the success of flavopiridol 29. Flavopiridol is 
structurally based on the natural product rohitukine 30 from the plant Dysoxylum 
binectariferum (Figure 1.17),143 and has the drug name Alvocidib.144-146 It is a potent 
inhibitor of cyclin-dependent kinases (CDK), which when inhibited in cancer cells, 
prevent cancer cell growth.143, 147, 148 Flavopiridol has undergone Phase I and II trials for 
anticancer effects,149 including breast cancer,150 chronic lymphocytic leukaemia,151 and 
a range of other tumours,152 and is reportedly in Phase III trials under the 
pharmaceutical company Sanofi Aventis.143 
 
Figure 1.17. Flavopiridol 29, based on the natural product rohitukine 30, is an anticancer agent. 
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1.2.4.3 Antidiabetic Activity 
Diabetes is a chronic condition currently affecting over 235 million people 
worldwide,153 with millions of people remaining undiagnosed.153, 154 This steadily growing 
epidemic is expected to escalate to over 439 million people by the year 2030.153 
Alarmingly, over 3.2 million people die each year from complications associated with 
diabetes.155 Diabetes is clinically characterised by an excess of glucose in the blood, a 
condition known as hyperglycaemia,154, 156 which results from the impaired action of the 
hormone insulin.157  
There are many ways in which to treat diabetes, including the protection of the β-
cells in the pancreas (which produce insulin), the stimulation of insulin production by the β-
cells, and the stimulation of glucose uptake into cells to remove excess glucose from the 
blood (through the targeting of receptors such as the Peroxisome Proliferator-Activated 
Receptors).154 Due to the link between oxidative stress and diabetic complications,158 it is 
understandable that many antioxidant flavonoids have been trialled for antidiabetic 
activity.159-161 
A study of over 200,000 people in the United States with over 3.64 million 
person years of follow up found that higher consumption of anthocyanins and 
anthocyanin-rich fruit was associated with a lower risk of Type 2 Diabetes.162 Extracts 
from food sources high in flavonoid content, including jambolana seeds,163 licorice,70, 
164 chamomile tea,165 and soy beans,166, 167 have also been analysed for antidiabetic 
activity.168, 169 
 Natural isolated flavonoids have been examined for antidiabetic activity through 
in vivo and in vitro testing.69, 159, 170-178 The anthocyanins in particular exhibit a number 
of beneficial properties in terms of Type 2 Diabetes, including inhibition of α-
Glucosidase, an enzyme which cleaves glycosidic bonds, resulting in higher glucose 
levels in blood (α-Glucosidase is the target of the current pharmaceutical acarbose)154. 
Anthocyanins have also been shown to protect the β-cells which produce insulin, and 
increase their production of insulin.179, 180 Quercetin 13 has been shown to protect β-
cells from damage in rat pancreas,181-183 enhance insulin release in rat pancreas cells,184 
and improve the glucose uptake of cells (thereby reducing plasma glucose levels).160 
Kaempferol 18, which is structurally similar to quercetin,160, 185 and genistein 17, an 
isoflavone from soy beans,183, 186, 187 also exhibit antidiabetic effects in in vivo and in 
vitro testing (Figure 1.18). 
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Figure 1.18. Quercetin 13, kaempferol 18 and genistein 17 all exhibit antidiabetic properties.  
 Novel synthetic flavonoids have also been examined for antidiabetic activity,188 
including novel chalcones and isoflavones as agonists of PPARα and PPARγ.161, 189, 190 
1.2.4.4 Cardiovascular/ Heart Disease  
Cardiovascular diseases are the leading cause of death worldwide.191 They are 
defined as those diseases which affect the heart and blood vessels, and include 
atherosclerosis (the blocking of arteries by fatty deposits),191 inflammation,192 coronary 
heart disease,192 and hypertension (increased blood pressure).193 
The flavonoids have been researched at length for their ability to prevent or 
reduce cardiovascular problems.6, 194-198 The most significant study in regards to 
flavonoid intake and coronary heart disease is the Zutphen Elderly Study.99 The study 
examined the medical history and flavonoid intake levels of quercetin, kaempferol, 
myricetin, apigenin and luteolin, of 805 men between 65 and 84 years old in 1985, with 
medical follow up for five years. There was a significant inverse correlation between 
flavonoid intake (mainly from tea, onions and apples in the diet) and the risk of 
coronary heart disease. This correlation has been further supported by other short term 
studies which have concluded that people with low flavonoid intake have higher risks 
of coronary disease.199-203 
 
Figure 1.19. Naringenin 31 exhibits antiatherosclerotic effects, whilst taxifolin 32 has anti-inflammatory effects. 
Citrus flavonoids including naringenin 31, and other natural flavonoids have 
been analysed for their antiatherosclerotic properties.204-208 The anti-inflammatory 
effects of some flavonoids have also been investigated, including the flavanol 
taxifolin 32,209 novel alkoxyflavonols,210 and others.40, 71, 211 The anthocyanins have 
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proven ideal in the treatment of many cardiovascular diseases, with a thorough review 
by Wallace describing their many effects.197 
Hypertension, which falls under the category of cardiovascular disease, is the 
therapeutic focus of this research and so will be addressed in more detail. 
1.3 Hypertension 
Hypertension is the clinical term for blood pressure exceeding 140/90 mmHg.193 
It occurs due to increased blood volume in the cardiovascular system, or the 
vasoconstriction (narrowing) of arterioles, and is the result of genetic predisposition or 
lifestyle.212 Hypertension is the leading cause of stroke,213, 214 and is estimated to cause 
7.1 million premature deaths worldwide per year.212, 213 It also constitutes 4.5% of the 
disease burden (64 million disability-adjusted life years, or DALYs), affecting over 800 
million people worldwide.213, 215 This epidemic is only expected to become worse: 
hypertension is predicted to affect over 1.56 billion people by the year 2025 
(Figure 1.20).214  
 
Figure 1.20. Frequency of hypertension for people over the age of 20 years, in 2000 and 2025.214 
The risk of developing hypertension increases with age, to the point where the 
probability of developing hypertension from 50 to 85 years of age is 90%.216 For all its 
frequency, however, hypertension is dubbed the ‘silent killer’, often showing no 
symptoms until it is too late.215 Studies in the USA have shown that up to 30% of 
American adults are unaware they have hypertension, 40% of those with hypertension 
are not using any form of treatment, and a further two thirds of those with hypertension 
are unable to effectively manage their blood pressure through treatment.193 However, 
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with proper management and treatment (lifestyle, exercise, and/ or pharmaceutical), 
hypertension is a manageable condition. 
1.3.1 The History of Antihypertensive Agents 
Hypertension has plagued humankind for centuries, dating back to 2600 BC 
when it was described as ‘hard pulse disease’.217, 218 Early treatments included 
acupuncture, venesection, and bleeding by leeches.217 A traditional Chinese medicine 
using the tree root of the Mudan plant (which contains polyphenols) has also been used 
for at least 2000 years for the treatment of high blood pressure.219  
The discovery that hypertension was due to improper blood flow is credited to 
Richard Bright, who associated left ventricular hypertrophy (the thickening of the 
muscle of the left ventricle of the heart) with high blood pressure in 1836.220 This was 
quite impressive, as a method to measure blood pressure would not be discovered for 
another 50 years, by von Basch and von Recklinghausen in Germany in the 1880s.221 
The term ‘hypertonie essential’ was then coined by Frank in 1925, which translated to 
essential (meaning ‘with unknown cause’) hypertension.217, 222 
Until the 1950s, only the Smithwick splanchnicectomy (to remove a portion of 
the splanchnic nerves),223, 224 and the Kempner low-salt rice diet225 existed in the way of 
treatments for hypertension, although neither had any real beneficial effect on 
patients.222 The first effective treatment was the ganglion-blocking drugs, including 
hexamethonium 33 and pentolinium 34 (Figure 1.21),226, 227 which blocked the 
parasympathetic and sympathetic nervous system, but were later dismissed due to a 
number of side effects (including hypotension and severe heart palpitations) and the 
availability of more specific antihypertensive drugs.228 
 
Figure 1.21. The first effective pharmaceutical treatment of hypertension was the ganglion-blockers, including 
hexamethonium 33 and pentolinium 34. 
Although lifestyle changes, including exercise, weight loss, and change of diet, 
are the first port of call in terms of hypertension treatment, these changes do not suit 
everyone.212 Therefore, numerous blood-pressure lowering pharmaceuticals have 
emerged, and can be categorised into five classes. These are the thiazide diuretics, beta-
blockers, calcium channel blockers, Angiotensin II receptor antagonists, and the 
Angiotensin Converting Enzyme (ACE) inhibitors. As shown in Table 1.1, each has a 
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different mode of action, and unfortunately, each pharmaceutical comes with its own 
side effects. 
 
Table 1.1. Antihypertensive pharmaceutical classes, their modes of action, and side effects.229, 230 
Pharmaceutical type Structural example Mode of action Side effects 
Thiazide Diuretics 
(Chlorithiazide, 
Metolazone)  
Promote excretion 
of water to 
decrease total 
blood volume 
Hyperglycaemia, 
hyponatraemia, 
postural hypotension, 
gout, impotency, 
cardiac arrhythmias, 
increased thirst 
Beta-Blockers 
(Atenolol, Carvedilol) 
 
Inhibit β-
adrenoreceptors to 
reduce heart rate 
Dyspnea (laboured 
respiration), sleep 
disturbances and vivid 
nightmares, erectile 
dysfunction, bronchial 
restriction, lethargy 
Calcium Channel 
Blockers 
(Verapamil, Diltiazem) 
 
Block Ca2+ 
channels to 
reduce cardiac 
muscle 
contraction 
Constipation, 
headache, flushing, 
oedema, postural 
hypotension, 
abdominal pain 
Angiotensin II 
Receptor Antagonists 
(Losartan, Candesartan) 
 
Block binding of 
angiotensin II to 
AT1 receptors, to 
prevent 
bradykinin 
destruction and 
cause vasodilation 
Hyperkalaemia, 
postural hypotension 
ACE Inhibitors 
(Captopril, Enalapril) 
 
Bind Angiotensin-
Converting 
Enzyme (ACE) to 
cause vasodilation 
Postural hypotension, 
cough, hyperkalaemia, 
hyponatraemia, 
 
1.3.2 Angiotensin-Converting Enzyme (ACE) 
Of the most interest to the research performed in this project are the 
Angiotensin-Converting Enzyme (ACE) inhibitors. ACE was first isolated from horse 
blood in 1956, and labelled a “hypertensin-converting enzyme”.231 This chloride-
dependent metallopeptidase is a part of the Renin-Angiotensin-Aldosterone System 
(RAAS), and exists in the endothelium of the vascular bed, kidney, and lung.232 
The Renin-Angiotensin-Aldosterone System is responsible for the regulation of 
blood pressure (Figure 1.22).233 When blood volume is low, the kidneys secrete the 
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enzyme renin, which converts angiotensinogen (an α-globulin protein produced by the 
liver) into the decapeptide Angiotensin I. The role of ACE is to cleave the decapeptide 
Angiotensin I to form the octapeptide Angiotensin II.233  
 
Figure 1.22. The Renin-Angiotensin-Aldosterone System regulates blood pressure.233 
Angiotensin II ultimately affects blood pressure in four ways: increased thirst 
leading to increased blood volume, the degradation of bradykinin (a natural 
antihypertensive present in the body), systemic vasoconstriction, and the production of 
aldosterone and the antidiuretic hormone (ADH) vasopressin, which reabsorb water and 
sodium into the blood to increase blood volume.232, 234, 235 While the action of ACE is 
useful in terms of increasing blood volume and therefore blood pressure, it is 
detrimental to those already experiencing high blood pressure. The inhibition of ACE 
was therefore seen as a possible treatment for hypertension. 
1.3.3 ACE Inhibitors 
In the late 1960s, the first ACE inhibitor was discovered; a nonapeptide known 
as ‘teprotide’ 41 from snake venom (of Bothrops jararaca, a Brazilian pit viper), which 
was noted to cause a sudden drop in blood pressure when administered to humans.236-238 
Further peptide-based research and Structure Activity Relationship studies by Ondetti 
and Cushman revealed that ACE contained three important ‘pockets’ for binding to 
inhibitors (Figure 1.23); one for binding a carboxyl group at the C-terminal (S2ʹ), a 
second pocket with affinity for the C-terminal peptide bond (S1ʹ), and a tightly bound 
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zinc ion that could co-ordinate with the carbonyl of the penultimate peptide bond 
(Zn++).239 
 
 
Figure 1.23. The binding of angiotensin I 40, teprotide 41, and captopril 39 to the pockets of ACE. 240 
This significant find lead to two different research approaches to ACE 
inhibition; peptidomimetic ACE inhibitors and peptidic ACE inhibitors.  
1.3.3.1 Peptidomimetic ACE Inhibitors 
Targeting three key binding pockets of ACE, captopril 39 (Figure 1.24), a 
peptide-based structure with a sulfhydryl group to bind the zinc ion (Figure 1.23), was 
the first peptidomimetic ACE inhibitor to be synthesised.241 
 
Figure 1.24. Captopril 39, the first peptidomimetic ACE inhibitor, has a sulfhydryl moiety to bind the zinc ion of ACE. 
It was soon discovered that captopril, whilst being an extremely potent 
competitive inhibitor of ACE (with an IC50 of 2.0 × 10-8 M),242 produced a number of 
side effects in patients. These included bone marrow suppression (a decrease in cells 
responsible for oxygen transport and blood clotting),243 nephrotic syndrome (kidney 
damage resulting in protein being leaked from blood to urine),244 rashes, and loss of 
taste amongst others, which were all associated with the sulfhydryl moiety of 
captopril.242, 245 Research began for a second generation of ACE inhibitors, and in 1980, 
enalaprilat 42 became available, in which the sulfhydryl was replaced with a carboxylic 
acid to bind the zinc ion of ACE, and a phenyl group was incorporated to bind the 
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S1 pocket of ACE (Figure 1.25). Enalaprilat 42 was found to be even more potent than 
captopril (with an IC50 of 1.2 × 10-9 M), and avoided the sulfhydryl side effects.242 
 
Figure 1.25. Enalaprilat 42 binds to ACE through its phenyl group, carboxylic acids, methyl, and proline moieties.240 
Unfortunately, enalaprilat 42 is poorly bioavailable when taken orally. To 
increase its bioavailability, enalaprilat is administered as its ethyl ester, known as 
enalapril 43 (Figure 1.26). Wyvratt and Patchett proposed that the installation of this 
ethyl ester assists in membrane transport in two ways: (i) by removing the charge of the 
carboxylate group and increasing lipophilicity, and (ii) by lowering the pKa of the NH 
group.246 The ethyl group makes enalapril a prodrug; prodrugs are inactive forms of a 
pharmaceutical compound (usually inactive to as to provide a benefit such as greater 
bioavailability) which in vivo, by virtue of enzymatic and/or chemical lability, supply 
the active compound (in this case enalaprilat 42) to the body.247 
 
Figure 1.26. Enalapril 43 is the ethyl ester prodrug of the active compound enalaprilat 42. 
Many peptidomimetic ACE inhibitors have since been synthesised, including 
ramipril 44 and lisinopril 45.240 These ACE inhibitors contain the same structural 
pharmacophores as captopril 39 and enalapril 43 (Figure 1.27); proline or a structurally 
related compound to bind the S2ʹ pocket (blue), an amide bond to the proline with an 
alkyl side chain for the S1ʹ pocket (green), a chelator to bind the zinc pocket (red), and 
often a phenyl group to bind the S1 pocket (purple).240 
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Figure 1.27. Peptidomimetic ACE inhibitors follow a general pharmacophoric structure. 
Many other molecular structures have been investigated for their ACE 
inhibition. Hydrophobic ACE inhibitors have clinical superiority over hydrophilic ones, 
as while both are able to bind the C-terminal (S2ʹ) catalytic site, only hydrophobic 
structures are able to bind the N-terminal (S1) catalytic site.248 Antioxidant ACE 
inhibitors are also of particular interest in terms of treating hypertension, as 
hypertension and oxidative stress are interdependent.249-251 Examples have included 
selenium analogues of captopril (Figure 1.28),250, 252 as well as enalapril and captopril 
themselves.253-255 The Heart Outcomes Prevention Evaluation (HOPE) and Study to 
Evaluate Carotid Ultrasound changes in patients treated with Ramopril and Vitamin E 
(SECURE) studies have demonstrated that long term ACE inhibition reduces 
cardiovascular events, suggesting that the therapeutic effects of ACE inhibitors extend 
to the reduction of oxidative stress.256-259 
 
Figure 1.28. Selenium analogues of captopril 46, 47, and 48 exhibit antioxidant and ACE inhibiting effects. 
As these peptidomimetic ACE inhibitors alter the peripheral action of hormones 
rather than the central nervous system, they avoid many of the side effects that plague 
other antihypertensive agents, such as drowsiness, impotence, depression and energy 
loss.245 However, this does not exclude ACE inhibitors from side effects (other than 
those specifically associated with captopril’s sulfhydryl group): hypotension (low blood 
pressure), a persistent cough, increased potassium levels and decreased sodium levels in 
the blood are commonly associated with ACE inhibitors.230 
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1.3.3.2 Peptidic ACE Inhibitors  
Following the lead from teprotide 41 (the nonapeptide from snake venom), 
extensive research has been conducted regarding the isolation of ACE-inhibiting 
peptide sequences from natural sources, such as salmon and krill,260-262 peanuts 
(IKP),263 garlic,264 algae265, 266 and eggs,267 amongst others.268-270 A number of peptides 
from fermented milk, including the tripeptides Isoleucine-Proline-Proline (Ile-Pro-Pro) 
49 and Valine-Proline-Proline (Val-Pro-Pro) 50, have demonstrated ACE inhibiting 
activity in both animal270-272 and human trials (Figure 1.29).273, 274 Indeed, a product 
containing both Ile-Pro-Pro 49 and Val-Pro-Pro 50 has been commercialised.275 
 
Figure 1.29. Ile-Pro-Pro 49 and Val-Pro-Pro 50, tripeptides from fermented milk, are peptidic ACE inhibitors.275 
As with the peptidomimetic ACE inhibitors, the binding of peptidic ACE 
inhibitors is strongly influenced by the C-terminal tripeptide.232 Predictive modelling 
for ACE inhibitor peptides using databases has found that for tripeptides, the most 
favourable residues for the C-terminal were aromatic amino acids, while positively-
charged amino acids were preferred for the middle position, and hydrophobic amino 
acids were preferred for the N-terminal.275 
A major problem with peptidic ACE inhibitors is their lack of bioavailability, 
which is the result of their susceptibility to digestion (hydrolysis) during gastrointestinal 
passage absorption, and their low intestinal permeability.276 Many in vitro tests do not 
take into account the low bioavailability of peptides;232 consequently, only a minority of 
ACE-inhibiting peptides administered will actually reach the site of action.276 This 
problem can be overcome however, with the strict selection of amino acids: dipeptides 
with proline, serine, threonine and asparagine at the C-terminal and proline, glycine and 
asparagine at the N-terminal are more stable to peptide hydrolysis.276 
1.3.4 Flavonoids in Hypertension 
The flavonoids have been investigated in terms of their antihypertensive 
properties, especially as the antioxidant activity of flavonoids contributes to their 
cardioprotective activity.100, 199, 206, 277 Plants and foodstuffs rich in flavonoids, such as 
tea,195 grape juice,278 soybeans,279 propolis280 and wine281 all exert antihypertensive 
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effects, although the pathways of their activity is unknown. Natural isolated flavonoids, 
including xanthoangelol 51 and 4-hydroxyderricin 52 (isolated from the plant Angelica 
keiskei, Figure 1.30),282 and the flavone apigenin also exert hypotensive actions.283  
 
Figure 1.30. Xanthoangelol 51 and 4-hydroxyderricin 52 have antihypertensive properties. 
Some synthetic flavonoids also exhibit antihypertensive activity. Synthetic 
hydroxylated chalcones have been shown to bind ACE, with their free phenols binding 
the zinc pocket of ACE.284 However it is the synthetic 3ʹ,4ʹ-dihydroxyflavonol that has 
received the most attention for its antihypertensive activity. 
1.3.4.1 3ʹ,4ʹ-Dihydroxyflavonol 
In 1993, Duarte et. al. investigated the vasorelaxant effects of seven structurally 
distinct flavonoids on rat aortic tissue, and found that flavonols exhibited a stronger 
vasorelaxant effect than flavones or flavanols.285 Woodman et. al. performed further 
Structure-Activity Relationship (SAR) studies using both flavones and flavonols,286 and 
identified three structural features which contributed to their vasorelaxant activity 
(Figure 1.31): the structure must be a flavonol (shown in red), lack substitution on Ring 
A (shown in green), and contain hydroxyl groups at the 3- and 4-positions of Ring B 
(shown in blue). These three criteria give 3ʹ,4ʹ-dihydroxyflavonol 53. Interestingly, two 
of these three criteria are also relevant for the antioxidant activity of flavonoids: (i) an 
ortho-dihydroxy structure on Ring B, and (ii) a 2,3-double bond with a hydroxyl at the 
3-position and a ketone at the 4-position of Ring C.11, 97, 103, 113 
 
Figure 1.31. 3ʹ,4ʹ-Dihydroxyflavonol 53 is a vasorelaxant flavonoid. 
 Since the identification of 3ʹ,4ʹ-dihydroxyflavonol 53 as a vasorelaxant 
compound, Woodman and co-workers have thoroughly investigated its manner of 
action. Early studies in rat cells, live rats and sheep revealed that the flavonoid 
possesses antioxidant activity which, through its scavenging of O2-•, increases the 
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vasorelaxant effect of acetylcholine (a neurotransmitter that lowers heart rate) in the 
body.277, 287 Further research revealed that this flavonol can increase vasodilation in 
rats,288-290 and can improve vascular function after ischemia and reperfusion injury in 
rats and sheep,291-293 leading to its establishment as a cardioprotective agent.294 3ʹ,4ʹ-
Dihydroxyflavonol has also been shown to restore endothelial function and relaxation 
in rat aorta in the case of diabetes-induced endothelial dysfunction. 295, 296  
While the exact pathway through which 3ʹ,4ʹ-dihydroxyflavonol 53 produces its 
vasorelaxant activity is unknown, Woodman and co-workers have shown that it 
decreases vascular contraction at least in part by inhibition of the RhoA/Rho-kinase 
pathway in endothelium-denuded rat aorta.289 It also causes Ca2+ desensitisation in 
vascular smooth muscle, resulting in reduced vascular smooth muscle contraction.290 
 As mentioned previously, a major problem with the use of flavonoids as 
therapeutic agents is their lack of solubility and bioavailability. However, this problem 
has been overcome in the case of 3ʹ,4ʹ-dihydroxyflavonol 53, with the installation of 
amine salts and carboxylic acid chains on Ring A,62 or the inclusion of phosphates and 
hemiadipates at the 3-hydroxyl position (Figure 1.32, flavonols 54 and 55 
respectively).61 
 
Figure 1.32. Different functionalities (blue) have made 3ʹ,4ʹ-dihydroxyflavonol more bioavailable. 
 While the antioxidant and vasorelaxant compound 3ʹ,4ʹ-dihydroxyflavonol 53 
suffers from a lack of bioavailability due to its lack of solubility, enalapril and other 
ACE inhibitors have the opposite problem, in that they are too water soluble. It was 
thought that by combining both of these compounds into a single structure could avoid 
the solubility problems, and provide a double-action antihypertensive. Pharmaceuticals 
of this type are known as Designed Multiple Ligands, and will be discussed in more 
detail in Chapter Five. 
1.4 Project Aims 
 Given the established therapeutic potential of flavonoids, it was the purpose of 
this research to further investigate the therapeutic effects of the flavonoids, specifically 
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flavonoids which were novel or had been further functionalised so as to improve their 
bioavailability. The synthesis of a library of novel halogenated and functionalised 
flavonoid compounds was the first aim within this research, as it enabled the 
establishment of synthetic methodology and also provided various flavonoid structures 
for preliminary biochemical evaluation, including cytotoxicity evaluations (Chapters 
Two and Three). It was envisaged that the compounds would then be evaluated for 
therapeutic effects, including antibacterial, anticancer, and antidiabetic evaluations.  
The installation of halogens onto the flavonoid scaffolds was also an aim of this 
project. A number of current pharmaceuticals take advantage of the incorporation of 
halogens,297 as these provide not only steric bulk to occupy binding sites of molecular 
targets,297 but also form halogen bonds in drug-target interactions, which contribute to 
the stability of protein-ligand complexes.297, 298 Halogenated compounds provide this 
benefit as the halogen ‘X’ acts as a Lewis acid, and forms direct close contacts with 
electron donor moieties in binding sites.299 This interaction is driven by the σ-hole, a 
positively-charged region on the hind side of ‘X’, caused by an anisotropy of electron 
density on the halogen (Figure 1.33). 
 
Figure 1.33. Halogen bonding between halogenated pharmaceuticals and molecular targets is driven by the σ-hole, shown as 
a red δ+.299 
One halogenated example discussed already in this chapter is Flavopiridol 29, a 
chlorinated flavonol which has undergone Phase I and II trials for anticancer effects 
(Figure 1.34).143, 149-152 Other examples of halogenated therapeutic compounds include 
numerous natural products from marine sponges and seaweeds which incorporate 
bromine atoms. These brominated structures have been shown to exhibit antifungal 
activity,300 HIV protease inhibition,301 and even antifouling properties.302 Also, the 
brominated compound 4,5,6,7-tetrabromobenzimidazole 56 (TTB) is a potent protein 
kinase CK2 inhibitor, utilised for its antiviral activity (Figure 1.34).303-306  
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Figure 1.34. Flavopiridol 29 and TTB 56 are examples of halogenated pharmaceuticals. 
These halogenated flavonoid structures also provided an opportunity to 
investigate the Heck reaction (a palladium-mediated reaction) in order to incorporate 
other functionalities (Chapter Four); for example, to add ‘handles’ for further synthesis. 
 The final aim of this research was the synthesis of a series of Designed Multiple 
Ligand (DML) compounds, incorporating the ACE-inhibiting effect of specific peptides 
and the vasorelaxant 3ʹ,4ʹ-dihydroxyflavonol 53 into a single, highly bioavailable 
cardioprotective compound (Chapters Five and Six). 
 With these aims in mind, the synthesis of a series of 2ʹ-hydroxychalcones, a 
synthetic stepping stone to many flavonoid structures including flavanones, flavones 
and flavonols, was investigated first.  
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Chapter Two: 
Synthesis of 2′-Hydroxychalcones 
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2.1 Chapter Overview 
As outlined in Chapter One, the flavonoids are commonly used as therapeutic 
agents; two common uses are as antihypertensive or anticancer agents. To synthetically 
access many different members of the flavonoid family, the 2′-hydroxychalcones are an 
ideal starting material, and these compounds also offer therapeutic benefits.307 This 
chapter will begin by looking at the Claisen-Schmidt condensation, the most common 
method used to synthesise chalcones. The traditional methodology, as well as modern 
techniques including the use of microwave technology and even solid and cellular 
supports, will be discussed.  
In order to synthesise a library of 2′-hydroxychalcones, the optimisation of a 
microwave-assisted methodology was undertaken, and provided a number of highly-
functionalised, and in particular highly-halogenated, 2′-hydroxychalcones. Some of the 
members of this small library were also evaluated for their cytotoxic properties, the 
results of which will be presented at the end of this chapter. 
The methodology developed within was published in Current Organic 
Chemistry (2012, 16(1), 121-126) (see Appendix A). 
2.2 The Claisen-Schmidt Condensation 
The term ‘chalcone’ 4 is used to describe an aromatic enone (α,β-unsaturated 
ketone), whereby an aryl group is present on either end of the enone (Figure 2.1). The 
condensation reaction of a benzaldehyde and an acetophenone to form a chalcone was 
first reported in 1881, by two separate research groups. The first was published by 
Schmidt,308 who outlined the reaction using acetone, furfurol (furan-2-carbaldehyde) 
and bittermandelol (benzaldehyde).  
 
Figure 2.1. The most simple chalcone 4, also known as benzylideneacetophenone or 1,3-diphenyl-2-propene-1-one. 
In the following issue of Berichte der Deutschen Chemischen Gesellschaft, 
Claisen and Claparede published their work regarding the condensation of a ketone and 
an aldehyde.309 Both groups detailed the use of a base (sodium hydroxide) in order to 
access the desired product.  
The reaction, named the Claisen-Schmidt condensation, is a form of the aldol 
condensation, whereby a ketone and an aldehyde react to form water and a new carbon-
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carbon bond in the aldol compound. The mechanism of the Claisen-Schmidt 
condensation is as shown in Scheme 2.1. First, the base (B) removes an α-proton from 
the acetophenone 57, and the resultant enolate 58 attacks the electrophilic carbonyl 
carbon of benzaldehyde 59. This is followed by protonation of the negatively-charged 
oxygen 60 to form aldol 61. Finally, dehydration via an E1cb mechanism provides the 
trans-chalcone 4.310, 311  
 
Scheme 2.1. The mechanism of the Claisen-Schmidt condensation between acetophenone 57 and benzaldehyde 59. 
 The stereoselectivity of the reaction (where the trans- rather than cis- product is 
formed) arises during the dehydration step. Due to the presence of an unfavourable 
steric interaction between the two phenyl groups of the chalcone, the trans-product is 
favoured (Figure 2.2).312 
 
Figure 2.2. The trans-chalcone 4 is favoured in the Claisen-Schmidt condensation.312 
2.2.1 Conventional Claisen-Schmidt Condensation 
Over the years, the Claisen-Schmidt condensation has been used to form 
chalcones from many functionalised acetophenones and aldehydes.77, 313-316 In more 
recent times, adaptations to make these Claisen-Schmidt condensations “green” have 
included solvent-free conditions, with the use of silica chloride (chlorinated silica 
gel),317 solid NaOH318 and KOH,319 solid supports,320 and even near-critical water.321 
Ultrasonic irradiation with zeolites has also been applied to chalcone synthesis.322 Ionic 
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liquids have also been investigated as catalysts for Claisen-Schmidt reactions, including 
room temperature ionic liquids (RTILs),323 basic ionic liquids,324 and acyclic acidic 
ionic liquids.325 
One problematic side reaction of base-catalysed Claisen-Schmidt condensation 
reactions is the Cannizzaro reaction.326 This reaction occurs between two molecules of 
benzaldehyde 59 and a hydroxide base to produce a benzyl alcohol 64 and a carboxylic 
acid 65 (Scheme 2.2). As these reagents are present in the Claisen-Schmidt 
condensation, it is understandable that there have been reports of the Cannizzaro 
reaction providing undesired benzyl alcohol 64 and carboxylic acid 65 in the synthesis 
of chalcones.327 However, the absence of the Cannizzaro product has been noted 
previously, in the case of ultrasound-accelerated Claisen-Schmidt condensation.328 
 
Scheme 2.2. The mechanism of the Cannizzaro reaction. 
Research within this chapter focuses on the synthesis of 2ʹ-
hydroxychalcones 66, which are formed by reactions between functionalised 2ʹ-
hydroxyacetophenones and functionalised benzaldehydes. These particular chalcones 
were of interest as they provide a stepping stone from which to synthesise other 
members of the flavonoid family, including the flavanones,329, 330 flavones,331, 332 
isoflavones,333 and flavonols.334, 335  
The formation of 2ʹ-hydroxychalcones was first reported by Pfeiffer in 1933,336 
and since then, many functionalised forms have been synthesised.189, 337-341 Generally, 
the traditional methods of 2′-hydroxychalcone synthesis, via a base-catalysed Claisen-
Schmidt condensation of 2′-hydroxyacetophenones and benzaldehydes,342 employ long 
reaction times (around 24 hours), require strong bases, and yields range from poor to 
very good (16%-81%).161, 189  
Yet another problem that must be avoided in 2ʹ-hydroxychalcone synthesis is 
their conversion to the analogous flavanone 6, which can occur via an acid-343 or base-
catalysed344 process (see Schemes 2.3 and 2.4 respectively). 
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Scheme 2.3. The acid-catalysed cyclisation of 2ʹ-hydroxychalcone 66 to form flavanone 6. 
This phenomenon means that same conditions used to synthesise the 2ʹ-
hydroxychalcones may also produce some of the cyclised analogue.329, 345, 346 This 
phenomenon has been reported numerous times,329, 330, 347 and once again, flavanone 
formation can be avoided through careful selection of reaction conditions, including 
reaction time and acid or base strength. Along with the careful choice of reaction 
conditions to increase yields and avoid isomerisation, microwave chemistry has also 
been embraced in chalcone synthesis. 
 
Scheme 2.4. The base-catalysed cyclisation of 2ʹ-hydroxychalcone 66 to form flavanone 6. 
2.2.2 Microwave Chemistry 
In the electromagnetic radiation spectrum, microwaves (0.3 GHz–300 GHz) lie 
between radiowave (Rf) and infrared (IR) frequencies. Microwaves, a nonionizing 
radiation incapable of breaking bonds, are a form of energy rather than heat. However, 
this energy is manifested as heat through its interaction with materials wherein they can 
be reflected (metals), transmitted (good insulators that will not heat) or absorbed 
(decreasing the available microwave energy and rapidly heating the sample).348 
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The heating of samples (including foodstuffs, solvents, and chemical reactions) 
using microwave irradiation involves first the alignment of dipoles and ions with an 
electric field.349, 350 As the field oscillates, the dipoles or ions attempt to continue to 
align with the electric field, resulting in the loss of energy through heat. The amount of 
heat produced is relative to the ability of the dipoles or ions to align with the field, and 
is dependent on the dielectric properties of the sample. As the microwave irradiation is 
able to penetrate the sample, unlike conventional heating methods, efficient and rapid 
internal heating is achieved.349, 350  
This rapid internal form of heating, as well as the use of increased pressure, 
allows for the superheating of solvents, whereby the solvent can be heated to 
temperatures greater than its boiling point.351 The superheating of chemical reactions 
has been shown to enhance reaction rates; Baghurst and co-workers note that 
superheating chemical reactions by 100 °C results in a rate enhancement of 
approximately 1000.352 
Microwave-assisted organic chemistry is a modern method in which microwave 
irradiation is applied to organic reactions, with this rapid heating leading to reduced 
reaction times. Microwave irradiation was first applied to organic reactions in 1986, 
using domestic microwaves.353, 354As microwave chemistry increased in popularity, 
more opportunities were realised, including the use of ‘dry’ media including solid 
support and solvent-free reactions.355 However, domestic microwave reactors have 
since been deemed unreliable in a chemistry setting, as they do not offer reproducible 
results, reaction stirring is not possible, they offer little control over reaction conditions, 
and their use has even caused explosions.355 
In the 1990s, research into more specialised microwave reactors began, in order 
to allow controllable and safer reactions. Magnetic stirrers were incorporated to ensure 
uniform temperature through the reaction mixture, the ability to add chemicals and 
remove samples during heating was offered, and computer-controlled power input 
became possible. More importantly in terms of safety, these specialised reactors could 
provide concurrent heating and cooling, minimising any chance of explosion.355 
In the year 2000, the commercialisation of these specialised laboratory 
microwave reactors began.356 In addition to the advantages of the first specialised 
microwave reactors, these commercial microwave reactors offered far greater control 
over the parameters used: temperature, reaction time, microwave power, and cooling 
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methods can now all be regulated and strictly monitored, providing reproducibility 
between reactions.356 Commercial microwave reactors also influence reaction 
selectivity, provide cleaner transformations, and improve yields.356 Reduced solvent 
volumes, to the point of ‘neat’ reactions, and the use of ionic liquids357 or water as 
solvents,358 have also been realised. It is also noted that every 10 °C increase in 
microwave reaction temperature halves the reaction time;355 by this approximation, if a 
reaction is heated by conventional methods (oil bath or hot plate) at 80 °C for 16 hours, 
the same reaction could be carried out at 200 °C for 16 seconds with microwave 
irradiation.355 
Microwave chemistry is recognised as a ‘green’ chemistry approach, due to the 
reduced energy and solvent required. The application of microwave irradiation to 
organic reactions has been very broad;359-361 cycloaddition reactions,362 heterocycle 
synthesis363, 364 and nanomaterial synthesis361 have all enjoyed the benefits of 
microwave chemistry. The use of microwave irradiation has also extended to the 
synthesis of flavonoids and chalcones. 
2.2.3 Microwave-Assisted Claisen-Schmidt Condensation 
Microwave-assisted chalcone synthesis has been introduced over the last 15 
years, and greatly-reduced reaction times have been realised (2-60 minutes).339, 365-372 
The first report of microwave-assisted 2′-hydroxychalcone synthesis employed a 
domestic microwave reactor, and eight chalcones (varying only in the functionality of 
the benzaldehyde) were synthesised.339  
In the microwave, the use of solid support and heterogeneous catalysts in place 
of solvents to synthesise chalcones has also been explored, including montmorillonite 
K10 clay,366 Al2O3,370 hydroxyapatite,371 and mesoporous zirconium phosphate,373 
among others.374-377 However, only one of these microwave-assisted methods 
specifically address the formation of the 2′-hydroxychalcones.370 
More recently, functionalised cellulose supports have been successfully 
employed by Bowman et al. for the SPOT-synthesis of chalcones, and excellent 
functional group tolerance was realised.367, 368 However, only two 2′-hydroxychalcones 
(which as mentioned earlier are valuable as precursors for other flavonoids) were 
synthesised in moderate yields (40% and 52%).368  
Whilst microwave-assisted chalcones synthesis has been reported, it is difficult 
to find methods specifically for 2′-hydroxychalcones. In 2002, Stoyanov and co-
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workers339 also noted that previous microwave-assisted chalcone formation methods366, 
372, 378 could not be applied to 2′-hydroxychalcones. They found that applying the earlier 
microwave-assisted methods lead to the formation of the flavanone rather than the 2′-
hydroxychalcone, and that the additional step of hydroxyl protection was required.379 In 
order to overcome the need for hydroxyl protection, they developed and optimised a 
procedure which utilised KOH, EtOH, and a domestic microwave (which, as noted 
previously, lacks the precision and control that is guaranteed by a purpose-built 
microwave).356  
Given that only one literature method specifically addressed the synthesis of the 
2ʹ-hydroxychalcones via a microwave-assisted approach, and that this method utilised 
the unreliable domestic microwave, a study was undertaken to determine a reliable and 
robust method for the microwave-assisted synthesis of 2′-hydroxychalcones.  
2.3 Results and Discussion 
2.3.1 The Traditional Claisen-Schmidt Condensation 
Conditions 
In order to compare the use of the traditional method (a mineral hydroxide base 
in ethanol (EtOH), stirred at room temperature overnight) and the microwave-assisted 
method, a trial reaction was carried out using the traditional conditions.342 The 
condensation was attempted using 2′-hydroxyacetophenone 72 (2.9 mmol) and an 
excess of benzaldehyde 59 (4.4 mmol), with potassium hydroxide (KOH, 15.0 mmol) as 
the base, and EtOH (10 mL) as the solvent. To the solution of KOH in EtOH, the 
acetophenone was added, followed by the benzaldehyde. The reaction was stirred at 
room temperature for 16 hours, and acidic work up provided a crude product which was 
analysed by Proton Nuclear Magnetic Resonance (1H NMR) spectroscopy (Figure 2.3). 
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Figure 2.3. The reactants, products and side products of the traditional methodology and 1H NMR spectrum of the crude 
product material (CDCl3). 
The spectrum showed trace amounts of the acetophenone 72 (signified by the 
methyl peak at δ 2.58 ppm) and benzaldehyde 59 (signified by the aldehyde peak at 
δ 9.98 ppm) starting materials, as well as significant amounts of 2′-hydroxychalcone 66 
(signified by the hydroxyl proton peak at δ 12.84 ppm). The corresponding flavanone 
compound 6 was also present (by a multiplet at δ 2.83-3.10 ppm, and a doublet of 
doublets centred at δ 5.43 ppm, which had relative integrations of 2 and 1 respectively). 
As mentioned in Chapter 2.2, this phenomenon is quite common due to the equilibrium 
between chalcones and their corresponding flavanones in the presence of either acid or 
base. A trace amount of the Cannizzaro product 64 was also present in the crude 
reaction material, as identified by a singlet at δ 4.69 ppm, representative of the CH2 of 
the benzyl alcohol. 
According to the 1H NMR spectrum, excellent conversion was realised, with the 
ratio of the acetophenone 72 to desired chalcone 66 to flavanone 6 as approximately 
1:100:10. However, there was still room for improvement, due to the formation of the 
flavanone and Cannizzaro products, and the 16 hour reaction time. 
As the aim of this research was to identify ideal conditions for the microwave-
assisted reaction, no further optimisation was performed on the traditional bench 
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method. The results from this method were simply used for comparison to the 
microwave method. 
2.3.2 Optimisation of the Microwave-Assisted Claisen-
Schmidt Condensation 
For the optimisation of the microwave-assisted formation of the functionalised 
2′-hydroxychalcones, the parameters of base used, solvent, reaction time, and 
microwave temperature were all examined. 
An important point that must be explained is the integration of the chalcone 66 
hydroxyl peak in 1H NMR spectra. When purified, the hydroxyl peak of 2ʹ-
hydroxychalcone 66 at δ 12.84 ppm was observed as the only peak that represented the 
chalcone and was instantly distinguishable from the peaks of any other products or 
reactants in the reaction mixture (Figure 2.4). This peak was therefore the only peak 
that could be used for integration ratios (against the acetophenone 72 CH3 peak at 
δ 2.58 ppm). 
The hydroxyl peak was consistently observed to have an integration of 0.85 
rather than an integration of one, when compared to the integration of the aryl peaks (in 
particular those from δ 6.90-7.05 ppm, representing the two alkene CH peaks). This 
could be explained by the proton-deuterium exchange of the phenol proton resulting in 
a reduced integration value, however the assumption that the integration is always 0.85 
could provide problems if this integration was not reproducible between experiments. 
For this reason, the deuterated chloroform used for NMR experiments was stored over 
molecular sieves and under nitrogen, to ensure that the presence of water in the 
chloroform would not distort the proportion of proton-deuterium exchange. Also, all 
reaction mixtures and purified products were dried for at least six hours under a high-
vacuum system prior to performing spectroscopy, to remove any water. This method of 
‘drying’ the chloroform and reaction material proved reproducible (the reaction was 
repeated numerous times) and the hydroxyl peak always provided an integration of 
0.85. 
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Figure 2.4. The hydroxyl peak of the purified 2ʹ-hydroxychalcone 66 (δ 12.84 ppm) had an integration of 0.85, in 
comparison to the full integration of the two alkene CH peaks (shown in blue). 
With this in mind, optimisation could begin, using integration to determine the 
relative ratio of products and starting materials in each reaction. 
2.3.2.1 Base 
 The first parameter investigated was the base used. Numerous bases, mainly 
hydroxides, have been used previously for chalcone formation in a conventional 
reaction setting.189, 342, 380-383 Therefore, many different types of bases were examined, 
including hydroxides, amines, and other bases.  
Parameters of the microwave reactor were kept constant; a 50 °C reaction 
temperature for 15 minutes at 300 watts. Unsubstituted 2′-hydroxyacetophenone 72 and 
benzaldehyde 59 were reacted together in a 1:1 ratio on a 0.5 millimolar scale, and 
tetrahydrofuran (THF) was chosen as the solvent (2 mL), as it provided a polar aprotic 
medium in which to carry out the reaction. 
It was found during the first reaction that one equivalent of benzaldehyde 59 
was inadequate to achieve complete conversion. According to the 1H NMR spectrum, 
the reaction mixture contained the desired 2′-hydroxychalcone 66 and acetophenone 
reagent 72 (in a ratio of 2:1 chalcone 66 to acetophenone 72 respectively), and no 
benzaldehyde 59. This lack of benzaldehyde did not coincide with the appearance of the 
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peak representing the Cannizzaro product (at δ 4.69 ppm), and as the acetophenone and 
benzaldehyde react in a 1:1 ratio, the lack of benzaldehyde suggested that it may be 
evaporating (due to low vapour pressure)384 during the reaction and acidic workup. 
When the reaction was repeated using two equivalents of benzaldehyde, conversion to 
desired chalcone 66 increased, with a ratio of 100:1 for chalcone 66 to acetophenone 72 
respectively. This increase in conversion occurred with no sign of the Cannizzaro or 
flavanone products. Therefore, all reactions using the unfunctionalised benzaldehyde 
were completed using a 2:1 ratio of benzaldehyde 59 to acetophenone 72. 
Due to the use of excess benzaldehyde, conversion ratios in the following tables 
show only the relative amount of residual acetophenone 72 to chalcone 66. The 
chalcone hydroxyl proton at δ 12.84 ppm was integrated as 0.85, and the acetophenone 
methyl peak at δ 2.58 ppm was then integrated, and its total was divided by three as it 
represents three protons. This gave a relative conversion ratio by comparing the amount 
of starting material to product, and avoided the problem of benzaldehyde volatility 
giving inaccurate conversion rates. In any case where the conversion ratio to the 
flavanone was required, the methine (CH) peak at δ 5.43 ppm with an integration of one 
was used, and for the Cannizzaro product, the methylene (CH2) peak at δ 4.69 ppm with 
an integration of two was used (Figure 2.5). 
 
Figure 2.5. The representative peaks and their integrations used for 1H NMR conversion ratios. 
It was also important to use an excess of base in these reactions. As shown in 
Scheme 2.2, one equivalent of base is needed to carry out the Claisen-Schmidt 
condensation with an unfunctionalised acetophenone. However, with the use of 2ʹ-
hydroxyacetophenone 72 as a reagent, an additional equivalent of base is required in 
order prevent any problems regarding the deprotonation of the hydroxyl rather than the 
desired α-proton of the acetophenone. Theoretically, two equivalents of base may have 
been adequate for the reaction to be carried out, however it was noted that previous 
attempts at 2ʹ-hydroxychalcone synthesis had used four or more equivalents of base,342 
and so four equivalents of base were used. With these molar ratios of base and aldehyde 
determined, attention returned to the choice of base. 
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The microwave reaction using two equivalents of benzaldehyde 59 and four 
equivalents of KOH (Table 2.1, entry 1) resulted in complete conversion to the desired 
2′-hydroxychalcone 66, as indicated in the 1H NMR spectrum by the complete loss of 
the acetophenone methyl peak (δ 2.58 ppm), and identical 1H NMR peaks to those 
previously published in the literature, including the chalcone hydroxyl peak 
(δ 12.84 ppm).385 Purification of the product by column chromatography (40% 
dichloromethane (CH2Cl2) in petroleum spirits (Pet)) isolated chalcone 66 in 
quantitative yield. There was no sign of the undesired Cannizzaro product or flavanone. 
Although this was an excellent result, the identification of other suitable bases was 
pursued to provide other options for the synthesis of more functionalised products. 
Table 2.1. Choice of base for microwave-assisted 2′-hydroxychalcone 66 formation. 
 
Entry Base 72:66
a 
(yield)b 
1 KOH 0:1 (quant.) 
2 NaOH 0:1 (95%) 
3 Ba(OH)2 1:16 (92%) 
4 LiOH 2:1 
5 NaOAc 1:0 
6 NEt3 1:0 
7 DIPA 1:0 
8 NaHMDS 1:0 
9 DBU 1:2c 
10 Bu4NOHd 0:1 (81%) 
a Ratio determined by 1H NMR integration 
b Isolated yield (%) after column chromatography  
c Ratio of 72:66:6(flavanone) was 1:2:2 
d As a 1.0 M solution in MeOH 
 First, other mineral bases were examined. As expected, complete conversion 
was realised when sodium hydroxide (NaOH) was used (Table 2.1, entry 2), and an 
isolated yield of 95% was obtained upon purification of the 2′-hydroxychalcone 66. 
Barium hydroxide (Ba(OH)2) was also successfully applied to the reaction, with a very 
good ratio of 16:1 chalcone 66 to acetophenone 72, and an isolated yield of 92% 
achieved (Table 2.1, entry 3). Lithium hydroxide (LiOH) provided a reduced 
conversion ratio of 2:1 for acetophenone 72 to chalcone 66 respectively.  
Sodium acetate, a weak base whose corresponding acid (acetic acid) has a pKa 
of 4.76 in water,386 was also tested in the reaction (Table 2.1, entry 5), as it has been 
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reported to convert the chalcone 66 via ring closure to the flavanone 6.382, 387 However, 
even in an extreme excess of 14 equivalents, no conversion from acetophenone 72 to 
chalcone 66 was noted. 
Amine bases were the next to be trialled. While their use in traditional chalcone 
formation is not common, they have been used previously in microwave-assisted 
chalcone formation.388 Triethylamine (NEt3), diisopropylamine (DIPA), and sodium 
bis(trimethylsilyl)amide (NaHMDS) were all trialled (Table 2.1, entries 6, 7, and 8), 
however none provided desired chalcone 66.  
Interestingly, when the amidine base 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) 
was used (Table 2.1, entry 9), the product included not only some of desired chalcone 
66, but also flavanone 6. This reaction provided a 1:2:2 ratio of acetophenone 72 to 
chalcone 66 to flavanone 6 respectively. It has previously been reported that DBU can 
be used under microwave irradiation to convert chalcones to flavanones,344 which 
would explain the presence of flavanone 6. This result will be discussed further in 
Chapter 3.2.2. 
Lastly, tetrabutylammonium hydroxide (Bu4NOH, Table 2.1, entry 10) was used 
(as a one molar solution in methanol (MeOH)). This base provided the desired 2′-
hydroxychalcone 66 with 100% conversion, however an isolated yield of only 81% was 
achieved. While this isolated yield was not as high as those achieved with the other 
hydroxide bases, this result was of note as, unlike KOH or NaOH, Bu4NOH is soluble 
in organic solvents other than MeOH and EtOH (the most commonly used solvents for 
this reaction), and therefore more base/solvent combinations were potentially possible 
for the microwave-assisted reaction. 
In conclusion, KOH and NaOH were identified as the best bases, which was in 
accordance with the previous 2ʹ-hydroxychalcone synthesis publication,339 as well as 
the traditional methodology.342 In addition, 1.0 M Bu4NOH in MeOH was established 
as an option, allowing more scope in terms of solvent choice. With this information in 
hand, attention turned to the selection of solvent. 
2.3.2.2 Solvent 
In order to identify an ideal solvent, the best base (KOH) was utilised for the 
reaction. The other parameters (reaction time, temperature and power) were also kept 
constant, with a reaction of 15 minutes at 50 °C and a power setting of 300 watts. 
 43 
 
Traditionally, polar protic alcohols are the solvents of choice in Claisen Schmidt 
reactions, due to their ability to dissolve hydroxide bases.189, 342, 381-383 Therefore, 
MeOH and EtOH were examined first. Their use in the microwave-assisted method 
gave very good, but not complete conversion to the 2′-hydroxychalcone 66 (Table 2.2, 
entries 1 and 2), with a ratio of 19:1 of the desired 2ʹ-hydroxychalcone 66 to 
acetophenone 72. However, when the polar aprotic solvents N,N-dimethylformamide 
(DMF) and tetrahydrofuran (THF) were tested, complete conversion to the desired 
product 66 was noted (Table 2.2, entry 3 and Table 2.1, entry 1 respectively). 
Understandably, the less polar solvents dioxane and toluene (Table 2.2, entries 5 and 6) 
did not facilitate the reaction, likely due to their inability to dissolve the hydroxide 
bases. Acetone was also trialled (Table 2.2, entry 4) as it was the solvent of choice (and 
reagent) in Schmidt’s original work,308 and gave an approximate ratio of 2:1, 
acetophenone 72 to 2′-hydroxychalcone 66 respectively. 
Table 2.2. Optimisation of solvent used for microwave-assisted 2′-hydroxychalcone 66 formation. 
 
Entry Solvent 
72:66a 
(yield) 
1 MeOH 1:19 
2 EtOH 1:19 
3 DMF 0:1 
4 acetone 2:1 
5 dioxane 1:0 
6 PhMe 3:1 
a Ratio determined by 1H NMR integration 
 
The ideal solvents identified for this microwave reaction were therefore THF 
and DMF, rather than the expected MeOH and EtOH. It was decided that THF would 
be utilised in future reactions, as DMF is more difficult to remove from reactions. 
2.3.2.3 Microwave reaction time 
Microwave reaction time is another parameter that affects the conversion of 
acetophenone to chalcone. With base (KOH) and solvent (THF) already determined, the 
microwave was set at 300 W power and a reaction temperature of 50 °C. 
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Table 2.3. Optimisation of reaction time for microwave-assisted 2′-hydroxychalcone 66 formation. 
 
Entry Reaction 
time 
72:66a 
1 10 min 1:19 
2 15 min 0:1 
3 20 min 0:1 
4 30 min 1:19 
a Ratio determined by 1H NMR integration  
 
While faster reaction times than the traditional method (16 hours)342 were 
achieved through the use of the microwave reactor, it was found that there was a very 
fine balance regarding reaction time and conversion. While reaction times of 15 and 
20 minutes ensured complete conversion to the desired 2′-hydroxychalcone 66 
(Table 2.3, entries 2 and 3), it was noted that extending or reducing these reaction times 
resulted in very slightly reduced conversions (19:1 ratio of 2′-hydroxychalcone 66 to 
acetophenone 72, see Table 2.3, entries 1 and 4). The extension of reaction time 
resulting in decreased product formation may be attributed to the formation of water, 
which may then cause a retro-aldol reaction, in which the acetophenone and 
benzaldehyde starting materials are re-formed.343 As short reaction times were desired, 
a 15 minute reaction under microwave irradiation was deemed ideal. 
2.3.2.4 Microwave temperature 
The final parameter to be optimised for these reactions was microwave 
temperature. With the other three reaction parameters set (KOH, THF, 15 minutes) and 
a power setting of 300 W, the temperature of the microwave reaction was examined. 
As Luthman and co-workers had used 170 °C in their synthesis of flavanones 
from acetophenones and benzaldehydes,388 this was identified as an ideal starting point 
to pursue chalcone formation. However, this high temperature gave no conversion to 
the desired chalcone 66 (see Table 2.4, entry 1), and resulted in the loss of 
benzaldehyde 59, possibly due to evaporation. Therefore, lower temperatures were 
used. 
Lowering the temperature to 120 °C and 100 °C (Table 2.4, Entries 2 and 3 
respectively) also resulted in no conversion to the 2′-hydroxychalcone 66, with only 
acetophenone 72 present in 1H NMR spectra. When a reaction temperature of 100 °C 
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and reaction time of 5 minutes was tested, almost complete conversion to chalcone 66 
was noted (Table 2.4, entry 4), however this increase in desired product was 
accompanied by the presence of the Cannizzaro product, in a ratio of 4:1 chalcone 66 to 
benzyl alcohol 64. These results lead to the conclusion that temperatures in excess of 
100 °C were too high for chalcone formation in good yield and purity. 
Table 2.4. Optimisation of reaction temperature for microwave-assisted 2′-hydroxychalcone 66 formation. 
 
Entry Temp (°C) Time (min) 72:66a 
1 170 60 1:0 
2 120 30 1:0 
3 100 20 1:0 
4 100 5 1:10b 
5 80 10 1:10 
6 50 15 0:1 
a Ratio determined by 1H NMR integration 
b Also produced Cannizzaro product 64 in relative ratio of 2.5 
 
When the lower temperature of 80 °C was employed, good conversion to the 2′-
hydroxychalcone 66 was noted (Table 2.4, entry 5), by the presence of the δ 12.84 ppm 
peak representing the hydroxyl proton in the 1H NMR spectrum. As this reduction in 
temperature afforded great conversion without the occurrence of the Cannizzaro 
reaction, the temperature was again lowered to 50 °C (Table 2.4, entry 6), and found to 
provide 2′-hydroxychalcone with 100% conversion from the starting acetophenone, and 
none of the corresponding Cannizzaro product. 
2.3.2.5 Optimisation Summary 
 The ideal conditions for the microwave-assisted 2′-hydroxychalcone formation 
were a reaction time of 15 minutes at 50 °C. Microwave power was not investigated, 
but kept constant at 300 watts. The best bases were the mineral bases KOH or NaOH, as 
well as Bu4NOH (as a 1.0 M solution in MeOH), in a ratio of 4:1 base to acetophenone, 
with THF as the solvent. These conditions produced the desired 2′-hydroxychalcone 66 
in a far greater yield than the trialled traditional method, with the benefits of no side 
products (undesired flavanone and Cannizzaro products), and significantly reduced 
reaction time (15 minutes compared to 16 hours). Attention could now turn to the 
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conversion of more functionalised starting materials to their corresponding 2′-
hydroxychalcones. 
2.3.3 Synthesis of a Library of Functionalised 2′-
Hydroxychalcones 
The starting materials incorporated a number of different functionalities into 
their 2′-hydroxyacetophenone and benzaldehyde scaffolds. In particular, starting 
materials with halogens were favoured, as these were noted as ideal in medicinal 
chemistry scaffolds,297, 298, 389 provided the opportunity to investigate the effect of 
halogen bonding of flavonoid compounds with therapeutic targets,299 and also allowed 
for research into the use of the Heck reaction with flavonoid scaffolds (to be discussed 
in Chapter Four).390, 391  
As the optimisation reactions identified both potassium hydroxide (KOH) and 
tetrabutylammonium hydroxide (Bu4NOH) as ideal bases, each reaction was completed 
in duplicate; once each with these selected bases. In each case, only the reaction which 
provided greater conversion to the desired chalcone was purified. Each of the 
compounds was identified by comparison to literature 1H and 13C NMR spectra in the 
case of previously synthesised compounds. Novel compounds were fully characterised 
by 1H NMR spectroscopy, including their hydroxyl peak at approximately δ 12.20-
12.90 ppm, as well as High Resolution Mass Spectrometry (HRMS) and 13C NMR 
spectroscopy. Note that the compounds underlined in the following tables were novel 
compounds. 
2.3.3.1 Reaction of 2ʹ-Hydroxyacetophenone with Substituted 
Benzaldehydes 
The first series of 2ʹ-hydroxychalcones were those synthesised using 2ʹ-
hydroxyacetophenone 72 and various substituted benzaldehydes. As the unsubstituted 
2ʹ-hydroxychalcone 66 had already been synthesised in the optimisation reactions 
(Table 2.1, entries 1 and 2), the next chalcone to be synthesised was the product of 2ʹ-
hydroxyacetophenone 66 and 4-bromobenzaldehyde 73 (chalcone 74, Table 2.5, entries 
3 and 4). The greatest conversion was achieved using KOH, and the product was 
isolated as a yellow solid in excellent yield (96%) with the characteristic chalcone 
hydroxyl peak appearing at δ 12.76 ppm.392 
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Table 2.5. Microwave-assisted synthesis of functionalised 2′-hydroxychalcones.a 
 
Entry Product R1 R2 Base 3:5b (yield)c 
1 
66 H H 
KOH 0:1 (100) 
2 Bu4NOH 0:1 (81) 
3 
74 4-Br H 
KOH 0:1 (96) 
4 Bu4NOH 1:2 
5 
76 3-Br 5-Br 
KOH 1:0 
6 Bu4NOH 1:5 (52) 
7 
78 3-OBn H 
KOH 1:10 (88) 
8 Bu4NOH 1:5 
9 
80 2,4-OMe 5-Br 
KOH 0:1 (90) 
10 Bu4NOH 1:2 
11 
82 4-F H 
KOH 1:17(58) 
12 Bu4NOH 3:1 
13 
85 4-NO2 H 
KOH 1:1 (16) 
14 Bu4NOH 1:0 
15 
87 2,4,5-MeO H 
KOH 1:0 
16 Bu4NOH 1:0 
17 
88 4-NHCOCH3 H 
KOH 1:0 
18 Bu4NOH 1:0 
19 
91 2-COOH H 
KOH 9:1d 
20 Bu4NOH 1:0e 
a underlined compounds are novel 
b Ratio determined by 1H NMR integration 
c Isolated yield (%) after column chromatography  
d The corresponding flavanone 92 was also identified, in a ratio of 9:1:9 for 3:5:92 respectively  
e The corresponding flavanone 92 was also identified, in a ratio of 1:0:2 for 3:5:92 respectively  
 
As the reaction to form the mono-halogenated benzaldehyde had been 
successful, 3,5-dibromobenzaldehyde 75 was also predicted to react well. Greater 
conversion was achieved with the use of Bu4NOH rather than KOH (Table 2.5, entries 6 
and 5 respectively), and column chromatography (1:1 CH2Cl2:Pet) isolated the novel 
chalcone 76 in a moderate 52% yield. The compound was fully characterised using 1H 
NMR (including its hydroxyl peak at δ 12.60 ppm) and 13C NMR, as well as HRMS. 
2ʹ-Hydroxyacetophenone 72 was next reacted with 3-benzyloxybenzaldehyde 77 
to produce chalcone 78 (Table 2.5, entries 7 and 8). This aldehyde was utilised as it 
provided a pathway to a hydroxylated chalcone, through benzyl deprotection under 
hydrogenation conditions.393 Conversion was better when KOH was used, and the 
desired compound 78 was afforded as a bright yellow solid in an isolated yield of 78% 
as confirmed by comparison with the literature.394 
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Another novel compound was synthesised from the reagents 2ʹ-
hydroxyacetophenone 72 and 5-bromo-2,4-dimethoxybenzaldehyde 79. Using KOH as 
the base gave complete conversion to the desired novel chalcone 80 (Table 2.5, entry 
9), which was isolated as a yellow solid in a yield of 90%. This compound was 
characterised by 1H and 13C NMR spectroscopy, as well as HRMS. 
The reaction of a more electron-withdrawn benzaldehyde was then attempted, in 
the form of 4-fluorobenzaldehyde 81. Its reaction with 2ʹ-hydroxyacetophenone 72 was 
attempted using both KOH and Bu4NOH (Table 2.5, entries 11 and 12 respectively), 
with the greater conversion (1:17 acetophenone 72 to chalcone 81) occurring with 
KOH. Column chromatography provided the desired chalcone 82 as a bright yellow 
solid, in a yield of 58%.  
 
Figure 2.6. 1H NMR spectrum of crude reaction material of 2ʹ-hydroxyacetophenone 72 and 4-fluorobenzaldehyde 81, 
showing the SNAr aldehyde product 83 and acetophenone starting material 72 (CDCl3). 
It was also interesting to note that the 1H NMR spectrum of the product from the 
Bu4NOH reaction indicated the presence of a methoxy group, with the appearance of a 
singlet peak with an integration of three at δ 3.85 ppm (Figure 2.6). Also present was an 
aldehyde peak at δ 9.84 ppm with an integration of one. These peaks suggested that the 
aldehyde starting material 81 had undergone an nucleophilic aryl substitution (SNAr) 
reaction, in which the methoxy anion (produced from the Bu4NOH and its methanol 
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solvent) attacks the para-fluoro position of the aldehyde to produce aldehyde 83 
(Scheme 2.5).395  
 
Scheme 2.5. Nucleophilic aryl substitution (SNAr) of p-fluorobenzaldehyde 81. 
Unfortunately, the SNAr product could not be isolated from the reaction mixture, 
and therefore its formation could not be confirmed. However, this ipso-substitution has 
been reported previously by Kumar et. al., who used benzyltrimethylammonium 
hydroxide (Triton B) in MeOH to effect the synthesis of aryl alkyl ethers from 
heteroaryl fluorides.396  
 Another highly electron-withdrawn reagent, 4-nitrobenzaldehyde 84, was then 
reacted with 2ʹ-hydroxyacetophenone 72 (Table 2.5, entries 13 and 14). The conversion 
ratios for the KOH and Bu4NOH reactions were much lower than all of the previously 
synthesised 2ʹ-hydroxychalcones, presumably due to the electron-withdrawing nature of 
the nitro group. Nevertheless, the desired chalcone 85 was isolated, albeit in a poor 
yield of 16%. As the nitro-substituted product was not a focus in this study, and other 
researchers had also experienced low yields with nitro-analogues, further optimisation 
was not attempted. 
 The reaction of 2,4,5-trimethoxybenzaldehyde 86 with 2ʹ-hydroxyacetophenone 
72 provided no conversion to the desired chalcone 87 with either base (Table 2.5, 
entries 15 and 16), and only starting materials were observed in the 1H NMR spectrum. 
For this reason, 2,4,5-trimethoxybenzaldehyde was not utilised in any further chalcone 
formation reactions.  
 Synthesis of chalcone 88 was then attempted using 4-acetamidobenzaldehyde 89 
and 2ʹ-hydroxyacetophenone 72 (Table 2.5, entries 17 and 18), however no conversion 
was effected with either base. This chalcone 88 has been synthesised previously by 
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Cabrera and co-workers using the traditional method (NaOH in EtOH, room 
temperature for 16 hours), however no yield was reported in that case.141 
 Finally, 2ʹ-hydroxyacetophenone 72 was reacted with 2-carboxybenzaldehyde 
90 (Table 2.5, entries 19 and 20). The results from these reactions were quite 
interesting, as it was noted that the 1H NMR spectrum showed a ratio of 9:1:9 
acetophenone 72 to chalcone 91 to flavanone 92 respectively. Purification provided the 
flavanone 92 in a yield of 46%, however the acetophenone and chalcone could not be 
separated. The reason for this increased formation of the cyclised product is unknown. 
As the aim of this section was the synthesis of a 2ʹ-hydroxychalcone library, and not the 
corresponding flavanones, 2-carboxybenzaldehyde 90 was not utilised in any more 
reactions. 
In total, seven 2′-hydroxychalcones were synthesised from 2′-
hydroxyacetophenone and substituted benzaldehydes, including two novel compounds 
(76 and 80). Generally, less substituted benzaldehydes provided 2′-hydroxychalcones in 
greater yields, and KOH effected greater conversions than Bu4NOH. It was also noted 
that benzaldehydes with electron-withdrawing substituents (including nitro, carboxylic 
acid, and acetamide groups) did not perform well, with little to none of the desired 
products isolated in these cases. 
As the entire series of chalcones synthesised to this point used 2′-
hydroxyacetophenone 72, attention turned to the synthesis of chalcones using multiply-
substituted acetophenone starting materials. Note that due to poor results in the 
synthesis of chalcones 87, 88, and 91, 2,4,5-trimethoxybenzaldehyde 86, 4-
acetamidobenzaldehyde 89 and 2-carboxybenzaldehyde 90 were not used. 
2.3.3.2 Reaction of 2ʹ,4ʹ-Dihydroxyacetophenone 93 and 2ʹ,4ʹ,6ʹ-
Trihydroxyacetophenone 94 with Substituted Benzaldehydes 
 The reactions of more hydroxylated acetophenones were examined next. This 
was of importance as natural flavonoids and chalcones are highly hydroxylated, and as 
established in Chapter One, it is these compounds (including quercetin 13 and 
kaempferol 18) that often produce the greatest therapeutic activity.139, 279, 397-400 
First, 2′,4′-dihydroxyacetophenone 93 was reacted with benzaldehyde 59, with 
KOH and then Bu4NOH (Table 2.6, entries 1 and 2 respectively). However, only the 
starting material 93 could be verified by 1H NMR spectroscopy in the case of the KOH-
catalysed reaction, and the Bu4NOH equivalent showed a mixture of products, 
 51 
 
including the acetophenone 93, chalcone 94, flavanone 95, Cannizzaro benzyl alcohol 
64 (in an approximate ratio of 1:10:10:6 respectively), and other unknown compounds. 
From this result, it appeared that the protection of hydroxyl groups was required. 
To ensure that these results were due to the substitution of the acetophenone, 
2′,4′-dihydroxyacetophenone 93 was also reacted with 4-bromobenzaldehyde 73, 3,5-
dibromobenzaldehyde 75 and 3-benzyloxybenzaldehyde 77. In all of these examples, 
and with both bases, analysis of the crude material revealed a mixture of products, with 
the desired chalcone in each case accounting for less than 50% of the total mass. For 
this reason, the similar 2′,6′-dihydroxyacetophenone 96 was not applied to the reaction. 
Table 2.6. Microwave-assisted synthesis of functionalised 2′,4ʹ-dihydroxychalcones. 
 
Entry Starting Material R1 Base 
Acetophenone: 
Chalcone a 
1 
93 H 
KOH 1:0 
2 Bu4NOH 1:10b 
3 
97 6′-OH 
KOH 1:0 
4 Bu4NOH 1:0 
a Ratio determined by 1H NMR integration 
b A relative ratio of 10 was found for the corresponding flavanone 95 and 6 for benzyl alcohol 64 
 
Reacting 2′,4′,6′-trihydroxyacetophenone 97 with benzaldehyde 59 and each of 
the bases also proved unsuccessful (Table 2.6, entries 3 and 4), and, as expected, only 
starting materials were seen in the 1H NMR spectrum.  
The obvious next step was the protection of the additional hydroxyl groups of 
2′,4′-dihydroxyacetophenone 93 and 2′,6′-dihydroxyacetophenone 96, and their 
subsequent reaction with various substituted benzaldehydes. 
2.3.3.3 Monoprotection of Dihydroxyacetophenones 93 and 96 
 Methyl protection was initially pursued, as the formation of methyl ethers is 
simple, and their small size would prevent any steric issues.401 A literature method for 
the methyl monoprotection of these dihydroxylated acetophenones was used, in which 
the acetophenone was reacted with one equivalent of potassium carbonate (K2CO3), 
followed by the slow addition of one equivalent of dimethyl sulfate (Me2SO4) with 
reflux in acetone for an hour.401-403 
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 This method was first applied to 2′,4′-dihydroxyacetophenone 93. After workup, 
a golden-orange oil was afforded, from which a crude NMR spectrum was obtained. An 
approximate 1:1 ratio of the 2ʹ-hydroxy-4ʹ-methoxychalcone 98 to the 4ʹ-hydroxy-2ʹ-
methoxychalcone 99 was noted (Scheme 2.6). As it was desired that only the 4ʹ-
hydroxyl group of the acetophenone would be protected (as the 2ʹ-hydroxyl group was 
required in future reactions for Ring C closure to other flavonoids), the protection of 
this compound for use in chalcone synthesis was abandoned.  
 
Scheme 2.6. The mixture of products obtained by mono-methyl protection of 2ʹ,4ʹ-dihydroxyacetophenone 93. 
 The reaction was then applied to 2′,6′-dihydroxyacetophenone 96. Following 
workup, the desired product 2ʹ-hydroxy-6ʹ-methoxyacetophenone 100 was isolated as 
yellow needle-like crystals in a yield of 97%, as confirmed by comparison to literature 
data, including a singlet with an integration of three at δ 3.88 ppm in the 1H NMR 
spectrum.402 As the product was mono-protected, and protection of either the 2′- or 6′-
hydroxyl still left a free hydroxyl group for Ring C closure to flavonoids (Figure 2.7), 
this protected acetophenone 100 was used in chalcone synthesis. 
 
Figure 2.7 Mono-methyl protection of 2ʹ,6ʹ-dihydroxyacetophenone 96 gives one product. 
2.3.3.4 Reaction of 2ʹ-Hydroxy-6ʹ-methoxyacetophenone 100 with 
Substituted Benzaldehydes 
With 2′-hydroxy-6′-methoxyacetophenone 100 in hand, attention turned to its 
use in microwave-assisted 2′-hydroxychalcone formation. The first reaction of this 
series was that of the mono-protected acetophenone 100 with benzaldehyde 59 
(Table 2.7, entries 1 and 2). While both KOH and Bu4NOH effected good conversion 
ratios, the product from the KOH reaction was purified by column chromatography to 
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afford chalcone 101 as a yellow oil in a yield of 67%. Comparison to literature data 
confirmed the desired product.404 
Table 2.7. Microwave-assisted synthesis of functionalised 2′-hydroxy-6ʹ-methoxychalcones.a 
 
Entry Product R1 R2 Base 
100:chalconeb 
(yield)c 
1 
101 H H 
KOH 0:1 (67) 
2 Bu4NOH 1:10 
3 
102 4-Br H 
KOH 0:1 (46) 
4 Bu4NOH 1:3 
5 
103 3-Br 5-Br 
KOH 1:0 
6 Bu4NOH 2:1(26) 
7 
104 3-OBn H 
KOH 0:1 (83) 
8 Bu4NOH 1:2 
9 
105 2,4-OMe 5-Br 
KOH 0:1 (52) 
10 Bu4NOH 2:1 
11 
106 4-F H 
KOH 1:0 
12 Bu4NOH 1:0 
13 
107 4-NO2 H 
KOH 1:0 
14 Bu4NOH 1:0 
a Underlined compounds are novel 
b Ratio determined by 1H NMR integration  
c Isolated yield (%) after column chromatography  
 
Next, the mono-protected acetophenone was reacted with 4-bromobenzaldehyde 
73 (Table 2.7, entries 3 and 4). Once again, KOH was more effective than Bu4NOH, 
and the desired chalcone 102 was isolated in a yield of 46%, and the structure 
confirmed by comparison to literature data.405  
The dihalogenated 3,5-dibromobenzaldehyde 75 was the next reactant with 2ʹ-
hydroxy-6ʹ-methoxyacetophenone 100 (Table 2.7, entries 5 and 6). Once again with this 
aldehyde, Bu4NOH provided the greater conversion to the chalcone 103 (see also 
Table 2.5, Entry 6). However, conversion using this base was only 2:1 for the starting 
acetophenone 100 to desired 2ʹ-hydroxychalcone 103. Due to such a poor conversion, 
and as a poor yield had already been experienced from this benzaldehyde (52%, Table 
2.5, Entry 6), the yield for chalcone 103 was understandably low (26%). This novel 
structure was fully characterised by 1H and 13C NMR Spectroscopy, as well as HRMS.  
The microwave reaction of 2ʹ-hydroxy-6ʹ-methoxyacetophenone 100 with 3-
benzyloxybenzaldehyde 77 was attempted next (Table 2.7, entries 7 and 8). Using KOH 
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as the base gave full conversion to the chalcone, with purification yielding chalcone 104 
in 83%. Once again, comparison to literature data confirmed the structure as that of the 
desired.406 
The next benzaldehyde to be trialled was 5-bromo-2,4-dimethoxybenzaldehyde 
79 (Table 2.7, entries 9 and 10). Complete conversion was achieved using KOH as the 
base, and the synthesis of the novel chalcone 105 (52%) was fully characterised by 1H 
and 13C NMR spectroscopy, as well as HRMS. 
The reaction of 2′-hydroxy-6′-methoxyacetophenone 100 with 4-
fluorobenzaldehyde 81 was the next microwave reaction to be attempted (Table 2.7, 
entries 11 and 12). Conversion to the desired chalcone 106 did not occur with either 
base. However, the presence of an aldehyde peak at δ 9.80 ppm and a methoxyl peak at 
δ 3.80 ppm in the spectrum from the Bu4NOH reaction suggested that once again an 
SNAr reaction (seen previously in Table 2.5, entry 12) had occurred to substitute the 
para-fluoro group for a methoxyl group on the benzaldehyde (see previous Scheme 
2.5).396 
Although the 4-nitrobenzaldehyde 84 had proven to be a poor reactant 
previously (see Table 2.5, entries 13 and 14), it was thought that reaction with a more 
electron-donating substituent on the acetophenone (2′-hydroxy-6′-
methoxyacetophenone) would be more successful. However, this was not the case, and 
no conversion to desired compound 107 could be seen when either base was used 
(Table 2.7, entries 13 and 14). 
In summary, it was found that chalcones synthesised with 2′-hydroxy-6′-
methoxyacetophenone 100 generally gave lower yields than those synthesised with 2′-
hydroxyacetophenone 72. This may have simply been because of the added 
functionality complicating the electronics of the reaction. A total of five compounds 
were synthesised in this series, with two of those (chalcones 103 and 105) being novel 
compounds. 
 As the series of 2′-hydroxy-6′-methoxychalcones had now been examined, the 
microwave reaction of the halogenated starting material 5ʹ-bromo-2ʹ-
hydroxyacetophenone 108 in the Claisen-Schmidt condensation was then investigated. 
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2.3.3.5 Reaction of 5′-Bromo-2′-hydroxyacetophenone 108 with 
Substituted Benzaldehydes 
 The next acetophenone to be investigated in the synthesis of the library of 2ʹ-
hydroxychalcones was 5ʹ-bromo-2ʹ-hydroxyacetophenone 108. As mentioned earlier, 
halogenated reagents were desired as they provided the benefit of halogen bonding in 
drug-target interactions,299 and also could allow the application of palladium-catalysed 
reactions (including the Heck reaction) to introduce various other functional groups to 
chalcone or flavonoid scaffolds by means of new carbon-carbon bond formation (see 
Chapter Four). 
 This halogenated acetophenone 108 was first reacted with benzaldehyde 59 
under microwave irradiation using the optimal conditions (KOH or Bu4NOH, THF, 
MW, 50 °C, 15 minutes). Both bases gave full conversion to the desired chalcone 109 
(Table 2.8, entries 1 and 2), which was isolated in a yield of 86%, as confirmed by 
comparison to literature data.394 
Table 2.8. Microwave-assisted synthesis of functionalised 5ʹ-bromo-2′-hydroxychalcones.a 
 
Entry Product R1 R2 Base 
108:chalconeb 
(yield)c 
1 
109 H H 
KOH 0:1(86) 
2 Bu4NOH 0:1 
3 
110 4-Br H 
KOH 0:1(64) 
4 Bu4NOH 1:5 
5 
111 3-OBn H 
KOH 1:10(80) 
6 Bu4NOH 3:10 
7 
112 2,4-OMe 5-Br 
KOH 4:1 
8 Bu4NOH 1:8(66) 
9 113 
4-F H 
KOH 0:1(87) 
10 114 Bu4NOH 0:1(88)d 
11 
115 4-NO2 H 
KOH 1:0 
12 Bu4NOH 1:0 
a Underlined compounds are novel 
b Ratio determined by 1H NMR integration 
c Isolated yield (%) after column chromatography  
d Isolated product had 4-MeO as R1 in place of 4-F 
 
 The next benzaldehyde trialled was 4-bromobenzaldehyde 73 (Table 2.8, entries 
3 and 4). Greater conversion was accomplished using KOH, and purification gave the 
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desired product 110 as a bright yellow solid in a yield of 64%, as confirmed by 
comparison to literature data.407 
Following this, 3-benzyloxybenzaldehyde 77 was reacted with the 5ʹ-bromo-2ʹ-
hydroxyacetophenone 108. Once again, KOH provided the greatest conversion (Table 
2.8, entry 5), and the novel chalcone 111 was isolated as a bright yellow solid (80%), 
and fully characterised.  
Another novel compound was then synthesised, by reacting 5ʹ-bromo-2ʹ-
hydroxyacetophenone 108 with 5-bromo-2,4-dimethoxybenzaldehyde 79. Notably, the 
reaction using Bu4NOH proved to be better than that of KOH (Table 2.8, entries 8 and 7 
respectively), and purification by column chromatography isolated chalcone 112 as a 
bright orange solid in a yield of 66%. This structure was characterised by HRMS, and 
1H and 13C NMR spectroscopy. 
Next, the polar 4-fluorobenzaldehyde 81 was reacted with 5ʹ-bromo-2ʹ-
hydroxyacetophenone 108 to synthesise chalcone 113. When the reaction was 
conducted using KOH (Table 2.8, entry 9), complete conversion to chalcone 113 was 
noted, and purification gave the desired compound as a bright yellow solid in a yield of 
87%.407  
 
Scheme 2.7. SNAr chalcone 114 is formed from chalcone 113 in the presence of Bu4NOH and MeOH. 
However, when the 1.0 M Bu4NOH in MeOH was used as a base (Table 2.8, 
Entry 10), evidence of an SNAr reaction was once again present in the 1H NMR 
spectrum, with peaks representing a chalcone hydroxyl group (singlet at δ 12.87 ppm) 
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and a methoxyl group (at δ 3.84 ppm with an integration of three), and was predicted to 
occur as shown in Scheme 2.7. As with all SNAr reactions, a resonance-stabilised 
intermediate is formed.395 Purification provided the di-substituted 2ʹ-hydroxychalcone 
114 in an excellent yield of 88%, as a bright yellow solid. 
Finally, 4-nitrobenzaldehyde 84 was reacted with 5ʹ-bromo-2ʹ-
hydroxyacetophenone 108 (Table 2.8, Entries 11 and 12). Previous experience with this 
aldehyde gave little hope for success, and this proved true as neither base provided the 
desired chalcone 115. 
 In conclusion, six chalcones were synthesised using 5ʹ-bromo-2ʹ-
hydroxyacetophenone 108 as the starting material. Of these, two were novel (chalcones 
111 and 112), and full characterisation for these compounds was completed. 
Interestingly, using Bu4NOH as a base produced greater conversion ratios than KOH in 
more instances with this acetophenone than any other. 
 As the use of an acetophenone with a single halogen substitution had been 
successfully employed in this microwave-assisted chalcone synthesis, attention turned 
to the use of the dihalogenated 3ʹ-bromo-5ʹ-chloro-2ʹ-hydroxyacetophenone 116. 
2.3.3.6 Reaction of 3ʹ-Bromo-5ʹ-chloro-2ʹ-hydroxyacetophenone 116 
with Substituted Benzaldehydes 
Introducing another halogen into the chalcone scaffold was achieved through the 
reaction of 3ʹ-bromo-5ʹ-chloro-2ʹ-hydroxyacetophenone 116 with various 
benzaldehydes under the microwave-assisted conditions. Once again, all known 
compounds were compared to literature data, and novel compounds were characterised 
by 1H and 13C NMR spectroscopy, as well as HRMS. 
The first of this series of 2ʹ-hydroxychalcones was synthesised though the 
reaction of acetophenone 116 with 59 and KOH or BU4NOH under microwave 
irradiation. Greater conversion was achieved with KOH (Table 2.9, entry 1), and 
chalcone 117 was isolated as an orange-yellow solid in excellent yield (86%), as 
confirmed by comparison to the literature data.408  
In the reaction of 3ʹ-bromo-5ʹ-chloro-2ʹ-hydroxyacetophenone 116 with 4-
bromobenzaldehyde 73, yet another halogen could be introduced onto the scaffold 
(Table 2.9, entries 3 and 4). Once again, KOH provided the best conversion, and 
purification isolated the novel chalcone 118 as a yellow solid in a yield of 80%. 
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Synthesising a tetrahalogenated 2ʹ-hydroxychalcone proved difficult. After 
reacting 3ʹ-bromo-5ʹ-chloro-2ʹ-hydroxyacetophenone 116 and 3,5-
dibromobenzaldehyde 75 under the optimised conditions (KOH or Bu4NOH, THF, 
MW, 50 °C, 15 minutes), none of the desired chalcone 119 was observed by 1H NMR 
Spectroscopy (Table 2.9, entries 5 and 6); only starting materials were identified. This 
result was anticipated, as the 3,5-dibromobenzaldehyde had proven to be a poor reagent 
in previous experiments (see also Table 2.5, entry 6 and Table 2.7, entry 6). 
Table 2.9. Microwave-assisted synthesis of functionalized 3ʹ-bromo-5ʹ-chloro-2′-hydroxychalcones.a 
 
Entry Product R1 R2 Base 
116:chalconeb 
(yield)c 
1 
117 H H 
KOH 0:1 (86) 
2 Bu4NOH 1:6 
3 
118 4-Br H 
KOH 0:1 (80) 
4 Bu4NOH 2:3 
5 
119 3-Br 5-Br 
KOH 1:0 
6 Bu4NOH 1:0 
7 
120 3-OBn H 
KOH 1:10 (78) 
8 Bu4NOH 1:3 
9 
121 2,4-OMe 5-Br 
KOH 1:4 (71) 
10 Bu4NOH 4:5 
11 
122 4-F H 
KOH 
Bu4NOH 
0:1(93) 
1:0 12 
13 
123 4-NO2 H 
KOH 1:0 
14 Bu4NOH 1:0 
a Underlined compounds are novel 
b Ratio determined by 1H NMR integration 
c Isolated yield (%) after column chromatography  
 
 After this, 3ʹ-bromo-5ʹ-chloro-2ʹ-hydroxyacetophenone 116 and 3-
benzyloxybenzaldehyde 77 were reacted (Table 2.9, entries 7 and 8). The best 
conversion was achieved with KOH, and chalcone 120 was isolated in a yield of 78%. 
This novel 2ʹ-hydroxychalcone was fully characterised. 
 The next chalcone 121 was the product of 3ʹ-bromo-5ʹ-chloro-2ʹ-
hydroxyacetophenone 116 and 5-bromo-2,4-dimethoxybenzaldehyde 79 (Table 2.9, 
entries 9 and 10). A greater conversion ratio was achieved with KOH (1:4 acetophenone 
116 to chalcone 121), and purification isolated the novel chalcone 121 as a bright 
yellow solid in a yield of 71%, which was fully characterised. 
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 Following this, 4-fluorobenzaldehyde 81 was reacted with 3ʹ-bromo-5ʹ-chloro-
2ʹ-hydroxyacetophenone 116. Complete conversion to the desired 2ʹ-hydroxychalcone 
122 was seen in the KOH reaction (Table 2.9, entry 11), and purification isolated a 
yellow solid in a yield of 93%. No conversion to a chalcone product was noted in the 
Bu4NOH reaction (Table 2.9, entry 12), although the singlet benzaldehyde peak (δ 9.80 
ppm) and singlet methoxy peak (δ 3.81 ppm) in the 1H NMR spectrum indicated that 
nucleophilic aryl substitution (SNAr) had occurred (Scheme 2.5). 
 4-Nitrobenzaldehyde 84 was also utilised as the benzaldehyde in this series 
(Table 2.9, Entries 13 and 14), however none of the desired chalcone 123 could be 
identified in the 1H NMR spectrum, and as this aldehyde has been proven to be 
unsuccessful in other cases, the synthesis of chalcone 123 was abandoned. 
 In conclusion for this series of compounds, five compounds were synthesised 
using 3ʹ-bromo-5ʹ-chloro-2ʹ-hydroxyacetophenone 116 and various substituted 
benzaldehydes, including three novel compounds (Table 2.9, chalcones 118, 120 and 
121). Most of the compounds were achieved in greater conversions with the base KOH, 
and all were characterised by 1H and 13C NMR spectroscopy, as well as HRMS. 
2.3.3.7 Conclusion for 2ʹ-Hydroxychalcones 
 A total of 23 chalcones were synthesised using the optimised methodology, with 
the majority of these provided through the KOH-mediated reaction. Of these, nine 
chalcones were novel compounds, and have been fully characterised. With this library 
of chalcones in hand, a significant attempt towards the synthesis of a flavonoid library 
had been completed, in accordance with the first aim of this research. As the synthesis 
was progressing, thirteen of these 2ʹ-hydroxychalcones were evaluated for cytotoxicity 
using a colourimetric MTT Assay, as carried out by Doctor Sunil Ratnayake. These 
studies were completed in order to select ideal candidates to be submitted for further 
evaluation of possible therapeutic effects, yet another aim of this research.  
2.4 Cytotoxicity Evaluation 
The colourimetric MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide) assay can be used to examine the proliferation or cell toxicity of a number of 
different cell lines. This assay relies on the reduction of MTT 124, a yellow tetrazole 
(Figure 2.8), to its corresponding purple formazan, by mitochondrial succinate 
dehydrogenase. As the optical density of the dye at a particular wavelength is directly 
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correlated to the number of metabolically active cells, measurement of the absorption of 
the dye using an ELISA reader (spectrophotometer) at a particular wavelength allows 
for the determination of live cell numbers.409 Through the addition and incubation of 
healthy cells with test compounds, the concentration of the compound at which 50% of 
the cells are killed (LC50) can be determined, giving an indication of the compound’s 
cell toxicity. 
 
Figure 2.8. Colorimetric MTT assays rely on the reduction of the yellow tetrazole MTT 124. 
In more recent times, water-soluble tetrazoles (WSTs) have been applied to the 
MTT assay.410 These dyes make the assay much quicker and easier, as they remove the 
need for any solubilisation steps of the dyes, give a more effective signal than MTT, 
and are less toxic to the cells. The dye used for the cytotoxicity testing in this research 
was the pale yellow 2-(4-iodophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-
tetrazolium, which is also known as WST-1 125.411 When reduced by the mitochondrial 
succinate dehydrogenase of healthy cells, the corresponding formazan 126 is produced 
(Scheme 2.8), which is dark yellow in colour and its relative concentration can be 
determined from its absorbance at 438 nm. 
 
Scheme 2.8. The reduction of WST-1 125 to its corresponding dark yellow formazan 126. 
Thirteen 2ʹ-hydroxychalcones were chosen for cytotoxic evaluation, against 
both human embryonic kidney (HEK) and hepatocellular carcinoma (HepG2) cell lines. 
The general method used is described in the Experimental Chapter (See Chapter Eight), 
and involved the incubation of the 2ʹ-hydroxychalcones with the cells for a period of 
24 hours, at concentrations of 1, 2, 4, 10, 20, 40, and 80 μg/mL. Positive (Triton (10% 
v/v)) and negative controls (no compound added) were also analysed. Following this, 
WST-1 was added, and after a further incubation period of 20 minutes, the cells were 
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viewed under the spectrophotometer at 440 nm. From these results, the LC50 values 
were determined for each compound (Table 2.10) for both the HEK and HepG2 cell 
lines (See Appendix B for the cytotoxicity results in graph form). 
In the results from the HEK cell line, it was found that most of the tested 2ʹ-
hydroxychalcones LC50 values were at concentrations less than 20μg/mL (Table 2.10, 
entries 1-3, 6-9, 10 and 12). Interestingly, 2ʹ-hydroxy-3-benzyloxychalcone 78 had an 
extremely low LC50 value of 1.5 μg/mL. However the remaining three compounds 80, 
118 and 121, two of which contained the 5-bromo-2,4-dimethoxy substitutions at R3 
and R4, were not toxic at the highest concentration tested (80 μg/mL). 
Table 2.10. Cytotoxicity LC50 values of 2ʹ-hydroxychalcones for HEK and HepG2 cells. 
 
Entry Chalcone R1, R2 R3, R4 
HEK LC50 
values 
(μg/ml) 
HepG2 LC50 
values 
(μg/ml) 
1 66 H H 18 19 
2 74 H Br (4) 12 20 
3 76 H Br (3,5) 14 35 
4 78 H OBn(3) 1.5 14 
5 80 H Br (5) MeO (2,4) >80 >80 
6 101 MeO (6ʹ) H 12 14 
7 102 MeO (6ʹ) Br (4) 11 19 
8 104 MeO (6ʹ) OBn(3) 13 17 
9 105 MeO (6ʹ) Br (5) MeO (2,4) 15 18 
10 117 Br (3ʹ) Cl (5ʹ) H 17 28 
11 118 Br (3ʹ) Cl (5ʹ) Br (4) >80 >80 
12 120 Br (3ʹ) Cl (5ʹ) OBn (3) 20 70 
13 121 Br (3ʹ) Cl (5ʹ) Br (5) MeO (2,4) >80 >80 
  
The HepG2 cell line showed comparable results, in that once again chalcones 
80, 118 and 121 (as shown in Table 2.10, entries 5, 11, and 13, Figure 2.9) were not 
toxic to cells at the maximum concentration tested (80 μg/mL). Chalcone 120 (Table 
2.10, entry 12) also gave a relatively high LC50 value of 70 μg/mL. The remainder of 
the chalcones showed LC50 values of between 14 and 35 μg/mL. 
 
Figure 2.9. Three 2ʹ-hydroxychalcones, 80, 118 and 121, were not toxic at the highest concentration tested (80 μg/mL), in 
both liver and kidney cell lines. 
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From this information, it could be concluded that chalcones 80, 120, and 121 
could serve as potential therapeutic agents due to their low cytotoxicity for both liver 
and kidney cell lines. For this reason, these three chalcones were sent for biochemical 
evaluation in terms of their antibacterial, anticancer (breast and prostate), and 
antidiabetic activity, and results are expected in the near future. Also, chalcone 78 could 
be ideal as an anticancer agent due to its high cytotoxicity for the kidney cell line, but 
not the liver cell line. 
2.5 Conclusion 
In conclusion, an optimised method for the microwave-assisted synthesis of 2ʹ-
hydroxychalcones from functionalised 2ʹ-hydroxyacetophenones and benzaldehydes 
using the Claisen-Schmidt condensation was developed. This method took advantage of 
microwave irradiation, with an optimised reaction time of 15 minutes and a temperature 
of 50 °C, and used THF as a solvent (Scheme 2.9).  
 
Scheme 2.9. An optimised, microwave-assisted methodology for the synthesis of 2ʹ-hydroxychalcones by the Claisen-Schmidt 
condensation was developed. 
Two bases, KOH and NaOH, were found to produce the highest yields, in 
accordance with the traditional method, and the base Bu4NOH, as a 1.0 M solution in 
MeOH, was also found for the first time to give good conversion ratios to the 2ʹ-
hydroxychalcones. These conditions avoided the side reactions of flavanone formation 
and Cannizzaro reaction, a quality not seen when the traditional method was trialled. 
While KOH generally gave the higher conversion ratios in the synthesis of 2ʹ-
hydroxychalcones, there were a few exceptions. It was observed that these exceptions 
shared the fact that the starting materials and products contained multiple bromine 
substituents (see those reactions with 3,5-dibromobenzaldehyde 75, and also the 
reaction of 5ʹ-bromo-2ʹ-hydroxyacetophenone 108 with 5-bromo-2,4-
dimethoxybenzaldehyde 79). However, this phenomenon could not be explained. 
 The application of the optimised methodology to numerous substituted 2ʹ-
hydroxyacetophenones and benzaldehydes produced 23 2ʹ-hydroxychalcones (Table 
2.11). These included nine novel compounds, which are underlined in the table. 
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As mentioned earlier, this methodology, along with characterisation details for a 
number of the synthesised chalcones, was published in Current Organic Chemistry 
(2012, 16(1), 121-126) (see Appendix A). 
Table 2.11. The microwave-assisted Claisen-Schmidt condensation produced 23 functionalised 2′-hydroxychalcones.a 
 
Entry Product R1 R2 R3 R4 Base Yield (%)b  
1 66 H H H H KOH >99 
2 74 H H 4-Br H KOH 96 
3 76 H H 3-Br 5-Br Bu4NOH 52 
4 78 H H 3-OBn H KOH 88 
5 80 H H 2,4-OMe 5-Br KOH 90 
6 82 H H 4-F H KOH 58 
7 85 H H 4-NO2 H KOH 16 
8 101 6ʹ-OMe H H H KOH 67 
9 102 6ʹ-OMe H 4-Br H KOH 46 
10 103 6ʹ-OMe H 3-Br 5-Br Bu4NOH 26 
11 104 6ʹ-OMe H 3-OBn H KOH 83 
12 105 6ʹ-OMe H 2,4-OMe 5-Br KOH 52 
13 109 5ʹ-Br H H H KOH 86 
14 110 5ʹ-Br H 4-Br H KOH 64 
15 111 5ʹ-Br H 3-OBn H KOH 80 
16 112 5ʹ-Br H 2,4-OMe 5-Br Bu4NOH 66 
17 113 5ʹ-Br H 
4-F H 
KOH 87 
18 114 5ʹ-Br H Bu4NOH 88c 
19 117 3ʹ-Br 5ʹ-Cl H H KOH 86 
20 118 3ʹ-Br 5ʹ-Cl 4-Br H KOH 80 
21 120 3ʹ-Br 5ʹ-Cl 3-OBn H KOH 78 
22 121 3ʹ-Br 5ʹ-Cl 2,4-OMe 5-Br KOH 71 
23 122 3ʹ-Br 5ʹ-Cl 4-F H KOH 93 
a Underlined compounds are novel 
b Isolated yield (%) after column chromatography  
c Isolated product had 4-MeO as R3 in place of 4-F 
 
Thirteen substituted 2ʹ-hydroxychalcones were tested for their cytotoxicity, and 
three of these were not toxic at the highest concentration tested (80 μg/mL, Figure 2.9), 
in both liver and kidney cell lines (see Appendix B).  
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Of these three nontoxic compounds, it is also noted that two of these (118 and 
121) were novel compounds. This work provides a starting point for the development of 
new, nontoxic chalcone and flavonoid-based therapeutic agents. 
 
Figure 2.9. Three 2ʹ-hydroxychalcones, 80, 118 and 121, were not toxic at the highest concentration tested (80 μg/mL), in 
both liver and kidney cell lines. 
In conclusion, a simple and rapid microwave-assisted methodology for the 
synthesis of 2ʹ-hydroxychalcones has been developed. 
 
 
 
 65 
 
Chapter Three: 
Synthesis of a Flavonoid Library 
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3.1 Chapter Overview 
In accordance with the aim of synthesising a library of flavonoid compounds, 
attention turned to the synthesis of other members of the flavonoid family, utilising the 
previously synthesised 2ʹ-hydroxychalcones as starting materials. These flavonoids 
were to be synthesised by existing or newly developed methods, so as to provide a 
library of novel, highly halogenated compounds for biochemical evaluations. The 
flavonoids synthesised and discussed in this chapter include flavanones (via an acid or 
base-catalysed cyclisation) and flavones (via an I2-mediated cyclisation). 
3.2 Flavanones 
3.2.1 The Synthesis of Flavanones 
The flavanone structure 6 is the ring-closed equivalent of 2ʹ-hydroxychalcone 
66, and is defined by the presence of a single bond between positions 2 and 3 
(corresponding to –an– in flavanone), and a ketone at position 4 (corresponding to –one 
in flavanone).1 As already explained in Chapter 1.2.1, the three rings of flavonoids are 
labelled A, C and B from left to right, and the flavanones are numbered as shown in 
Figure 3.1. 
 
Figure 3.1. The simplest flavanone 6 is also known as 2,3-dihydroflavone or 2-phenyl-2,3-dihydro-4H-chromen-4-one. 
As mentioned in Chapter One, flavanones are commonly found in plants and 
fruits as their glycosylated products; examples include naringin 127 found in grapefruit, 
and hesperidin 16 found in citrus fruits (Figure 3.2).13 In plants, flavanones are 
synthesised asymmetrically by chalcone isomerase (CHI) from 2ʹ-hydroxychalcones.329 
 
Figure 3.2. Naringin 127 and hesperidin 16 are two natural glycosylated flavanones. 
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There are a number of methods available for the laboratory synthesis of the 
flavanones. The first of these is the acid- or base-catalysed cyclisation of 2ʹ-
hydroxychalcones. These pathways have been discussed previously in Chapter 2.2, and 
occur via the mechanisms shown in Schemes 2.3 and 2.4. It is important to 
acknowledge once again that this isomerisation is reversible, and that 100% conversion 
to flavanones from chalcones is a significant challenge. 
 In 1904, Kostanecki was the first to accomplish the acid-catalysed cyclisation, 
using hydrochloric acid, although no yield was published (Scheme 3.1).412 Since then, 
many acids have been applied to the cyclisation, including H2SO4 and CF3COOH.413, 414 
Base-catalysed cyclisations have utilised pyridine,415 Co(salpr) (a cobalt Schiff base 
complex) under O2,416 KOH in MeOH (pH 10),383 and NaOAc heated in refluxing 
EtOH.417 However, as noted by Sagrera, basic conditions are less commonly used as 
they can lead to a retro-aldol reaction, in which the acetophenone and benzaldehyde 
starting materials are re-formed.343 
 
Scheme 3.1. Kostanecki published the first acid-mediated cyclisation of 2ʹ-hydroxychalcone 66. 
The recent focus on ‘green chemistry’ has ensured the investigation of 
microwave-assisted methods for the cyclisation, with Patonay using a microwave-
assisted, solvent free methodology with DBU as a base,418 and Nie synthesising 
flavanone hydrazones from chalcones and hydrazides using 2-propanol as a solvent.419 
Other methods for the isomerisation of chalcones to flavanones include the use 
of chiral Brønsted acids and bases to form asymmetric flavanones,329 MgO powder in 
place of a base,420, 421 and even a chiral thiourea catalyst,422 amongst others.338, 343, 423  
Flavanones have also been synthesised directly from acetophenones and 
benzaldehydes. In such cases, the 2ʹ-hydroxychalcone intermediate is formed in 
solution, and reacts further to form the corresponding flavanone compound. Conditions 
reported to effect this two-step conversion include solvent-free synthesis over 
aminopropyl-functionalized SBA-15 (Scheme 3.2),424 L-Proline,425 and Li-Al layered 
double hydroxides,426 amongst others.427-431  
 68 
 
 
Scheme 3.2. Aminopropyl-functionalised SBA-15(SBA-NH2-10-P) has been used to synthesise flavanones.424 
3.2.1.1 Ionic Liquids 
One approach that has not been thoroughly investigated for flavanone formation 
is the use of ionic liquids. Ionic liquids are simply salts that have melting points below 
100 °C, making most of them liquids at room temperature.432 They are valued for their 
high thermal and chemical stability, low vapour pressure, and non-flammability.433 Due 
to these properties, they have emerged over the last 20 years as both catalysts and ideal 
solvents in chemical reactions.324, 431, 432, 434-445 There two main types of ionic liquids, 
based on the ionic species present; aprotic and protic ionic liquids. The protic variety 
has an acidic proton on the cationic species, the aprotic does not.446  
Ionic liquids have also commonly been coupled with microwave reactors in 
synthetic methodologies. This provides a number of benefits, as the combination results 
in the need for little to no solvent, decreases reaction times, increases reaction 
efficiency, provides simple work-up procedures, allows for greater catalyst recovery, 
and has also been shown to increase yields.433, 447-452 
Protic Ionic Liquids (pILs) have emerged as an ideal means of carrying out acid-
promoted reactions and rearrangements cleanly and rapidly.438, 439 pILs are made by 
mixing strictly equimolar amounts of Brønsted acids and bases, and are neutral as there 
is no free H+ in the reaction media.453 However, it is possible to ‘tune’ the acidity of the 
pIL, through the careful selection of the acid and base counter-ions.454 This selection 
gives rise to pILs with different proton activity values, as measured by pKa: pILs 
containing cations of low pKa values have higher proton activity.455, 456 
While different types of ionic liquids have been utilised in the formation of 
chalcones from acetophenones and benzaldehydes,325, 441, 442, 457 there are only two 
reports of ionic liquids in flavanone synthesis. The first describes the use of a Zn-Al 
hydrotalcite adhered with ionic liquid 1-(triethoxysilylpropyl)-3-methylimidazolium 
chloride (TESP-MImCl), to form flavanones directly from the corresponding 2ʹ-
hydroxyacetophenones and benzaldehydes (Scheme 3.3).431  
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Scheme 3.3. The ionic liquid TESP-MImCl, adhered to a Zn-Al hydrotalcite-like clay (CHTlc), has been used for the 
synthesis of flavanones and chalcones from acetophenones and benzaldehydes.431 
The second reports the use of the ionic liquid 1-butyl-3-methylimidazolium 
tetrafluoroborate ([bmim][BF4]) as a solvent, with ytterbium triflate (Yb(OTf)3) as the 
catalyst to isomerise chalcones (Scheme 3.4).458 In both cases, few flavanones were 
produced (five and seven respectively), and products in which Ring A was substituted 
were not examined.  
 
Scheme 3.4. The ionic liquid [bmim][BF4] has been used as a solvent with Yb(OTf)3 to synthesise flavanones. 
The use of ionic liquids, in particular pILs, as dual reagent/solvent for 2ʹ-
hydroxychalcone isomerisation to the flavanone had not been investigated. Given their 
pseudo-acidic nature, and the fact that most flavanone syntheses occur under acidic 
conditions, an investigation into the pIL-mediated, microwave-assisted cyclisation of 
2ʹ-hydroxychalcones to flavanones was pursued. 
3.2.2 Flavanones: Results and Discussion 
3.2.2.1 Base-Mediated Flavanone Synthesis 
As the aim of this synthesis was the development of a pIL-mediated 
methodology, it was first pertinent to examine a base-mediated method for comparison. 
This base-mediated method for flavanone synthesis took advantage of results from the 
optimisation of chalcone formation. Following the DBU-mediated, microwave-assisted 
reaction of 2ʹ-hydroxyacetophenone 72 and benzaldehyde 59 (See Chapter Two, Table 
2.1, entry 9), it was noted that the 1H NMR spectrum of the crude material showed not 
only the desired chalcone 66, but also the corresponding flavanone 6 (Figure 3.3), in a 
ratio of 1:2:2 for the acetophenone to chalcone to flavanone respectively. This 
integration ratio was determined in accordance with those of Chapter Two; the 
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integrations of the chalcone hydroxyl (0.85 at δ 12.84 ppm), flavanone (1.0 at δ 5.33 
ppm) and acetophenone (3.0 at δ 2.57 ppm) peaks were used. 
 
Figure 3.3. 1H NMR spectrum of the DBU-mediated, microwave-assisted synthesis of flavanone 6 and chalcone 66 (CDCl3). 
This result was reasonable, however the appearance of unknown peaks at 
approximately δ 2.90 ppm, δ 3.90 ppm and δ 11.92 ppm warranted further investigation 
(as outlined in blue in Figure 3.3). It was found that Patonay et. al. had established that 
a microwave-assisted, DBU-mediated flavanone synthesis from 2ʹ-hydroxychalcones 
produced not only the analogous flavanone, but also dimers incorporating the chalcone 
and flavanone compounds.418 These dimers corresponded to those unknown peaks in 
the 1H NMR spectrum. This addition of complexity to the reaction mixture would 
complicate purification and reduce yields. 
Whilst this conversion was not great, the purpose of this reaction was to identify 
any complications that may be experienced, and provide a point of reference between 
the base- and pIL-mediated reactions. 
3.2.2.2 Optimisation of pIL-Mediated Microwave-Assisted Flavanone 
Synthesis 
Attention turned to the use of the slightly acidic pILs in combination with 
microwave irradiation to synthesise flavanones from acetophenone and benzaldehyde 
starting materials. As explained previously, in such methods the 2ʹ-hydroxychalcone is 
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formed in situ, and then cyclises to the flavanone. In an attempt to achieve this two-step 
method, 2ʹ-hydroxyacetophenone 72 (0.5 mmol) and benzaldehyde 59 (1.0 mmol) were 
reacted according to the microwave method optimised for chalcone synthesis in the 
previous chapter (MW, 50 °C, 15 minutes). However, in place of a base and solvent, the 
readily available pIL, TeaHSO4 (triethylamine: sulphuric acid), was used (Scheme 3.5).  
 
Scheme 3.5. pIL-mediated flavanone synthesis from 2ʹ-hydroxyacetophenone 72 and benzaldehyde 59 gave a 19:1:9 ratio of 
72:66:6. 
Analysis of the crude product by 1H NMR spectroscopy revealed a mixture of 
acetophenone 72, chalcone 66 and flavanone 6 in a ratio of 19:1:9 respectively. While 
full conversion from the acetophenone was not achieved, the 1:9 ratio of chalcone to 
flavanone was encouraging, as it suggested that this combination of pIL and microwave 
irradiation may be promoting cyclisation. Therefore, the conversion of chalcones 
synthesised in Chapter Two to flavanones via a pIL-mediated reaction was investigated. 
For the optimisation of the pIL-mediated, microwave-assisted formation of 
flavanones from 2ʹ-hydroxychalcones, 4-bromochalcone 74 was chosen as model 
substrate (Scheme 3.6). It was easily accessible (a yield of 96% was achieved using the 
microwave-assisted methodology from Chapter Two), and the resulting flavanone 130 
is a well-documented compound.141 Also, literature examples suggest that para-
substituted chalcones and acetophenones are typically easier to convert to their 
corresponding flavanones than those with substitutions at other positions.420, 424 
Conversion ratios were once again measured by comparison of the bromochalcone 74 
2ʹ-hydroxyl peak (a singlet peak at δ 12.74 ppm, with an integration of 0.85) and the 
CH peak of the corresponding 4ʹ-bromoflavanone 130 (a doublet of doublets at 
δ 5.44 ppm, with an integration of 1). 
 
Scheme 3.6. 4-Bromochalcone 74 was the substrate chosen for the optimisation of pIL-mediated, microwave-assisted 
flavanone synthesis. 
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Using four available pILs of varying proton activity (note once again that pILs 
containing cations of low pKa values have higher proton activity),455, 456 each were 
trialled using different microwave reaction times and temperatures, so as to determine 
an ideal set of conditions for each pIL. In all reactions, the microwave power was set to 
an upper limit of 50 W, as the degradation of both reagents and ionic liquids had been 
noted in previous explorations when excess power was employed.438, 439  
The first pIL examined was TeaFA (triethylamine: formic acid), which was 
reacted under microwave irradiation with bromochalcone 74 at 100 °C for 20 minutes. 
Analysis of the crude product by 1H NMR spectroscopy showed 42% conversion to 
flavanone 130 (Table 3.1, entry 1). This was an encouraging result, and further 
optimisation commenced.  
Table 3.1. Optimisation of pIL-mediated, microwave-assisted flavanone synthesis. 
 
Entry pIL pKa of acid456 Temp (°C) Time (min) 74:130
a 
1 TeaFA 3.75 100 20 58:42 
2 TeaFA  130 20 26:65b 
3 TeaFA  100 40 29:69b 
4 TeaFA  100 60 29:68b 
5 EAN -1.3 100 20 100:0 
6 TeaMs -1.9 100 20 62:38 
7 TeaHSO4 -9 100 20 46:54 
8 TeaHSO4  130 20 34:66c 
9 TeaHSO4  100 40 48:52 
10 TeaHSO4  100 10 59:41 
a Ratio determined by 1H NMR spectroscopy 
b A trace amount (< 10%) of 2ʹ-hydroxyacetophenone 74 was observed in the crude 1H NMR spectrum 
c An isolated yield of 60% was obtained in this instance 
Increasing the reaction temperature to 130 °C (Table 3.1, entry 2), increased 
conversion to flavanone 130 (65%), however trace amounts of 2ʹ-hydroxyacetophenone 
72 and 4-bromobenzaldehyde 73 was observed in the 1H NMR spectrum of the crude 
material (as indicated by singlet peaks at δ 2.61 ppm and δ 9.95 ppm respectively). 
These presumably formed from a retro-aldol reaction facilitated by adventitious 
moisture (Scheme 3.7). As the presence of acetophenone and benzaldehyde complicate 
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purification, the optimal temperature for this conversion was established as 100 °C, and 
optimisation of reaction time was pursued. 
 
Scheme 3.7. Adventitious moisture may have cause the undesired retro-aldol reaction, as shown in this mechanism. 
Using TeaFA and a reaction temperature of 100 °C, extended reaction times of 
40 and 60 minutes were trialled (Table 3.1, entries 3 and 4). These reactions gave 
similar conversion to entry 2, however trace amounts of 2′-hydroxyacetophenone 72 
were again observed in the 1H NMR spectrum. Therefore, while good conversion was 
achieved using TeaFA, the formation of side products was undesirable and so other pIL 
alternatives were investigated. 
When EAN (ethylamine: nitric acid, Table 3.1, entry 5) was trialled, no 
conversion to the desired flavanone 130 was observed with the microwave conditions of 
100 °C and 15 minutes. Similarly, when another common pIL, TeaMs (triethylamine: 
methanesulfonic acid) was tested (Table 3.1, entry 6), poor conversion to flavanone 130 
was noted (36%), and so no further optimisation was carried out with this pIL.  
Finally, TeaHSO4 (triethylamine:sulfuric acid), a pIL with high ‘proton activity’ 
and a low cationic pKa value, was employed, and using the microwave conditions of 
100 °C for 20 minutes with bromochalcone 74, a conversion of 54% (Table 3.1, entry 7) 
was achieved. Analysis of the product by 1H NMR spectroscopy showed no sign of the 
retro-aldol products, and so further optimisation using this pIL was performed. 
Increasing the reaction temperature to 130 °C with a reaction time of 20 minutes 
(Table 3.1, entry 8) gave excellent conversion to flavanone 130 (66%),* and no trace of 
the side products was noted by 1H NMR spectroscopy. In this case, the desired product 
130 was isolated by column chromatography (1:1 CH2Cl2:Pet) in good yield (60%).  
                                                 
* Note once again that the isomerisation of chalcones to form flavanones is reversible, and so 100% 
conversion to flavanones from chalcones is a significant challenge  
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When the reaction time was increased (40 minutes, Table 3.1, entry 9) or 
decreased (10 minutes, Table 3.1, entry 10) at a temperature of 100 °C, conversions of 
52% and 41% respectively were realised. These results were acceptable, but as the 
conditions of 130 °C and 20 minutes had produced the greatest conversion to flavanone 
130 (66%, Table 3.1, entry 8), further changes to reaction time were not examined. 
As the greatest conversion of 4-bromochalcone 74 to its corresponding 
flavanone 130 was achieved using TeaHSO4, with microwave conditions of 50 W, 
130 °C and 20 minutes, these conditions were then applied to a series of available 2ʹ-
hydroxychalcones, which had been previously synthesised (Chapter Two). 
3.2.2.3 Synthesis of a Library of Functionalised Flavanones 
It must be repeated at this point that the due to the isomerisation of chalcones 
and flavanones, flavanone synthesis from 2ʹ-hydroxychalcone substrates are relatively 
low yielding reactions. Many authors report the impressive conversion ratios of 
chalcone to flavanone,420, 424 but isolated yields are rarely reported. Bromoflavanone 
130, which has been synthesised seven times from 2ʹ-hydroxychalcones according to 
the literature, has been isolated in isolated yields ranging from 30%459 to 59%,460 whilst 
our pIL method produced bromoflavanone 130 in 65% yield (Table 3.2, entry 1). Given 
this information, it is noted once again that isolated yields of greater than 50% for 
flavanone synthesis from substituted 2ʹ-hydroxychalcones are actually considered 
impressive. Also, many of the flavanones synthesised in this research were either novel, 
or had not been synthesised via chalcone isomerisation (but rather by halogenation of 
unsubstituted flavanones,461 or rhodium-catalyzed 1,4-addition of phenylboronic acids 
to chromenone462). 
Flavanones synthesised by method were isolated by column chromatography 
(1:1 CH2Cl2:Pet). Flavanones were identified in the 1H NMR spectrum by the 
appearance of a multiplet at approximately δ 3.00 ppm representing the CH2 and a 
doublet of doublets at approximately δ 5.50 ppm representing the CH of the flavanone. 
The spectra obtained for the known compounds synthesised were compared to literature 
data, and novel compounds were fully characterised by 1H, 13C NMR spectroscopy, and 
HRMS. 
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Table 3.2. Synthesis of functionalised flavanones using the novel pIL-mediated, MW-assisted reaction.a 
 
Entry Product R1 R2 R3 R4 Yield (%)b 
1 130 H H 4ʹ-Br H 65 
2 6 H H H H 60 
3 131 H H 3ʹ-OBn H 36 
4 132 H H 2ʹ,4ʹ-OMe 5ʹ-Br 14 
5 133 5-MeO H H H 0 
6 134 5-MeO H 4ʹ-Br H 0 
7 135 5-MeO H 3ʹ-OBn H 0 
8 136 5-MeO H 2ʹ,4ʹ-OMe 5ʹ-Br 0 
9 137 6-Br H H H 56 
10 138 6-Br H 4ʹ-Br H 22 
11 139 6-Br H 3ʹ-OBn H 59 
12 140 6-Br H 2ʹ,4ʹ-OMe 5ʹ-Br 0 
13 141 6-Cl 8-Br H H 54 
14 142 6-Cl 8-Br 4ʹ-Br H 19 
15 143 6-Cl 8-Br 3ʹ-OBn H 50 
16 144 6-Cl 8-Br 2ʹ,4ʹ-OMe 5ʹ-Br 0 
a underlined compounds are novel 
b isolated yields following column chromatography 
 
When the optimal conditions (MW, TeaHSO4, 130 °C, 20 min) were applied to 
the unsubstituted 2′-hydroxychalcone 66, a good isolated yield of flavanone 6 (60%, 
Table 3.2, entry 2) was obtained (Figure 3.4). This unsubstituted flavanone has been 
synthesised previously in better yields (99%),463 however the method herein was 
‘greener’ than those used previously, and was novel in its approach. 
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Figure 3.4. The 1H NMR spectrum of flavanone 6, as synthesised using the MW-assisted pIL-mediated method (CDCl3). 
The effect of Ring B functionalisation on flavanone formation was investigated 
first (Table 3.2, entries 3 & 4, Scheme 3.8). The reaction of chalcone 78 under the 
optimised reaction conditions gave the corresponding flavanone 131 in a lower yield 
than that of the previous examples (36%, entry 3), whilst the reaction of the 5-bromo-
2,4-dimethoxy variant 80 showed very little conversion to the desired flavanone 132 
(14%, entry 4). These compounds were both novel. 
 
Scheme 3.8. Synthesis of flavanones 131 and 132 from functionalised 2ʹ-hydroxychalcones. 
The 2ʹ-hydroxy-6ʹ-methoxy chalcones were reacted next (Table 3.2, entries 5-8). 
Interestingly, none of the desired flavanones could be formed from this set of chalcones 
(Scheme 3.9). Data in the literature revealed that 2ʹ-hydroxy-6ʹ-methoxychalcones are 
prone to aurone formation rather than flavanone formation under the same 
conditions,464 however as the desired flavanones had not been accessed, the products of 
these reactions were not analysed further. It is worth noting that of these desired 
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flavanones, only 5-methoxyflavanone 133 (entry 5) has been accessed previously, in a 
yield of 59% from the same starting material, through the use of a cobalt Schiff-base 
complex.416 
 
Scheme 3.9. 2ʹ-Hydroxy-6-methoxychalcones did not cyclise under the pIL-mediated, MW-assisted conditions. 
The reaction conditions were then applied to the 5ʹ-bromo-2ʹ-hydroxychalcones. 
These fared better than their alkoxyl variants, with the formation of the unsubstituted 
Ring B flavanone 137 in a yield of 56% when reacted under the pIL-mediated, 
microwave-assisted method (Table 3.2, entry 9). The 4-bromo and 3-benzyloxy 
members (110 and 111) were also converted to their flavanones (138 and 139), in yields 
of 22% and 59% respectively (entries 10 and 11). This last result was quite interesting, 
as it was the only example in this study where a flavanone with a Ring B 
functionalisation was formed in a greater yield than the unsubstituted version. Also, 
flavanones 138 and 139 (entries 10 and 11) were novel compounds. When the 5-bromo-
2,4-dimethoxy chalcone 140 was reacted, no conversion was noted (entry 12). 
Finally, the conversion of the 3ʹ-bromo-5ʹ-chloro-2ʹ-hydroxychalcones to their 
analogous flavanones was attempted. Chalcone 117, with an unsubstituted Ring B, was 
reacted first and the analogous flavanone 141 was produced in a yield of 54% (Table 
3.2, entry 13). 3ʹ-Bromo-5ʹ-chloro-2ʹ-hydroxychalcones with substitutions on Ring B 
were also reacted, and produced flavanones in lower yields to those previously 
synthesised (19% and 50% respectively for the 4-bromo and 3-benzyloxy chalcones, 
entries 14 and 15). Flavanones 142 and 143 (entries 14 and 15) were also novel 
compounds. Once again, the 5-bromo-2,4-dimethoxy version produced none of the 
desired flavanone 144 (entry 16), as indicated by the presence of only the starting 
material in the 1H NMR spectrum. 
3.2.3 Flavanones: Conclusion 
A new method for the formation of flavanones from analogous chalcones was 
developed, using the combination of protic ionic liquids and microwave irradiation to 
provide a rapid, efficient, and simple synthesis. Ten flavanones were produced in yields 
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of 14-65% (Scheme 3.10), including six novel compounds 131, 132, 138, 139, 142 and 
143. 
 
Scheme 3.10. The synthesis of ten flavanones, including six novel compounds, was accomplished using the novel pIL-
mediated, MW-assisted methodology. 
A number of trends were identified in these microwave-assisted pIL-mediated 
reactions. An increase in substitutions on Ring A resulted in decreased yields (Scheme 
3.11). This trend was also generally seen in Ring B substitutions, to the point where 
those chalcones with 3 substituents on Ring B (5-bromo-2,4-dimethoxy) returned none 
of the desired flavanone. Methoxyl substituents on the 6ʹ-position of chalcones also 
prevented cyclisation to the flavanones. 
 
Scheme 3.11. Increasing Ring A substitution decreased yields in pIL-mediated, MW-assisted flavanone synthesis. 
It was also noted that while Choudhary et. al. found in their research that 
chalcones with para-withdrawing groups provided greater conversion to flavanones 
when using nanocrystalline MgO,420 this was not the case for the majority of the pIL-
mediated conversions performed in this study.  
With this handful of flavanone compounds synthesised, and a new synthetic 
method devised, the synthesis of another flavonoid family derivative, the flavones, was 
investigated. 
3.3 Flavones 
3.3.1 The Synthesis of Flavones 
The flavones 7, or 2-phenylchromones, are distinguished from other flavonoids by 
an alkene at the 2-position of Ring C, as well as a ketone at the 4-position (Figure 3.5). 
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Note that the flavones are not to be confused with flavonols 8, which also contain a 
hydroxyl group at the 3-position and will be discussed in Chapter Five. 
 
Figure 3.5. The simplest flavone 7 is also known as 2-phenyl-4H-chromen-4-one, and must not be confused with flavonol 8. 
Examples of natural flavones include apigenin 145 (found as glycosides in 
parsley and celery)8, 12, 465 and luteolin 146 (found in alfalfa and celery),12, 286, 465, 466 
both of which have been identified as possessing anticancer,467-471 antidiabetic,472 and 
antihypertensive properties (Figure 3.6).286  
 
Figure 3.6. Apigenin 145 and luteolin 146 are two natural flavones found in plants. 
3.3.1.1 Baker-Venkataraman Rearrangement 
 There are a number of methods available for the synthesis of the flavone 
scaffold, most commonly via the Baker-Venkataraman Rearrangement.473, 474 This 
rearrangement involves the reaction of 2ʹ-hydroxyacetophenone 72 and an aroyl 
chloride 147 in pyridine to form an ester 148, followed by treatment with base to form a 
1,3-diketone 149 (Scheme 3.12).  
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Scheme 3.12. Mechanism of the Baker-Venkataraman synthesis of 1,3-diketone 149.473, 474 
From this 1,3-diketone 149, flavone 150 can be synthesised by treatment with 
strong acid, through the mechanism shown in Scheme 3.13.475 
 
Scheme 3.13. Mechanism of acid-catalysed flavone 150 formation from the Baker-Venkataraman diketone 149.475 
Whilst the conditions used for the 1,3-diketone formation are fairly uniform 
throughout the literature, a number of different conditions have been used to convert 
1,3-diketones to flavones. Li et. al. have published a thorough review on the acid-
catalysed,473, 474 base-catalysed,476 solid supported, microwave-assisted, and other 
methods used to obtain flavones from 1,3-diketones.477 In more recent times, the 
application of microwave irradiation has provided reduced reaction times, with 
conditions including CuCl2 in EtOH for 5 minutes,478 K2CO3 and pyridine reacted for 
10 minutes,479 as well as acetic acid and H2SO4.81, 480 Even pILs have been applied to 
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the microwave-assisted reaction, with [bmim]BF4 and [EtNH3]NO3 employed by Pawar 
and co-workers.435, 481 
3.3.1.2 Oxidative Cyclisation by Iodine and DMSO 
Another common method for the synthesis of flavones is the oxidative 
cyclisation of 2ʹ-hydroxychalcones. An early paper on the subject demonstrated the 
SeO2 oxidation of 2-hydroxy-5-acetaminochalcone to its corresponding flavone,482 and 
recently, ionic liquids such as [bmim][NTf2] have also been applied.436 The most 
common conditions to effect this transformation are reflux with iodine (I2) in DMSO.483 
The I2-mediated mechanism is shown in Scheme 3.14. It is related to that of the Swern 
oxidation, and was proposed by Patonay and co-workers when they could find no 
evidence of nuclear iodination (the formation of an iodonium ion).484-486 
 
Scheme 3.14. Mechanism of oxidative cyclisation of chalcones by I2.486  
First, ring closure of the chalcone 151 to form chroman-4-one 152 occurs. The 
iodine reacts with the solvent to form I2/DMSO reagent 154. When reagent 154 reacts 
with chroman-4-one 152, chroman-4-one sulfoxide 155 is formed and hydrogen iodide 
is lost. Removal of the proton at the 2-position of the chroman-4-one sulfoxide 155 by I- 
is followed by the loss of hydrogen iodide and DMSO, to form flavone 156. DMSO and 
two HI molecules reform the catalytic iodine, along with dimethylsulfide and water.486 
This method is commonly used as the formation of side products is rarely observed; the 
2,3-dichloro-5,6-dicyanobenzoquinone (DDQ)-mediated formation of flavones from 
chalcones produces a mixture of flavanone, flavone and aurone products.487 
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While conventional heating with reflux for over 16 hours is the traditional 
method,141, 331, 417, 488, 489 microwave irradiation has been recently applied to the 
reaction,332 although with the use of conventional microwave, which as explained in 
Chapter 2.2.2 are generally unreliable and irreproducible. Solid supported iodine, in the 
form of I2-Al2O3, has also been used to effect microwave-assisted flavone synthesis, 
with reaction times of less than five minutes.370, 490 
Many other methods for flavone synthesis are possible, including the oxidation 
of flavanones by manganese acetate, which has provided flavones in 90-96% yields.491 
A microwave-assisted radical method synthesis using N-bromosuccinimide and 
azabisisobutyronitrile (AIBN) effects the same transformation.492 Ferrocenyl-
substituted flavones have also been accessed using KCN, oxone, DCM/acetone and a 
carbonate buffer.493 Even an intramolecular photochemical Wittig reaction in water has 
been used to synthesise flavones.494 
When attention turned to the synthesis of substituted flavones, it was established 
that the I2-mediated oxidation of 2ʹ-hydroxychalcones was an ideal method, as a series 
of 2ʹ-hydroxychalcones were already in hand (See Chapter Two).  
3.3.2 Flavones: Results and Discussion 
To synthesise flavones from the 2ʹ-hydroxychalcones in hand, a microwave-
assisted method was first attempted, based on the conditions used by Menezes (who 
used a conventional microwave).332 Chalcone 66 was reacted with I2 in DMSO under 
microwave irradiation for 5 minutes at 180 °C. However, due to extreme pressure build-
up, the microwave safety system turned the microwave off. Lower reaction 
temperatures were then trialled (100 °C and 120 °C, Scheme 3.15), however only 
starting material was returned. For this reason, attention turned to the traditional method 
(5% Iodine in DMSO under reflux for 16 hours), in accordance with Yamasaki et. al.331 
and Chimenti et. al.417 
 
Scheme 3.15. Microwave-assisted flavone formation of 2ʹ-hydroxychalcone 66 did not proceed at lower temperatures. 
The conventional method was applied to 16 of the 2ʹ-hydroxychalcones 
synthesised in Chapter Two, beginning with those chalcones with an unsubstituted Ring 
A (apart from the 2ʹ-hydroxyl group). Note that novel flavones were fully characterised, 
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by 1H and 13C NMR spectroscopy, and HRMS. The 1H NMR spectroscopic analysis 
included the loss of the chalcone hydroxyl peak (approximately δ 12.50-13.00 ppm), the 
movement of the aromatic peaks, and also the appearance of the CH peak of the flavone 
at approximately δ 6.80 ppm in the 1H NMR spectrum (Figure 3.7). Known flavones 
were compared to literature data to confirm their structure. 
The unfunctionalised chalcone 66 (Table 3.3, entry 1) was treated with 5% I2 in 
DMSO, and refluxed for 16 hours. After cooling to room temperature, excess water was 
added until the solution became opaque. Extraction, followed by column 
chromatography (10% MeOH in CHCl3) gave the desired flavone 7 in 61% yield 
(Figure 3.7).  
 
Figure 3.7. 1H NMR spectrum of flavone 7, as synthesised by the I2/DMSO method (CDCl3). 
Next, 4-bromochalcone 74 was reacted under the same conditions, and the 
desired flavone 157 was formed in a yield of 71% (Table 3.3, entry 2). The 3-
benzyloxy, and 5-bromo-2,4-dimethoxy analogues were also successfully reacted 
(entries 3 and 4 respectively), and formed their corresponding flavones 158 and 159 in 
yields of 57% and 88% respectively. It was noted from these few reactions that the 
more substituents on Ring B, the greater the yield, the opposite trend to that seen in 
flavanone synthesis. 
The 2ʹ-hydroxy-6ʹ-methoxychalcones were investigated next. Chalcone 101 was 
reacted first, and the corresponding flavone 160 was isolated in a yield of 66% (Table 
 84 
 
3.3, entry 5). This success was in complete contrast to earlier attempts at flavanone 
synthesis, wherein none of the 2ʹ-hydroxy-6ʹ-methoxychalcones could be converted to 
their corresponding flavanones. The 4-bromo analogue 102 was reacted next, and 
produced the desired novel flavone 161 in a yield of 59% (entry 6).  
3-Benzyloxychalcone 104 was also reacted (entry 7), and produced the 
debenzylated flavone 162 in 14% yield, as confirmed by comparison to known spectral 
data in the literature, including the lack of a benzyl peak at approximately δ 5.10 ppm 
and the presence of only eight aromatic protons in the 1H NMR spectrum (Figure 3.8). 
To validate this deprotection, the reaction was repeated and the same result was 
observed. Of note was that this deprotection did not occur with any of the other 
benzylated chalcones in the synthesis of flavones. A review of the literature revealed 
that Anuradha and co-workers also experienced removal of benzyl groups in the 
synthesis of flavones from 2ʹ-hydroxychalcones (using I2 in glycol), however no 
explanation or mechanism was provided.495 
 
Figure 3.8. Hydroxyflavone 162 was synthesised from benzylated chalcone 104 (CDCl3). 
Finally, the 5-bromo-2,4-dimethoxy analogue 105 was also reacted, and 
produced the corresponding flavone 164 in a poor yield of 26% (entry 8). Once again, 
there were no trends in the reactivity of this series of chalcones. 
Next, the 5ʹ-bromo-2ʹ-hydroxychalcones were reacted. Chalcone 109 with its 
unsubstituted Ring B was reacted first, and flavone 165 was isolated in a good yield of 
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72% (Table 3.3, entry 9). When the 4-bromo and 3-benzyloxy analogues (chalcones 
110 and 111 respectively) were applied to the reaction conditions, lower isolated yields 
of the corresponding flavones were acquired (44% and 48%, entries 10 and 11 
respectively). However, the novel 5-bromo-2,4-dimethoxyflavone 168 was isolated in 
very good yield (75%) when its analogous chalcone was reacted (entry 12).  
Table 3.3. Synthesis of functionalised flavones from 2ʹ-hydroxychalcones using the I2/DMSO method.a 
 
Entry Product R1 R2 R3 R4 
Isolated 
Yield (%) 
1 7 H H H H 61 
2 157 H H 4ʹ-Br H 71 
3 158 H H 3ʹ-OBn H 57 
4 159 H H 2ʹ,4ʹ-OMe 5ʹ-Br 88 
5 160 5-MeO H H H 66 
6 161 5-MeO H 4ʹ-Br H 59 
7 162 5-MeO H 3ʹ-OH H 14b 
8 164 5-MeO H 2ʹ,4ʹ-OMe 5ʹ-Br 26 
9 165 6-Br H H H 72 
10 166 6-Br H 4ʹ-Br H 44 
11 167 6-Br H 3ʹ-OBn H 48 
12 168 6-Br H 2ʹ,4ʹ-OMe 5ʹ-Br 75 
13 169 6-Cl 8-Br H H 70 
14 170 6-Cl 8-Br 4ʹ-Br H 12 
15 171 6-Cl 8-Br 3ʹ-OBn H 38 
16 172 6-Cl 8-Br 2ʹ,4ʹ-OMe 5ʹ-Br 33 
a underlined compounds are novel 
b starting material chalcone 104 was benzylated (3-OBn) 
 
Finally, the 3ʹ-bromo-5ʹ-chloro-2ʹ-hydroxychalcones were reacted. The 
unsubstituted Ring B chalcone 117 was reacted to form the desired flavone 169 in a 
yield of 70% (Table 3.3, entry 13). However the remainder of this family of chalcones 
did not react as well, with the 4-bromo, 3-benzyloxy and 5-bromo-2,4-dimethoxy 
analogues all being formed in much lower yields (12%, 38% and 33% respectively, 
Table 3.3, entries 14-16). It is also noted that although produced in low yields, the latter 
two flavones, 171 and 172, were novel compounds. 
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3.3.3 Flavones: Conclusion 
A series of flavones were synthesised from the 2ʹ-hydroxychalcones synthesised 
in Chapter Two, using the traditional method of reflux with iodine in DMSO for 16 
hours. A total of 16 flavones were synthesised in yields of 12-88% (Scheme 3.16), 
including seven novel compounds (Table 3.3, entries 3, 6, 8, 11, 12, 15 and 16).  
 
Scheme 3.16. The synthesis of 16 flavones, including seven novel compounds, was accomplished using the traditional 
I2/DMSO/reflux conditions. 
While there appeared to be no reactivity trends in the synthesis of the flavones, 
their synthesis was accomplished in greater yields than those of the flavanones (which 
were synthesised from the same 2ʹ-hydroxychalcones). This was noticed especially in 
the case of the 2ʹ-hydroxy-6ʹ-methoxychalcones, which were unreactive in the 
conditions used to form the flavanones.  
3.4 Conclusion 
The 2ʹ-hydroxychalcones are an ideal stepping stone from which to access a 
number of flavonoid substructures, including their constitutional isomers the 
flavanones, and the flavones. It was the aim of this research to access a library of 
flavonoid-based compounds, and also to incorporate halogens into these structures, so 
as to take advantage of the Heck reaction (discussed in Chapter Four). 
The research in this chapter outlined attempts to access flavanones and flavones. 
A new method was developed for the synthesis of flavanones from 2ʹ-
hydroxychalcones, using the combination of protic ionic liquids (pILs) and microwave 
irradiation (Scheme 3.17). This methodology allowed for the synthesis of ten 
flavanones in yields varying from 14-65%, including six novel compounds (Table 3.2, 
entries 3, 4, 10, 11, 14 and 15);  
• 2-(3-benzyloxyphenyl)chroman-4-one 131, 
• 2-(5-bromo-2,4-dimethoxyphenyl)chroman-4-one 132, 
• 6-bromo-2-(4-bromophenyl)chroman-4-one 138, 
• 6-bromo-2-(3-benzyloxyphenyl)chroman-4-one 139, 
• 8-bromo-6-chloro-2-(4-bromophenyl)chroman-4-one 142, and  
• 8-bromo-6-chloro-2-(3-benzyloxyphenyl)chroman-4-one 143. 
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This work was the basis of a publication in Current Organic Chemistry (2012, 
16(1), 121-126), (Appendix A). 
 
Scheme 3.17. The pIL-mediated, MW-assisted methodology provided ten flavanones. 
To further increase this flavonoid library, the synthesis of flavones from their 
corresponding 2ʹ-hydroxychalcones was performed using I2 and DMSO (Scheme 3.18). 
Sixteen flavones were accessed, in yields varying from 12-88%, including seven novel 
compounds (Table 3.3, entries 3, 6, 8, 11, 12, 15 and 16);  
• 2-(3-benzyloxyphenyl)chromen-4-one 158, 
• 5-methoxy-2-(4-bromophenyl)chromen-4-one 161, 
• 5-methoxy-2-(5-bromo-2,4-dimethoxyphenyl)chromen-4-one 164, 
• 6-bromo-2-(3-benzyloxyphenyl)-4H-chromen-4-one 167, 
• 6-bromo-2-(5-bromo-2,4-dimethoxyphenyl)chromen-4-one 168, 
• 8-bromo-6-chloro-2-(3-benzyloxyphenyl)chromen-4-one 171, and 
• 8-bromo-6-chloro-2-(5-bromo-2,4-dimethoxyphenyl)chromen-4-one 172. 
 
Scheme 3.18. The synthesis of flavones from 2ʹ-hydroxychalcones with I2 and DMSO provided 16 flavones. 
With a library of flavonoid structures now synthesised (a total of 49 including 
2ʹ-hydroxychalcones, flavanones and flavones), the first aim of this research was 
completed. As with the 2ʹ-hydroxychalcones, these flavanones and flavones were 
submitted for biochemical evaluation of their cytotoxic effects, the results of which are 
expected in the near future. With these flavonoids in hand, many incorporating 
halogens, attention turned to the use of the Heck reaction for further functionalisation of 
these flavonoids, and the introduction of synthetic handles for use in the synthesis of 
DMLs (Chapter Five). 
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Chapter Four: 
Functionalisation of Flavonoids: 
The Heck Reaction 
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4.1 Chapter Overview 
 With a number of halogenated 2ʹ-hydroxychalcones, flavanones and flavones in 
hand, attention turned to their functionalisation using the Heck reaction, in order to 
further functionalise the flavonoid scaffolds, and also to provide synthetic handles for 
use in the synthesis of Designed Multiple Ligands (Chapter Five). 
4.2 Heck Reaction of Halogenated Flavonoids 
4.2.1 Palladium Chemistry 
The use of palladium in chemistry has become established as a convenient 
means to form carbon-carbon bonds. The importance of such ‘cross coupling’ reactions 
was recognised when in 2010, three of the pioneers in this field (R. F. Heck, E. Negishi, 
and A. Suzuki) were awarded a joint Nobel Prize in Chemistry "for palladium-catalyzed 
cross couplings in organic synthesis".496 
Examples of palladium-catalysed cross coupling reactions include the Heck-
Mizoroki reaction (commonly known as the Heck reaction),497, 498 Sonogashira 
coupling,499 Negishi coupling,500 Stille cross coupling,501 Suzuki-Miyaura reaction 
(commonly known as the Suzuki reaction),502 Hiyama coupling,503 Kumada reaction,504, 
505 and the Buchwald-Hartwig amination reaction (Figure 4.1).506, 507  
 
Figure 4.1. Numerous palladium-catalysed reactions are possible, and can introduce various functional groups. 
These reactions all utilise an organohalide substrate and a palladium catalyst. 
Depending on the reaction conditions, reagents and other organometallic species used, a 
variety of functional groups can be installed.508, 509 
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Palladium-catalysed cross coupling reactions are ubiquitous in total syntheses 
(see Nicolaou et. al. for a thorough review),510 but their application to flavonoids has 
been largely unresearched, likely due to flavonoid research largely revolving around 
hydroxylated rather than halogenated flavonoids. The Suzuki reaction has been applied 
to flavone substrates,511, 512 and the Stille coupling applied to a coumarin,513 and a 
relatively thorough investigation into microwave-assisted Suzuki and Buchwald-
Hartwig reactions to numerous flavone structures has been conducted.508 The most 
thorough investigation of palladium-based reactions with flavonoids to date applied the 
Stille, Heck, Suzuki, and Sonogashira reactions to 2-aryl/styryl-8-bromo-6-chloro-3-
hydroxychromone scaffolds (Scheme 4.1).408, 514 
 
Scheme 4.1. A Sonogashira and a Stille coupling, as applied to halogenated flavonol 173 by Dahlèn and co-workers.408 
However, there has been very little investigation into the use of the Heck 
reaction with halogenated flavonoid substrates. With a number of halogenated 
acetophenones, benzaldehydes, chalcones, flavanones and flavones in hand, attention 
turned to functionalising these substrates using the Heck reaction. 
4.2.2 The Heck Reaction 
The Heck-Mizoroki reaction is a vinylic substitution reaction, in which a vinylic 
hydrogen is replaced with an aryl, benzyl or vinyl group (Scheme 4.2).515 It was 
discovered independently by the groups of Heck and Moritani in 1967 and 1968.497, 516-
523 Heck first detailed the use of palladium salts with substituted vinyls and 
arylmercuric salts to produce arylated vinyl products. However, these reactions used 
stoichiometric amounts of the palladium source, and involved toxic mercuric salts.497 
Moritani produced the same vinylic products, but via organopalladium intermediates 
generated by the direct electrophilic palladation of arenes.516, 524 
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Scheme 4.2. The general scheme of the Heck reaction. 
Two years later, Mizoroki et. al. published modifications to Heck’s reaction,498 
detailing the use of only a catalytic amount of the palladium source (PdCl2), and 
showed that halogens, in particular iodides, could be used in place of the toxic mercuric 
reagents. Mizoroki also detailed the use of potassium acetate as a scavenger for the 
hydrogen iodide formed during the reaction.498  
The requirements for a Heck reaction are as follows: a palladium(0) or 
palladium(II) complex, a ligand (most commonly a phosphine ligand) to co-ordinate to 
the palladium, and a base, in addition to the organohalide (which is often an aryl halide) 
and a vinylic substrate. The generally accepted mechanism is shown in Scheme 4.3.  
 
Scheme 4.3. The generally accepted mechanism of the Heck reaction. 
The Heck reaction begins with preactivation of the palladium complex by the 
ligand to form the active catalyst, a Pd(0) species 176. This undergoes oxidative addition 
with organohalide 177, ‘inserting’ the palladium-ligand species between the carbon and 
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halogen. Displacement of either a ligand or the halide allows for co-ordination to the 
alkene, forming a π-complex 180. Migratory insertion of the complex into the olefin, 
otherwise known as carbometallation, occurs next with syn stereochemistry. In this step, 
the alkene reactant 180 is incorporated via the less-substituted alkene carbon. Rotation 
around the carbon-carbon bond provides a β-hydrogen that is syn-periplanar to the 
palladium, allowing syn-β-hydride elimination to produce the thermodynamically stable 
(Z)- (or trans-) alkene 183. Finally, reductive elimination by the base re-forms the 
catalytic palladium species 176.515, 525 
 There are a number of factors which influence the success of the Heck reaction. 
First, aryl iodides are the most reactive to Heck reactions, followed by bromides and 
triflates.526 Chlorides are far less reactive, due to the strength of the carbon-chloride 
bond, however Heck reactions of aryl chlorides are still possible.526 In terms of the 
vinylic substrates, higher yields are generally associated with electron-poor vinyls 
(including acrylates).525 Also, the use of more substituted vinyl substrates effects slower 
reactions,525 as the steric hindrance obstructs access to the alkene for the formation of 
the π-complex.  
The Heck reaction is widely used in organic chemistry, being used in the 
synthesis of natural products,527, 528 novel polymers,390 and in domino reactions.529-534 It 
has even been used to synthesise flavonoid scaffolds, including the anthocyanidins,535 
2-arylchromenes,536 chalcones,338 and even flavones.537 However, the use of the Heck 
reaction on flavonoid substrates is not well explored. Few examples exist in the 
literature, including application to hydroxychromones,538 and flavones with 1,3-
dienes.539 Dahlèn and co-workers in particular successfully conducted the Heck reaction 
at the 6-chloro and 8-bromo positions of substituted flavonols, and yields of 64-85% 
and 80-87% respectively for the acrylate products were obtained (with a total of only 
six examples, Scheme 4.4).408  
 
Scheme 4.4. One example of Dahlèn’s application of the Heck reaction to halogenated flavonol 185. 
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At the time of our research, Akçok et. al. published an attempt to introduce a 
series of stilbenes to 3ʹ-bromoflavanone 187 using the Heck reaction, although a low 
43% yield was their only result, using palladium acetate (Pd(OAc)2) and 
triethanolamine (Scheme 4.5).382 The use of other functionalised stilbenes resulted in 
inseparable mixtures of products, and indicated that the Heck reaction of flavanones 
was difficult. 
 
Scheme 4.5. Akçok and co-workers introduced a stilbene onto flavanone 187 using the Heck reaction, in low yield. 
When Akçok applied the Heck reaction to 3-bromobenzaldehyde 189, and used 
the stilbene product 190 in a Claisen-Schmidt condensation and then flavanone 
formation, a series of stilbene-functionalised flavanones including 193 were produced, 
with overall yields of approximately 40-50% (Scheme 4.6).  
 
Scheme 4.6. Akçok used a Heck reaction with 3-bromobenzaldehyde 189 to access flavonoids with stilbene substituents. 
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This review of the literature showed little precedence in the application of the 
Heck reaction to flavonoids, and so provided an avenue for this research. Brominated 
acetophenone, benzaldehyde, chalcone, flavanone and flavone substrates were all 
available for this research. While it was realised that the use of base in the Heck 
reaction may cause the isomerisation of the chalcone or flavanone substrates, it was 
envisioned that careful base selection could avoid or minimise this isomerisation. 
The use of the Heck reaction with brominated flavonoids provided an avenue 
from which to introduce functional groups to attach other pharmacophores or 
therapeutic agents.† This was in line with the aims of functionalising flavonoids, as well 
as synthesising Designed Multiple Ligands for the treatment of diseases. 
4.3 Heck Reaction: Results and Discussion 
In the selection of substrates for the Heck reaction of flavonoids, 2ʹ-
hydroxychalcones, flavanones and flavones with bromine substituents were chosen. 
This included chalcones 74 and 109, flavanones 130 and 137, and also flavones 157 and 
165, which incorporated bromine atoms into either Ring A or Ring B of the flavonoids. 
Research towards functionalisation of Ring B will be addressed first, followed by Ring 
A functionalisation. 
4.3.1 Heck Reaction: Ring B 
To trial the Heck reaction conditions, 4-bromobenzaldehyde 73 was used as the 
aryl halide (Scheme 4.7). Palladium acetate (Pd(OAc)2) was chosen as the palladium 
catalyst, as it is relatively inexpensive, commonly used in such reactions, and stable in 
air. Triphenylphosphine (PPh3) was selected as the phosphine ligand,390, 540 and N,N-
dimethylformamide (DMF) was chosen as the solvent, as it is the ideal solvent for this 
catalyst-ligand set, as it weakly co-ordinates to the palladium catalyst, increasing its 
stability.540  
 
Scheme 4.7. The optimisation of the Heck reaction was conducted using 4-bromobenzaldehyde 73. 
                                                 
† This will be addressed further in Chapter Five. 
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The acrylate substrates were chosen based on availability (Figure 4.2), and 
included normal-butyl (CO2nBu) and tert-butyl (CO2tBu) acrylate. These esters, 
although similar, are cleaved using different methods (saponification and acid treatment 
respectively).541 Acrylonitrile (CN), acrylamide (CONH2) and acrylic acid (COOH) 
were also available. Note that nBu acrylate was the acrylate substrate used for the trial 
reactions. 
 
Figure 4.2. The five acrylate substrates used in this research. 
Of particular interest for these trial reactions was the identification of numerous 
suitable bases, in order to avoid the undesired chalcone to flavanone isomerisation 
when using the Heck reaction.329, 418 Sodium acetate (NaOAc), triethylamine (NEt3) and 
sodium or potassium carbonate (Na2CO3 or K2CO3) are all noted as ideal bases for the 
Heck reaction.390, 540 N-methylmorpholine is another commonly-used base,540 however 
as this was unavailable in our laboratory at the time, the similar amine base N,N-
dicyclohexylmethylamine (Cy2NMe) was also trialled.531 Strong hydroxide bases, 
including KOH, NaOH, and Bu4NOH were not used, as these hydroxide bases facilitate 
chalcone to flavanone isomerisation; DBU was also avoided for this reason (see 
Chapters Two and Three). 
To compare the success of these bases, the benzaldehyde peaks of 4-
bromobenzaldehyde 73 (δ 9.95 ppm) and the desired acrylate product (δ 10.01 ppm) 
were each given an integration of 1 to determine the ratio of reactant to product.  
4.3.1.1 Heck Reaction: Trials 
The following methodology was used; palladium acetate (Pd(OAc)2, 
0.02 mmol), triphenylphosphine (PPh3, 0.02 mmol), and base (0.40 mmol) were stirred 
in DMF under an inert atmosphere for 20 minutes, followed by addition of 
benzaldehyde 73 (0.13 mmol) and nBu acrylate (0.13 mmol). The reaction was refluxed 
for 16 hours, filtered through a celite plug, the solvent removed in vacuo, and analysis 
of the crude product was conducted using 1H NMR spectroscopy. 
When NaOAc was trialled (Table 4.1, entry 1), analysis of the crude reaction 
product by 1H NMR spectroscopy revealed the presence of desired acrylate 194, as 
confirmed by comparison to literature data,542 including the appearance of a doublet 
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representing the β-vinylic proton at δ 6.50 ppm and additional peaks between δ 7.40-
8.00 ppm representing the α-vinylic proton. The benzaldehyde starting material 73 was 
also observed (δ 9.95 ppm), in a ratio of 1:1 with the desired product. With this 
reasonable conversion, other bases were trialled. 
Dicyclohexyl-N-methylamine (Cy2NMe) was examined next (Table 4.1, 
entry 2), and a ratio of 1:0.3 of starting material 73 to nBu acrylate product 194 was 
determined by 1H NMR spectroscopy. This low conversion was somewhat expected, as 
Cy2NMe is not commonly utilised in Heck reactions,531 and has previously shown to be 
low yielding when used with Pd(OAc)2 in comparison to more specialised palladium 
catalysts.543 
Table 4.1. Trial of bases for the Heck reaction with 4-bromobenzaldehyde 73. 
 
Entry Base 
Equivalents 
of alkene 
73:194 
(yield)a 
1 NaOAc 1 1:1 
2 Cy2NMe 1 1:0.3 
3 NEt3 1 1:1.5 (42%) 
4 K2CO3 1 1:1.5 (50%) 
5 NEt3 4 1:1.4 
6 K2CO3 4 1:5 (82%) 
a Isolated yield (%) after column chromatography 
 
Triethylamine (NEt3) was the next base to be trialled (Table 4.1, entry 3). 
Analysis of the crude material by 1H NMR spectroscopy showed the starting material 
73 and product 194 in a ratio of 1:1.5 respectively. Purification by column 
chromatography (1:1 CH2Cl2:Pet) isolated the desired product in 42% yield. 
Next, K2CO3 was used (Table 4.1, entry 4), and 1H NMR analysis showed the 
starting material 73 and product 194 in a ratio of 1:1.5. Acrylate 194 was isolated by 
column chromatography (1:1 CH2Cl2:Pet) in 50% yield.  
With only moderate conversions achieved using the four bases, attention turned 
to the use of increased equivalents of the acrylate. Using four equivalents of nBu 
acrylate with NEt3 as the base (Table 4.1, entry 5) produced a slightly lower conversion 
of 1:1.4 for benzaldehyde 73 to acrylate 194 respectively.  
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However, when four equivalents of nBu acrylate were used with K2CO3 as the 
base (Table 4.1, entry 6), very good conversion to the acrylate product was noted 
(1:5 for the starting material 73 to product 194 respectively). Purification by column 
chromatography (1:1 CH2Cl2:Pet) isolated the desired acrylate 194 as a pale gold oil in 
a yield of 82% (Table 4.2, entry 1).  
While the use of NEt3 with one equivalent of acrylate was one option, the 
K2CO3 methodology (K2CO3 as the base with four equivalents of the acrylate) had 
provided the greatest conversion, and as such this system was used for the reaction of 
other acrylates with 4-bromobenzaldehyde 73. 
4.3.1.2 Heck Reaction of 4-Bromobenzaldehyde with Acrylates 
The next acrylate used was tBu acrylate (Table 4.2, entry 2). Purification by 
column chromatography isolated the desired acrylate 195 in 60% yield. 
Acrylonitrile was trialled next (Table 4.2, entry 3). Analysis of the crude 
material by 1H NMR spectroscopy showed a complex mixture of products, as indicated 
by nine peaks in the aldehyde region (from δ 9.96-10.12 ppm), and numerous sets of 
peaks representing the vinylic β-hydrogen (δ 5.60-6.06 ppm). Analysis by thin layer 
chromatography (TLC) showed numerous barely separable spots, and literature 
revealed that the use of acrylonitrile in Heck reactions can be problematic;544 therefore, 
the product was not purified.  
Acrylamide and acrylic acid were also trialled (Table 4.2, entries 4 and 5). 
Analysis of the crude reaction product by 1H NMR spectroscopy revealed only the 
benzaldehyde reactant, with no sign of the desired products.  
Table 4.2. The Heck reaction of 4-bromobenzaldehyde 73. 
 
Entry Acrylate R Product (yield)a 
1 nBu acrylate CO2Bu 194 (82%) 
2 tBu acrylate CO2tBu 195 (60%) 
3 Acrylonitrile CN mixture 
4 Acrylamide CONH2 - 
5 Acrylic acid COOH - 
a Isolated yield (%) after column chromatography 
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Overall, the only successful Heck reactions of 4-bromobenzaldehyde 73 were 
with nBu and tBu acrylate. Attention then turned to the use of a different aryl halide 
scaffold, in the hope that more functionalised products could be obtained. 
Another benzaldehyde, 5-bromo-2,4-dimethoxybenzaldehyde 79, was also 
trialled, with nBu acrylate and the optimised conditions (Pd(OAc)2, PPh3, K2CO3 and 
DMF, Scheme 4.8), however only the benzaldehyde starting material was observed in 
the 1H NMR spectrum of the crude reaction material. No evidence of the successful use 
of this substrate in the Heck reaction could be found, and so the use of this substrate 
was discontinued and attention turned to the use of the halogenated flavonoids.  
 
Scheme 4.8. Heck reaction with 5-bromo-2,4-dimethoxybenzaldehyde 79 gave only the starting material. 
4.3.1.3 Heck Reaction of 4-Bromochalcone 74 
 The reaction of 4-bromochalcone 74 was then attempted using the same reaction 
conditions (Scheme 4.9). Analysis of the crude product by 1H NMR spectroscopy 
revealed a mixture of compounds, including a trace amount of the corresponding 
halogenated flavanone (verified by the appearance of multiplet peaks at δ 2.80-3.20 
ppm and δ 5.40 ppm representing the CH2 and CH of Ring C), and the chalcone 74 and 
acrylate starting materials.  
 
Scheme 4.9. Heck reaction of bromochalcone 74 with nBu acrylate did not proceed, but the crude reaction product revealed 
the starting material and a trace amount of bromoflavanone 130. 
With no sign of the desired acrylate product 197, attention turned to the Heck 
reaction of brominated flavonoids, 4ʹ-bromoflavanone 130 and 4ʹ-bromoflavone 157. 
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4.3.1.4 Heck Reaction of 4ʹ-Bromoflavanone 130 and 4ʹ-Bromoflavone 
157 
Using the established conditions (Pd(OAc)2, PPh3, K2CO3, DMF, 4ʹ-
bromoflavanone 130 and four equivalents of nBu acrylate, see Scheme 4.10), 1H NMR 
analysis showed the presence of only the flavanone starting material, and none of the 
desired acrylate product 198. Of note was the fact that there was also no sign of the 
corresponding brominated chalcone isomer 74, indicating that K2CO3 did not cause 
isomerisation. 
 
Scheme 4.10. Heck reaction of bromoflavanone 130 with nBu acrylate showed only the using K2CO3 was unsuccessful; only 
starting material was seen in the 1H NMR spectrum.  
The reaction was then repeated, with NEt3 as the base with only one equivalent 
of the acrylate (Scheme 4.11). However, the 1H NMR spectrum of the crude material in 
this case showed the presence of the flavanone starting material 130 and its 
corresponding chalcone 74 in a ratio of 3:2, indicating that the NEt3 had caused the 
isomerisation of the flavanone starting material. 
 
Scheme 4.11. The Heck reaction of bromoflavanone 130 using NEt3 produced a 3:2 mixture of the starting material and 
corresponding chalcone 74 respectively, with none of the desired acrylate 198. 
While both of these reactions were unsuccessful in synthesising the Heck 
product, it was interesting that when K2CO3 was used as a base, none of the 
corresponding chalcone was detected, inferring that K2CO3 may be used in other base-
mediated reactions and applied to this flavanone. Attention then turned to the use of the 
Heck reaction with 4ʹ-bromoflavone 157; note that the flavones are not subject to 
isomerisation as the chalcones and flavanones are. 
When the Heck reaction was attempted using 4ʹ-bromoflavone 157 as a 
substrate (Scheme 4.12), analysis of the crude product by 1H NMR spectroscopy 
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revealed the presence of the corresponding acetophenone 72 and benzaldehyde 73, as 
exhibited by representative peaks at δ 2.60 ppm and δ 9.97 ppm respectively. These 
degradation products were present in a ratio of 3:3:1 with the flavone starting material 
157 respectively, and there was no sign of the desired flavone acrylate 199. While 
others have previously used the Heck reaction with flavones, it must be noted they used 
1,3-dienes rather than acrylates, as well as different reagents (5mol% Pd(dba)2, 5mol% 
dppe, 200mol% Ag2CO3 in dioxane and H2O at 100 °C for 24 hours) to form annulated 
products.539  
 
Scheme 4.12. The Heck reaction of 4ʹ-bromoflavone 157 did not proceed. 
Although the Heck reactions of the Ring-B substituted chalcone 74, flavanone 
130 and flavone 157 were unsuccessful, the effective application to the corresponding 
benzaldehyde provided a means to access the flavonoid equivalents.  
The Heck reaction of brominated Ring A substrates was then examined. 
4.3.2 Heck Reaction: Ring A 
4.3.2.1 Heck Reaction of 5ʹ-Bromo-2ʹ-Hydroxyacetophenone 108 with 
Acrylates 
 Attempts were then made to access acrylate products from a brominated 
acetophenone, or flavonoid with a bromine atom on Ring A. The first substrate 
examined was 5ʹ-bromo-2ʹ-hydroxyacetophenone 108, using the optimised conditions 
(Pd(OAc)2, PPh3, K2CO3, DMF, aryl halide and four equivalents of acrylate). Note that 
the synthesis of acrylate products from 5ʹ-bromo-2ʹ-hydroxyacetophenone 108 had not 
been attempted previously. 
 First, nBu acrylate was trialled (Table 4.3, entry 1, and Scheme 4.13), and 
analysis of the crude product by 1H NMR spectroscopy revealed full conversion of the 
starting material and excess nBu acrylate.  
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Scheme 4.13. The Heck reaction of 5ʹ-bromo-2ʹ-hydroxyacetophenone 108 with nBu acrylate proceeded in 76% yield. 
Purification by column chromatography (1:1 CH2Cl2:Pet) isolated acetophenone 
nBu acrylate 200 in a yield of 76% (Figure 4.3). Acrylate 200 was identified in the 1H 
NMR spectrum by peaks representing the β-vinylic proton as a doublet at δ 6.31 ppm, 
and the 2ʹ-hydroxyl proton as a singlet peak at δ 12.45 ppm. Also, the appearance of 
peaks representing the nBu group at δ 0.95 ppm, δ 1.30-1.80 ppm and δ 4.20 ppm 
further established the formation of the desired acetophenone 200. With this success, 
attention turned to the use of other acrylates. 
 
Figure 4.3. 1H NMR spectrum of purified acetophenone n-butyl acrylate 200 (CDCl3). 
 Next, tBu acrylate was trialled (Table 4.3, entry 2), and following purification 
by column chromatography, acetophenone tBu acrylate 201 was isolated in 90% yield.  
Table 4.3. The Heck reaction of 5ʹ-bromo-2ʹ-hydroxyacetophenone 108 with various acrylates. 
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Entry Acrylate R Product (yield) 
1 nBu acrylate CO2nBu 200 (76%) 
2 tBu acrylate CO2tBu 201 (90%) 
3 Acrylonitrile CN - 
4 Acrylamide CONH2 - 
5 Acrylic acid COOH - 
 
Acrylonitrile, acrylamide and acrylic acid were also reacted with 5ʹ-bromo-2ʹ-
hydroxyacetophenone 108 (Table 4.3, entries 3, 4 and 5). However, as with the Heck 
reactions of 4-bromobenzaldehyde 73 (see Table 4.2, entries 3, 4 and 5), analysis of the 
crude material showed only the acetophenone starting material, with no sign of the 
acrylate reagents or desired acrylate product. As these reagents had twice proven 
unsuccessful, these acrylates were examined no further.  
The Heck reaction conditions were also applied to 3ʹ-bromo-5ʹ-chloro-2ʹ-
hydroxyacetophenone 116, using nBu acrylate (Scheme 4.14). The reaction was 
predicted to occur via the more reactive bromine rather than the chlorine substituent,525 
however 1H NMR spectroscopy showed only peaks representing the starting material 
acetophenone, and so this was abandoned as a substrate. 
 
Scheme 4.14. The Heck reaction of 3ʹ-bromo-5ʹ-chloro-2ʹ-hydroxyacetophenone 116 only provided starting material. 
 Attention then turned to the use of 5ʹ-bromochalcone as the aryl halide substrate. 
4.3.2.2 Heck Reaction of 5ʹ-Bromochalcone 109 
When the Heck reaction was applied to 5ʹ-bromochalcone 109 (Scheme 4.15), 
only the chalcone starting material, benzaldehyde 59 (formed from a retro-aldol 
reaction, as indicated by a singlet peak at δ 9.98 ppm), and a trace amount of the 
corresponding flavanone 137 were noted in the 1H NMR spectrum. The fact that the 
desired acrylate product 203 could not be seen in the 1H NMR spectrum, as well as the 
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formation of the undesired benzaldehyde, meant that no further reactions were carried 
out using bromochalcone 109 as a substrate. Again, only a trace amount of conversion 
between chalcone 109 and flavanone 137 occurred with the use of K2CO3. 
 
Scheme 4.15. The Heck reaction did not proceed with bromochalcone 109, with only benzaldehyde 59, 5ʹ-bromochalcone 109 
and a trace amount of the corresponding flavanone 137 identified in the 1H NMR spectrum. 
4.3.2.3 Heck Reaction of 6-Bromoflavanone 137 and 6-Bromoflavone 
165 
Following application of the Heck reaction to brominated flavanone 137 
(Scheme 4.16), analysis of the crude material showed only the flavanone and nBu 
acrylate starting materials. There was a trace amount of the corresponding chalcone 109 
(in a ratio of 1:9 for chalcone 109 to flavanone 137 respectively), as indicated by a 
small broad singlet at δ 12.76 ppm representing the 2ʹ-hydroxyl proton of the chalcone.  
 
Scheme 4.16. The Heck reaction of 6-bromoflavanone 137 did not produce the desired acrylate 204. 
 The reaction conditions were also applied to 6-bromoflavone 165, however, as 
with 4ʹ-bromoflavone 157, only starting material 165 and the corresponding 
acetophenone 108 and benzaldehyde 59 were identified in the 1H NMR spectrum of the 
crude product material, in a ratio of 1:2:2 respectively (Scheme 4.17). 
 
Scheme 4.17. The Heck reaction of 6-bromoflavone 165 also did not proceed. 
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4.3.3 Alternate Pathway to Flavonoid Acrylates 
 While the Heck reaction could not be successfully applied to Ring A or Ring B 
brominated chalcones, flavanones and flavones, an alternate method was trialled. It was 
thought that the use of acetophenone acrylate 200 in a Claisen-Schmidt condensation 
would allow access to these desired chalcone and flavonoid acrylates, and so 
acetophenone nBu acrylate was reacted under the optimal Claisen-Schmidt 
condensation conditions identified in Chapter Two (benzaldehyde 59, 2ʹ-
hydroxyacetophenone acrylate 200, KOH, THF, MW, 50 °C, 15 min, Scheme 4.18).  
 
Scheme 4.18. The Claisen-Schmidt condensation of acetophenone acrylate 201 allowed access to chalcone acrylate 206. 
Analysis of the crude material by 1H NMR spectroscopy (Figure 4.4) revealed 
complete conversion of the acetophenone starting material 200 (from the loss of the 
acetophenone CH3 peak at δ 2.61 ppm), along with the presence of excess benzaldehyde 
59 (the aldehyde peak at δ 9.99 ppm) and the desired chalcone acrylate 206 (by the 
‘movement’ of aromatic peaks, and the appearance of a singlet at δ 13.10 ppm 
representing the chalcone hydroxyl). A small amount of the corresponding flavanone 
207 was also present in the 1H NMR spectrum, as two multiplets at δ 2.65-2.87 ppm 
and δ 5.12-5.22 ppm representing the CH2 and CH respectively. The ratio of chalcone 
206 to flavanone 207 was approximately 4:1, as determined from the integrations of the 
hydroxyl peak of the chalcone (integration of 0.85 at δ 13.10 ppm), and the CH peak of 
the flavanone (integration of 1 at δ 5.12 ppm). 
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Figure 4.4. 1H NMR spectrum of the Claisen-Schmidt condensation of acetophenone acrylate 200 and benzaldehyde 59 
(CDCl3). 
It was also noted that the nBu protecting group was still attached, by the 
presence of peaks at δ 0.90-1.70 ppm and δ 4.20 ppm. Purification by column 
chromatography (1:1 CH2Cl2:Pet) isolated the protected chalcone nBu acrylate 206 in a 
yield of 87%, which was then fully characterised. This result allowed access to 
chalcone and flavonoid acrylates, even though the direct Heck reaction with brominated 
chalcones and flavonoids had been unsuccessful. 
4.4 Heck Reaction of Flavonoids: Conclusion 
Trials of known Heck reaction conditions were carried out using 4-
bromobenzaldehyde 73 as the aryl halide and nBu acrylate as the acrylate substrate. 
While Pd(OAc)2, PPh3 and DMF were selected as the palladium source, ligand and 
solvent respectively, due to their common use in Heck reactions,390, 540 K2CO3 was 
found to be the base that gave the greatest yields, and NEt3 was the next best. It was 
also determined that when using K2CO3, the acrylate should be used in a 4:1 ratio with 
the aryl bromide in order to maximise conversion. Five acrylates were reacted under the 
optimised conditions: nBu acrylate, tBu acrylate, acrylonitrile, acrylamide and acrylic 
acid; however with the brominated benzaldehyde and acetophenone substrates, only the 
two acrylic esters were successfully reacted.  
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The application of the Heck reaction conditions to chalcone, flavanone and 
flavone substrates brominated on either Ring A or Ring B was unsuccessful. However, 
such flavonoid acrylates could still be accessed: Scheme 4.19 shows that through the 
acetophenone nBu acrylate 200, chalcone and flavanone acrylates were able to be 
synthesised. 
 
Scheme 4.19. Flavonoid acrylates could be accessed through the use of acetophenone nBu acrylate 200 in Claisen-Schmidt 
condensation and isomerisation or flavone formation reactions.  
With this knowledge, attention turned to the synthesis of Designed Multiple 
Ligands (DMLs), which included the use of acetophenone acrylates 200 and 201.  
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Chapter Five: 
‘Conjugate’ Designed Multiple 
Ligands: Functionalised 
3ʹ,4ʹ-Dihydroxyflavonols and 
Peptidomimetic ACE Inhibitors 
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5.1 Chapter Overview 
Designed Multiple Ligands, or DMLs, are therapeutic agents which incorporate 
two or more pharmacophores or pharmaceutical structures into a single compound. 
Such compounds offer a number of advantages, including synergistic effects leading to 
reduced doses, lower costs for patients and increased compliance to medications.545 
This chapter will discuss attempts to synthesise a number of DML compounds for the 
treatment of hypertension, incorporating 3ʹ,4ʹ-dihydroxyflavonol compounds with 
various linker groups as one ligand, and enalapril analogues as another ligand. 
5.2 Designed Multiple Ligands 
 Designed Multiple Ligands, or DMLs,545-548 are a relatively new development in 
pharmaceutical drug design. Their main premise is that they incorporate two or more 
known bioactives with similar therapeutic effects into a single compound, thus 
providing more than one beneficial effect in the treatment of a particular disease. There 
are a number of different names for DMLs in the literature, including codrugs,549 Multi-
Target-Directed Ligands,550 hybrid drugs,551, 552 bi- or multifunctional drugs,553 and 
multitarget drugs,554 however DML is the most commonly used title, and was coined by 
Morphy and Rankovic.545-548, 555 DMLs fall under the topic of polypharmacology, or the 
development of therapies that modulate multiple targets simultaneously.545, 547  
There are two approaches in the design and synthesis of DML compounds; the 
knowledge based approach and the screening approach (Figure 5.1). In both 
approaches, a lead generation phase accesses either two highly-selective ligands, one 
selective ligand (of two), or a non-selective ligand (with two other selective ligands). 
The processes of ‘designing in’ desirable structural features, ‘balancing’ of the ligands’ 
features to configure ligand selectivity, and ‘designing out’ undesirable features is used 
to access a DML lead candidate from the lead compound. Next is the lead optimisation 
phase, to balance the activity ratio of the ligands, optimise the selectivity of the DML to 
target sites and other receptors in the body, optimise the physicochemical properties, 
absorption, distribution, metabolism, excretion (ADME) and toxicological properties of 
the DML, so as to increase the compound’s bioavailability. This results in a DML drug 
candidate, ready for clinical trials.548 
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Figure 5.1. The knowledge-based and screening approaches to the discovery of DMLs.548 
5.2.1 Knowledge-Based Approach to the Discovery of DMLs 
The knowledge-based approach to the discovery of DML compounds utilises 
marketed drugs with known targets, or compounds which are historically known to 
provide certain therapeutic effects.548 There are three different ways in which the 
ligands of DMLs may be joined. The first is the attachment of the ligands through a 
linker group, and such compounds are known as ‘conjugate’ DMLs (Figure 5.2a). This 
linker must be structurally different to the ligands themselves, and its length, strength 
and flexibility can be carefully selected to accommodate the ligands and their respective 
target sites.548 A commonly used liker is poly(ethylene glycol), as it can be simply used 
to install different linker lengths, and also confers good aqueous solubility.548  
 
Figure 5.2. ‘Conjugate’, ‘fused’, and ‘merged’ are the three ways in which the ligands of knowledge-based DMLs can be 
attached to one another. 
Linkers may also be enzymatically cleavable, to allow the ligands to be cleaved 
from one another to reach different or distant active sites.545, 548, 556 Most of the 
cleavable conjugates reported in the literature contain an ester-based linker, which is 
designed to be cleaved by plasma esterases to release the two or more individual drugs 
that then act independently.548 One such example is the non-steroidal anti-inflammatory 
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drug (NSAID) DML 209, which links the NSAID ibuprofen through an ester linker 
group to an NO-donor (Figure 5.3).557 The ester is cleaved by plasma esterases to 
provide two bioactives, which act separately.548 
 
Figure 5.3. The NSAID DML 209 links ibuprofen to an NO-donor through a cleavable linker group. 
As the size of this linker group decreases, it reaches a point where the ligands 
are essentially touching. Such compounds are known as ‘fused’ DMLs, and involve the 
direct linking of the ligands (Figure 5.2b).548 The non-peptide gastrin receptor 210, 
developed for the prevention of peptic ulcers caused by chemotherapy with histamine 
H2 receptor antagonists,558 is such an example, where a hydrophobic gastrin antagonist 
(shown in blue) and a hydrophilic histamine H2 pharmacophore (shown in green) are 
‘fused’ to provide the DML.548 
 
Figure 5.4. ‘Fused’ DML 210 was developed for the prevention of peptic ulcers in chemotherapy. 
Finally, the most common form of knowledge-based DMLs is ‘merged’ DMLs, 
which incorporate the pharmacophores of two or more different pharmaceuticals onto a 
single scaffold, by taking advantage of commonalities in the structures of the starting 
ligands (Figure 5.2c).545, 548 Once such example is omapatrilat 211, which will be 
discussed in more detail under the topic of cardiovascular DMLs (Chapter 5.2.4).551, 559 
Possibly the greatest advantage of the DMLs is that the design process 
eliminates many of their potential disadvantages. The ‘designing in’ of structural 
features that are associated with beneficial therapeutic effects, or the ‘designing out’ of 
structural features known to cause side effects, is of great value to the design process. 
Following the development of a lead compound through this knowledge-based 
strategy, the lead optimisation phase can begin. This involved the balancing of the 
activity ratio, the optimisation of physicochemical properties (to promote 
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bioavailability, for example), and the optimisation of ADME properties, once again to 
promote bioavailability.548 
5.2.2 Screening-Based Approach to the Discovery of DMLs 
The screening approach to discover DMLs involves either high throughput 
screening (HTS), where numerous small molecules are tested against a number of 
targets, or focused screening, where compound classes that are already known to be 
active against one of the targets of interest are screened against another target.545, 548 
The latter is more commonly utilised than HTS,548 potentially due to a lower probability 
of the screening of compounds delivering suitable combinations of activities, or the 
logistical complications and costs associated with conducting multiple screens.546 
DMLs discovered through a screening approach also take advantage of the 
design process to eliminate potential disadvantages. Lead DML compounds identified 
through either screening process offer the advantage of possible further modification, 
through the ‘designing in’ of desired activities through the incorporation of certain 
functionalities, as well as the ‘designing out’ of specific structural features associated 
with detrimental effects,545, 548 The ‘balancing’ of these lead DML compounds through 
the modification of their structural features also helps to ensure that the compound has 
optimal affinity for all targets.548 
As with the knowledge-based strategy, once a lead compound has been 
developed, the lead optimisation phase modifies the physicochemical properties and 
affinity for targets to optimise bioavailability of the compound.548 
5.2.3 Advantages of DMLs 
As well as the benefits associated with the design process of DMLs, there are a 
number of other advantages for DMLs. First and foremost, their different ligands allow 
for more than one target to be reached, providing more than one beneficial effect or 
pathway of action from a single pharmaceutical.545, 548 Whilst this advantage can also be 
assigned to the administration of multiple drugs (a ‘drug cocktail’) and ‘fixed dose 
combinations’ (FDCs, where two or more drugs are co-formulated into a single 
tablet),545 the latter approaches are associated with complications due to highly 
complex/ different pharmacokinetic and pharmacodynamic relationships. 
DMLs are also known to exhibit ‘synergistic’ effects,545, 550, 553, 554 whereby the 
combination of ligands leads to a stronger response from the body than the 
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administration of the ligands separately. Once again, this effect does not apply to FDCs 
or drug cocktails.545 This synergistic effect allows for the administration of lower doses 
of the DMLs, and is therefore also beneficial in the case of side effects, which may be 
reduced or even removed with lower doses. 
Another benefit is patient compliance; the simple fact that a pharmaceutical plan 
with one tablet is easier to follow than three tablets indicates that patients are more 
likely to comply with their medication. This leads to a significant reduction to 
healthcare costs associated with lack of medication.545 Also, the risks and costs of 
developing DMLs are in principle no different to the development of any other single 
entity, therefore DMLs should not be any more costly than single drugs.546 
A possible disadvantage of DMLs is that each ligand incorporated into the 
structure may have different active concentrations. This may result in either an 
overdose or cytotoxic effects from one ligand, or insufficient response or effect from 
the other ligand. This is a common problem in the synthesis of DML compounds,545, 548 
and in most examples, the aim has been to obtain in vitro activities within an order of 
magnitude of each other in animal models, with the assumption that this will lead to 
similar levels of receptor occupancy in vivo.548 Ultimately, the results of these animal 
model studies help to identify the optimal ratio of the ligands to design a second 
generation of DML compounds.548 
Another problem with the DMLs is that incorporating two or more compounds 
into a single structure often leads to large molecular weights,560 which are associated 
with poor drug absorption and cell permeation, in accordance with Lipinski’s Rule of 
Five (especially those with molecular weights greater than 500).561 This can be avoided, 
once again in the design process, through the use of smaller linker groups and ligands 
when ‘conjugate’ DMLs are concerned, and is less problematic in the case of ‘merged’ 
DMLs, where only a single scaffold is required and so molecular weights can be kept 
down.545, 547, 548 
With the many advantages of DMLs, and the design process allowing for the 
removal of many of the potential disadvantages, there have been a number of diseases 
for which the DMLs have been designed. Of particular relevance to this research are 
those which have been developed for cardiovascular diseases. 
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5.2.4 Cardiovascular DMLs 
DMLs have been developed for a number of different diseases, including 
malaria,552 cancer,560 and HIV,562 Alzheimer’s disease,563 diabetes,563 inflammation,563 
infection,563 and diseases of the central nervous system (CNS, including depression and 
schizophrenia),563 amongst others.553, 564, 565 Of note to this research is the fact that no 
DMLs published to date incorporate a flavonoid scaffold; as mentioned in Chapter One, 
the flavonoids are associated with a large number of biological benefits.  
A number of cardiovascular DMLs have been developed.551, 554, 563 Omapatrilat 
211 was one such ‘merged’ example (Figure 5.5), which inhibited both the 
Angiotensin-Converting Enzyme (ACE) and neutral endo-peptidase (NEP, an enzyme 
which cleaves a natural peptide known to reduce blood pressure). It incorporates 
features of compound SQ28603 212, an inhibitor of neutral endo-peptidase (NEP, an 
enzyme which cleaves a natural peptide known to reduce blood pressure), and captopril 
39, an ACE inhibitor (Figure 5.5).551 Omapatrilat elicited cardiovascular effects greater 
than either component alone (a synergistic effect),559 and offered the advantage of a 
reduced risk of serious side effects (including death and hospitalisation) in comparison 
to enalapril 43.566 However, after reaching Phase III Clinical trials, omapatrilat was 
linked to angioedema (swelling of the skin), and was not approved by the FDA.554, 563 
 
Figure 5.5. Omapatrilat 211, a DML incorporating pharmacophores of the NEP inhibitor SQ28603 212 and the ACE 
inhibitor captopril 39, causes angioedema. 
Following omapatrilat, the cardiovascular compound CGS35601 213 has 
advanced furthest in clinical trials.563 CGS35601 213 is a triple vasopeptidase inhibitor 
(VPI) of ACE, NEP and endothelin-converting enzyme (ECE, an enzyme which 
produces a vasoconstrictive peptide).567 It was developed from ECE inhibitor 
CGS30084 214 at Novartis,568 and underwent further modification to produce the triple-
action DML (Figure 5.6).569, 570  
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Figure 5.6. CGS35601 213, a potent triple vasopeptidase inhibitor, was discovered through modifications made to the ECE 
inhibitor CGS30084 214.  
CGS35601 213 is potent at all three active sites, with IC50 concentrations (half 
maximal inhibitory concentration) of 22 nM, 2 nM, and 119 nM for ACE, NEP and 
ECE respectively.570 Preclinical pharmaco-toxicological evaluations have also been 
performed using the prodrug of CGS35601 (known as CGS37808 215, Figure 5.7) in 
rats, and found that it presented no safety concerns and did not cause angioedema.570 
Further testing and clinical trials are still required,567, 571 and as of February 2012, 
neither CGS35601 213 nor its prodrug 215 had entered the Novartis drug pipeline.563 
 
Figure 5.7. CGS37808 215, the prodrug of CGS35601 213, does not cause angioedema in rats. 
 With the knowledge that no one had taken advantage of the antioxidant activity 
of the flavonoids, in particular the vasorelaxant and antioxidant compound 3ʹ,4ʹ-
dihydroxyflavonol 53, our attention turned to its use in the synthesis of DMLs 
combining this antihypertensive compound with peptidomimetic ACE inhibitors.  
5.3 The Ligands of the ‘Conjugate’ DMLs 
 With the vasorelaxant and antioxidant 3ʹ,4ʹ-dihydroxyflavonol 53 in mind, as 
well as analogues of the peptidomimetic ACE-inhibitor enalapril 43, it was thought that 
a series of ‘conjugate’ (joined through a linker group) DMLs could be synthesised and 
evaluated for their antihypertensive activity. The research herein describes attempts to 
synthesise a series of antihypertensive DMLs incorporating 3ʹ,4ʹ-dihydroxyflavonol 53 
and peptidomimetic (enalapril) analogues attached through a linker group. A number of 
linker groups were explored, and will be explained in turn. Note that following the 
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synthesis of the DMLs, biochemical analysis of the DML compounds as well as the 
individual ligands was to be performed, to compare both individual and combined 
effects, as well as identify any synergistic effects. 
5.3.1 Ligand 1: 3ʹ,4ʹ-Dihydroxyflavonol 53 
As explained in Chapter 1.3.4.1, 3ʹ,4ʹ-dihydroxyflavonol 53 is a vasorelaxant 
flavonoid. Three important features have been identified as responsible for its 
vasorelaxant activity (Figure 5.8); it is a flavonol (shown in red), it lacks substitution on 
Ring A (shown in green), and contains hydroxyl groups on both positions 3 and 4 of 
Ring B (shown in blue).286 Coincidentally, two of these features (shown in red and blue) 
are also linked to the antioxidant activity of flavonoids, and so it is no surprise that this 
flavonol also offers the benefit of antioxidant activity.277, 288 
 
Figure 5.8. 3ʹ,4ʹ-Dihydroxyflavonol 53 is a vasorelaxant, antioxidant flavonoid. 
While the exact pathway through which 3ʹ,4ʹ-dihydroxyflavonol 53 produces its 
vasorelaxant activity is unknown, Woodman and co-workers have shown that it 
decreases vascular contraction at least in part by inhibition of the RhoA/Rho-kinase 
pathway in endothelium-denuded rat aorta.289 It also causes Ca2+ desensitisation in 
vascular smooth muscle, resulting in reduced vascular smooth muscle contraction.290 
Biochemical and biological evaluation has revealed other therapeutic effects, including 
antioxidant properties, the ability to reduce tissue death after ischaemia and reperfusion 
(in sheep hearts and rat brains),61, 277, 292 and the prevention of diabetes-induced 
endothelium dysfunction.295, 296  
As the biological target of 3ʹ,4ʹ-dihydroxyflavonol 53 is unknown, so is its 
active concentration. This makes the ‘designing in’ and ‘designing out’ process to 
ensure affinity to the receptor target for the flavonol, as well as ACE for the dipeptides, 
as well as determine similar active concentrations, impossible at this stage.  
As mentioned in Chapter 1.3.4.1, a problem in the use of 3ʹ,4ʹ-
dihydroxyflavonol 53 as a pharmaceutical is its lack of solubility and therefore 
bioavailability. In fact, in order to conduct biochemical testing, Williams and co-
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workers had to dissolve the compound in DMSO for administration to cells.61 However, 
this lack of solubility was overcome through the introduction of various functionalities. 
One of these in particular was succinamic acid, attached to the 6-position of the 3ʹ,4ʹ-
dihydroxyflavonol (Figure 5.9).  
 
Figure 5.9. Woodman and co-workers synthesised the succinamic acid 54 (shown in blue) of 3ʹ,4ʹ-dihydroxyflavonol 53 to 
increase solubility. 
The sodium salt of the succinamic acid on Ring A has also been reported to 
greatly increase solubility in water (Figure 5.3 c); from less than 10-7 M for 3ʹ,4ʹ-
dihydroxyflavonol to 10-1 M for the sodium salt.62 When the succinamic derivative 54 
was applied to rat aorta in vasorelaxant studies, it exhibited none of the vasorelaxant 
activity of 3ʹ,4ʹ-dihydroxyflavonol 53, however maintained some of its antioxidant 
activity.62 However, no studies were completed regarding the enzymatic digestion of 
the compound, providing the possibility that enzymatic cleavage may produce the 
vasorelaxant flavonol to the body. This soluble flavonol was an ideal compound for the 
synthesis of the ‘conjugate’ DMLs, as it provided not only the antioxidant 3ʹ,4ʹ-
dihydroxyflavonol 53 but also a linker group from which to attach the second ligand, a 
peptidomimetic ACE inhibitor. 
 Another possible linker group for the 3ʹ,4ʹ-dihydroxyflavonol ligand arose from 
the acetophenone acrylates synthesised using a Heck reaction in Chapter Four 
(Scheme 5.1). Acetophenone acrylates 200 and 201, which were successfully used in 
Claisen-Schmidt condensations to access their corresponding 2ʹ-hydroxychalcones 
(Chapter 4.2.3.2), were ideal starting materials for the synthesis of 3ʹ,4ʹ-
dihydroxyflavonol compounds 216 with an acrylic side chain on Ring A. 
 
Scheme 5.1. 3ʹ,4ʹ-Dihydroxyflavonol compound 216 with an acrylic acid side chain could be accessed from the acetophenone 
acrylates 200 and 201 synthesised in Chapter Four. 
 117 
 
 As both the flavonol succinamic acid 54 and flavonol acrylic acid 216 provided 
a carboxylic acid linker group, it was ideal that the peptidomimetic ACE inhibitors, 
based on enalapril 43, would contain an amine for coupling to the carboxylic acid of the 
flavonols. 
5.3.2 Ligand 2: Peptidomimetic ACE Inhibitors 
For the second ligand of these DMLs, compounds were synthesised based on the 
peptidomimetic ACE inhibitor, enalapril 43 (Figure 5.10). Enalapril 43 is able to bind 
the pockets of ACE through its carboxylic acid (red), methyl substituent (green) and C-
terminal proline unit (blue). These functionalities were used to produce a general 
scaffold for the enalapril analogues synthesised for the DMLs. These enalapril 
analogues also required an amine functionality (purple), so that they may be linked to 
the acid of the flavonols 54 and 216 through an amide bond. Lysine 217 was noted as 
an ideal functionality for these enalapril analogues, as it provided both a carboxylic acid 
and an amine group for linking, leaving the methyl substituent to be incorporated 
between the proline and lysine units. 
 
Figure 5.10. Enalapril 43, and the enalapril analogue 218 of this project which incorporated lysine 217. 
As the two antihypertensive ligands had now been selected, attention first turned 
to the synthesis of the flavonol ligands. The synthesis of each of the 3ʹ,4ʹ-
dihydroxyflavonol ligands 54 and 216 will be discussed in turn, followed by the 
synthesis of the enalapril analogues, and finally the coupling of the two ligands. The 
synthesis of the succinamic acid-3ʹ,4ʹ-dihydroxyflavonol 216 will be addressed first. 
5.4 The Succinamic Acid-Linked DMLs 
5.4.1 Retrosynthesis of Succinamic Acid-Linked DMLs 
For the succinamic acid-linked DMLs, the following retrosynthesis was 
developed (Scheme 5.2). 
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Scheme 5.2. Retrosynthetic pathway for the synthesis of succinamic acid-linked DMLs 219. 
This retrosynthetic method begins with the benzyl deprotection of the phenols of 
Ring B of flavonol 220, followed by the amide coupling of the amine of the enalapril 
analogue 218 to the carboxylic acid of the flavonol succinamic acid 221 (Scheme 5.1). 
The flavonol succinamic acid 221 could be accessed using the methodology of 
Woodman and co-workers, from p-anisidine 222 and 3,4-dihydroxybenzaldehyde 223.62 
5.4.2 Synthesis of the Flavonol Succinamic Acid 
To access flavonol succinamic acid 221 (Figure 5.11), acetophenone acetamide 
224 had to be first synthesised, using a method from Bennett et. al..98 The protection of 
the 3,4-dihydroxybenzaldehyde 223 was also required. The chalcone and flavonol 
compounds could then be synthesised using the conditions provided by Woodman.62 
 
Figure 5.11. The desired benzyl-protected flavonol succinamic acid 221. 
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5.4.2.1 Acetamide formation and Friedel-Crafts reaction 
Acetophenone 224 was synthesised from para-anisidine 222 in two steps.98 
First, p-anisidine 222 was stirred with acetic anhydride in CH2Cl2 at room temperature 
for three hours (Scheme 5.3). Following work up, acetamide 225 was isolated as a 
purple solid in 98% yield.  
 
Scheme 5.3. The synthesis of acetophenone acetamide 224 over two steps from p-anisidine 222. 
Friedel-Crafts acylation of acetamide 225 using acetyl chloride (AcCl) and 
aluminium chloride (AlCl3) was performed in CH2Cl2 under reflux for five hours. The 
crude product was recrystallised from EtOH to give acetophenone 224 in 47% yield as 
pale green crystals (Scheme 5.3). The structure was confirmed by comparison to 
literature data,98 including an acetamide CH3 peak at δ 2.16 ppm, the acetophenone CH3 
peak at δ 2.60 ppm, and the acetophenone OH peak at δ 12.09 ppm in the 1H NMR 
spectrum (Figure 5.12). Note that the amide N-H proton was obscured by the aromatic 
peak of proton HA (Figure 5.10, δ 7.24-7.33 ppm). With acetophenone 224 in hand, the 
protection of 3,4-dihydroxybenzaldehyde 223 was investigated, to provide a protected 
benzaldehyde to react with the acetophenone acetamide 224 in a Claisen-Schmidt 
condensation. 
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Figure 5.12. 1H NMR spectrum of acetophenone acetamide 224 (CDCl3). 
5.4.2.2 Protecting 3,4-Dihydroxybenzaldehyde 223 
The most common protecting group for catechols (ortho-dihydroxyl groups on 
an aromatic ring) is an acetal,393 and is relatively simple to introduce.572 However, the 
deprotection of acetals relies on strongly acidic conditions, which is known to cause 
problems in terms of chalcone-flavanone isomerisation (see Chapters 2.2.1 and 3.2 for 
our experiences with this isomerisation).393 For this reason, the protection of each 
phenol individually (as phenolic ethers) was attempted. Methyl and benzyl protection 
was selected, as these groups could be easily installed, and deprotected using methods 
that would not affect the flavonoid scaffold (BBr3 demethylation and hydrogenation 
respectively).393 
 First, dimethylation of 3,4-dihydroxybenzaldehyde 223 was attempted 
(Table 5.1, entry 1). Reflux of the benzaldehyde with K2CO3, dimethyl sulfate 
((CH3)2SO4) and acetone for two hours, followed by column chromatography (2:1 
Pet:EtOAc) isolated 3,4-dimethoxybenzaldehyde 226 in 93% yield. While this reaction 
was successful, the use of (CH3)2SO4 in large scale reactions is hazardous,401 and 
therefore benzyl protection was also investigated. 
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Table 5.1. Protection of 3,4-dihydroxybenzaldehyde 223. 
 
Entry Product R Yield 
1 226 Me 93% 
2 227 Bn 74% 
 
 For the dibenzyl protection of 3,4-dihydroxybenzaldehyde 223, conditions from 
the work of Woodman and co-workers were used.291 The unprotected benzaldehyde 223 
was stirred with benzyl bromide (BnBr, 2.2 equivalents) and K2CO3 (2.4 equivalents) in 
EtOH for 72 hours at room temperature (Table 5.1, entry 2). Recrystallisation of the 
crude material from EtOH isolated 3,4-dibenzyloxybenzaldehyde 227 in 74% yield, as 
confirmed by comparison to literature data,291 including the appearance of peaks 
corresponding to the benzyl (δ 5.21 ppm and δ 5.23 ppm) and aldehyde (δ 9.80 ppm) of 
the desired product (Figure 5.13). While benzyl bromide is also hazardous in large scale 
reactions, this protection was ideal as 3,4-dibenzyloxybenzaldehyde 227 had been 
successfully used in the synthesis of flavonols by Woodman and co-workers,291 whose 
methodologies were also used in the current synthesis. 
 
Figure 5.13. 1H NMR spectrum of the protected compound, 3,4-dibenzyloxybenzaldehyde 227 (CDCl3). 
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With the protected 3,4-dibenzyloxybenzaldehyde 227 in hand, attention turned 
to the reaction of this aldehyde with acetophenone acetamide 224 to access the desired 
chalcone acetamide 228, using a Claisen-Schmidt condensation. 
5.4.2.3 Claisen-Schmidt Condensation to Synthesise Chalcone 
Acetamide 228 
To synthesise chalcone acetamide 228, a number of methods were trialled using 
acetophenone acetamide 224 and protected benzaldehyde 227 as starting materials 
(Scheme 5.4). These methods included the microwave-assisted Claisen-Schmidt 
methodology developed in Chapter Two, as well as that of Woodman and co-workers.62 
Note that the conversion ratios were determined by the comparison of the integration 
values of the CH3 peak of acetophenone 224 (δ 2.60 ppm with an integration of 3), and 
the hydroxyl peak of chalcone 228 (δ 12.75 ppm with an integration of 0.85, as 
explained in Chapter 2.3.2). 
 
Scheme 5.4. The synthesis of chalcone acetamide 228 was attempted using a number of methods. 
The first method attempted was the optimised microwave-assisted Claisen-
Schmidt condensation developed in Chapter Two (Table 5.2, entry 1). Following work 
up, analysis by 1H NMR spectroscopy revealed both the acetophenone 224 and desired 
chalcone 228, in a ratio of 1:3. Purification by recrystallisation (1:1 Pet:THF) isolated 
the desired chalcone acetamide 228 in 65% yield. The synthesis of the desired 
compound was confirmed by comparison to the literature data,62 including the 
appearance of the chalcone hydroxyl peak (δ 12.75 ppm) in the 1H NMR spectrum 
(Figure 5.14). The success of this reaction validates the practical utility of the method 
developed herein, as Woodman and co-workers were unable to effect the same 
transformation without first protecting the acetophenone hydroxyl group, which 
required an additional two steps in the synthesis (p-methoxybenzyl (PMB) protection 
and deprotection).62  
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Figure 5.14. 1H NMR spectrum of purified chalcone acetamide 228 (CDCl3). 
While chalcone acetamide 228 had been isolated in good yield, a number of 
other methods were also trialled in the hope of greater conversion and yields. When the 
reaction was repeated using microwave irradiation, with EtOH in place of THF as the 
solvent (EtOH is the solvent of choice for the conventional Claisen-Schmidt 
condensation method),189, 342, 381-383 decreased conversion (2:1 acetophenone 224 to 
chalcone 228) was noted (Table 5.2, entry 2). 
Table 5.2. Claisen-Schmidt condensation of acetophenone acetamide 224 with 3,4-dibenzyloxybenzaldehyde 227. 
 
Entry Conditions Solvent 224:228 (yield) 
1 MW 70 °C 30 min THF 1:3 (65%) 
2 MW 70 °C 30 min EtOH 2:1 
3 16 hrs rt THF 2:1 
4 40 hrs rt THF 1:0 
5 16 hrs 40 °C EtOH 1:4 (79%) 
 
The reaction was then repeated using the conventional methodology, KOH in 
THF at room temperature for 16 hours (Table 5.2, entry 3), and chalcone acetamide 228 
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was produced in a ratio of 1:2 with acetophenone 224. When these conditions were 
repeated with a reaction time of 40 hours (Table 5.2, entry 4), none of the desired 
chalcone 228 was produced; only starting materials were observed in the 1H NMR 
spectrum. This outcome suggested that increased reaction times could allow the retro-
aldol reaction (shown previously in Scheme 3.7). 
 The reaction was also carried out in EtOH for 16 hours at 40 °C, in accordance 
with Woodman’s Claisen-Schmidt conditions (Table 5.2, entry 5).62 This provided the 
best conversion (1:4 acetophenone 224 to chalcone 228). Recrystallisation from 
1:1 Pet:THF afforded chalcone acetamide 228 in 79% yield, and its structure was 
confirmed by 1H NMR spectroscopy. With chalcone acetamide 228 in hand, the 
synthesis of the flavonol acetamide was attempted.  
Before discussing the synthesis of the flavonol acetamide, a brief introduction to 
the synthesis of flavonols is required. 
5.4.2.4 Flavonols 
5.4.2.4.1 Flavonols: Synthesis 
As mentioned in Chapter One, the flavonols 8 are structurally distinguishable 
from other flavonoids due to the alkene in the 2-position, hydroxyl in the 3-position, 
and ketone in the 4-position of Ring C (Figure 5.15). The flavonols are simply flavones 
with an added hydroxyl group, giving rise to another name, 3-hydroxyflavones. 
 
Figure 5.15. The general structure of the flavonols 8, or 3-hydroxyflavones. 
As also established in Chapter One, two well-known flavonols found in nature 
are quercetin 13,13 which is commonly found in its glycosidic forms in green and black 
teas,573 onion,574 and cranberries,575 and kaempferol 18, which can be found in many 
plant species (see the mini-review by Calderon-Montano et. al. for an extensive list),576 
including tea573 and spinach574 (Figure 5.16). Quercetin 13 and kaempferol 18 both 
exhibit antileishmanial,91 antidiabetic,160, 185 and anticancer properties,131 and numerous 
other flavonol compounds exhibit these and other beneficial qualities.61, 84, 210, 577, 578 In 
plants, the flavonols are synthesised from flavanols (which lack the double bond 
between the 2- and 3-positions) by flavonol synthase. However, there are numerous 
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methods available for the laboratory synthesis of flavonols, from various starting 
materials.  
 
Figure 5.16. Quercetin 13 and kaempferol 18 are two common flavonols found in nature. 
5.4.2.4.2 The Auwers Synthesis 
In 1908, the first synthetic methodology for the synthesis of flavonols, the 
Auwers Synthesis, was discovered.579 This method transforms 2-bromo-2-(α-
bromobenzyl)coumarones 229 to flavonols 8 using hydroxides, (Scheme 5.5).580 The 
formation of oxonium 230 results from the loss of the α-bromine from dibromide 229. 
This is followed by attack of the activated α-position by the hydroxide, and then 
removal of a β-hydrogen to give chalcone-like structure 232. Finally, attack at the β-
position of the alkene, and loss of the β-bromine gives the desired flavonol 8. This 
method is quite dated,581-584 and other syntheses with simpler starting materials have 
been developed in more recent years. 
 
Scheme 5.5. Mechanism of the Auwers reaction for the synthesis of flavonol 8.580 
5.4.2.4.3 DMDO-mediated synthesis 
 Another method for the synthesis of flavonols uses dimethyldioxirane (DMDO) 
234 as an epoxidising reagent with 2ʹ-hydroxychalcones585, 586 or flavones.331, 493 
DMDO 234 is an extremely unstable compound, and is generated in situ in quite low 
concentrations, typically 0.04-0.12 M solutions, from acetone, oxone, sodium 
bicarbonate (NaHCO3), and H2O (Scheme 5.6).587-590 Its concentration can be 
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determined by the NMR or GLC titration of the oxidation of thioanisole,589, 591 which is 
oxidised to its sulfoxide and then sulfone.218, 220  
 
Scheme 5.6. DMDO 234 is synthesised from acetone, NaHCO3 and oxone. 
Whilst produced only in low concentrations,588 DMDO 234 is made from 
extremely cheap reagents, and the by-product of its reaction with alkenes is the 
relatively safe acetone. Due to its instability, DMDO 234 must be synthesised for 
immediate use, or can be stored under refrigeration for a maximum of three to four 
days. Disadvantages of its use in flavonol formation include long reaction times of up to 
140 hours, and the use of excess reagent (up to 15 equivalents).585, 586, 592-597 The 
application of DMDO to 2ʹ-hydroxychalcones leads to the formation of aurones as a 
side product,598 while the DMDO reaction of flavones does not (Scheme 5.7). 
 
Scheme 5.7. Mechanism of flavonol 8 formation from flavone 7 using DMDO. 
 This DMDO-mediated synthesis was attempted in our hands, using flavone 7 as 
a substrate (synthesised in Chapter 3.3.2). DMDO solution 234 was synthesised 
according to a method by Wright,588 and using thioanisole, NMR titrations determined 
the concentration of DMDO as approximately 0.10 M in acetone, as also seen in 
Wright’s results. The solution was used immediately. 
Treatment of flavone 7 with fresh DMDO 234 (Scheme 5.8) revealed only the 
starting material in the 1H NMR spectrum. Even when the reaction was repeated with 
greater than ten equivalents of the DMDO solution and reaction times of up to 40 hours, 
flavonol 8 could not be accessed.  
 
Scheme 5.8. The DMDO-mediated epoxidation of flavone 7 did not proceed. 
As this DMDO-mediated method had proven unsuccessful, attention turned to 
another method, the Algar-Flynn-Oyamada reaction. 
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5.4.2.4.4 The Algar-Flynn-Oyamada Reaction 
In 1934, the Algar-Flynn-Oyamada (AFO) reaction was developed for the 
synthesis of flavonols.334, 335 This method involves the oxidation of 2ʹ-
hydroxychalcones by hydrogen peroxide (H2O2) under basic conditions (usually NaOH 
or KOH) at 0 °C. There has been much debate over the years as to whether the 
mechanism proceeds via an epoxide derivative599, 600 or not.601, 602 The mechanism of 
the epoxide-generated flavonol involves the cis-Weitz-Scheffer epoxidation of the 
alkene 66 by H2O2 (Scheme 5.9). The phenoxide of 235 then attacks the β-position to 
form the flavanol 236, followed by oxidation to form the desired flavonol 8.600, 603 
 
Scheme 5.9. The mechanism of the Algar-Flynn-Oyamada reaction via an epoxide intermediate. 
On the other hand, the non-epoxide mechanism involves the attack of the alkene 
by the deprotonated oxygen, followed by re-protonation to give the hydroxyl group at 
the 3-position (Scheme 5.10). Finally, oxidation of flavanol 236 gives flavonol 8.602, 603 
 
Scheme 5.10. The non-epoxide mechanism of the AFO reaction. 
A problem in the synthesis of flavonols by the AFO reaction is the formation of 
side products, namely the aurones 5, which form in a 5-exo-tet fashion, rather than the 
desired 6-exo-tet closure which leads to the flavonol.604 Both of these processes are 
favoured by Baldwin’s Rules.605 These compounds are formed when the deprotonated 
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oxygen of 235 attacks the α-position rather than the β-position, followed by dehydration 
to produce aurone 5 (Scheme 5.11).600, 602  

Scheme 5.11. Aurones 5 are formed in a 5-exo-tet fashion, a side product in the AFO reaction. 
Whilst the formation of aurones provides evidence for the epoxide mechanism, 
aurones don’t form in all cases, and thus the topic is still open for debate. Certain 
structural features promote aurone formation in the AFO reaction; a methoxyl 
substituent at the 6ʹ-position of 2ʹ-hydroxychalcones, or a lack of the 6ʹ-methoxyl group 
accompanied by hydroxyl groups at the 2ʹ- and 4ʹ-positions of the chalcone 93 produce 
a mixture of the aurone 5 and flavonol 8 (Scheme 5.12).603, 606-608 Aurones can also be 
synthesised from 2ʹ-hydroxychalcones using other reagents, including Hg(OAc)2493, 609 
and DDQ.487 
 
Scheme 5.12. The AFO reaction of 2ʹ,4ʹ-Dihydroxychalcone 93 leads to a mixture of aurone 5 and flavonol 8 products. 
Even with the risk of side-product formation, the AFO reaction has been highly 
popular in the synthesis of flavonols from 2ʹ-hydroxychalcone starting materials.303, 407, 
606, 610 Reactions have even been attempted with α-substituted chalcones.607, 608 
More recently, a ‘Modified’ AFO method has become popular, in which 2ʹ-
hydroxyacetophenones and benzaldehydes are reacted under Claisen-Schmidt 
Condensation conditions to afford a 2ʹ-hydroxychalcone, which is then directly treated 
with AFO conditions (without isolation of the chalcone) to afford the flavonol.291, 599, 611, 
612 Whilst this ‘Modified’ method appeared ideal for the synthesis of flavonols required 
in this project, the traditional, two-step AFO reaction was first trialled to access the 
desired flavonol acetamide. 
5.4.2.4.5 Algar-Flynn-Oyamada Reaction of Chalcone Acetamide 238 
The AFO method for flavonol formation from chalcone acetamide 228 was 
taken directly from that of Woodman and co-workers.62 In our hands, chalcone 228 was 
stirred with 2M NaOH and EtOH, and cooled to 0 °C. Hydrogen peroxide (H2O2) was 
 129 
 
added slowly, and the solution stirred for a further two hours at 0 °C before stirring for 
16 hours at room temperature (Scheme 5.13). 
 
Scheme 5.13. AFO reaction using Woodman’s conditions provided flavonol acetamide 238 in 91% yield. 
Neutralisation, followed by filtration, provided the desired flavonol in a yield of 
91%. The structure was confirmed through comparison to literature data, and included 
the loss of the chalcone hydroxyl peak (δ 12.75 ppm) and the slight downfield shifts of 
the acetamide CH3 (δ 2.21 ppm) and benzyl CH2 (δ 5.24 ppm) peaks in the 1H NMR 
spectrum (Figure 5.17). Note that the peaks of the spectra are somewhat broad, likely 
due to the π-π stacking of the flavonol.58 
 
Figure 5.17. 1H NMR spectrum of purified flavonol acetamide 238 (CDCl3). 
 However, when this reaction was repeated (numerous times, using not only the 
same conditions but also longer reaction times and at larger and smaller scales), none of 
the desired flavonol was produced. Nevertheless, a limited quantity of the requisite 
flavonol 238 was available to be used in the formation of the amine.  
Before advancing to the amine formation of the flavonol acetamide, the 
‘Modified’ AFO reaction was examined for the synthesis of the flavonol acetamide 238 
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from acetophenone 224 and benzaldehyde 227. The ‘Modified’ AFO reaction was 
successful in previous flavonol syntheses by Woodman and co-workers,291 and so their 
methodology was utilised. It was hoped that this method would provide the desired 
flavonol acetamide 238 in a reproducible manner, allowing access to larger quantities of 
the flavonol. 
5.4.2.4.6 ‘Modified’ Algar-Flynn-Oyamada Reaction 
Using acetophenone acetamide 224 and 3,4-dibenzyloxybenzaldehyde 227 as 
substrates, the ‘Modified’ AFO conditions were applied; stirring at room temperature 
with 40% KOH, EtOH and dioxane for five days, followed by treatment with 30% H2O2 
and 2M NaOH in EtOH and dioxane at 0 °C for two hours, and then 16 hours at room 
temperature (Scheme 5.14). Following this two-step reaction, analysis of the crude 
product by 1H NMR spectroscopy revealed a spectrum with broad peaks, including 
those of the benzaldehyde 227 (CHO at δ 9.80 ppm), Cannizzaro primary alcohol 
(δ 4.77 ppm, as produced by the intramolecular reaction of benzaldehydes with KOH, 
see Chapter 2.2.1), and broad aromatic peaks. Analysis of the reaction mixture by MS, 
revealed the presence of the desired flavonol, however purification by either column 
chromatography (2:1 Pet:EtOAc) or recrystallisation (EtOAc) failed to isolate the 
desired flavonol acetamide 238. 
 
Scheme 5.14. The ‘Modified’ Algar-Flynn-Oyamada conditions were used to access flavonol acetamide 238, however the 
desired flavonol could not be isolated. 
While the ‘Modified’ methodology could not be used to access the flavonol 
acetamide, the small amount of flavonol 238 accessed through the AFO reaction of the 
chalcone acetamide 228 was in hand to access the desired flavonol succinamic acid 221. 
5.4.2.5 Amine Formation 
The final step for the synthesis of the flavonol succinamic acid 221 involved 
two parts: the formation of the amine (as its hydrochloride salt) from the flavonol 
acetamide 238 under acidic conditions, followed by the reaction of this amine with 
succinic acid in pyridine to form flavonol succinamic acid 221 (Scheme 5.15).  
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Scheme 5.15. Formation of amine 239, followed by reaction with succinic anhydride, provides the desired flavonol 
succinamic acid 221. 
The amine formation step had previously been carried out on similar substrates 
by Woodman and co-workers using either 5M HCl in EtOH or 12M HCl in acetic acid 
(AcOH) under reflux for 2-3 hours, which was also reported to remove the benzyl 
protecting groups.62 Therefore, both of these methods were attempted (Table 5.3). 
Table 5.3. Attempted synthesis of flavonol amine 239 from flavonol acetamide 238. 
 
Entry Conditions Solvent 238:239 
1 5M HCl, reflux 2hr EtOH 1:0 
2 12M HCl, reflux 3hr AcOH 1:0a 
a only chalcone 228 was isolated 
 
First, flavonol acetamide 238 was reacted with 5M HCl in EtOH (Table 5.3, 
entry 1), and analysis of the crude material by 1H NMR spectroscopy revealed only the 
starting material. While Woodman and co-workers were able to use these conditions to 
not only access the amine, but also deprotect the benzyl groups,62 in our hands neither 
transformation occurred.  
Flavonol acetamide 238 was then reacted with 12M HCl in AcOH (Table 5.3, 
entry 2), and unexpectedly, the corresponding chalcone 228 was produced. This 
structure was confirmed by the presence of the chalcone hydroxyl peak (δ 12.76 ppm), 
and the appropriate peaks and integrations for the benzyl (δ 5.23 ppm) and acetamide 
(δ 2.21 ppm) peaks in the 1H NMR spectrum. Once again, in our hands there was also 
no deprotection of the benzyl groups.62 
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Without amine 239, the desired flavonol succinamic acid 221 could not be 
synthesised, and succinamic acid-linked DMLs were therefore not accessed. With this 
lack of access, attention turned to the use of acetophenone acrylates, which were 
accessed using the Heck reaction in Chapter Four. 
5.5 The Acrylic Acid-Linked DMLs 
Another opportunity to produce DMLs incorporating 3ʹ,4ʹ-dihydroxyflavonol 53 
arose from the acetophenone acrylates 201 and 200 synthesised in Chapter Four 
(Scheme 5.16). These acetophenones were accessed using the Heck reaction with 5ʹ-
bromo-2ʹ-hydroxyacetophenone 108 and tBu or nBu acrylate, and could provide a 
carboxylic acid to link the enalapril-derived ligand through the deprotection of their tBu 
or nBu groups respectively. 
 
Scheme 5.16. 3ʹ,4ʹ-Dihydroxyflavonol compound 216 with an acrylic acid side chain could be accessed from the 
acetophenone acrylates 201 and 200 synthesised in Chapter Four. 
5.5.1 Retrosynthesis of Acrylic Acid-Linked DMLs 
For the acrylic acid-linked DMLs 240, retrosynthetic analysis was performed 
(Scheme 5.17). This retrosynthesis begins with the benzyl deprotection of the phenols 
of Ring B of the flavonol 240, followed by the amide coupling of the amine of enalapril 
analogue 218 to the carboxylic acid of flavonol acrylate 242. Deprotection of the tBu or 
nBu group would provide the carboxylic acid required for coupling. 
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Scheme 5.17. Retrosynthetic pathway for the synthesis of the acrylic acid-linked DMLs 240. 
The flavonol acrylates 243 and 244 could be accessed from 3,4-
dibenzyloxybenzaldehyde and their corresponding acetophenone acrylates 201 and 200 
respectively, using a Claisen-Schmidt condensation followed by an Algar-Flynn-
Oyamada reaction. 
5.5.2 Synthesis of Flavonol tBu Acrylate 243 
The first flavonol to be synthesised was that of the acetophenone tBu acrylate 
201 (Scheme 5.18). 
 
Scheme 5.18. The desired benzyl-protected flavonol acrylic acid 242 was to be accessed from acetophenone tBu acrylate 201. 
 The starting material, acetophenone tBu acrylate 201, was synthesised in 
Chapter 4.2.3.2, in 90% yield, using Pd(OAc)2, PPh3 and K2CO3 in toluene under reflux 
for 16 hours (Scheme 5.19). 
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Scheme 5.19. Acetophenone tBu acrylate 201 was synthesised in 90% yield using the Heck reaction. 
The next step of this synthetic pathway was the formation of the corresponding 
2ʹ-hydroxychalcone, using the Claisen-Schmidt condensation with acetophenone tBu 
acrylate 201 and 3,4-dibenzyloxybenzaldehyde 227. 
5.5.2.1 Claisen-Schmidt Condensation to Synthesise Chalcone tBu 
Acrylate 245 
 A number of methods were trialled in attempts to synthesise chalcone tBu 
acrylate 245. In order to compare the success of these methods, conversion ratios were 
determined using 1H NMR spectroscopy. The determination of conversion was 
accomplished by allocating the CH3 peak of acetophenone tBu acrylate 201 at 
δ 2.60 ppm with an integration of 3, and the hydroxyl peak of chalcone 245 at 
δ 13.24 ppm was integrated as 0.85 (as explained in Chapter 2.3.2). 
First, a literature method from Woodman et. al. was applied to acetophenone 
tBu acrylate 201 and 3,4-dibenzyloxybenzaldehyde 227.291 The starting materials were 
stirred with NaOH in EtOH for 16 hours at 40 °C (Table 5.4, entry 1). However, 
following acidic work up, analysis of the reaction mixture by 1H NMR spectroscopy 
revealed none of the desired chalcone 245. Another literature method by Ko et. al. 
which utilised Ba(OH)2 was also unsuccessful (Table 5.4, entry 2), with only starting 
materials identified in the 1H NMR spectrum.613  
Next, the optimised microwave-assisted Claisen-Schmidt conditions established 
in Chapter Two (MW, 4.0 equivalents KOH, THF, 50 °C, 15 minutes) were applied to 
acetophenone tBu acrylate 201 and 3,4-dibenzyloxybenzaldehyde 227 (Table 5.4, 
entry 3). However, once again only starting materials were present in the crude 
material. Repeating the reaction for 30 minutes (Table 5.4, entry 4), also produced none 
of the desired chalcone.  
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Table 5.4. The synthesis of chalcone tBu acrylate 245 by Claisen-Schmidt condensation methods. 
 
Entry Base Solvent Conditions 201:245 
1 NaOH MeOH  16 hr 40 °C 1:0 
2 Ba(OH)2 MeOH 16 hr 40 °C 1:0 
3 KOH THF MW 50 °C 15 min 1:0 
4 KOH THF MW 50 °C 30 min 1:0 
5 KOH THF MW 70 °C 30 min 1:2 
6 KOH THF MW 100 °C 30 min 1:0 
 
Increasing the microwave temperature to 70 °C for 30 minutes (Table 5.4, 
entry 5), analysis of the crude material by 1H NMR spectroscopy showed acetophenone 
201 and desired chalcone 245 in a ratio of 1:2, with the tBu group visible as a singlet at 
δ 1.56 ppm. Attempts to isolate the chalcone using column chromatography (using a 
variety of solvent systems, including CH2Cl2/Pet, Pet/EtOAc, MeOH/CHCl3 and 
ether/Pet in different ratios) were not successful as the products co-eluted. 
 
Figure 5.18. 1H NMR spectrum of the impure chalcone tBu acrylate 245, with acetophenone 201 in a ratio of 10:1 
respectively (CDCl3). 
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Figure 5.18 shows the purest sample obtained by column chromatography (40% 
CH2Cl2 in Pet), in a ratio of approximately 10:1 desired chalcone tBu acrylate 245 to 
acetophenone tBu acrylate 201.  
 When the reaction was repeated at 100 °C (Table 5.4, entry 6), none of the 
desired chalcone was produced, and so the impure sample of chalcone 245 (10:1 
chalcone tBu acrylate 245 to acetophenone tBu acrylate 201 respectively) was used for 
flavonol formation. 
5.5.2.2 Algar-Flynn-Oyamada (AFO) Reaction 
The Algar-Flynn-Oyamada reaction was then applied to the impure chalcone 
tBu acrylate 245. Using conditions from Woodman and co-workers (Scheme 5.20),291 
impure chalcone acrylate 245 was dissolved in EtOH with 5% NaOH, and cooled to 
0 °C. Then 15% H2O2 in H2O was added, and the solution stirred at 0 °C for 2 hours. 
Further stirring at room temperature for 16 hours, followed by work up and purification 
by column chromatography (2:3 CH2Cl2:Pet) isolated flavonol 243 in a respectable 
yield of 43% over two steps (from acetophenone 201 to chalcone 245 to flavonol 243). 
 
Scheme 5.20. The AFO reaction was used to synthesise flavonol tBu acrylate 243 from chalcone 245, in 43% yield from 
acetophenone 201. 
The isolated compound 243 was characterised using 1H NMR spectroscopy, 
including the loss of the chalcone and acetophenone peaks, the appearance of a broad 
singlet at δ 8.31 ppm indicative of the 3-hydroxyl group of the flavonol, and the 
movement of the aromatic peaks (Figure 5.19). The structure of this novel 
functionalised flavonol was further confirmed by 13C NMR spectroscopy and HRMS. 
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Figure 5.19. 1H NMR spectrum of flavonol tBu acrylate 243 (CDCl3). 
With flavonol tBu acrylate 243 in hand, the next synthetic step was the removal 
of the tBu group, to provide the carboxylic acid required for coupling to the enalapril 
analogue. 
5.5.2.3 Removal of the tBu Group 
 The final step of this flavonol synthesis was the removal of the tBu group to 
provide the free carboxylic acid. Most deprotection methods for tBu esters involve 
acidic hydrolysis.541 One of the most common methods is treatment with trifluoroacetic 
acid (TFA) in CH2Cl2, and so flavonol 243 was reacted with 5% TFA in CH2Cl2 for 16 
hours (Table 5.5, entry 1). However, analysis of the crude material revealed only the 
starting material. When the reaction was repeated for 48 hours, and also when the 
concentration was increased to 15% TFA in CH2Cl2 for 16 hours (Table 5.5, entries 2 
and 3), the 1H NMR spectra showed only the acetophenone 201 of the starting material, 
signified by a singlet peak at δ 2.68 ppm, and fewer aromatic peaks, indicating the 
degradation of the starting material. 
Other acidic conditions were also trialled (Table 5.5 entries 4-7), including 
acetyl chloride (AcCl) in MeOH, HCl in acetic acid (AcOH),614 and the pIL TeaHSO4 
under microwave irradiation at 100 °C for 5 minutes. In all cases, the method was either 
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unable to remove the tBu group, or degraded the starting material to form an insoluble 
black tar. 
Table 5.5. Deprotection of the flavonol tBu acrylate 243. 
 
Entry Conditions 243:242 
1 5% TFA/ CH2Cl2 16 hr 1:0 
2 5% TFA/ CH2Cl2 48 hr 0:0a 
3 15% TFA/CH2Cl2 16 hr 0:0a 
4 AcCl/MeOH 10 min 1:0 
5 AcCl/MeOH 16 hrs 0:0b 
6 HCl/ AcOH 0:0b 
7 TeaHSO4 MW 100 °C 5 min 1:0 
8 HNO3 CH2Cl2 rt 2 hrs615 1:0 
9 p-TSA MW 100 °C 10 min616 1:0 
10 NaH DMF 16 hrs617 1:0 
11 Silica MW 50W 50 °C 4 min618 1:0 
12 Silica MW 50W 120 °C 4 min 1:0 
a only acetophenone 201 was seen in 1H NMR spectrum 
b product was undissolvable black tar 
 
When these common methods were unable to remove the tBu group, alternative 
methods were sought. Stirring the flavonol with nitric acid (HNO3)615 in CH2Cl2 for two 
hours at room temperature (Table 5.5, entry 8) provided only the deprotected 
acetophenone acrylate 246, and the use of p-toluenesulfonic acid under microwave 
irradiation (100 °C for 10 minutes, Table 5.5, entry 9) gave the same result.616 Even a 
basic method was trialled,617 using sodium hydride in DMF for 16 hours at room 
temperature, however once again only starting material was recovered. Finally, a 
method from Park et. al. was applied to the flavonol tBu acrylate 243,618 which 
involved treatment with silica under microwave irradiation at 50 °C for 4 minutes 
(Table 5.3, entry 11). When no deprotection occurred, the reaction was repeated at 
120 °C, with the same result (Table 5.5, entry 12).  
 With nine different methods unsuccessful in the removal of the tBu group of 
flavonol acrylate 243, attention turned to the use of acetophenone nBu acrylate 200 to 
access the flavonol nBu acrylate, in the hope that the nBu group could be removed.  
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5.5.3 Synthesis of Flavonol nBu Acrylate 244 
Once again following the retrosynthetic pathway in Scheme 5.18, flavonol 
acrylic acid 242 (Scheme 5.21), was to be synthesised from acetophenone nBu acrylate 
200. 
 
Scheme 5.21. The desired benzyl-protected flavonol acrylic acid 242 was to be accessed from acetophenone 201. 
Acetophenone nBu acrylate 200 was previously synthesised in Chapter 4.2.3.2, 
in 76% yield, using Pd(OAc)2, PPh3 and K2CO3 in toluene under reflux for 16 hours 
(Scheme 5.22). 
 
Scheme 5.22. Acetophenone nBu acrylate 201 was synthesised in 76% yield using the Heck reaction. 
 With this acetophenone in hand, as well as the protected 3,4-
dibenzyloxybenzaldehyde 227, the synthesis of chalcone nBu acrylate 247 was 
attempted. 
5.5.3.1 Claisen-Schmidt Condensation to Synthesise Chalcone nBu 
Acrylate 247 
 As both chalcone formation and the deprotection of esters occur with the use 
strong hydroxide bases, it was reasoned that the removal of the nBu protecting group to 
produce chalcone 248 could also occur during Claisen-Schmidt condensation of 
acetophenone nBu acrylate 200 and 3,4-dibenzyloxybenzaldehyde 227. The resultant 
carboxylic acid was not expected to react under the Algar-Flynn-Oyamada reaction 
conditions, therefore deprotection of the ester at this stage was not considered a 
problem. In accordance with the previous determination of conversion ratios, the CH3 
peak of acetophenone 200 at δ 2.62 ppm was allocated an integration of 3, and the 
hydroxyl peak of the chalcone at δ 13.25 ppm was allocated an integration of 0.85 (as 
explained in Chapter 2.3.2). 
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The first method attempted utilised the microwave-assisted Claisen-Schmidt 
conditions from Chapter Two (MW, 4.0 equivalents KOH, THF, 50 °C, 15 minutes), 
with acetophenone nBu acrylate 200 and 3,4-dibenzyloxybenzaldehyde 227 (Table 5.6, 
entry 1). Following acidic work up, analysis by 1H NMR spectroscopy revealed only 
the starting materials. Increasing microwave reaction times to 30 and 60 minutes (Table 
5.6, entries 2 and 3 respectively) also produced none of the desired chalcone.  
Table 5.6. Claisen-Schmidt condensation of acetophenone nBu acrylate 200 and benzaldehyde 227. 
 
Entry Base Solvent Conditions 200:245 
1 KOH THF MW 50 °C 15 min 1:0 
2 KOH THF MW 50 °C 30 min 1:0 
3 KOH THF MW 50 °C 60 min 1:0 
4 KOH THF MW 70 °C 30 min 1:30a 
5 NaOH EtOH 16 hr rt 1:0 
6 Ba(OH)2 MeOH 16 hr 40 °C 10:1 
7 Ba(OH)2 MeOH 72 hr 40 °C 7:1 
8 Ba(OH)2 MeOH MW 50 °C 30 min 2:1 
a benzaldehyde 225 was also present in a ratio of 1:30:60 for 201:247:227 
 
Increasing the reaction temperature to 70 °C for 30 minutes (Table 5.6, entry 4) 
produced some of the nBu-protected chalcone 247, as indicated by the appearance of 
the chalcone hydroxyl peak at δ 13.25 ppm in the 1H NMR spectrum, and peaks at 
δ 0.99-1.56 ppm, and δ 4.25 ppm representing the nBu group (Figure 5.15). A trace 
amount of the acetophenone was also present, as indicated by a small peak at 
δ 2.64 ppm, and a large amount of benzaldehyde, as indicated by the peak at 
δ 9.79 ppm. The ratio of benzaldehyde 227 to chalcone 247 was approximately 2:1 
respectively (Figure 5.20). This lack of acetophenone 200 (in comparison to the large 
amount of benzaldehyde still present) suggested that degradation of the acetophenone 
starting material at this increased temperature was occurring, and an alternate Claisen-
Schmidt condensation method was required. 
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Figure 5.20. Higher microwave temperatures resulted in the degradation of acetophenone 200 in the 70 °C, 30 minute 
Claisen-Schmidt condensation reaction (Table 5.6, entry 4). 
 The literature method from Woodman and co-workers291 was also applied to the 
reaction (NaOH, EtOH, rt for 16 hours, Table 5.6, entry 5), however only starting 
materials were returned. 
Another literature method from Ko et. al.613 was also applied to acetophenone 
nBu acrylate 200 and benzaldehyde 227 (Table 5.6, entry 6), providing acetophenone 
200 and chalcone 247 (still nBu-protected) in a ratio of 10:1 respectively. In an attempt 
to increase conversion, the reaction was repeated for 72 hours (Table 5.6, entry 7), and 
resulted in a small increase in conversion to the chalcone (acetophenone 200 to 
chalcone 247, 7:1). 
Using the base and solvent from the previous method (Ba(OH)2 and MeOH), 
with microwave irradiation (50 °C, 30 min, Table 5.6, entry 8) greatly improved 
conversion to nBu-protected chalcone acrylate 247 (2:1 acetophenone to chalcone). 
However, when attempts were made to isolate the chalcone by column chromatography, 
it was found that once again the acetophenone co-eluted with the chalcone, making 
purification impossible. The purest sample was produced by column chromatography 
(1:1 CH2Cl2:Pet), in a ratio of 1:30 for acetophenone 200 to chalcone 247 respectively 
(Figure 5.21). It was also noted that the nBu group had not been removed, due to the 
presence of representative peaks at δ 0.99-1.56 ppm and δ 4.25 ppm.  
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Figure 5.21. Chalcone nBu acrylate 247 co-eluted with its corresponding acetophenone 200, and so purification provided the 
chalcone in a ratio of approximately 30:1 with the acetophenone.  
As per the previous reaction of impure chalcone tBu acrylate 245 (Chapter 
5.5.2.1), this slightly impure sample of the chalcone nBu acrylate 247 was used in the 
Algar-Flynn-Oyamada reaction to synthesise the desired flavonol nBu acrylate 249. 
5.5.3.2 Algar-Flynn-Oyamada Reaction 
 Once again, the AFO methodology of Woodman and co-workers was used,291 in 
an attempt to synthesise flavonol acrylic acid 244 from its corresponding chalcone 247 
(5% NaOH, 15% H2O2, EtOH for 2 hours at 0 °C, then 16 hours at rt, Scheme 5.23). 
Note that once again, the strong hydroxide used for this reaction was expected to cleave 
the nBu group to provide flavonol acrylic acid 244. 
 
Scheme 5.23. Algar-Flynn-Oyamada reaction of chalcone nBu acrylate 247. 
 Analysis of the crude material by 1H NMR spectroscopy showed the presence of 
the chalcone starting material 247 (hydroxyl peak at δ 13.25 ppm) as well as the 
acetophenone 200 (hydroxyl peak at δ 12.33 ppm), and appeared to show some other 
product, due to the integrations of the benzyl and aromatic peaks being far greater than 
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that of the chalcone alone. The peaks of the spectrum were quite broad, which is 
common with flavonol compounds due to π-π stacking.58 However, when the sample 
was examined using Mass Spectrometry, neither the mass of the desired flavonol 
acrylic acid 244 or its butyl ester could be found.  
The structure of this unknown product or products could not be determined, 
although it was thought that the alkene of the nBu acrylate side chain may be providing 
another position for epoxidation. It was reasoned therefore, that the removal of this 
alkene by hydrogenation (Pd/C, H2 gas) could allow for the formation of the desired 
flavonol. A hydrogenation reaction after the Claisen-Schmidt condensation would 
remove the alkene of the chalcone and remove the benzyl-protection of Ring B of the 
flavonol, and after the Algar-Flynn-Oyamada step would also remove the benzyl-
protection of Ring B. For this reason, the hydrogenation step had to be performed 
following the synthesis of the acetophenone nBu acrylate 200. With this in mind, 
attention turned to the synthesis of flavonol propanoic acid 249. 
5.5.4 Synthesis of Flavonol Propanoic Acid 249 
Acetophenone nBu acrylate 200 was once again the starting material in the 
synthesis of flavonol propanoic acid 249 (Scheme 5.24). 
 
Scheme 5.24. The desired benzyl-protected flavonol propanoic acid 249 was to be accessed from acetophenone nBu acrylate 
200. 
 The first step of this synthesis was the hydrogenation of acetophenone nBu 
acrylate 200, to remove the alkene functionality. Acetophenone nBu acrylate 200 was 
accessed previously in Chapter 4.2.3.2 in 76% yield, using the Heck reaction. 
5.5.4.1 Acetophenone nBu Ester 250 
With acetophenone nBu acrylate 200 in hand, hydrogenation was carried out 
using 10% palladium on carbon (Pd/C), hydrogen gas (H2), and a solvent of 1:1 MeOH 
and toluene (Scheme 5.25).  
 
Scheme 5.25. Hydrogenation of acetophenone nBu acrylate 200 provided the acetophenone nBu ester 250. 
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The desired acetophenone nBu ester 250 was isolated in quantitative yield. The 
structure was confirmed by the loss of the alkene CH peaks (one at δ 6.29 ppm and the 
other within the aromatic peaks, δ 7.54-7.65 ppm, Figure 5.22), the appearance of the 
new ethyl CH2 resonances as a triplet at δ 2.88 ppm and a multiplet between δ 2.58-
2.61 ppm. The hydroxyl group also shifted to δ 12.10 ppm in the 1H NMR spectrum. 
Novel acetophenone 250 was fully characterised by 13C NMR spectroscopy and HRMS.  
 
Figure 5.22. Hydrogenation of acetophenone nBu acrylate 200 provided acetophenone nBu ester 250 in quantitative yield. 
With acetophenone nBu ester 250 in hand, the next step of the synthesis was the 
Claisen-Schmidt condensation to synthesise chalcone propanoic acid 251. 
5.5.4.2 Claisen-Schmidt Condensation to Synthesise Chalcone 
Propanoic Acid 251 
 As before, conversion ratios were determined using 1H NMR spectroscopy. 
Deprotection of the nBu ester was once again expected under the reaction conditions, to 
provide chalcone propanoic acid 251. 
The optimised microwave-assisted Claisen-Schmidt conditions from Chapter 
Two were the first to be applied to acetophenone nBu ester 250 and 3,4-
dibenzyloxybenzaldehyde 227 (MW, 4.0 equivalents KOH, THF, 50 °C, 15 minutes, 
Table 5.7, entry 1), however analysis of the crude material by 1H NMR spectroscopy 
revealed only starting materials. 
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Table 5.7. Claisen-Schmidt condensation of acetophenone nBu ester 250 and benzaldehyde 227. 
 
Entry Solvent Scale Conditions 250:251 (isolated yield) 
1 THF 0.3 mmol MW 50 °C 15 min 1:0 
2 THF 0.3 mmol MW 50 °C 30 min 2:1 
3 THF 0.3 mmol MW 70 °C 30 min 2:1 
4 EtOH 0.3 mmol rt 16 hrs 1:4 (48%) 
5 EtOH 1.1 mmol rt 16 hrs 1:1 
6 EtOH 1.1 mmol rt 16 hrs 1:4a 
a dilute reaction with slow addition of benzaldehyde 227 reduced occurrence of Cannizzaro reaction 
 
Increasing the microwave reaction time to 30 minutes resulted in some of the 
desired compound being formed, in a ratio of 2:1 of the acetophenone 250 to the desired 
chalcone 251 (Table 5.7, entry 2). In an attempt to increase formation of the desired 
chalcone 251, the reaction was also repeated at 70 °C (Table 5.7, entry 3), however no 
additional conversion was achieved. 
 The literature method of Woodman et. al.291 was then trialled, with KOH in 
EtOH on a 0.30 mmol scale (Table 5.7, entry 4). Analysis by 1H NMR spectroscopy 
revealed the ratio of acetophenone 250 to chalcone 251 as 1:4 respectively, and 
following purification by column chromatography (2:1 Pet:EtOAc), chalcone 251 was 
isolated in 48% yield. This was confirmed by the loss of the acetophenone (δ 2.61 ppm) 
and benzaldehyde (δ 9.80 ppm) peaks and the appearance of the chalcone hydroxyl 
peak (δ 12.81 ppm) in the 1H NMR spectrum (Figure 5.23), as well as 13C NMR 
spectroscopy and HRMS. Also evident in the spectrum was the loss of the nBu group, 
by the absence of peaks between δ 0.90-1.20 ppm and δ 4.20 ppm. It was of interest to 
note that both acrylic esters 245 and 247 were not deprotected under these same 
conditions. While no further experiments were performed, it seemed that the inability to 
deprotect those acrylic esters was somehow linked to the conjugation of the starting 
materials. 
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Figure 5.23. 1H NMR spectrum of the chalcone propanoic acid 251 (CDCl3).  
When this reaction was repeated on a larger scale (1.1 mmol, Table 5.7, 
entry 5), chalcone 251 formation decreased to a ratio of 1:1 with acetophenone 250, 
with a relative ratio of 1 for benzaldehyde 227. This decrease in conversion coincided 
with the appearance of a singlet peak at δ 4.57 ppm, which suggested the formation of 
the benzyl alcohol Cannizzaro side product, as shown in Scheme 5.26 (see Chapter 
2.3.1 for a review of the Cannizzaro reaction and its occurrence in Claisen-Schmidt 
condensations). 
 
Scheme 5.26. The Cannizzaro reaction of 3,4-dibenzyloxybenzaldehyde 227 results in benzyl alcohol 252 and carboxylic acid 
253. 
To confirm that this peak was due to Cannizzaro benzyl alcohol 252, 
benzaldehyde 227 was reduced to its primary alcohol using sodium borohydride 
(NaBH4) in MeOH (Scheme 5.27). The 1H NMR spectrum of the product exhibited a 
peak at δ 4.57 ppm (CH2 of the benzyl alcohol), which corresponded to the unknown 
peak of the Claisen-Schmidt condensation. This product was therefore determined to be 
present in a ratio of 0.4:1:1 with the acetophenone and chalcone respectively (the peak 
at δ 4.57 ppm was allocated an integration of 2).  
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Scheme 5.27. Reducing benzaldehyde 225 produced benzyl alcohol 251, which exhibited a singlet peak at δ 4.57 ppm in the 
1H NMR spectrum, which was assigned to the CH2 of benzyl alcohol. 
 As the Cannizzaro products were undesired, and signified a decrease in the 
formation of the desired chalcone 251, a method to prevent this side reaction was 
investigated. The reaction was repeated in a dilute solution, and with slow addition of 
benzaldehyde 227 (Table 5.7, entry 6), so as to prevent the aldehyde molecules from 
reacting with themselves rather than acetophenone 250. The conversion ratio returned 
to 1:4 acetophenone to chalcone respectively, and only a trace amount of Cannizzaro 
benzyl alcohol 252 was present in the 1H NMR spectrum. Purification by column 
chromatography (2:1 Pet:EtOAc) isolated chalcone propanoic acid 251 in 46% yield. 
 With chalcone propanoic acid 251 in hand, attention turned to the formation of 
its corresponding flavonol 254, using the Algar-Flynn-Oyamada reaction. 
5.5.4.3 Algar-Flynn-Oyamada Reaction to Synthesise Flavonol 
Propanoic Acid 254 
 The formation of flavonol 254 was then attempted using the Algar-Flynn-
Oyamada reaction conditions of Woodman and co-workers (5% NaOH, 15% H2O2, 
EtOH for 2 hours at 0 °C, then 16 hours at rt, Scheme 5.28).291 
 
Scheme 5.28. Synthesis of flavonol propanoic acid 254 from chalcone propanoic acid 251 using the AFO reaction. 
Analysis of the crude material by 1H NMR spectroscopy revealed broadened 
peaks, suggesting the presence of the desired flavonol 254 (Figure 5.24). However, the 
integration values for the benzyl CH2 peaks were too large. The presence of the 
chalcone starting material 251 was also confirmed by a small peak at δ 12.78 ppm.  
Attempts to purify the flavonol by recrystallisation were unsuccessful (EtOAc, 
1:1 THF:Pet), and column chromatography (2:1 Pet:EtOAc, 5% MeOH in CHCl3) 
could not separate chalcone 251 and flavonol 254. Although flavonol 254 could not be 
isolated, its presence was confirmed by MS (as well as chalcone propanoic acid 251). 
This impure sample, in a ratio of approximately 0.15:1 chalcone 251 to flavonol 254, 
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was kept in the hope that attempts at its coupling to the enalapril analogue of the DML 
might afford a product that would be more readily purified.  
 
Figure 5.24. 1H NMR spectrum of the impure flavonol propanoic acid 254 (CDCl3). 
Attempts to repeat the reaction were also unsuccessful, and so attention turned 
to the use of the ‘Modified’ AFO reaction, to access pure flavonol propanoic acid 254.  
5.5.4.4 ‘Modified’ Algar-Flynn-Oyamada Reaction to Synthesise 
Flavonol Propanoic Acid 254 
Using the methodology from Woodman et. al. (Scheme 5.29),291 the ‘Modified’ 
AFO reaction was applied to acetophenone nBu ester 250 and benzaldehyde 227. 
 
Scheme 5.29. Application of the ‘Modified’ AFO reaction to acetophenone nBu ester 250 and protected benzaldehyde 227 
did not produce the desired flavonol propanoic acid 254. 
Following acidic work up, analysis of the crude material by 1H NMR 
spectroscopy revealed none of the desired flavonol 254. The spectrum consisted of 
extremely broad peaks, however showed only the benzaldehyde peak at δ 9.81 ppm, 
and many aromatic peaks (δ 7.15-7.99 ppm). There was no sign of the acetophenone 
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250 (δ 2.60 ppm) or chalcone 251 (δ 12.78 ppm) in the spectrum. The lack of flavonol 
propanoic acid 254 was confirmed by MS. This was disappointing, however the sample 
of impure flavonol propanoic acid 254 (synthesised through the Claisen-Schmidt 
condensation and then AFO reaction) in hand was able to be used to synthesise the 
desired DMLs. 
5.6 Peptidomimetic ACE Inhibitor Ligands 
As mentioned earlier in this chapter (Chapter 5.3.2), the second ligand chosen 
for these DMLs were analogues of the peptidomimetic ACE inhibitor enalapril 43 
(Figure 5.25). These analogues were based on a scaffold which incorporated certain 
functional groups of enalapril responsible for its binding to the ACE pocket 
(Figure 5.25), including a carboxylic acid (red), methyl group (green) and C-terminal 
proline unit (blue), as well as an amine (purple) to couple to the carboxylic acid side 
chain of flavonol propanoic acid 254. Lysine was noted as an ideal functionality for 
these enalapril analogues 218, as it provided the required carboxylic acid and the amine 
group for linking, leaving the methyl substituent to be incorporated between the proline 
and lysine units. 
 
Figure 5.25. Enalapril 43, and the enalapril analogue 218 of this project which incorporated lysine 217, contain a carboxylic 
acid (red), methyl group (green), and a terminal proline unit (blue). 
 Two strategies were developed to incorporate the desired functionalities into the 
enalapril analogue ligands; the first incorporated the methyl substituent (Strategy A), 
and the second did not (Strategy B). These strategies will be addressed in turn. 
5.6.1 Enalapril Analogue: Strategy A 
5.6.1.1 Retrosynthesis: Strategy A  
Strategy A was based on the methodology used in the commercial synthesis of 
enalapril (Scheme 5.30).619 Beginning with amine 255, deprotection of the amine 
provides the protected amine 256, which could be accessed using a reductive amination 
reaction with ketone 257 and diprotected lysine 258. It was noted that this step would 
give rise to diastereomers, a potential problem that is solved in the commercial 
synthesis of enalapril by fractional crystallography.619 In this project, the formation of 
 150 
 
diastereomers was not predicted to be problematic, as it is noted that both diastereomers 
of enalapril are active ACE inhibitors (with IC50 values of 1.2 × 10-9 M and 8.2 × 10-7 
M). Ketone 257 could be synthesised from the amide coupling of protected proline 259 
and pyruvic acid 260, with the final retrosynthetic step being the protection of the 
carboxylic acid of proline 261. 
 
Scheme 5.30. Retrosynthesis of Strategy A. 
5.6.1.2 Synthesis of Enalapril Analogue: Strategy A 
5.6.1.2.1 Protection of L-Proline 261 
To benzyl-protect the C-terminal proline 261, benzyl alcohol (BnOH), thionyl 
chloride (SOCl2) and L-Proline were reacted for 48 hours whilst warming from 0 °C to 
rt, as per the literature method of Ramachandran (Scheme 5.31).620  
 
Scheme 5.31. Benzyl protection of L-proline 261 occurred in 95% yield. 
Following recrystallisation in ether, Pro-OBn 259 was isolated as a white solid 
in 95% yield as confirmed by comparison to literature data,620 including the appearance 
of the benzyl CH2 peak (multiplet, δ 5.13-5.26 ppm) and aromatic peaks (δ 7.33 ppm) 
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in the 1H NMR spectrum. With Pro-OBn 259 in hand, coupling of proline to pyruvic 
acid 260 was attempted. 
5.6.1.2.2 Coupling Pro-OBn 259 to Pyruvic Acid 260 
The methodology of Jou et. al. was used for this reaction,621 and utilised 1-ethyl-
3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDCI.HCl) and 1-
hydroxybenzotriazole (HOBt) in CH2Cl2 (Scheme 5.32).  
 
Scheme 5.32. EDCI-mediated coupling of pyruvic acid 2560 to Pro-OBn 259 proceeded in 48% yield. 
Following purification by column chromatography (30% EtOAc in Pet), the 
desired ketone 257 was isolated in 48% yield, and the 1H NMR spectrum identical to 
that of Jou et. al..621  
The next step was the coupling of ketone 257 to lysine, however lysine required 
protection to provide the desired free amine for reductive amination with ketone 257.  
5.6.1.2.3 Synthesis of Lys(Boc)-OBn 258 
Di-protected Lys(Boc)-OBn 258 was synthesised from Nα-9-
fluorenylmethoxycarbonyl-Nε-tert-butoxycarbonyl-L-lysine 262 (Fmoc-Lys(Boc)-OH) 
(Scheme 5.33). The free carboxylic acid was first benzyl protected (BnBr, NEt3, 
EtOAc),622 as the benzyl group is orthogonal to the Fmoc- and Boc-protecting groups 
on lysine 262. Purification by column chromatography (30% EtOAc in Pet) isolated the 
desired tri-protected lysine 263 in quantitative yield.622 
 
Scheme 5.33. Benzyl protection of Fmoc-Lys(Boc)-OH 262 occurred in quantitative yield. 
 Fmoc-Lys(Boc)-OBn 263 was then stirred with 20% piperidine in DMF for two 
hours (Scheme 5.34),623 and purification by column chromatography (3% MeOH in 
CHCl3), isolated desired Lys(Boc)-OBn 258 in 80% yield.624 
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Scheme 5.34. Fmoc-deprotection of lysine 263 proceeded in 80% yield. 
5.6.1.2.4 Reductive Amination of Ketone 257 and Lysine 258 
Next, the coupling of ketone 257 and lysine 258 was attempted, using a 
reductive amination. Reductive aminations are conducted with an amine and a ketone or 
aldehyde substrate to produce an imine 264, which is then reduced in situ to amine 256 
by sodium cyanoborohydride (Scheme 5.35).  
 
Scheme 5.35. The reductive amination of protected lysine 258 and pyruvic compound 257 occurs via an imine intermediate 
264. 
Using the literature method of traditional enalapril synthesis,619 sodium 
cyanoborohydride (NaCNBH3), EtOH, and 4A molecular sieves were stirred with lysine 
258 and an excess of ketone 257 (1.3 equivalents) at room temperature for 16 hours. 
Following a careful workup, the crude material was analysed by 1H NMR spectroscopy, 
which showed only the lysine starting material 258, and no sign of ketone 257, desired 
imine 264 or amine 256. 
The reaction was then repeated using 1.6 equivalents of ketone 257, however the 
same result was obtained, and none of the desired amine 256 was observed. This 
reaction may have been unsuccessful due to the steric bulk of the benzyl-protected 
lysine preventing access to the carbonyl carbon of the ketone, and also the presence of a 
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second (although less reactive secondary) amine. As this reductive amination was 
unsuccessful, a second strategy (Strategy B) was derived. 
5.6.2 Enalapril Analogue: Strategy B 
5.6.2.1 Retrosynthesis: Strategy B  
Strategy B did not incorporate the methyl substituent seen in enalapril, and 
required only SN2 reactions and amide bond formations in the retrosynthetic pathway 
(Scheme 5.36). The amine 265 required for coupling to the carboxylic acid of flavonol 
propanoic acid 254 was provided by the amine side chain of compound 266 (following 
Boc-deprotection). Compound 266 could be accessed by the SN2 reaction of the amine 
of di-protected lysine 258 and brominated compound 267. Finally, the bromo-acetyl-
Pro-OBn 267 was to be synthesised by coupling bromoacetic acid 268 and Pro-OBn 
259.  
 
Scheme 5.36. Retrosynthesis of Strategy B. 
Although this retrosynthesis provided an enalapril analogue without the methyl 
substituent, the inclusion of the proline unit and carboxylic acid (seen in red and blue 
respectively, Scheme 5.40) should be adequate in their ability to bind to ACE. It must 
be noted once again that antihypertensive evaluations were to be conducted on not only 
the DML compounds, but also their individual ligands, to identify the activities and 
verify modes of action for the joined (DML) and separate (ligand) compounds. This 
would allow for the determination of activity depending on whether the compound may 
act as a joined DML, or in a prodrug approach, where the ligands are cleaved.  
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5.6.2.2 Synthesis of Enalapril Analogue: Strategy B  
5.6.2.2.1 Protection of L-Proline 261 
Once again, synthetic methodology began with Pro-OBn 261, as accessed 
previously in 95% yield (Scheme 5.29). The next step of this approach was the coupling 
of the free amine with bromoacetic acid, to provide bromoacetyl-Pro-OBn 267. 
5.6.2.2.2 Coupling Pro-OBn 259 to Bromoacetic Acid 268 
Benzyl proline 259 was stirred with bromoacetic acid 268, EDCI and HOBt in 
CH2Cl2 for 16 hours at room temperature. Following workup, solvent removal in vacuo, 
and purification by column chromatography (2:1 Pet:EtOAc), bromoacetyl-Pro-OBn 
267 was isolated in 48% yield (Scheme 5.37). This structure was confirmed using 1H 
NMR spectroscopy by the appearance of a multiplet at δ 3.99-4.10 ppm with an 
integration of two which was assigned to the CH2 of the bromoacetate, as well as by 13C 
NMR spectroscopy and HRMS (Figure 5.26). 
 
Scheme 5.37. Amide coupling between Pro-OBn 259 and bromoacetic acid 268 provided bromoacetyl-Pro-OBn 267. 
 
Figure 5.26. 1H NMR spectrum of bromoacetyl-Pro-OBn 267 (CDCl3). 
 155 
 
5.6.2.2.3 SN2 Reaction of Bromoacetyl-Pro-OBn 267 and Lys(Boc)-OBn 258 
The next step of Strategy B was the coupling of bromoacetyl-Pro-OBn 267 to 
the free amine of previously synthesised Lys(Boc)-OBn 258 using an SN2 reaction. 
With both compounds in hand, Lys(Boc)-OBn 258 and NaH were stirred in DMF at 0 
°C for one hour, before addition of bromoacetyl-Pro-OBn 267, and further stirring for 
16 hours at room temperature (Scheme 5.38). Following column chromatography (2:1 
Pet:EtOAc), novel compound 266 was isolated in 68% yield. The compound was fully 
characterised by 1H NMR and 13C NMR spectroscopy, as well as HRMS. 
 
Scheme 5.38. An SN2 reaction coupled di-protected lysine 268 with bromoacetyl-Pro-OBn 267 in 68% yield.  
5.6.2.2.4 Boc-Deprotection of Compound 266 
The final step for the synthesis of the enalapril analogue ligand of the DML was 
deprotection of compound 266, to free the amine for coupling with the carboxylic acid 
of flavonol propanoic acid 254. Compound 266 was stirred in 20% TFA in CH2Cl2 for 
two hours at room temperature (Scheme 5.39) and following work up, the desired 
amine 265 was produced in quantitative yield. 
 
Scheme 5.39. Removal of the Boc-group provided enalapril analogue 265 in quantitative yield. 
 156 
 
The structure was confirmed using 1H NMR spectroscopy, by the complete loss 
of the tBu peak at δ 1.34 ppm, and fully characterised by 13C NMR spectroscopy and 
HRMS. With this Strategy B enalapril analogue 265 in hand, attention turned to the 
coupling of this amine to the carboxylic acid of flavonol propanoic acid 254, using an 
amide coupling reaction. 
5.7 Coupling of Flavonol Propanoic Acid 254 with 
Enalapril Analogue 265 
The coupling of the amine of enalapril analogue 265 with the carboxylic acid of 
the semi-pure flavonol propanoic acid 254 to produce the desired DML compound 269 
was then attempted, using EDCI, HOBt, NEt3 and CH2Cl2 (Scheme 5.40). The reaction 
was stirred at room temperature for 16 hours, and following work up, the crude material 
was analysed by 1H NMR spectroscopy. The 1H NMR spectrum showed no sign of the 
chalcone 251 impurity (δ 12.87 ppm), however the broad peaks of the spectrum and the 
overlapping of the alkyl peaks of both the flavonol side chain and the enalapril analogue 
made the spectrum difficult to interpret. When the crude material was analysed by MS, 
the masses of desired DML 269 or its salts and dimers could not be found. 
 
Scheme 5.40. Attempted amide coupling of (impure) flavonol 254 with enalapril analogue 265 did not proceed. 
 The reaction was repeated for 40 hours, and then again without the use of base, 
however in both cases, the desired DML 269 could not be detected using MS. While 
side reactions were possible, including the EDCI-mediated coupling of two flavonol 
propanoic acid 254 through the hydroxyl and carboxylic acid groups or coupling 
through the secondary amine of amine 265 rather than the primary amine, these 
products were not identified in the 1H NMR spectrum or by MS.  
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Unfortunately, this reaction used the last sample of the available flavonol 
propanoic acid 254, and the reaction could not be repeated. As mentioned in Chapter 
5.5.4.3 and 5.5.4.4, attempts to re-synthesise the flavonol propanoic acid 254 were 
unsuccessful. 
Unfortunately, none of the desired ‘conjugate’ DMLs were accessed. 
Nevertheless, a series of ‘fused’ DMLs were also the target of this project, and these 
will be discussed in Chapter Six. 
5.8 ‘Conjugate’ DMLs: Conclusion 
For the synthesis of ‘conjugate’ DMLs incorporating a 3ʹ,4ʹ-dihydroxyflavonol 
structure with a carboxylic acid side chain, and an enalapril analogue with an amine for 
coupling to the carboxylic acid, a number of synthetic methodologies were attempted. 
First, the synthesis of flavonol succinamic acid 221 was attempted 
(Scheme 5.41). Using the methodology of Woodman and co-workers,62 flavonol 
acetamide 238 was synthesised. However, attempts to deprotect the acetamide to form 
the required amine 239 (before its coupling with succinic acid to provide the carboxylic 
acid required for coupling to enalapril analogues) were unsuccessful, and either no 
reaction, or the formation of the corresponding chalcone 228 was observed. 
 
Scheme 5.41. Amine 239, and therefore flavonol succinamic acid 221, could not be accessed. 
Following this, the synthesis of three flavonol acrylates was attempted. The first 
flavonol 243 was synthesised from acetophenone tBu acrylate 201 in two steps in an 
overall yield of 43% (Scheme 5.42). However, at this point the tBu group could not be 
cleaved to provide the desired carboxylic acid 242.  
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Scheme 5.42. Flavonol tBu acrylate 243 could not be deprotected. 
The next attempt to synthesise a flavonol acrylate used acetophenone nBu 
acrylate 200 as a starting material (Scheme 5.43). The Claisen-Schmidt condensation of 
acetophenone 200 with 3,4-dibenzyloxybenzaldehyde 227 provided 2ʹ-hydroxychalcone 
247, albeit slightly impure due to the co-elution of acetophenone 200 and chalcone 247 
during column chromatography. However, application of the AFO reaction to this 
impure sample was unsuccessful.  
 
Scheme 5.43. Flavonol nBu acrylate 244 also could not be synthesised. 
The final attempt to synthesise a flavonol with an acid side chain began with the 
hydrogenation of acetophenone nBu acrylate 200 in quantitative yield (Scheme 5.44). 
This was followed by the Claisen-Schmidt condensation (48% yield) and then the 
Algar-Flynn-Oyamada reaction. While the flavonol 254 produced was slightly impure 
(in a ratio of approximately 0.15:1 chalcone 251 to flavonol 254, approximately 85% 
pure), it was this flavonol propanoic acid 254 that was used to attach to the enalapril 
analogues. Unfortunately, attempts to repeat the synthesis of the flavonol were 
unsuccessful, and quantities of flavonol propanoic acid 254 were limited. 
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Scheme 5.44. Flavonol propanoic acid 254 was accessed, although slightly impure. 
Two strategies were devised for the synthesis of enalapril analogues. The first, 
Strategy A, had as its target an enalapril analogue that incorporated a methyl group 
(Scheme 5.45). However, reductive amination of compound 257 with Lys(Boc)-OBn 
258 failed to produce the desired amine 256.  
 
Scheme 5.45. The Strategy A enalapril analogue could not be synthesised, as the reductive amination step was unsuccessful. 
Strategy B, in which the target contained no methyl group (Scheme 5.46), was 
successful and began with Pro-OBn 259, which was coupled to bromoacetic acid 268 to 
provide bromoacetyl-Pro-OBn 267 in 46% over two steps. With Lys(Boc)-OBn 258, 
the two were joined using an SN2 reaction, in 68% yield. Finally, deprotection of 266 
provided enalapril analogue 265 in quantitative yield.  
 160 
 
 
Scheme 5.46. Strategy B enalapril analogue 265 was successfully synthesised in six steps. 
Attempts were then made to couple enalapril analogue 265 to the slightly 
impure flavonol propanoic acid 254 (Scheme 5.47). However, these amide bond 
formations were unsuccessful, and used the remainder of flavonol propanoic acid 254, 
which unfortunately could not be resynthesised.  
 
Scheme 5.47. Attempts to couple enalapril analogue 265 and flavonol propanoic acid 254 were unsuccessful. 
 Overall, the synthesis of 3ʹ,4ʹ-dihydroxyflavonols incorporating a Ring A side 
chain (through the use of acetophenones with acetamide and acrylate functionalities) 
was unreliable. The purification of the Claisen-Schmidt condensation products often 
proved problematic, as the acetophenone and chalcone analogues would co-elute in 
column chromatography. Also, the synthesis of flavonols from the corresponding 
chalcones by the AFO reaction proved highly unreliable. The few times that these 
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flavonols were synthesised, with either protected or unprotected carboxylic acid side 
chains, the reactions were not reproducible. 
 Although the synthesis of ‘conjugate’ DMLs incorporating 3ʹ,4ʹ-
dihydroxyflavonol and an enalapril analogue was not achieved, the synthesis of ‘fused’ 
DMLs was also pursued in this project, once again combining the 3ʹ,4ʹ-
dihydroxyflavonol structure, as well as peptidic ACE inhibitors. This more successful 
approach will be discussed in Chapter Six.  
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Chapter Six: 
‘Fused’ Designed Multiple Ligands: 
3ʹ,4ʹ-Dihydroxyflavonol and Peptidic 
ACE Inhibitors 
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6.1 Chapter Overview 
As explored in Chapter Five, Designed Multiple Ligands, or DMLs, are 
therapeutic agents that incorporate two or more pharmacophores or pharmaceutical 
structures into a single compound. In this chapter, the ‘fused’ DMLs, where the two or 
more ligands of the DML are essentially touching, are the focus. This chapter will 
discuss attempts to synthesise a number of DML compounds for the treatment of 
hypertension, incorporating 3ʹ,4ʹ-dihydroxyflavonol 53 and di- or tripeptides as ligands. 
6.2 The Ligands of the ‘Fused’ DMLs 
 With the vasorelaxant and antioxidant 3ʹ,4ʹ-dihydroxyflavonol 53 in mind, as 
well as ACE-inhibiting di- and tripeptides, it was thought that a series of ‘fused’ 
(directly joined) DMLs could be synthesised and evaluated for their antihypertensive 
activity. Herein, the synthesis of a series of completely nature-inspired, potentially 
antihypertensive DMLs incorporating 3ʹ,4ʹ-dihydroxyflavonol 53 and a series of di- and 
tripeptides is described. Once synthesised, biochemical evaluation of the DML 
compounds and the individual ligands is to be performed to identify any 
antihypertensive or synergistic effects.  
6.2.1 Ligand 1: 3ʹ,4ʹ-Dihydroxyflavonol 53 
As explained in Chapter 5.3.1, 3ʹ,4ʹ-dihydroxyflavonol 53 is a vasorelaxant and 
antioxidant flavonoid (Figure 6.1).  
 
Figure 6.1. 3ʹ,4ʹ-Dihydroxyflavonol 53 is a vasorelaxant, antioxidant flavonoid. 
Research in Chapter Five, using functionalised forms of 3ʹ,4ʹ-dihydroxyflavonol 
were unsuccessful in attempts to synthesise a series of ‘conjugate’ DMLs. Following 
this failure, attention turned to the use of this flavonol in a ‘fused’ sense, in that the 
flavonol could be attached directly (without a linker group) to the other DML ligand. 
An ideal position from which to attach the second ligand was the 3-hydroxyl position of 
flavonol 53. The attachment of other functionalities to this 3-hydroxyl position had 
been completed previously by Woodman and co-workers to form hemiadipate 270 and 
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phosphate 271 prodrugs (Figure 6.2).61 This also provides an unfunctionalised Ring A, 
a feature associated with increased vasorelaxant activity of the flavonol.286 
 
Figure 6.2. Woodman and co-workers have added functionalities (blue) to the 3-hydroxyl position of 3ʹ,4ʹ-dihydroxyflavonol 
53, to increase its solubility and therefore bioavailability. 
Amino acids have also been previously attached to the 3-hydroxyl position of 
flavonols.625 Through carbodiimide-mediated ester formation, Boc- (tert-
butoxycarbonyl) protected amino acids were coupled through their carboxylic acid to 
the 3-hydroxyl position of quercetin-based flavonol 272 (Scheme 6.1). This 
methodology was deemed suitable for the attachment of the peptidic ligands of these 
‘fused’ DMLs to the 3-hydroxyl position of 3ʹ,4ʹ-dihydroxyflavonol. 
 
Scheme 6.1. The 3-hydroxyl position of quercetin-based flavonol 272 has been used to attach amino acids such as 273, using 
a coupling reaction.  
 While in this section, the final compounds are discussed as DMLs, the 
compounds are subject to cleavage by the esterases of the body. An example of a DML 
which incorporates an ester linkage to join its ligands is the previously mentioned 
(NSAID) DML 209, which links the NSAID ibuprofen through an ester linker group to 
an NO-donor (Figure 6.3).557 The ester is cleaved by plasma esterases to provide two 
bioactives, which act separately.548 This is a prodrug-like approach, in that the two 
joined ligands provide a benefit such as increased bioavailability or decreased 
gastrotoxicity in the case of DML 209, and are cleaved in vivo to provide the bioactive 
ligands. 
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Figure 6.3. The NSAID DML 209 has ester linkages which are cleaved in vivo by plasma esterases to provide the two 
bioactive ligands. 
 In a similar fashion, if 3ʹ,4ʹ-dihydroxyflavonol was to be joined to the second 
peptidic ligand through an ester linkage, improved bioavailability of the joined DML 
may result. Traditionally, peptide-based drugs suffer from a lack of bioavailability (due 
to hydrolysis during gastrointestinal absorption and poor intestinal permeability),276 and 
the flavonoids are also poorly bioavailable (due to solubility issues).55-57 Following 
cleavage of the joined DML by plasma esterases, the two bioactive ligands can be 
provided to the body. 
6.2.2 Ligand 2: Peptidic ACE Inhibitors 
For the second ligand of these DMLs, it was thought that peptidic, rather than 
peptidomimetic, ACE inhibitors would be ideal. This provided a wholly ‘nature-
inspired’ approach, whereby both DML ligands could be sourced from nature. The use 
of peptidic ligands was also beneficial as such compounds are commercially available, 
rather than the peptidomimetic ligand 265 synthesised in Chapter Five. 
A number of potentially antihypertensive dipeptides were chosen, taking 
inspiration from a number of ACE-inhibiting peptides from milk270-272 and other natural 
sources.261, 263 Many peptidomimetic (such as enalapril 43)240 and peptidic (such as Val-
Pro-Pro 50, a tripeptide from fermented milk)273-275 ACE inhibitors terminate in a 
proline unit (Figure 6.4), as it is this proline unit that binds the S2ʹ pocket of ACE.232, 
240, 275 For this reason, proline 261 was chosen as the C-terminal amino acid for the 
dipeptides. It is also noted that dipeptides with proline at the C-terminal are more stable 
to peptide hydrolysis,232, 276 which would help to avoid any problems in terms of lack of 
bioavailability during absorption and digestion. 
 
Figure 6.4. Enalapril 43 and Val-Pro-Pro 50 are two ACE inhibitors, and contain a C-terminal proline unit (blue). 
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For the synthesis of the dipeptides, the N-terminal amino acids to attach to the 
proline unit were selected from the literature. Alanine was chosen due to its position 
next to proline in enalapril 43,619 and lysine was selected due to its position next to 
proline in the pharmaceutical ACE inhibitor lisinopril 45 (Figure 6.5).240, 263 Finally, 
glutamine and glutamic acid were also selected for the dipeptide, as they provided 
different functionalities on their side chains (an amide and a carboxylic acid 
respectively). 
 
Figure 6.5. Alanine (blue) and lysine (red) were chosen as N-terminal amino acids in the dipeptides due to their presence in 
enalapril 43 and lisinopril 45 respectively. 
Tripeptides in the form of isoleucine-proline-proline (Ile-Pro-Pro) 49 and 
valine-proline-proline (Val-Pro-Pro) 50 were also selected for use as ligands in these 
DMLs. These tripeptides have been shown as ACE inhibitors in animal270-272 and 
human trials (Figure 1.28).273, 274 Indeed, a product containing both Ile-Pro-Pro 49 and 
Val-Pro-Pro 50 has been commercialised.275 These two tripeptides were purchased with 
N-carboxybenzyl- (Cbz-) protection, in order to be coupled through the C-terminal 
proline unit (Figure 6.6). 
 
Figure 6.6. The Cbz-protected ACE-inhibiting tripeptides Ile-Pro-Pro 275 and Val-Pro-Pro 276 were used in the synthesis of 
‘fused’ DMLs.  
6.3 Retrosynthesis 
In order to synthesise these 3ʹ,4ʹ-dihydroxyflavonol DMLs, a retrosynthesis was 
first performed (Scheme 6.2). The desired DML compounds 277 could be obtained by 
deprotection of the peptide chain and 3ʹ,4ʹ-dihydroxyl positions. The coupling of the 3-
hydroxyl position of flavonol 281 and the C-terminal carboxylic acid of dipeptides 279 
could be completed using the aforementioned ester formation.625  
 167 
 
To synthesise the dipeptides 279, protection and deprotection steps were 
required, including benzyl protection and deprotection of the proline unit 261. An 
EDCI-mediated coupling reaction could join the two amino acids 280 and 261. 
The synthesis of flavonol 281 could be achieved using 2ʹ-hydroxyacetophenone 
72 and 3,4-dibenzyloxybenzaldehyde 227, using an Algar-Flynn-Oyamada (AFO) 
reaction and Claisen-Schmidt condensation. 
 
Scheme 6.2. Retrosynthesis of ‘fused’ DMLs incorporating 3ʹ,4ʹ-dihydroxyflavonol 281 and dipeptides 279. 
With this retrosynthesis in mind, attention turned to the synthesis of 3ʹ,4ʹ-
dibenzyloxyflavonol 281. 
6.4 Synthesis of 3ʹ,4ʹ-Dihydroxyflavonol-Dipeptide 
DMLs 
As the synthesis of the flavonol required the protection of the 3,4-dihydroxyl 
groups to prevent any undesired couplings, the first step of the synthesis was the benzyl 
protection of 3,4-dihydroxybenzaldehyde. This was previously completed in 74% yield 
(Scheme 6.3).291 
 
Scheme 6.3. Benzyl protection of 3,4-dihydroxybenzaldehyde 223. 
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With 3,4-dibenzyloxybenzaldehyde 227 in hand, attention turned to the use of 
this aldehyde with 2ʹ-hydroxyacetophenone 72 to access the desired 2ʹ-
hydroxychalcone 282, using a Claisen-Schmidt condensation. 
6.4.1 Claisen-Schmidt Condensation 
 As with previous chapters, the conversion ratio for this condensation was 
determined by comparing the integrations of relevant peaks in the 1H NMR spectrum of 
the crude reaction product. 
 To synthesise the desired 3,4-dibenzyloxy-2ʹ-hydroxychalcone 282, the 
optimised microwave-assisted Claisen-Schmidt Condensation conditions from Chapter 
Two (KOH, THF, MW, 50 °C, 15 minutes) were applied to the substrates 2ʹ-
hydroxyacetophenone 72 and 3,4-dibenzyloxybenzaldehyde 227 (Table 6.1, entry 1). 
However, analysis of the crude material by 1H NMR spectroscopy revealed only 
starting materials. 
Table 6.1. Claisen-Schmidt condensation of 2ʹ-hydroxyacetophenone 72 and 3,4-dibenzyloxybenzaldehyde 227. 
 
Entry Conditions Solvent 72:282 
1 MW 50 °C 15 min THF 1:0 
2 MW 70 °C 30 min THF 3:2 
3 16 hrs rt EtOH 1:2 
4 16 hrs rt THF 4:1 
 
The reaction was then repeated using a higher temperature and longer reaction 
time (70 °C and 30 minutes, Table 6.1, entry 2), which provided 2ʹ-
hydroxyacetophenone 72 and chalcone 282 in a ratio of 2:1. Unfortunately, when 
purification was attempted using column chromatography (with a number of solvent 
combinations including 2:1 Pet:EtOAc, 5% MeOH in CHCl3 and 40% CH2Cl2 in Pet), 
the acetophenone and chalcone would co-elute, making isolation of the desired 
chalcone 282 impossible.  
In an attempt to effect full conversion to chalcone 282 and thereby negate the 
need for purification, conventional methodology was also trialled.291 Stirring 
acetophenone 72 and benzaldehyde 227 with KOH in EtOH for 16 hours (Table 6.1, 
entry 3) produced acetophenone 72 and chalcone 282 in a ratio of 1:2 respectively. As 
purification by column chromatography had proven unsuccessful in the previous 
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attempt, the crude material was purified by recrystallisation (1:1 THF:Pet), resulting in 
a product with a ratio of 1:30 acetophenone 72 to chalcone 282 respectively 
(Figure 6.7).  
 
Figure 6.7. 1H NMR spectrum of the impure chalcone 282 following recrystallisation, in a 30:1 ratio of chalcone 280 to 
acetophenone 72 respectively (CDCl3). 
The reaction was also repeated using THF as the solvent (Table 6.1, entry 4); a 
conversion ratio of 4:1 acetophenone 72 to chalcone 282 was noted. As such, the 
slightly impure chalcone 282 from Table 6.1, entry 3 was used in the Algar-Flynn-
Oyamada reaction, as it was envisioned that purification following flavonol synthesis 
would remove the unwanted acetophenone.  
As the purest sample of chalcone 282 was provided by the conventional 
methodology (the product of the reaction in Table 6.1, entry 3), this was used in the 
next synthetic step, the synthesis of the corresponding flavonol 281. This process of 
purification after a second reaction was successfully used previously in Chapter Five. 
6.4.2 Algar-Flynn-Oyamada Reaction 
 The Algar-Flynn-Oyamada (AFO) methodology of Woodman and co-workers 
was used to synthesise flavonol 279,62 which involved the addition of 30% hydrogen 
peroxide (H2O2) in H2O to the impure sample of chalcone 282 (1:30 acetophenone 72 to 
chalcone 282), with 2M NaOH in EtOH and 1,4-dioxane at 0 °C for two hours, 
 170 
 
followed by stirring at room temperature for 16 hours (Scheme 6.4). Recrystallisation 
from EtOAc isolated the desired flavonol 281 in an extremely poor yield of 9%, as 
confirmed by comparison to literature data.626 Analysis of the mother liquor revealed 
only the presence of chalcone 282 and its corresponding acetophenone. 
  
Scheme 6.4. 3ʹ,4ʹ-Dihydroxyflavonol 281 was accessed in a poor 9% yield from impure 2ʹ-hydroxychalcone 282. 
As flavonol 281 was afforded in such a small yield (8% over two steps), 
attention turned to the use of the ‘Modified’ Algar-Flynn-Oyamada reaction. 
6.4.3 ‘Modified’ Algar-Flynn-Oyamada Reaction 
 In the ‘Modified’ methodology, the starting materials are reacted under Claisen-
Schmidt Condensation conditions to form the 2ʹ-hydroxychalcone, which is then 
directly treated with AFO conditions (without isolation of the chalcone) to afford the 
flavonol.291, 599, 611, 612 While the ‘Modified’ AFO reaction had proven unsuccessful in 
our hands in the synthesis of flavonol acetamides and acrylates in Chapter Five, it had 
been successfully utilised by Woodman and co-workers in the synthesis of flavonols 
similar to 281, and so their methodology was utilised.291 
The starting materials 2ʹ-hydroxyacetophenone 72 and 3,4-
dibenzyloxybenzaldehyde 227 were reacted with 40% KOH in EtOH and dioxane for 
five days according to the methodology of Woodman,291 followed by treatment with 
30% H2O2 in H2O and 2M NaOH in EtOH and dioxane for 2 hours at 0 °C and then 16 
hours at room temperature (Scheme 6.5).291  
 
Scheme 6.5. The ‘Modified’ AFO reaction was used to synthesise 3ʹ,4ʹ-dibenzyloxybenzaldehyde 281 in 53% yield. 
Following recrystallisation from EtOAc, the desired flavonol 281 was isolated 
in 53%, as confirmed by comparison to literature data.626 The 1H NMR spectrum of 
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flavonol 281 shows the loss of the acetophenone CH3 peak (δ 2.57 ppm), chalcone 
hydroxyl peak (δ 12.86 ppm), and benzaldehyde peak (δ 9.80 ppm) (Figure 6.8). Note 
that the broadness of the 1H NMR peaks is due to the π-π stacking configuration of the 
flavonol.58 This ‘Modified’ AFO method provided the desired flavonol in a greater 
yield (53%) than the two-step Claisen-Schmidt condensation and AFO reaction (8%). 
 
Figure 6.8. 1H NMR spectrum of 3ʹ,4ʹ-dibenzyloxyflavonol 281 (CDCl3). 
With 3ʹ,4ʹ-dibenzyloxyflavonol 281 in hand, attention turned to the synthesis of 
the dipeptides. As these dipeptides were to be linked to the flavonol through its 3-
hydroxyl position, a late stage deprotection of the 3ʹ,4ʹ-dibenzyloxy ethers was required, 
and therefore flavonol 281 could be used in its protected form in the coupling reactions.  
6.4.4 Synthesis of Dipeptides 
As explained in Chapter 6.2.2, all dipeptides selected for use in these DMLs 
contained a C-terminal proline unit. For the second amino acid, alanine and lysine were 
chosen from the literature based on their appearance in other ACE inhibitors (enalapril 
43 and lisinopril 45 respectively),240, 263, 619 and glutamine and glutamic acid were also 
selected as they provided different functionalities on their side chains (an amide and a 
carboxylic acid respectively). Fmoc- (9-fluorenylmethyloxy-) protected amino acids 
were utilised in this synthesis as they prevented any undesired side couplings 
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(Figure 6.9). The amino acids used also had side chain protecting groups where 
required. 
 
Figure 6.9. The Fmoc- and side chain-protected amino acids used for dipeptide synthesis all contained different 
functionalities in their side chains (shown in blue). 
The protection of the C-terminal proline unit 261 was the first step of the 
dipeptide synthesis. Benzyl protection was ideal, as it could be removed under 
hydrogenation conditions, which were orthogonal to those of the Fmoc- and side group 
protections of the amino acids.393 
6.4.4.1 Protection of L-Proline 261 
This was completed previously in 95% yield (Scheme 6.6).620 The next step of 
the dipeptide synthesis was coupling to the second amino acid. 
 
Scheme 6.6. Benzyl protection of L-proline 261. 
6.4.4.2 Coupling of Pro-OBn 259 to Second Amino Acid 
The general method for the coupling of Pro-OBn 259 to the N-terminal amino 
acid of the dipeptide involved stirring the N-terminal amino acid in EDCI, HOBt and 
CH2Cl2 for 10 minutes, followed by the addition of Pro-OBn 259 (Scheme 6.7). The 
reaction was stirred for 16 hours at room temperature, and following work up and 
purification by column chromatography (3% MeOH in CHCl3), each of the desired 
dipeptides were isolated in good yields (46-63%). 
 173 
 
 
Scheme 6.7. Four dipeptides were synthesised using an EDCI-mediated coupling reaction. 
 With Fmoc-dipeptides 287-290 in hand, the next step was the deprotection of 
the benzyl group of the proline unit, to provide the C-terminal carboxylic acid for 
coupling to the 3-hydroxyl position of 3ʹ,4ʹ-dibenzyloxyflavonol 281. 
6.4.4.3 Deprotection of the Benzyl Group of Fmoc-Dipeptides 287-290 
 Hydrogenation was used to deprotect the benzyl group Fmoc-dipeptides 287-
290. The dipeptides were each stirred with 10% palladium on carbon (Pd/C) in MeOH 
and H2 gas for 16 hours at room temperature (Scheme 6.8). Purification by column 
chromatography (3% MeOH in CHCl3) isolated the desired deprotected dipeptides 291-
294 in good to excellent yields (50-92%). The deprotected dipeptides were confirmed 
by the loss of the benzyl CH2 peaks (approximately δ 5.20 ppm) and aromatic peaks 
(with an integration of five) in the 1H NMR spectrum, and also confirmed by HRMS. 
 
Scheme 6.8. Benzyl deprotection provided the four deprotected dipeptides 291-294 in good yields.  
 With these four dipeptides in hand, each with a carboxylic acid for coupling, the 
next step of the synthesis was the coupling of the dipeptides to the 3-hydroxyl position 
of 3ʹ,4ʹ-dibenzyloxyflavonol 281. 
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6.5 Coupling of 3ʹ,4ʹ-Dihydroxyflavonol 281 to 
Dipeptides 291-294 
6.5.1 EDCI-Mediated Coupling of 3ʹ,4ʹ-Dihydroxyflavonol 
281 to Dipeptides 291-294 
As mentioned earlier, the coupling of similar substrates had been completed 
previously by Huang and co-workers, using DCC, DMAP and THF.625 With EDCI on 
hand in our laboratory, this was used in place of DCC, and CH2Cl2 in place of THF.  
A trial reaction was conducted using 3ʹ,4ʹ-dibenzyloxyflavonol 281 and N-
acetylglycine 295, to ensure that these conditions and reagents were suitable (Scheme 
6.9). Following reaction for 16 hours, the compound 296 was purified by 
recrystallisation (EtOH) in 72% yield. With this success, attention turned to the 
coupling of the four synthesised dipeptides 291-294 to the 3-hydroxyl position of 3ʹ,4ʹ-
dibenzyloxy flavonol 281. 
 
Scheme 6.9. The trial coupling of N-acetylglycine 295 to flavonol 281 succeeded in 72% yield. 
 Dipeptides 291-294 were then coupled to 3ʹ,4ʹ-dibenzyloxyflavonol 281 
(Scheme 6.10), and following workup and purification by column chromatography (2:1 
Pet:EtOAc), were analysed by 1H NMR and 13C NMR spectroscopy and HRMS. Three 
of the four DMLs, the alanine, lysine and glutamine derivatives, were successfully 
synthesised (protected DMLs 297, 298 and 299) in good yields (45%, 70% and 48% 
respectively).  
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Scheme 6.10. The protected DMLs 297-299 were successfully synthesised, however the glutamic acid derivative 300 could 
not be accessed. 
However, it was noted during the addition of the glutamic acid dipeptide to the 
reaction mixture that it was not soluble. Following the reaction, only starting materials 
were noted in the 1H NMR spectrum. The reaction was then repeated with a small 
amount of DMF to aid solubility, however this also did not produce the desired 
flavonol-dipeptide 300. With the other three dipeptides successfully synthesised, the use 
of this glutamic acid dipeptide was abandoned. Attention then turned to the removal of 
the benzyl groups of the flavonol, to provide the 3,4-dihydroxyl groups of Ring B. 
6.5.2 Removal of the Flavonol Benzyl Groups 
Next, the deprotection of the flavonol benzyl groups of protected DMLs 297-
299 was performed. Using a hydrogenation method from Huang et. al.,625 the DMLs 
297, 298 and 299 were each stirred in 1,4-dioxane and EtOH with H2 and Pd/C for 
16 hours at room temperature (Scheme 6.11). Following filtration, the desired 
deprotected DMLs 301, 302 and 303 were isolated in quantitative yield, as established 
by the loss of the benzyl and aromatic peaks (δ 5.0-5.2 ppm and δ 7.0-8.0 ppm 
respectively) in the 1H NMR spectra, the observance of signals representing the desired 
compounds including the Fmoc group (δ 4.2-5.0 ppm and δ 7.0-8.0 ppm for the CH2 
and CH, and aromatic protons respectively), as well as confirmation by HRMS. 
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Scheme 6.11. Deprotection of the benzyl groups provided the DMLs 301, 302 and 303. 
6.5.3 Removal of the Fmoc-Group of the Peptides 
The final step for the synthesis of the flavonol-dipeptide DMLs was the 
deprotection of the Fmoc-group of the peptide. To trial the deprotection, a small scale 
reaction of Fmoc-Ala-Pro-flavonol 301 and 20% piperidine in DMF was stirred for 20 
minutes at room temperature (Scheme 6.12).627 However, analysis of the crude material 
by 1H NMR spectroscopy revealed none of the desired deprotected product 304, nor any 
of the starting material. Analysis by MS also revealed neither the Fmoc- starting 
material nor the deprotected product.  
 
Scheme 6.12. Fmoc-deprotection of Fmoc-Ala-Pro-flavonol 304 was unsuccessful. 
It was possible that the use of the base piperidine caused the degradation of the 
starting material, and so a weaker piperidine solution was then trialled (5% piperidine in 
DMF) for 20 minutes. Once again, analysis of the crude product by 1H NMR 
spectroscopy and MS revealed neither the starting material 301, nor the desired 
deprotected amine product 304. As this degradation was believed to be the result of 
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using a base, and all other Fmoc-deprotection conditions utilised bases, (piperazine, 
morpholine, dicyclohexylamine, and tetrabutylammonium fluoride (TBAF),627 the 
deprotection of the Fmoc-DMLs was not attempted using these conditions. Huang and 
co-workers had also noted difficulties in deprotecting amines of similar flavonol 
compounds,625 albeit using acidic conditions to remove a Boc-protected amine and 
hydrogenation to remove benzyl groups. 
It was also thought that the acidic nature of the phenols may be interfering with 
the use of base in the deprotection. To test this theory, the benzyl-protected flavonol 
281 was coupled to Fmoc-Ala-OH 283 using the coupling conditions identified earlier 
(EDCI and DMAP in CH2Cl2 for 16 hours at room temperature, Scheme 6.13). This 
product 305 was then treated with 20% piperidine in DMF, and the crude product 
analysed by 1H NMR spectroscopy and HRMS, revealing once again the degradation of 
the flavonol-amino acid 305. This was unfortunate, as it meant that the Fmoc- group 
could not be removed.  
 
Scheme 6.13. Fmoc-deprotection of compound 305 degraded the starting material once again, proving that the use of 
piperidine was detrimental to the flavonol-dipeptide DMLs. 
The presence of the Fmoc-group during biochemical evaluation might prove 
problematic due to its hydrophobic nature, however compounds 301-303 have 
nevertheless been submitted for biochemical evaluation. Another strategy, involving the 
use of the milk-derived ACE-inhibiting tripeptides Ile-Pro-Pro 49 and Val-Pro-Pro 50 
was then pursued. 
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6.6 Coupling of 3ʹ,4ʹ-Dihydroxyflavonol 281 to 
Tripeptides 275 and 276 
 Two tripeptides were purchased for coupling to the 3-hydroxyl position of 3ʹ,4ʹ-
dibenzyloxyflavonol. These were carboxybenzyl (Cbz-) protected Ile-Pro-Pro (Cbz-Ile-
Pro-Pro-OH) 275, and Val-Pro-Pro (Cbz-Val-Pro-Pro-OH) 276 (Figure 6.10). As 
mentioned earlier, these tripeptides exhibit ACE-inhibiting activity,270-275 and were 
Cbz-protected at the N-terminal amine; benzyl and Cbz- groups can both be deprotected 
under hydrogenation conditions.393 This provided a free C-terminal carboxylic acid for 
coupling to the 3-hydroxyl position of 3ʹ,4ʹ-dibenzyloxyflavonol 281. 
 
Figure 6.10. Cbz-Ile-Pro-Pro-OH 275 and Cbz-Val-Pro-Pro-OH 276, with slightly different side chains (shown in blue) were 
purchased for coupling to 3ʹ,4ʹ-dihydroxyflavonol 281. 
6.6.1 EDCI-Mediated Coupling of 3ʹ,4ʹ-Dihydroxyflavonol 
27981 to Tripeptides 275 and 276 
The tripeptides Cbz-Ile-Pro-Pro-OH 275 and Cbz-Val-Pro-Pro-OH 276 were 
coupled to 3ʹ,4ʹ-dihydroxyflavonol 281 using EDCI and DMAP in CH2Cl2 for 16 hours 
at room temperature (Scheme 6.14). Purification by column chromatography (5% 
MeOH in CH2Cl2) provided flavonol-Pro-Pro-Ile-Cbz 307 in 97% yield, and flavonol-
Pro-Pro-Val-Cbz 308 in 81% yield. 
 
Scheme 6.14. Coupling of Cbz-Ile-Pro-Pro-OH 275 and Cbz-Val-Pro-Pro-OH 276 to 3ʹ,4ʹ-dihydroxyflavonol 281 occurred in 
good yields. 
  The structure of these novel compounds was confirmed by 1H and 13C NMR 
spectroscopy, as well as HRMS. In the 1H NMR spectrum, the compounds (Figure 6.11 
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shows that of flavonol-Pro-Pro-Ile-Cbz 307) were confirmed by the presence of the 
benzyl (δ 5.24 and 5.34 ppm) and Cbz- (δ 5.08 ppm) groups in the correct integrations 
(four and two respectively), and the presence of appropriate aromatic peaks (δ 7.03-8.22 
ppm) with an integration of 22 for the aromatic protons. 
 
Figure 6.11. 1H NMR spectrum of the Cbz-Ile-Pro-Pro-flavonol compound 307, highlighting the benzyl, Cbz- and aromatic 
peaks (CDCl3). 
6.6.2 Global Deprotection of the Benzyl and Cbz- Groups 
Following these successful couplings, the final step for these flavonol-tripeptide 
DMLs was the global deprotection of benzyl and Cbz- groups. This was performed 
using hydrogenation conditions (H2 and Pd/C in 1,4-dioxane and EtOH for 16 hours at 
rt, Scheme 6.15), and the desired 3ʹ,4ʹ-dihydroxyflavonol-tripeptide DMLs 309 and 310 
were produced in quantitative yields.  
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Scheme 6.15. Deprotection of the Cbz- and Bn groups using hydrogenation conditions provided the desired flavonol-
tripeptide DMLs 309 and 310. 
These compounds were identified in the 1H NMR spectrum by the complete loss 
of the benzyl (δ 5.24 and 5.34 ppm) and Cbz- (δ 5.08 ppm) groups, however the 
extremely broad peaks of the spectrum were difficult to interpret. Further confirmation 
was provided by 13C NMR spectroscopy, as well as HRMS. These two 3ʹ,4ʹ-
dihydroxyflavonol-tripeptide DMLs 307 and 308 have been submitted for evaluation of 
their antihypertensive activity. 
6.7 Antihypertensive Analysis 
To analyse the antihypertensive activity of the synthesised DMLs 301, 302, 303, 
309 and 310, a number of biochemical assays are to be performed by Dr Kylie 
Venardos. Once again it should be noted that these analyses are to be performed on not 
only the DML compounds, but also the individual ligands, so as to identify the modes 
of action of the individual ligands, as well as any synergistic effects.  
The biochemical assays are to be performed on isolated mouse heart cells 
(cardiomyocytes) which have been stressed using various neurohormones, including 
endothelin, angiotensin II, aldosterone and noradrenaline. These particular 
neurohormones are elevated and circulate during hypertension in humans, and 
contribute to cardiac complications such as hypertrophy (where the pathological growth 
of cells causes an increase in organ size and a decrease in contractile function/cardiac 
output). Once the cells have been stressed, they are to be treated with and without the 
DML compounds, and then utilised in the biochemical assays listed below. As well as 
the measurements involved in the following assays, cell size will also be measured 
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using light microscopy. Ribonucleic acid (RNA) will also be collected for real-time 
polymerase chain reaction (PCR) of messenger RNA (mRNA) markers of hypertrophy, 
such as β-myosin heavy chain (β-MHC), brain natriuretic peptide (BNP) and atrial 
natriuretic factor (ANF). The measurement of cell size and presence of mRNA markers 
will help to determine if the DML compounds have direct antihypertrophic effects on 
heart cells. 
The compounds will be examined for their ability to stimulate nitric oxide (NO) 
production in the stressed cardiomyocytes. NO plays a pivotal part in the modulation of 
vascular tone and vascular smooth muscle proliferation, and its production is reduced in 
hypertensive patients.628 The assay to measure NO involves the treatment of the cells 
with the DML and ligand compounds, followed by the addition of 4-amino-5-
methylamino-2ʹ,7ʹ-dichlorofluorescein diacetate ([DAF-FM] diacetate).628 When 
oxidised by NO, [DAF-FM] forms 2ʹ,7ʹ-dichlorofluorescein, a fluorescent compound 
which can be measured on a fluorescence microplate reader at 495 nm excitation and 
538 nm emission. The measurement of fluorescence allows the determination of the 
amount of NO produced by the cells following treatment with the DML and ligand 
compounds. Endothelial cells will also be treated with the DML compounds to see if 
they directly cause NO production by the endothelium. This will be done under normal 
conditions as well as following neurohormone stress and oxidative stress (with H2O2 
and pyrogallol). All of these stress conditions are associated with hypertension and 
reduced endothelial bioavailability. 
 The DMLs and ligands will also be tested for their ability to relieve oxidative 
stress (which is increased in hypertension) in cardiomyocytes, through the measurement 
of Reactive Oxygen Species (ROS). The cells will be stressed with the neurohormones 
or treated with the ROS generator, pyrogallol, and then treated with and without the 
DML and ligand compounds. The cells are then loaded with the fluorescent probe 2ʹ,7ʹ- 
dichlorofluorescein diacetate.628 The ROS generated by the cells oxidises the 2ʹ,7ʹ-
dichlorofluorescein diacetate to form the fluorescent compound 2ʹ,7ʹ-
dichlorofluorescein, which can be measured a fluorescence microplate reader at 495 nm 
excitation and 538 nm emission. H2O2 treated cells will also be used as a positive 
control in the assay. The measurement of ROS in these cells will help to determine if 
oxidative stress is reduced in the presence of these compounds. 
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The compounds will also be analysed for their ability to reduce cellular necrosis 
in isolated mouse cardiomyocytes, through the measurement of lactate dehydrogenase 
(LDH). LDH is released by cells as their membranes are disrupted during cellular 
necrosis, thus the measurement of its activity reflects the amount of cell death. To 
measure LDH activity, culture media is collected from the heart cells (following 
neurohormone stress with and without the DML compounds) and added to a mixture of 
NADH, NaH2PO4, and sodium pyruvate.629 The LDH released from the necrotic cell 
into the media reduces the pyruvate to lactate using NADH, which is in turn oxidised to 
NAD+ and no longer produces light. Spectrophotometric measurement of the rate of 
decrease in absorbance at 340 nm over two minutes allows for the determination of the 
percentage of cellular necrosis caused by the compounds. 
 In conclusion, the measurements of cell size, and the analysis of mRNA markers 
will help to determine if the compounds have a direct antihypertrophic effects on heart 
cells. The ROS assay will help to identify the effect of the DML compounds on 
removing oxidative stress (which is increased during hypertension), and the NO assay 
will determine if the DML compounds have an effect on NO production (which is 
decreased during hypertension). Finally, if there are changes in the rate of cell death 
following treatment with the DML compounds (as compared to without treatment), then 
these other assays will allow for the determination of how the DML compounds are 
acting within the cells, and also whether or not they are cardioprotective and/or 
antihypertensive.  
6.8 ‘Fused’ 3ʹ,4ʹ-Dihydroxyflavonol-Peptidic DMLs: 
Conclusion 
 The synthesis of several 3ʹ,4ʹ-dihydroxyflavonol-peptidic DMLs was 
successfully completed. Three dipeptide (301, 302 and 303) and two tripeptide (309 
and 310) ‘fused’ DMLs were accessed.  
The 3ʹ,4ʹ-dihydroxyflavonol ligand 281 of the DMLs was synthesised using a 
‘Modified’ AFO reaction in good yield (53%, Scheme 6.16). 
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Scheme 6.16. 3ʹ,4ʹ-Dihydroxyflavonol 281 was accessed using a ‘Modified’ AFO reaction, in 53% yield. 
Four dipeptides were also synthesised, using an EDCI-mediated coupling 
reaction as well as protections and deprotection steps; Fmoc-Ala-Pro-OH 291, Fmoc-
Lys(Boc)-Pro-OH 292, Fmoc-Gln-Pro-OH 293, and Fmoc-Glu(tBu)-Pro-OH 294 
(Scheme 6.17). 
 
Scheme 6.17. Four dipeptides 291-294 were synthesised from L-Proline 261 in 3 steps, for coupling to the 3ʹ,4ʹ-
dihydroxyflavonol ligand 281. 
The first three of these dipeptides were then successfully coupled to the 3ʹ,4ʹ-
dihydroxyflavonol 281 ligand, and then hydrogenated to remove the benzyl groups of 
the flavonol (Figure 6.12). Unfortunately, the Fmoc group could not be deprotected. 
These compounds were submitted for biochemical evaluation of their antihypertensive 
properties, and results are still pending at the time of submission of this thesis. 
 
Figure 6.12. Three Fmoc-protected flavonol-dipeptide DMLs 301, 302 and 303 were successfully synthesised, and submitted 
for evaluation of their antihypertensive activity. 
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 Two known ACE-inhibiting tripeptides were also purchased for coupling to 
3ʹ,4ʹ-dihydroxyflavonol 281; Cbz-Ile-Pro-Pro-OH 275 and Cbz-Val-Pro-Pro-OH 276. 
These were used to access the two flavonol-tripeptide DMLs 309 and 310, in total 
yields of 97% and 81% respectively over two steps (Figure 6.13). These compounds 
were also submitted for biochemical evaluation of their antihypertensive properties, and 
results are still pending at the time of submission of this thesis. 
 
Figure 6.13. Two flavonol-tripeptide DMLs 309 and 310 were also successfully synthesised, and submitted for evaluation of 
their antihypertensive activity.  
A total of five ‘fused’ (whereby the ligands are joined directly) DMLs were 
synthesised, which incorporated both the vasorelaxant and antioxidant activity of 3ʹ,4ʹ-
dihydroxyflavonol and the ACE-inhibiting activity of various peptides.  
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Chapter Seven: 
Conclusions and Future Work 
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7.1 Thesis Conclusions 
 In conclusion, this thesis details the synthesis of a number of novel flavonoids. 
Both halogenated and peptide-functionalised flavonoids were synthesised, using a 
number of novel and established methodologies. A number of these compounds have 
submitted for evaluation of their bioactivity and therapeutic effects, including cytotoxic, 
antibacterial, anticancer, antidiabetic and antihypertensive properties.  
 The incorporation of halogens onto the flavonoid scaffold was of importance, as 
halogen bonding has been shown in medicinal and biomedical chemistry to strengthen 
drug-target interactions. It will be interesting to see how the halogenated flavonoids 
perform in assays compared to the non-halogenated analogues. 
Attempts were also made to further functionalise the halogenated flavonoids 
using the Heck reaction, and while brominated benzaldehydes and acetophenones were 
successfully utilised in the Heck reaction, chalcone, flavanone and flavone substrates 
could not be used to access acrylate products. 
 Finally, using both the methods developed and the compounds synthesised 
throughout Chapters Two to Four, the synthesis of a number of antihypertensive 
Designed Multiple Ligands was attempted. The synthesis of ‘conjugate’ DMLs 
incorporating the vasorelaxant compound 3ʹ,4ʹ-dihydroxyflavonol and peptidomimetic 
ACE-inhibiting enalapril-derived compounds attached through a linker group was not 
successful. Of four different functionalised 3ʹ,4ʹ-dihydroxyflavonols, only one was 
accessed (albeit slightly impure), and of two enalapril derivatives, only one was 
accessed. However, the flavonol and enalapril derivative could not be coupled. 
 A series of ‘fused’ DMLs were then synthesised, joining 3ʹ,4ʹ-
dihydroxyflavonol and potentially ACE-inhibiting di- and tripeptides through an ester 
linkage. These DMLs may be subject to cleavage by plasma esterases in the body, in 
which case the two ligands will be provided to the body and act separately (in a 
prodrug-like approach). Five DML compounds were successfully synthesised, and have 
been submitted for biochemical evaluation of their antihypertensive activity. 
7.2 Future Work 
There are a number of opportunities for future work. In terms of the 2ʹ-
hydroxychalcones, the use of other functionalised starting materials, particularly more 
hydroxylated compounds, would provide more functionalised 2ʹ-hydroxychalcones, 
which could therefore be used to identify further trends within the microwave-assisted 
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synthetic methodology. Also, once the biochemical evaluation results of 2ʹ-
hydroxychalcones 80, 118 and 121 are received, results will provide direction for 
further development. These evaluations will also help to identify whether or not 
flavonoids containing halogens offer the benefit of halogen-bonding with molecular 
targets, in comparison to non-halogenated flavonoids. 
There is also the option of applying the pIL-mediated, microwave-assisted 
flavanone synthetic methodology to a wider variety of chalcone substrates, in particular 
those incorporating hydroxyl substitutions. This too could provide more information in 
terms of Structure-Activity Relationships.  
A future aim for this research is the application of the Algar-Flynn-Oyamada 
reaction to 2ʹ-hydroxychalcone substrates to access a library of functionalised flavonol 
compounds, and for those compounds to be evaluated for therapeutic properties. 
Finally, in terms of the Designed Multiple Ligands, a future aim is to obtain 
other Cbz-protected dipeptides and tripeptides to attach to 3ʹ,4ʹ-dihydroxyflavonol. This 
protecting group should remove any problems concerning solubility that were 
associated with the inability to deprotect the Fmoc-group, and provide more 
bioavailable DML compounds. Results regarding the antihypertensive activity of the 
five original DML compounds will allow for the development of a second, more active 
generation of DML compounds for the treatment of hypertension. 
There is also the opportunity to attach the peptidomimetic ACE inhibitor 
enalaprilat 42 to 3ʹ,4ʹ-dihydroxyflavonol 53, so as to examine the benefit of a flavonol-
ester prodrug, rather than the ethyl ester utilised in enalapril. 
 
Figure 7.1. Future work includes the synthesis of the ‘flavonol-ester’ prodrug 311. 
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Chapter Eight: 
Characterisation 
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8.1 General Experimental 
8.1.1 Instrumentation 
Microwave reactions were conducted using a CM Discover S-Class Explorer 48 
Microwave Reactor, operating on a frequency of 50/60 Hz and continuous irradiation 
power from 0 to 200 W. All reactions were performed in 10mL septa vials with snap 
caps, with the following conditions: pressure (17 bar); power max (on); and stirring 
(high). 
All 1H and 13C NMR spectra were recorded on a JEOL JNM-EX 270 MHz FT-
NMR spectrometer or JEOL JNM-ECP 400 MHz FT-NMR spectrometer as indicated. 
Samples were dissolved in deuterated chloroform (CDCl3), with the residual solvent 
peak used as an internal reference (CDCl3 – δH 7.26 ppm and δC 77.10 ppm). Proton 
spectra are reported as follows: chemical shift δ (ppm), (integral, multiplicity (s = 
singlet, br s = broad singlet, d = doublet, dd = doublet of doublets, t = triplet, q = 
quartet, m = multiplet), coupling constant J (Hz), assignment). Carbon spectra are 
reported as chemical shift δ (ppm).  
Mass Spectra (MS), including High Resolution Mass Spectra (HRMS), were 
recorded on a 6210 MSD TOF mass spectrometer (Agilent Technologies, Australia) 
with the following conditions: drying gas nitrogen (7.0 L/min, 325 °C); nebuliser gas 
nitrogen (15 psi); capillary voltage 3.0 kV; vaporiser temperature 29 °C; and cone 
voltage 40 V. Acetonitrile was used as the mobile phase. Samples were dissolved in 
acetonitrile, with less than 1 mg sample per mL solvent.  
All melting points were obtained using a Bibby Stuart Scientific SMP3 melting 
point apparatus, version 5.0.  
8.1.2 Chromatography 
Thin Layer Chromatography (TLC) was performed using aluminium-backed 
Merck TLC Silica gel 60 F254 plates, and samples were visualised using 254 nm 
ultraviolet (UV) light, and potassium permanganate/potassium carbonate oxidising dip 
(1:1:100 KMnO4:K2CO3:H2O w/w).  
Column Chromatography was performed using silica gel 60 (70-230 mesh). All 
solvents used were AR grade. Petroleum spirits refers to the fraction boiling between 
40-60 °C. 
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8.1.3 Dry solvents 
THF, CHCl3 and DMF were dried using a Pure Solv (Innovative Technologies) solvent 
drying system. Solvents are degassed, and passed through two drying chambers of 
alumina and collected under a positive pressure of nitrogen gas. 
8.1.4 Reagents 
$OOJHQHUDOUHDJHQWVZHUHDQDO\WLFDOJUDGHDQGXVHGDVVXSSOLHGXQOHVV
RWKHUZLVH VWDWHG 3XULILFDWLRQ DQGRU GU\LQJ RI JHQHUDO UHDJHQWV ZDV
SHUIRUPHGaccording to Perrin et. al.630Specialist reagents such as peptide coupling 
reagents were supplied by Aldrich Chemical Co.,631 A.K Scientific Inc.632 or Auspep 
Pty. Ltd.633 and used without further purification. 
8.1.5 Example of Compound Ratio Calculation from 1H NMR 
Spectra  
 
 In the case of reactions involving chalcones, as reagents or products, the 
following calculations were conducted. The chalcone peak (approximately δ 12.5-13.5 
ppm) was allocated an integration of 0.85. The acetophenone CH3 peak (approximately 
δ 2.5-2.7 ppm) was then integrated, and its integration value divided by three (for each 
of the three protons). For the spectrum below, this calculation provides the ratio of 
chalcone 66 to acetophenone 72 as 1:0.45, or approximately 2:1. Note that when the 
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ratio involved comparison to flavanone compounds, that the integration of the methyne 
(CH) peak (approximately δ 5.3-5.7 ppm) was used, with an integration of one. 
 
Chalcone OH (highlighted in blue) integration = 0.85 
Acetophenone CH3 (highlighted in green) integration = 1.35/CH3, or 0.45/hydrogen 
? Normalised ratio of 66:72 = 1:0.45 ≈ 2:1 
8.2 Specific Experimental 
The following sections detail the specific experimental conditions for each of the 
compounds successfully synthesised during this research project. The compounds are 
listed in chronological order according to the chapter in which they first appear. 
8.3 Chapter Two Experimental 
8.3.1 General Procedure for 2ʹ-Hydroxychalcones 
Representative experimental procedure: Substituted 2′-hydroxyacetophenone 
(0.5 mmol) was added to a solution of base (2.0 mmol) in THF (2.0 mL) in a 
microwave vial. Substituted benzaldehyde (0.5 mmol) was added, the vial capped, and 
the solution heated to 50 °C for 15 minutes using microwave irradiation. Solvent was 
evaporated in vacuo, and 10% HCl solution (20 mL) added. The product was 
transferred to a separating funnel, extracted with EtOAc (3 × 10 mL), washed with H2O 
(10 mL) and brine (10 mL), dried over MgSO4, filtered, and the solvent removed under 
reduced pressure to give a resin. Purification of the crude material by column 
chromatography (1:1 CH2Cl2:Pet) gave the desired chalcone 
8.3.2 Compound Characterisation Data 
1-(2-hydroxyphenyl)-3-phenylprop-2-en-1-one 66381, 385 
2′-Hydroxyacetophenone 72 (0.06 mL, 0.5 mmol), KOH (112 mg, 
2.0 mmol) and benzaldehyde 59 (0.101 mL, 1.0 mmol) were 
reacted according to the general procedure. The desired compound 
was obtained as a pale-yellow solid (112 mg, 100%, Rf = 0.61 (1:1 
CH2Cl2:Pet)); mp 86.0-88.2 °C (lit. 88 °C)381; δH NMR (270 MHz, CDCl3): 6.90-6.97 
(1H, m, CH), 7.03 (1H, dd, J 8.4, J 0.9, CH),7.41-7.52 (4H, m, ArH), 7.62-7.67 (3H, m, 
ArH), 7.88-7.94 (2H, m, ArH), 12.84 (1H, s, OH); MS (ESI m/z): Calcd. for 
[C15H12O2+H]+ 225.09, found 225.09. 
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3-(4-bromophenyl)-1-(2-hydroxyphenyl)prop-2-en-1-one 74392, 407 
2′-Hydroxyacetophenone 72 (0.06 mL, 0.5 mmol), KOH (112 
mg, 2.0 mmol) and 4-bromobenzaldehyde 73 (139 mg, 0.5 
mmol) were reacted according to the general procedure. The 
desired compound was obtained as a bright-yellow solid (145 
mg, 96%, Rf = 0.61 (1:1 CH2Cl2:Pet)); mp 146.4-149.1 °C (lit. 138-140 °C)392; δH NMR 
(270 MHz, CDCl3): 6.89-6.96 (1H, m, CH), 7.01 (1H, dd, J 8.4, J 0.9, CH), 7.46-7.90 
(8H, m, ArH), 12.74 (1H, s, OH); MS (ESI m/z): Calcd. for [C15H11BrO2-H]- 300.99, 
found 300.99. 
3-(3,5-dibromophenyl)-1-(2-hydroxyphenyl)prop-2-en-1-one 76 
2′-Hydroxyacetophenone 72 (0.06 mL, 0.5 mmol), Bu4NOH 
(1.0 M in MeOH, 2.0 mL, 2.0 mmol) and 3,5-
dibromobenzaldehyde 75 (198 mg, 0.5 mmol) were reacted 
according to the general procedure. The desired compound was 
obtained as a bright-yellow solid (99 mg, 52%, Rf = 0.5 (1:1 
CH2Cl2:Pet)); mp 168.7-174.8 °C; δH NMR (270 MHz, CDCl3): 6.93-6.99 (1H, m, CH), 
7.03 (1H, dd, J 8.4, J 0.9, CH), 7.49-7.55 (1H, m, ArH), 7.58-7.76 (5H, m, ArH), 7.90 
(1H, dd, J 7.9, J 1.4, ArH), 12.60 (1H, s, OH); δC NMR (67.5 MHz, CDCl3): 118.9, 
119.1, 119.8, 122.8, 123.7, 129.8, 130.0, 135.8, 137.0, 138.2, 142.0, 163.8, 193.0; 
HRMS (ESI m/z): Calcd. for [C15H10Br2O2+Na]+ 404.89248, found 404.89040. 
3-(3-(benzyloxy)phenyl)-1-(2-hydroxyphenyl)prop-2-en-1-one 78394 
 2′-Hydroxyacetophenone 72 (0.06 mL, 0.5 mmol), 
KOH (112 mg, 2.0 mmol) and 3-
benzyloxybenzaldehyde 77 (106 mg, 0.5 mmol) were 
reacted according to the general procedure. The 
desired compound was obtained as a bright-yellow solid (146 mg, 78%, Rf = 0.57 (1:1 
CH2Cl2:Pet)); mp 122.8-128.3 °C; δH NMR (270 MHz, CDCl3): 5.12 (2H, s, CH2), 
6.91-7.07 (3H, m, ArH), 7.25-7.63 (10H, m, ArH), 7.84-7.92 (2H, m, ArH), 12.80 (1H, 
s, OH); MS (ESI m/z): Calcd. for [C22H18O3-H]- 329.12, found 329.12.  
3-(5-bromo-2,4-dimethoxyphenyl)-1-(2-hydroxyphenyl)prop-2-en-1-one 80 
2′-Hydroxyacetophenone 72 (0.06 mL, 0.5 mmol), KOH (112 
mg, 2.0 mmol) and 5-bromo-2,4-dimethoxybenzaldehyde 79 
(123 mg, 0.5 mmol) were reacted according to the general 
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procedure. The desired compound was obtained as a yellow solid (163 mg, 90%, Rf = 
0.35 (1:1 CH2Cl2:Pet)); mp 186.1-187.7 °C; δH NMR (270 MHz, CDCl3): 3.93 (3H, s, 
CH3), 3.94 (3H, s, CH3), 6.45 (1H, s, ArH), 6.45 (1H, s, ArH), 6.90-7.01 (2H, m, ArH), 
7.43-7.61 (2H, m, ArH), 7.79 (1H, s, ArH), 7.88-7.98 (1H, m, ArH), 8.07-8.13 (1H, m, 
ArH), 12.96 (1H, s, OH); δC NMR (67.5 MHz, CDCl3): 56.1, 56.5, 96.1, 102.9, 117.8, 
118.6, 118.8, 118.9, 120.2, 129.7, 133.0, 136.2, 139.3, 159.0, 159.9, 163.6, 193.9; 
HRMS (ESI m/z): Calcd. for [C17H15BrO4+H]+ 363.02320, found 363.02540. 
3-(4-fluorophenyl)-1-(2-hydroxyphenyl)prop-2-en-1-one 82419 
2′-Hydroxyacetophenone 72 (0.06 mL, 0.5 mmol), KOH (112 
mg, 2.0 mmol) and 4-fluorobenzaldehyde 81 (0.053 mL, 0.5 
mmol) were reacted according to the general procedure. The 
desired compound was obtained as a bright-yellow solid (70 
mg, 58%, Rf = 0.52 (1:1 CH2Cl2:Pet)); mp 118.6-120.4 °C (lit. 118-120 °C)419; δH NMR 
(270 MHz, CDCl3): 6.91-7.16 (4H, m, ArH), 7.46-7.68 (4H, m, ArH), 7.84-7.92 (2H, 
m, ArH), 12.78 (1H, s, OH); MS (ESI m/z): Calcd. for [C15H11FO2+H]+ 243.08, found 
243.08. 
1-(2-hydroxyphenyl)-3-(4-nitrophenyl)prop-2-en-1-one 85634 
 2′-Hydroxyacetophenone 72 (0.06 mL, 0.5 mmol), KOH 
(112 mg, 2.0 mmol) and 4-nitrobenzaldehyde 84 (50.4 mg, 
0.5 mmol) were reacted according to the general procedure. 
The desired compound was obtained as an orange solid (21 
mg, 16%, Rf = 0.39 (1:1 CH2Cl2:Pet)); mp 204.8-206.6 °C (lit. 205-206 °C)634; δH NMR 
(270 MHz, CDCl3): 6.97 (1H, t, J 7.2, CH), 7.05 (1H, d, J 8.5, CH), 7.49-7.57 (1H, m, 
ArH), 7.72-7.94 (5H, m, ArH), 8.20-8.31 (2H, m, ArH), 12.57 (1H, s, OH); MS (ESI 
m/z): Calcd. for [C15H11NO4+H]+ 270.08, found 270.08. 
2-(4-oxochroman-2-yl)benzoic acid 92 
 2′-Hydroxyacetophenone 72 (0.06 mL, 0.5 mmol), KOH (112 
mg, 2.0 mmol) and 2-carboxybenzaldehyde 90 (75.7 mg, 0.5 
mmol) were reacted according to the general procedure. The 
flavanone compound was obtained as a pale brown solid (61.7 
mg, 46%, Rf = 0.05 (1:1 CH2Cl2:Pet)); mp 133.4-147.3 °C; δH NMR (270 MHz, 
CDCl3): 3.44 (1H, dd, J 17.7, J 6.6, CH2a), 3.75 (1H, dd, J 17.7, J 6.3, CH2b), 6.14 (1H, 
t, J 6.4, CH), 6.85-7.01 (2H, m, ArH), 7.45-7.70 (5H, m, ArH), 7.89-7.92 (1H, m, ArH), 
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11.99 (1H, s,CO2H); δC NMR (67.5 MHz, CDCl3):43.4, 69.7, 118.9, 119.2, 119.4, 
122.7, 126.0, 129.7, 129.9, 134.1, 134.5, 137.3, 149.4, 162.7, 170.0, 201.8; HRMS (ESI 
m/z): Calcd. for [C16H12O4+H]+ 269.08084, found 269.08212. 
2-hydroxy-6-methoxyacetophenone 100635 
2ʹ,6ʹ-Dihydroxyacetophenone 96 (441.2 mg, 2.9 mmol), K2CO3 (409.6 mg, 
2.9 mmol) and acetone (15 mL) were added to a round bottom flask. 
Dimethyl sulfide (Me2SO4, 0.277 mL, 2.9 mmol) was then added 
dropwise, and the solution refluxed for one hour. The solution was quenched with H2O, 
and extracted with EtOAc ×3. The organic phase was then washed with H2O and brine, 
and then dried over MgSO4. Purification by column chromatography (1:1 CH2Cl2:Pet) 
provided the desired acetophenone as a pale yellow solid (439.7 mg, 91%, Rf =0.66 (1:1 
CH2Cl2:Pet)); mp 61.2-62.0 °C (lit. 60 °C);635 δH NMR (270 MHz, CDCl3): 2.65 (3H, s, 
COCH3), 3.88 (3H, s, OCH3), 6.73 (1H, d, J 8.1, ArH), 6.55 (1H, d, J 8.4, ArH), 7.33 
(1H, t, J 8.4, ArH), 13.31 (1H, s, OH). 
1-(2-hydroxy-6-methoxyphenyl)-3-phenylprop-2-en-1-one 101636 
2′-Hydroxy-6′-methoxyacetophenone 100 (83 mg, 0.5 mmol), 
KOH (112 mg, 2.0 mmol) and benzaldehyde 59 (0.101 mL, 1.0 
mmol) were reacted according to the general procedure. The 
desired compound was obtained as a yellow oil (86 mg, 67%, Rf = 
0.5 (1:1 CH2Cl2:Pet)); δH NMR (270 MHz, CDCl3): 3.93 (3H, s, CH3), 6.42 (1H, d, J 
8.4, CH), 6.61 (1H, dd, J 8.4, J 0.9, ArH), 7.31-7.45 (4H, m, ArH), 7.58-7.63 (2H, m, 
ArH), 7.76-7.90 (2H, m, ArH), 13.14 (1H, s, OH); δC NMR (67.5 MHz, CDCl3): 56.1, 
101.7, 111.0, 112.1, 127.7, 128.6, 129.0, 130.4, 135.4, 136.1, 143.0, 161.1, 165.0, 
194.6; MS (ESI m/z): Calcd. for [C16H14O3-H]- 253.09, found 253.09. 
3-(4-bromophenyl)-1-(2-hydroxy-6-methoxyphenyl)prop-2-en-1-one 102405 
2′-Hydroxy-6′-methoxyacetophenone 100 (83 mg, 0.5 mmol), 
KOH (112 mg, 2.0 mmol) and 4-bromobenzaldehyde 73 (93 
mg, 0.5 mmol) were reacted according to the general 
procedure. The desired compound was obtained as an orange 
solid (77 mg, 46%, Rf = 0.44 (1:1 CH2Cl2:Pet)); mp 119.8-124.0 °C (lit. 125-127 °C)405; 
δH NMR (270 MHz, CDCl3): 3.92 (3H, s, CH3), 6.41 (1H, d, J 8.4, ArH), 6.60 (1H, dd, 
J 8.5, J 0.9, ArH), 7.34 (1H, t, J 8.4, ArH), 7.42-7.53 (4H, m, ArH), 7.66-7.85 (2H, m, 
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ArH), 13.07 (1H, s, OH); MS (ESI m/z): Calcd. for [C16H13BrO3-H]- 330.99, found 
330.99. 
3-(3,5-dibromophenyl)-1-(2-hydroxy-6-methoxyphenyl)prop-2-en-1-one 103 
2′-Hydroxy-6′-methoxyacetophenone 100 (83 mg, 0.5 mmol), 
KOH (112 mg, 2.0 mmol) and 3,5-dibromobenzaldehyde 75 
(132 mg, 0.5 mmol) were reacted according to the general 
procedure. The desired compound was obtained as a yellow 
solid (53.1 mg, 26%, Rf = 0.37 (1:1 CH2Cl2:Pet)); mp 159.4-
160.6 °C; δH NMR (270 MHz, CDCl3): 3.94 (3H, s, CH3), 6.41 (1H, d, J 8.3, ArH), 
6.61 (1H, d, J 8.4, ArH), 7.37 (1H, t, J 8.3, ArH), 7.54-7.67 (4H, m, ArH), 7.78 (1H, d, 
J 15.6, ArH), 12.92 (1H, s, OH); δC NMR (67.5 MHz, CDCl3): 56.2, 101.7, 111.1, 
111.9, 123.5, 129.9(2×C), 130.3, 135.2, 136.5, 139.1, 139.2, 161.1, 165.0, 193.9; 
HRMS (ESI m/z): Calcd. for [C16H12Br2O3+H]+ 410.92260, found 410.92075. 
3-(3-(benzyloxy)phenyl)-1-(2-hydroxy-6-methoxyphenyl)prop-2-en-1-one 104 
2′-Hydroxy-6′-methoxyacetophenone 100 (83 mg, 
0.5 mmol), KOH (112 mg, 2.0 mmol) and 3-
benzyloxybenzaldehyde 77 (98 mg, 0.5 mmol) were 
reacted according to the general procedure. The 
desired compound was obtained as an orange-yellow oil (142 mg, 76%, Rf = 0.40 (1:1 
CH2Cl2:Pet)); δH NMR (270 MHz, CDCl3): 3.91 (3H, s, CH3), 5.11 (2H, s, CH2), 6.42 
(1H, dd, J 8.4, J 0.9, ArH), 6.61 (1H, dd, J 8.4, J 0.9, ArH),7.00-7.04 (1H, m, ArH), 
7.20-7.47 (9H, m, ArH), 7.72-7.85 (2H, m, ArH), 13.10 (1H, s, OH); δC NMR (67.5 
MHz, CDCl3): 56.1, 70.2, 101.7, 111.0, 112.1, 114.8, 116.9, 121.5, 127.6, 128.0, 128.2, 
128.8, 130.0, 136.1, 136.8, 136.9, 142.8, 159.2, 161.1, 165.0, 194.6; HRMS (ESI m/z): 
Calcd. for [C23H20O4-H]- 359.12833, found 359.13010. 
3-(5-bromo-2,4-dimethoxyphenyl)-1-(2-hydroxy-6-methoxyphenyl)prop-2-en-1-one 
105 
2′-Hydroxy-6′-methoxyacetophenone 100 (83 mg, 0.5 
mmol), KOH (112 mg, 2.0 mmol) and 5-bromo-2,4-
dimethoxybenzaldehyde 79 (123 mg, 0.5 mmol) were reacted 
according to the general procedure. The desired compound 
was obtained as an orange-yellow solid (163 mg, 83%, Rf = 
0.39 (1:1 CH2Cl2:Pet)); mp 133.8-139.8 °C; δH NMR (270 MHz, CDCl3): 3.89 (3H, s, 
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CH3), 3.92 (3H, s, CH3), 3.93 (3H, s, CH3), 6.38-6.43 (1H, m, ArH), 6.56-6.59 (1H, m, 
ArH), 7.31 (1H, t, J 8.2, ArH), 7.72-7.78 (2H, m, ArH), 7.96-8.05 (1H, m, ArH), 13.28 
(1H, s, OH); δC NMR (67.5 MHz, CDCl3): 55.9, 56.0, 56.5, 96.1, 101.6, 102.7, 110.9, 
112.1, 118.4, 126.2, 132.6, 135.7, 137.0, 158.5, 159.6, 161.0, 164.9, 194.5; HRMS (ESI 
m/z): Calcd. for [C18H17BrO5-H]- 391.01811, found 391.0148. 
1-(5-bromo-2-hydroxyphenyl)-3-phenylprop-2-en-1-one 109407 
5′-Bromo-2′-hydroxyacetophenone 108 (108 mg, 0.5 mmol), 
KOH (112 mg, 2.0 mmol) and benzaldehyde 59 (0.101 mL, 
1.0 mmol) were reacted according to the general procedure. 
The desired compound was obtained as a bright yellow solid 
(131 mg, 86%, Rf = 0.59 (2:3 CH2Cl2:Pet)); mp 109.4-112.3 °C (lit. 109-110 °C)637; δH 
NMR (270 MHz, CDCl3): 6.91(1H, d, J 8.9, ArH), 7.41-7.46 (3H, m, ArH), 7.50-7.56 
(2H, m, ArH), 7.63-7.69 (2H, m, ArH), 7.89-7.98 (2H, m, ArH), 12.75 (1H, s, OH); MS 
(ESI m/z): Calcd. for [C15H11BrO2+H]+ 303.00, found 303.00. 
3-(4-bromophenyl)-1-(5-bromo-2-hydroxyphenyl)prop-2-en-1-one 110407 
5′-Bromo-2′-hydroxyacetophenone 108 (108 mg, 0.5 
mmol), KOH (112 mg, 2.0 mmol) and 4-
bromobenzaldehyde 73 (93 mg, 0.5 mmol) were reacted 
according to the general procedure. The desired compound 
was obtained as a bright yellow solid (123 mg, 64%, Rf = 0.36 (2:3 CH2Cl2:Pet)); mp 
178.7-179.4 °C (lit. 180-182 °)407; δH NMR (270 MHz, CDCl3): 6.93 (1H, d, J 8.9, 
ArH), 7.50-7.60 (6H, m, ArH), 7.83-7.89 (1H, m, ArH), 7.97 (1H, d, J 3.3, ArH), 12.67 
(1H, s, OH); MS (ESI m/z): Calcd. for [C15H10Br2O2+H]+ 380.91, found 380.91. 
3-(3-benzyloxyphenyl)-1-(5-bromo-2-hydroxyphenyl)prop-2-en-1-one 111 
5′-Bromo-2′-hydroxyacetophenone 108 (108 mg, 
0.5 mmol), KOH (112 mg, 2.0 mmol) and 3-
benzyloxybenzaldehyde 77 (98 mg, 0.5 mmol) 
were reacted according to the general procedure. 
The desired compound was obtained as a bright yellow solid (165 mg, 80%, Rf = 0.37 
(2:3 CH2Cl2:Pet)); mp 104.0-106.3 °C; δH NMR (270 MHz, CDCl3): 5.12 (2H, s, CH2), 
6.92 (1H, d, J 8.9, ArH), 7.05-7.08 (1H, m, ArH), 7.24-7.57 (10H, m, ArH), 7.85-7.96 
(2H, m, ArH), 12.76 (1H, s, OH); δC NMR (67.5 MHz, CDCl3): 70.3, 110.6, 114.8, 
117.9, 119.7, 120.8, 121.3, 122.0, 127.6, 128.3, 128.8, 130.3, 131.9, 135.8, 136.7, 
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139.1, 146.5, 159.3, 162.6, 192.7; HRMS (ESI m/z): Calcd. for [C22H17BrO3+H]+ 
409.04338, found 409.03946. 
3-(5-bromo-2,4-dimethoxyphenyl)-1-(5-bromo-2-hydroxyphenyl)prop-2-en-1-one 
112 
5′-Bromo-2′-hydroxyacetophenone 108 (108 mg, 0.5 
mmol), KOH (112 mg, 2.0 mmol) and 5-bromo-2,4-
dimethoxybenzaldehyde 79 (123 mg, 0.5 mmol) were 
reacted according to the general procedure. The desired 
compound was obtained as a bright orange solid (145.4 
mg, 66%, Rf =0.17 (3:1 Pet:CH2Cl2)); mp 224.4-228.3 °C; δH NMR (270 MHz, CDCl3): 
3.95 (3H, s, OCH3), 3.96 (3H, m, OCH3), 6.47 (1H, s, ArH), 6.91 (1H, d, J 8.9, ArH), 
7.46-7.55 (2H, m, ArH), 7.83 (1H, s, ArH), 7.99 (1H, d, J 2.6, ArH), 8.14 (1H, d, J 
15.4, ArH), 12.90 (1H, s, OH); δC NMR (67.5 MHz, CDCl3): 56.1, 56.5, 96.1, 110.4, 
114.1, 117.6, 118.1, 120.6, 131.9, 133.2, 138.7, 140.5, 160.1, 162.5, 192.9; HRMS (ESI 
m/z): Calcd. for [C17H14Br2O4+H]+ 440.93316, found 440.93169. 
3-(4-fluoro)-1-(5-bromo-2-hydroxyphenyl)prop-2-en-1-one 113407 
5′-Bromo-2′-hydroxyacetophenone 108 (108 mg, 0.5 
mmol), KOH (112 mg, 2.0 mmol) and 4-
fluorobenzaldehyde 81 (0.053 mL, 0.5 mmol) were 
reacted according to the general procedure. The desired 
compound was obtained as a bright yellow solid (139.0 mg, 87%, Rf =0.75 
(1:1Pet:CH2Cl2)); mp 178.6-179.9 °C (lit. 162-164 °C)407; δH NMR (270 MHz, CDCl3): 
6.92 (1H, d, J 8.9, ArH), 7.09-7.17 (2H, m, ArH), 7.43-7.70 (4H, m, ArH), 7.86-7.97 
(2H, m, ArH), 12.70 (1H, s, OH); MS (ESI m/z): Calcd. for [C15H10BrFO2+H]+ 320.99, 
found 320.99. 
3-(4-methoxy)-1-(5-bromo-2-hydroxyphenyl)prop-2-en-1-one 114394, 638 
5′-Bromo-2′-hydroxyacetophenone 108 (108 mg, 0.5 
mmol), Bu4NOH (2.0 M in MeOH, 2.0 mmol) and 4-
fluorobenzaldehyde 81 (0.053 mL, 0.5 mmol) were 
reacted according to the general procedure. The desired 
compound was obtained as a bright yellow solid (146.0 mg, 88%, Rf = 0.43 
(1:1Pet:CH2Cl2)); mp 102.6-105.6 °C (lit. 102-104 °C);638 δH NMR (270 MHz, CDCl3): 
3.84 (3H, s, CH3), 6.88-6.96 (3H, m, ArH), 7.36-7.63 (4H, m, ArH), 7.85-7.96 (2H, m, 
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ArH), 12.87 (1H, s, OH); MS (ESI m/z): Calcd. for [C16H13BrO3+H]+ 333.01, found 
333.01. 
1-(3-bromo-5-chloro-2-hydroxyphenyl)-3-phenylprop-2-en-1-one 117408 
 3′-Bromo-5′-chloro-2′-hydroxyacetophenone 116 (125 mg, 
0.5 mmol), KOH (112 mg, 2.0 mmol) and benzaldehyde 59 
(0.101 mL, 1.0 mmol) were reacted according to the general 
procedure. The desired compound was obtained as an orange-
yellow solid (146 mg, 86%, Rf = 0.74 (1:1 CH2Cl2:Pet)); mp 136.7-140.8 °C (lit. 128-
129 °C);408 δH NMR (270 MHz, CDCl3): 7.39-7.52 (4H, m, ArH), 7.61-7.71 (3H, m, 
ArH), 7.81 (1H, d, J 2.6, ArH), 7.92-7.97 (1H, m, ArH), 13.47 (1H, s, OH); MS (ESI 
m/z): Calcd. for [C15H10BrClO2-H]- 334.95, found 334.95. 
1-(3-bromo-5-chloro-2-hydroxyphenyl)-3-(4-bromophenyl)prop-2-en-1-one 118 
3′-Bromo-5′-chloro-2′-hydroxyacetophenone 116 (125 mg, 
0.5 mmol), KOH (112 mg, 2.0 mmol) and 4-
bromobenzaldehyde 73 (139 mg, 0.5 mmol) were reacted 
according to the general procedure. The desired compound 
was obtained as a yellow solid (166 mg, 80%, Rf = 0.74 (1:1 CH2Cl2:Pet)); mp 202.2-
207.1 °C; δH NMR (270 MHz, CDCl3): 7.50-7.61 (5H, m, ArH), 7.75-7.93 (3H, m, 
ArH), 13.40 (1H, s, OH); δC NMR (67.5 MHz, CDCl3): 113.3, 119.4, 120.9, 123.9, 
126.2, 128.2, 130.3, 132.6, 133.0, 139.0, 146.2, 158.9, 192.3; HRMS (ESI m/z): Calcd. 
for [C15H9Br2ClO2-H]- 414.85591, found 414.85560. 
3-(3-(benzyloxy)phenyl)-1-(3-bromo-5-chloro-2-hydroxyphenyl)prop-2-en-1-one 
119 
3′-Bromo-5′-chloro-2′-hydroxyacetophenone 116 
(125 mg, 0.5 mmol), KOH (112 mg, 2.0 mmol) 
and 3-benzyloxybenzaldehyde 77 (106 mg, 0.5 
mmol) were reacted according to the general 
procedure. The desired compound was obtained as a yellow solid (173 mg, 78%, Rf = 
0.54 (1:1 CH2Cl2:Pet)); mp 121.5-125.5 °C; δH NMR (270 MHz, CDCl3): 5.11 (2H, s, 
CH2), 7.06-7.09 (1H, m, ArH), 7.23-7.48 (9H, m, ArH), 7.72-7.94 (3H, m, ArH), 13.46 
(1H, s, OH); δC NMR (67.5 MHz, CDCl3): 70.4, 113.2, 115.0, 118.2, 119.2, 120.9, 
122.1, 123.8, 127.6, 128.2, 128.3, 128.8, 129.3, 130.3, 135.5, 136.6, 138.8, 139.0, 
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147.5, 158.9, 159.3, 192.4; HRMS (ESI m/z): Calcd. for [C22H16BrClO3-H]- 440.98931, 
found 440.9876. 
3-(5-bromo-2,4-dimethoxyphenyl)-1-(3-bromo-5-chloro-2-hydroxyphenyl)prop-2-
en-1-one 121 
3′-Bromo-5′-chloro-2′-hydroxyacetophenone 116 (125 
mg, 0.5 mmol), KOH (112 mg, 2.0 mmol) and 5-bromo-
2,4-dimethoxybenzaldehyde 79 (123 mg, 0.5 mmol) were 
reacted according to the general procedure. The desired 
compound was obtained as a bright yellow solid (169 mg, 
71%, Rf = 0.47 (1:1 CH2Cl2:Pet)); mp 227.5-232.1 °C; δH NMR (270 MHz, CDCl3): 
3.96 (3H, s, CH3), 3.97 (3H, s, CH3), 6.47 (1H, s, ArH), 7.45-7.84 (4H, m, ArH), 8.15-
8.21 (1H, m, ArH), 13.70 (1H, s, OH); δC NMR (67.5 MHz, CDCl3): 56.1, 56.6, 96.1, 
103.1, 113.0, 117.4, 121.2, 123.7, 128.2, 128.7, 133.4, 138.5, 141.5, 158.9, 159.6, 
160.3, 192.6; HRMS (ESI m/z): Calcd. for [C17H13Br2ClO4-H]- 474.87704, found 
474.8722. 
1-(3-bromo-5-chloro-2-hydroxyphenyl)-3-(4-fluorophenyl)prop-2-en-1-one 122639 
3′-Bromo-5′-chloro-2′-hydroxyacetophenone 116 (125 mg, 
0.5 mmol), KOH (112 mg, 2.0 mmol) and 4-
fluorobenzaldehyde 81 (0.053 mL, 0.5 mmol) were reacted 
according to the general procedure. The desired compound 
was obtained as a yellow solid (166 mg, 93%, Rf = 0.77 (1:1 CH2Cl2:Pet)); mp 198.4-
200.6 °C (lit. 178 °C)639; δH NMR (270 MHz, CDCl3): 7.13-7.23 (2H, m, ArH), 7.42-
7.48 (1H, m, ArH), 7.67-7.96 (5H, m, ArH), 13.44 (1H, s, OH); MS (ESI m/z): Calcd. 
for [C15H9BrClFO2+H]+ 354.95, found 354.95. 
8.3.3 Typical temperature, pressure and power profile for 
microwave reaction 
 
Temperature profile over 15 minutes. 
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Power profile over 15 minutes. 
 
Pressure profile over 15 minutes. 
Note: as the reaction is carried out at a temperature lower than the boiling point of THF, 
no increase in pressure was observed. The blue line indicated the upper safety pressure 
limit of the microwave reactor. 
8.4 Chapter 3 Experimental 
8.4.1 Preparation of Ionic Liquids 
The acid portion of the ionic liquid was added dropwise to an equimolar amount of neat 
triethylamine cooled to -78 °C (acetone/CO2(s) slurry). The resulting solution was 
stirred for one hour at -78 °C then allowed to warm to room temperature followed by 
stirring for 5 hours. In cases where an aqueous acid solution, such as in the case of 
H2SO4, was used, water was removed by heating at 60 °C under vacuum overnight. 
8.4.2 General Procedure for Flavanone Synthesis 
The pIL TeaHSO4 (0.25 mL) was added to chalcone in a 10 mL microwave tube. The 
solution was heated to 130 °C at 50 W for 20 minutes under microwave irradiation. 
Thin Layer Chromatography was carried out on the crude sample, and the solution was 
then filtered through a silica plug with a CH2Cl2 wash. The solvent was evaporated in 
vacuo, and purification of the crude material by Column Chromatography (1:1CH2Cl2: 
Petroleum Spirits) gave the desired flavanone. 
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2-(4-bromophenyl)chroman-4-one 130141 
3-(4-bromophenyl)-1-(2-hydroxyphenyl)prop-2-en-1-one 74 
(100 mg, 0.33 mmol) was reacted according to the general 
procedure. The desired compound was obtained as a pale 
yellow solid (64.7 mg, 65%, Rf = 0.19 (1:1 CH2Cl2:Pet)); mp 
115.5-120.1 °C (lit. 115.8-119.0 °C)141; δH NMR (270 MHz, CDCl3): 2.82-3.08 (2H, m, 
CH2), 5.44 (1H, dd, J 12.9, J 3.3, CH), 7.02-7.08 (2H, m, ArH), 7.34-7.37 (2H, m, 
ArH), 7.47-7.58 (3H, m, ArH), 7.90-7.93 (1H, m, ArH). 
2-phenyl-2,3-dihydrochromen-4-one 6460 
1-(2-hydroxyphenyl)-3-phenylprop-2-en-1-one 66 (96.6 mg, 0.43 
mmol) was reacted according to the general procedure. The 
desired compound was obtained as a pale yellow solid (58.0 mg, 
60%, Rf = 0.29 (1:1 CH2Cl2:Pet)); mp 76.5-79.5 °C (lit. 76-77 
°C)460; δH NMR (270 MHz, CDCl3): 2.85-3.14 (2H, m, CH2), 5.45-5.51 (1H, dd, J 13.1, 
J 2.8, CH), 7.02-7.08 (2H, m, ArH), 7.38-7.50 (6H, m, ArH), 7.91-7.95 (1H, m, ArH); 
δC NMR (67.5 MHz, CDCl3): 44.8, 79.7, 118.2, 121.0, 121.7, 126.3, 127.2, 128.9, 
129.0, 136.3, 138.8, 161.7, 192.1. 
2-(3-benzyloxyphenyl)chroman-4-one 131 
3-(3-benzyloxyphenyl)-1-(2-hydroxyphenyl)prop-2-
en-1-one 78 (77.0 mg, 0.23 mmol) was reacted 
according to the general procedure. The desired 
compound was obtained as a pale-yellow oil (27.9 
mg, 36%, Rf = 0.06 (1:1 CH2Cl2:Pet)); δH NMR (400 MHz, CDCl3): 2.86-3.11 (2H, m, 
CH2), 5.10 (2H, s, OCH2Ar), 5.45 (1H, dd, J 13.2, J 2.8, CH), 6.98-7.14 (5H, m, ArH), 
7.33-7.53 (7H, m, ArH), 7.93 (1H, dd, J 8.3, J 2.2, ArH); δC NMR (100 MHz, CDCl3): 
44.8, 70.2, 79.5, 113.0, 115.0, 118.2, 118.7, 121.8, 127.2, 127.6, 128.2, 128.7, 130.1, 
136.3, 140.4, 159.3, 161.6, 192.0; HRMS (ESI m/z): Calcd. for [C22H18O3+H]+ 
331.13342, found 331.13219. 
2-(5-bromo-2,4-dimethoxyphenyl)chroman-4-one 132 
3-(5-bromo-2,4-dimethoxyphenyl)-1-(2-hydroxyphenyl)prop-
2-en-1-one 80 (80.7 mg, 0.22 mmol) was reacted according to 
the general procedure. The desired compound was obtained 
as a pale-yellow solid (11.5 mg, 14%, Rf = 0.05 (1:1 
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CH2Cl2:Pet)); mp 289.9 °C (dec.); δH NMR (400 MHz, CDCl3): 2.88-2.90 (2H, m, 
CH2), 3.85 (3H, s, CH3), 3.93 (3H, s, CH3), 5.73 (1H, t, J 8.0, CH), 6.49 (1H, s, ArH), 
7.03-7.07 (2H, m, ArH), 7.48-7.53 (1H, m, ArH), 7.76 (1H, s, ArH), 7.91-7.93 (1H, m, 
ArH); δC NMR (100 MHz, CDCl3): 43.9, 55.8, 56.5, 74.0, 96.4, 118.2, 121.0, 121.2, 
121.6, 127.1, 130.9, 136.2, 156.4, 182.3, 192.6; HRMS (ESI m/z): Calcd. for 
[C17H15BrO4+H]+ 363.02320, found 363.02108. 
6-bromo-2-phenylchroman-4-one 137461 
3-phenyl-1-(5-bromo-2-hydroxyphenyl)prop-2-en-1-one 109 
(30.7 mg, 0.10 mmol) was reacted according to the general 
procedure. The desired compound was obtained as a pale-
yellow solid (17.1 mg, 56%, Rf = 0.40 (2:3 CH2Cl2:Pet)); mp 
113.9-116.1 °C (lit. 118-119 °C)461; δH NMR (270 MHz, CDCl3): 2.86-3.13 (2H, m, 
CH2), 5.43-5.49 (1H, dd, J 13.1, J 3.0, CH), 6.95 (1H, d, J 8.7, ArH), 7.38-7.47 (5H, m, 
ArH), 7.55-7.59 (1H, m, ArH), 8.03 (1H, d, J 2.3, ArH); δC NMR (67.5 MHz, CDCl3): 
43.3, 79.9, 114.4, 120.3, 122.3, 126.2, 129.0, 129.1, 129.6, 138.3, 138.9, 160.5, 190.8. 
6-bromo-2-(4-bromophenyl)chroman-4-one 138 
3-(4-bromophenyl)-1-(5-bromo-2-hydroxyphenyl)prop-2-
en-1-one 110 (39.5 mg, 0.10 mmol) was reacted according 
to the general procedure. The desired compound was 
obtained as a pale brown solid (8.6 mg, 22%, Rf = 0.30 
(1:1 CH2Cl2:Pet)); δH NMR (270 MHz, CDCl3): 2.84-3.07 (2H, m, CH2), 5.40-5.46 
(1H, dd, J 12.8, J 3.5, CH), 6.93-6.96 (1H, d, J 8.9, ArH), 7.32-7.35 (1H, m, ArH), 
7.54-7.57 (3H, m, ArH), 8.02 (1H, d, J 2.6, ArH); δC NMR (100 MHz, CDCl3): 44.2, 
79.1, 114.6, 120.3, 123.0, 127.9, 129.7, 130.3, 132.2, 132.5, 137.3, 139.2, 145.2, 160.2, 
190.3; Calcd. for [C15H10Br2O2+H]+ 382.91053, found 382.91164. 
6-bromo-2-(3-benzyloxyphenyl)chroman-4-one 139 
3-(3-benzyloxyphenyl)-1-(5-bromo-2-hydroxy-
phenyl)prop-2-en-1-one 111 (145.0 mg, 0.36 
mmol) was reacted according to the general 
procedure. The desired compound was obtained 
as a pale yellow solid (85.0 mg, 59%, Rf =0.63 (1:1 CH2Cl2:Pet)); mp 135.9-138.4 °C; 
δH NMR (270 MHz, CDCl3): 2.87-2.92 (1H, m, CH2), 3.01-3.09 (1H, m, CH2), 5.09 
(2H, s, CH2O), 5.41-5.46 (1H, dd, J 13.2, J 3.1, CH), 6.95-7.11 (4H, m, ArH), 7.33-7.45 
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(6H, m, ArH), 7.56-7.59 (1H, dd, J 8.7, J 2.4, ArH), 8.03 (1H, d, J 2.8, ArH); δC NMR 
(100 MHz, CDCl3):44.3, 70.2, 79.7, 113.0, 114.5, 115.1, 118.7, 120.3, 122.3, 
127.6(2×C), 128.2, 128.8(2×C), 129.6, 130.2, 136.7, 138.9, 139.9, 159.3, 160.4, 190.7; 
HRMS (ESI m/z): Calcd. for [C22H17BrO3+H]+ 409.04338, found 409.04272. 
8-bromo-6-chloro-2-phenylchroman-4-one 141640 
3-phenyl-1-(8-bromo-6-chloro-2-hydroxyphenyl)prop-2-en-1-
one 117 (99.7 mg, 0.30 mmol) was reacted according to the 
general procedure. The desired compound was obtained as a 
pale-yellow solid (53.6 mg, 54%, Rf = 0.40 (1:1 CH2Cl2:Pet)); 
mp 105.2-108.6 °C (lit. 98-100 °C)640; δH NMR (270 MHz, CDCl3): 2.98-3.13 (2H, m, 
CH2), 5.59 (1H, dd, J 12.1, J 3.8, CH) 7.39-7.50 (5H, m, ArH), 7.73 (1H, d, J 2.4, 
ArH), 7.84 (1H, d, J 2.4, ArH); δC NMR (67.5 MHz, CDCl3): 43.7, 80.0, 113.0, 122.4, 
125.9, 126.0, 127.4, 129.0, 137.8, 138.7, 156.6, 190.1. 
8-bromo-6-chloro-2-(4-bromophenyl)chroman-4-one 142 
3-(4-bromophenyl)-1-(8-bromo-6-chloro-2-hydroxy-
phenyl)prop-2-en-1-one 118 (70.0 mg, 0.17 mmol) was 
reacted according to the general procedure. The desired 
compound was obtained as a creamy-white solid (16.1 mg, 
19%, Rf = 0.7 (1:1 CH2Cl2:Pet)); mp 142.2-145.3 °C; δH NMR (270 MHz, CDCl3): 
2.95-3.10 (2H, m, CH2), 5.54 (1H, dd, J 10.7, J 5.1, CH), 7.34-7.38 (2H, m, ArH), 7.50-
7.61 (3H, m, ArH), 7.73-7.73 (1H, m, ArH), 7.82-7.83 (1H, m, ArH); δC NMR (67.5 
MHz, CDCl3): 43.5, 79.3, 113.0, 122.4, 123.1, 125.9, 127.7, 130.4, 132.2, 136.8, 138.8, 
156.4, 189.6; HRMS (ESI m/z): Calcd. for [C15H9Br2ClO2-H]- 414.85591, found 
414.85601.  
8-bromo-6-chloro-2-(3-benzyloxyphenyl)chroman-4-one 143 
3-(3-benzyloxyphenyl)-1-(8-bromo-6-chloro-2-
hydroxyphenyl)prop-2-en-1-one 120 (157.8 mg, 
0.36 mmol) was reacted according to the general 
procedure. The desired compound was obtained 
as a pale yellow solid (78.9 mg, 50%, Rf = 0.27 (1:1 CH2Cl2:Pet)); mp 134.1-137.1 °C; 
δH NMR (400 MHz, CDCl3): 2.98-3.10 (2H, m, CH2), 5.10 (2H, s, OCH2), 5.55 (1H, d, 
J 10.1, CH), 6.98-7.14 (3H, m, ArH), 7.35-7.45 (6H, m, ArH), 7.73 (1H, br s, ArH), 
7.83 (1H, br s, ArH); δC NMR (100 MHz, CDCl3): 43.6, 70.2, 79.7, 112.7, 113.0, 115.3, 
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118.4, 122.5, 125.9, 127.4, 127.6(2×C), 128.2, 128.7(2×C), 130.1, 136.8, 138.7, 139.4, 
156.5, 159.3, 190.0; HRMS (ESI m/z): Calcd. for [C22H16BrClO3+H]+ 443.00441, found 
443.00328. 
8.4.3 General Procedure for Flavones 
Substituted 2′-hydroxychalcone in DMSO was added to a round bottom flask. Catalytic 
iodine was added, and the solution refluxed overnight. The solution was cooled to rt, 
and H2O added until a precipitate formed. The solution was transferred to a separating 
funnel, extracted with 3×EtOAc (20 mL), and the organic layer washed with 1.0 M HCl 
(20 mL), H2O (20 mL), Na2S2O3 (20 mL), and brine (20 mL). The organic phase was 
dried (MgSO4), filtered, and the solvent removed in vacuo. Purification was conducted 
by column chromatography (40% CH2Cl2 in Pet). 
2-phenylchromen-4-one 7641  
2′-hydroxychalcone 66 (87.7 mg, 0.39 mmol), I2 (6.2 mg, 0.024 
mmol) and DMSO. Purification gave the desired product as a pale 
brown solid (52.6 mg, 61%, Rf = 0.22 (10% MeOH in CHCl3)); 
mp 95.3-98.8 °C (lit. 97-97 °C)641; δH NMR (270 MHz, CDCl3): 
6.81 (1H, s, CH), 7.37-7.43 (1H, m, ArH), 7.48-7.57 (4H, m, ArH), 7.65-7.71 (1H, m, 
ArH), 7.89-7.94 (2H, m, ArH), 8.21 (1h, dd, J 8.0, J 1.6, ArH); δC NMR (67.5 MHz, 
CDCl3): 107.7, 118.2, 124.0, 125.3, 125.8, 126.4, 129.1, 131.7, 131.9, 133.9, 156.4, 
163.5, 178.6. 
2-(4-bromophenyl)chromen-4-one 157642 
3-(4-bromophenyl)-1-(2-hydroxyphenyl)prop-2-en-1-one 74 
(115.0 mg, 0.38 mmol), I2 (6.0 mg, 0.02 mmol), and DMSO. 
Purification gave the desired as a white solid (90.0 mg, 79%, 
Rf =0.15 (10% EtOAc in CHCl3)); mp 179.1-179.7 °C (lit. 
164-166 °C)642; δH NMR (270 MHz, CDCl3): 6.76 (1H, s, CH), 7.36-7.42 (1H, m, 
ArH), 7.50-7.53 (1H, m, ArH), 7.59-7.77 (5H, m, ArH), 8.18 (1H, dd, J 8.0, J 1.6, 
ArH); δC NMR (67.5 MHz, CDCl3): 107.7, 118.1, 124.0, 125.5, 125.8, 126.4, 127.7, 
130.7, 132.4, 134.0, 156.2, 162.3, 178.3. 
2-(3-benzyloxyphenyl)chromen-4-one 158 
3-(4-bromophenyl)-1-(2-hydroxyphenyl)prop-2-en-1-one 78 (140.1 mg, 0.38 mmol), I2 
(6.0 mg, 0.02 mmol), and DMSO. Purification gave the desired as a cream-coloured 
solid (80.6 mg, 57%, Rf =0.40 (2:1 Pet:EtOAc) mp 114.2-117.1 °C; δH NMR (400 
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MHz, CDCl3): 5.13 (2H, s, OCH2Ph), 6.79 (1H, s, 
CH), 7.11-7.14 (1H, m, ArH), 7.33-7.55 (11H, m, 
ArH), 7.66-7.70 (1H, m, ArH), 8.21-8.23 (1H, dd, J 
8.0, J 1.6, ArH); δC NMR (100 MHz, CDCl3): 70.4, 
107.9, 113.0, 118.0, 118.2, 119.1, 124.1, 125.3, 125.8, 127.6(2×C), 128.3, 128.8(2×C), 
130.3, 133.3, 133.9, 136.5, 156.3, 159.3, 163.2, 178.5; HRMS (ESI m/z): Calcd. for 
[C22H16O3+H]+ 329.11722, found 329.11721. 
2-(5-bromo-2,4-dimethoxyphenyl)chromen-4-one 159643  
3-(5-bromo-2,4-dimethoxyphenyl)-1-(2-hydroxyphenyl)prop-
2-en-1-one 80 (120.9 mg, 0.27 mmol), I2 (4.2 mg, 0.017 
mmol), and DMSO. Purification gave the desired product as a 
pale brown solid (105.8 mg, 88%, Rf =0.89 (10% MeOH in 
CHCl3)); mp 200.0-203.5 °C (lit. 196 °C)643; δH NMR (270 MHz, CDCl3): 3.93 (6H, s, 
2×CH3), 6.48 (1H, s, CH), 7.12 (1H, s, ArH), 7.33-7.39 (1H, m, ArH), 7.49-7.51 (1H, 
m, ArH), 7.62-7.67 (1H, m, ArH), 8.06 (1H, s, ArH), 8.16 (1H, d, J 7.7, ArH); δC NMR 
(67.5 MHz, CDCl3): 56.1, 56.5, 96.4, 102.7, 111.7, 114.1, 118.1, 123.7, 125.0, 125.5, 
132.9, 133.7, 156.3, 158.9, 159.3, 179.0.  
5-methoxy-2-phenyl-4H-chromen-4-one 160644, 645 
1-(2-hydroxy-6-methoxyphenyl)-3-phenylprop-2-en-1-one 101 
(150.0 mg, 0.5 mmol), I2 (10.0 mg, 0.04 mmol), and DMSO. 
Purification isolated the product as pale brown crystals (83.7 mg, 
66%, Rf = 0.05 (10% EtOAc in CHCl3); mp 114.0-117.3 °C (lit. 
130 °C)644; δH NMR (270 MHz, CDCl3): 3.96 (3H, s, CH3), 6.71 (1H, s, ArH), 6.78 
(1H, d, J 8.2, ArH), 7.09 (1H, d, J 8.4, ArH), 7.45-7.56 (4H, m, ArH), 7.83-7.86 (2H, 
m, ArH); δC NMR (67.5 MHz, CDCl3): 56.6, 106.5, 109.1, 110.2, 114.6, 126.1, 129.0, 
131.5, 133.9, 158.3, 159.8, 161.2, 178.5.  
5-methoxy-2-(4-bromophenyl)chromen-4-one 161 
3-(4-bromophenyl)-1-(2-hydroxy-6-methoxyphenyl)prop-2-en-
1-one 102 (160.0 mg, 0.48 mmol), I2 (10.0 mg, 0.040 mmol), 
and DMSO. Purification isolated the product as an off-white 
solid (94.7 mg, 58%, Rf = 0.05 (10% EtOAc in CHCl3); mp 
171.6-174.8 °C; δH NMR (400 MHz, CDCl3): 3.96 (3H, s, CH3), 6.65 (1H, s, CH), 6.78 
(1H, d, J 8.3, ArH), 7.06 (1H, d, J 8.7, ArH), 7.50-7.59 (3H, m, ArH), 7.68-7.70 (2H, 
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m, ArH); δC NMR (67.5 MHz, CDCl3): 56.6, 106.6, 109.2, 110.1, 114.5, 126.1, 127.5, 
130.4, 132.3, 134.0, 158.2, 159.8, 160.0, 178.2; HRMS (ESI m/z): Calcd. for 
[C16H11BrO3+H]+ 330.99643, found 330.99305. 
5-methoxy-2-(3-hydroxy)chromen-4-one 162406 
3-(3-(benzyloxy)phenyl)-1-(2-hydroxy-6-methoxyphenyl)-
prop-2-en-1-one 104 (166.6 mg, 0.50 mmol), I2 (8.0 mg, 
0.032 mmol), and DMSO. Purification isolated the product as 
a pale brown solid (110.9 mg, 67%, Rf = 0.55 (10% EtOAc in 
CHCl3); mp 236.4-239.9 °C (lit. 237-238.5 °C)406; δH NMR (270 MHz, CDCl3): 3.96 
(3H, s, CH3), 6.67 (1H, s, CH), 6.79 (1H, d, J 8.2, ArH), 7.08 (1H, d, J 8.4, ArH), 7.51-
7.61 (3H, m, ArH), 7.69-7.72 (2H, m, ArH); δC NMR (67.5 MHz, CDCl3): 56.6, 106.7, 
109.2, 110.2, 126.1, 1127.6, 130.4, 132.3, 134.1, 158.2, 159.8, 160.1, 178.3. 
5-methoxy-2-(5-bromo-2,4-dimethoxyphenyl)chromen-4-one 164 
3-(5-bromo-2,4-dimethoxyphenyl)-1-(2-hydroxy-6-methoxy-
phenyl) prop-2-en-1-one 105 (165.5 mg, 0.42 mmol), I2 (9.0 
mg, 0.033 mmol), and DMSO. Purification isolated the product 
as a pale brown solid (43.6 mg, 26%, Rf = 0.15 (10% EtOAc in 
CHCl3); mp 205.5-207.7 °C; δH NMR (270 MHz, CDCl3): 3.94 
(6H, s, 2×CH3), 3.96 (3H, s, CH3), 6.50 (1H, s, CH), 7.67 (1H, d, J 8.2, ArH), 7.02 (1H, 
s, ArH), 7.07-7.10 (1H, m, ArH), 7.52 (1H, t, J 8.2, ArH), 8.04 (1H, s, ArH); δC NMR 
(67.5 MHz, CDCl3): 56.0, 56.5, 96.4, 102.6, 106.2, 110.2, 113.2, 132.8, 133.7, 157.1, 
158.7, 159.1, 159.7, 179.0; HRMS (ESI m/z): Calcd. for [C18H15BrO5+H]+ 391.01756, 
found 391.01778. 
6-bromo-2-phenyl-4H-chromen-4-one 165646 
3-phenyl-1-(5-bromo-2-hydroxyphenyl)prop-2-en-1-one 109 
(107.0 mg, 0.35 mmol), I2 (6.0 mg, 0.02 mmol), and DMSO. 
Purification isolated the product as white needle-like crystals 
(91.9 mg, 87%, Rf = 0.29 (10% EtOAc in CHCl3); mp 191.6-
193.6 °C (lit. 190-191 °C)646; δH NMR (270 MHz, CDCl3): 6.80 (1H, s, CH), 7.42-7.54 
(4H, m, ArH), 7.72-7.77 (1H, m, ArH), 7.86-7.89 (2H, m, ArH), 8.31 (1H, d, J 2.6, 
ArH); δC NMR (67.5 MHz, CDCl3): 107.6, 118.8, 120.1, 125.3, 126.4, 128.4, 129.2, 
131.4, 132.0, 136.8, 155.1, 163.7, 177.1. 
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6-bromo-2-(4-bromophenyl)chromen-4-one 16678 
3-(4-bromo)-1-(5-bromo-2-hydroxyphenyl)prop-2-en-1-
one 110 (84.3 mg, 0.22 mmol), I2 (4.0 mg, 0.016 mmol), 
and DMSO. Purification isolated the product as a white 
solid (37.1 mg, 44%, Rf = 0.37 (10% EtOAc in CHCl3); 
mp 243.9-245.5 °C (lit. 253 °C)78; δH NMR (270 MHz, CDCl3): 6.79 (1H, s, CH), 7.44 
(1H, d, J 8.9, ArH), 7.63-7.77 (4H, m, ArH), 8.33 (1H, d, J 1.9, ArH); δC NMR (67.5 
MHz, CDCl3): 107.8, 119.0, 120.1, 125.3, 126.7, 127.8, 128.5, 130.4, 132.5, 137.0, 
155.0, 162.7, 176.9.  
6-bromo-2-(3-benzyloxyphenyl)-4H-chromen-4-one 167 
3-(3-benzyloxyphenyl)-1-(5-bromo-2-
hydroxyphenyl) prop-2-en-1-one 111 (166.0 mg, 
0.41 mmol), I2 (7.0 mg, 0.03 mmol), and DMSO. 
Purification isolated the product as an off-white 
solid (80.0 mg, 48%, Rf = 0.23 (10% EtOAc in CHCl3); mp 147.2-148.1 °C; δH NMR 
(270 MHz, CDCl3): 5.12 (1H, s, CH2), 6.77 (1H, s, CH), 7.10-7.14 (1H, m, ArH), 7.33-
7.47 (9H, m, ArH), 7.71-7.75 (1H, m, ArH), 8.30 (1H, d, J 2.4, ArH); δC NMR (67.5 
MHz, CDCl3): 70.4, 107.8, 113.0, 118.2, 118.8, 119.1, 120.1, 125.3, 127.6, 128.3, 
128.4, 128.8, 130.3, 132.8, 136.4, 136.8, 155.0, 159.3, 163.4, 177.1; HRMS (ESI m/z): 
Calcd. for [C22H15BrO3+H]+ 407.02773, found 407.02457. 
6-bromo-2-(5-bromo-2,4-dimethoxyphenyl)chromen-4-one 168 
3-(4-bromo)-1-(5-bromo-2-hydroxyphenyl)prop-2-en-1-
one 112 (87.3 mg, 0.20 mmol), I2 (4.0 mg, 0.016 mmol), 
and DMSO. Purification isolated the product as a pale 
yellow solid (66.3 mg, 75%, Rf = 0.06 (10% EtOAc in 
CHCl3); mp 236.2-237.6 °C; δH NMR (270 MHz, CDCl3): 
3.95 (3H, s, OCH3), 3.96 (3H, s, OCH3), 6.52 (1H, s, CH), 7.14 (1H, s, ArH), 7.42 (1H, 
d, J 9.0, ArH), 7.73 (1H, dd, J 8.9, J 2.6, ArH), 8.07 (1H, s, ArH), 8.30 (1H, d, J 2.3, 
ArH); δC NMR (67.5 MHz, CDCl3): 56.1, 56.5, 96.4, 102.8, 111.7, 113.8, 118.4, 120.0, 
125.1, 128.3, 132.9, 136.6, 155.0, 159.3, 177.5; HRMS (ESI m/z): Calcd. for 
[C17H12Br2O4+H]+ 438.91751, found 438.91818. 
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8-bromo-6-chloro-2-phenyl-4H-chromen-4-one 169408 
1-(3-bromo-5-chloro-2-hydroxyphenyl)-3-phenylprop-2-en-1-
one 117 (115.7 mg, 0.34 mmol), I2 (5.0 mg, 0.020 mmol), and 
DMSO. Purification isolated the product as off-white crystals 
(79.7 mg, 70%, Rf = 0.10 (10% EtOAc in CHCl3); mp 178.4-
179.2 °C (lit. 178-179 °C)408; δH NMR (400 MHz, CDCl3): 6.84 (1H, s, CH), 7.50-7.58 
(4H, m, ArH), 7.87 (1H, d, J 2.8, ArH), 7.97 (2H, dd, J 7.8, J 1.4, ArH), 8.11 (1H, d, 
J 2.4, ArH); δC NMR (67.5 MHz, CDCl3): 107.3, 113.0, 124.7, 125.7, 126.6 (2×C), 
129.3(2×C), 131.0, 131.4, 132.3, 136.9, 151.5, 163.7, 176.7. 
8-bromo-6-chloro-2-(4-bromophenyl)chromen-4-one 170 
3-(4-bromo)-1-(3-bromo-5-chloro-2-hydroxyphenyl)prop-
2-en-1-one 118 (53.1 mg, 0.11 mmol), I2 (3.0 mg, 0.011 
mmol), and DMSO. Purification isolated the product as a 
pale yellow solid (28.5 mg, 12%, Rf = 0.34 (10% EtOAc in 
CHCl3); mp 253.5-254.6 °C; δH NMR (270 MHz, CDCl3): 6.83 (1H, s, CH), 7.65-7.71 
(2H, m, ArH), 7.82-7.87 (2H, m, ArH), 7.90 (1H, d, J 2.6, ArH), 8.13 (1H, d, J 2.3, 
ArH); δC NMR (67.5 MHz, CDCl3): 107.3, 118.8, 124.8, 126.3, 126.9, 128.9(2×C), 
130.6, 132.1(2×C), 133.4, 135.9, 151.4, 164.0, 178.0; HRMS (ESI m/z): Calcd. for 
[C15H7Br2ClO2+H]+ 333.93907, found 333.94135. 
8-bromo-6-chloro-2-(3-benzyloxyphenyl)chromen-4-one 171 
3-(3-(benzyloxy)phenyl)-1-(3-bromo-5-chloro-
2-hydroxyphenyl)prop-2-en-1-one 120 (160.6 
mg, 0.36 mmol), I2 (9.0 mg, 0.033 mmol), and 
DMSO. Purification isolated the product as an 
off-white solid (60.4 mg, 38%, Rf = 0.33 (10% EtOAc in CHCl3); mp 144.6-148.2 °C; 
δH NMR (270 MHz, CDCl3): 5.16 (2H, s, CH2), 6.93 (1H, s, CH), 7.14-7.23 (1H, m, 
ArH), 7.33-7.46 (5H, m, ArH), 7.55-7.58 (1H, m, ArH), 7.70 (1H, s, ArH), 7.86-7.88 
(1H, m, ArH), 8.13 (1H, d, J 2.13, ArH); δC NMR (67.5 MHz, CDCl3): 70.3, 107.3, 
112.7, 115.5, 119.1, 119.3, 121.2, 123.0, 124.7, 125.7, 127.5, 128.8, 129.7, 130.5, 
131.5, 132.3, 136.9, 159.3, 163.5, 171.3, 176.7; HRMS (ESI m/z): Calcd. for 
[C22H14BrClO3+H]+ 440.98876, found 440.98487. 
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8-bromo-6-chloro-2-(5-bromo-2,4-dimethoxyphenyl)chromen-4-one 172 
3-(5-bromo-2,4-dimethoxyphenyl)-1-(3-bromo-5-chloro-2-
hydroxyphenyl)prop-2-en-1-one 121 (53.1 mg, 0.11 
mmol), I2 (3.0 mg, 0.011 mmol), and DMSO. Purification 
isolated the product as a pale yellow solid (17.3 mg, 33%, 
Rf = 0.05 (10% EtOAc in CHCl3); mp 234.4-237.4 °C; δH 
NMR (270 MHz, CDCl3): 3.98 (6H, s, 2×OCH3), 6.53 (1H, s, CH), 7.23 (1H, s, ArH), 
7.86 (1H, d, J 2.6, ArH), 8.09 (1H, d, J 2.6, ArH), 8.30 (1H, s, ArH); δC NMR (67.5 
MHz, CDCl3): 56.2, 56.6, 96.3, 103.1, 111.2, 112.8, 113.3, 124.5, 131.0, 133.6, 136.6, 
151.4, 154.2, 159.6, 177.2; HRMS (ESI m/z): Calcd. for [C17H11Br2ClO4+H]+ 
472.87854, found 472.87410. 
8.5 Chapter 4 Experimental 
8.5.1 General Procedure for Heck Reaction 
Pd(OAc)2 (14 mg, 0.06 mmol), PPh3 (19.6 mg, 0.06 mmol), K2CO3 (224 mg, 1.62 
mmol) and DMF (10 mL) were stirred for 10 minutes in a round bottomed flask. The 
aryl bromide (0.54 mmol) was then added, followed by the acrylate (2.16 mmol), and 
the solution was refluxed for 16 hrs. The solvent was removed in vacuo, and EtOAc 
(20 mL) added. Following filtration through a celite plug, the solution was dried over 
MgSO4, filtered, solvent removed in vacuo, resulting in the crude product which was 
purified by column chromatography (20% ether in Pet) to provide the acrylate product. 
8.5.2 Compound Characterisation Data 
(E)-butyl 3-(4-formylphenyl)acrylate (benzaldehyde nBu acrylate) 194542  
Pd(OAc)2 (14 mg, 0.06 mmol), PPh3 (19.6 mg, 
0.06 mmol), K2CO3 (224 mg, 1.62 mmol), DMF (10 
mL), 4-bromobenzaldehyde 73 (100 mg, 0.54 mmol), 
and nBu acrylate (0.310 mL, 2.16 mmol). Purification 
by column chromatography (20% Ether in Pet) provided the desired acrylate as a pale 
brown oil (102.9 mg, 82%, Rf =0.82); δH NMR (400 MHz, CDCl3): 0.94 (3H, t, J 7.3, 
H14), 1.38-1.47 (2H, m, H13), 1.65-1.72 (2H, m, H12), 4.20 (2H, t, J 6.6, H11), 6.53 
(1H, d, J 15.9, H9), 7.65-7.75 (3H, m, H3, H5 & H8), 7.87-7.89 (2H, d, J 8.4, H2 & 
H6), 10.00 (1H, s, CHO); δC NMR (100 MHz, CDCl3): 13.8, 19.3, 30.8, 64.8, 121.6, 
128.6(2×C), 130.2(2×C), 137.2 140.2, 142.9, 166.5, 191.5. 
 210 
 
(E)-butyl 3-(4-formylphenyl)acrylate (benzaldehyde tBu acrylate) 195647 
Pd(OAc)2 (14 mg, 0.06 mmol), PPh3 (19.6 mg, 0.06 mmol), 
K2CO3 (224 mg, 1.62 mmol), DMF (10 mL), 4-
bromobenzaldehyde 73 (100 mg, 0.54 mmol), and tBu 
acrylate (0.316 mL, 2.16 mmol). Purification by column 
chromatography (20% Ether in Pet) provided the desired acrylate as a pale brown oil 
(75.3 mg, 60%); δH NMR (400 MHz, CDCl3): 1.51 (9H, s, H12), 6.46 (1H, d, J 16.3, 
H9), 7.44-7.71 (3H, m, H3, H5, H8), 7.85-7.87 (2H, d, J 8.0, H2 & H6), 9.99 (1H, s, 
CHO); δC NMR (100 MHz, CDCl3): 28.2, 81.1, 123.5, 128.5(2×C), 130.2(2×C), 132.5, 
137.0, 141.9, 165.7, 191.6.  
(E)-butyl 3-(3-acetyl-4-hydroxyphenyl)acrylate (acetophenone nBu acrylate) 200 
Pd(OAc)2 (14 mg, 0.06 mmol), PPh3 (19.6 mg, 
0.06 mmol), K2CO3 (224 mg, 1.62 mmol), DMF 
(10 mL), 5′-bromo-2′-hydroxyacetophenone 108 
(116 mg, 0.54 mmol), and nBu acrylate (0.23 mL, 2.16 mmol). Purification by column 
chromatography (20% Ether in Pet) provided the desired acetophenone as a pale brown 
oil (107.6 mg, 76%, Rf =0.19); δH NMR (270 MHz, CDCl3): 0.92 (3H, t, J 7.5, H10), 
1.33-1.46 (2H, m, H9), 1.59-1.70 (2H, m, H8), 2.62 (3H, s, H1), 4.16 (2H, t, J 6.6, H7), 
6.29 (1H, d, J 15.9, H6), 6.94 (1H, d, J 8.7, H4), 7.54-7.65 (2h, m, H2, H5), 7.81 (1H, 
d, J 2.1, H3), 12.43 (1H, s, OH); δC NMR (67.5 MHz, CDCl3): 13.8, 19.3, 26.7, 30.9, 
64.6, 116.9, 119.4, 119.7, 125.7, 131.5, 135.0, 143.1, 164.1, 167.1, 204.4; HRMS (ESI 
m/z): Calcd. for [C15H18O4+H]+ 263.12779, found 263.12866. 
(E)-t-butyl 3-(3-acetyl-4-hydroxyphenyl)acrylate (acetophenone tBu acrylate) 201 
Pd(OAc)2 (28 mg, 0.12 mmol), PPh3 (39.2 mg, 0.12 
mmol), K2CO3 (448 mg, 3.24 mmol), DMF (10 mL), 
5′-bromo-2′-hydroxyacetophenone 108 (232 mg, 1.08 
mmol) and tBu acrylate (0.732 mL, 4.32 mmol) . The 
desired product was obtained by column chromatography (1:1 CH2Cl2:Pet) as a yellow 
oil (245.3 mg, 90%, Rf =0.06); δH NMR (270 MHz, CDCl3): 1.48 (9H, s, H11ʹ), 2.60 
(3H, s, H2), 6.20 (1H, d, J 15.9, H8ʹ), 6.90 (1H, d, J 8.7, H3ʹ), 7.45 (1H, d, J 15.9, H7ʹ), 
7.58 (1H, dd, J 8.8, J 2.3, H6ʹ), 7.76 (1H, d, J 2.3, H4ʹ), 12.39 (1H, s, OH); δC NMR 
(67.5 MHz, CDCl3): 26.7, 28.3, 80.6, 118.9, 119.3, 128.0, 128.9, 131.2, 135.0, 142.1, 
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163.8, 166.3, 204.4; HRMS (ESI m/z): Calcd. for [C15H18O4+K]+ 301.08367, found 
301.08444. 
(E)-butyl 3-(3-cinnamoyl-4-hydroxyphenyl)acrylate (chalcone nBu acrylate) 206 
To a microwave vial, KOH (992 mg, 1.64 
mmol) and THF (2 mL) were added. 
Acetophenone 201 (107.2 mg, 0.41 mmol) 
and benzaldehyde 59 (0.083 mL, 0.82 
mmol) were then added to the vial, and the reaction stirred under microwave irradiation 
at 200W for 15 minutes at 50 °C. Solvent was then removed in vacuo, and 1.0 M HCl 
(20 mL) added and the solution transferred to a separating funnel. Following extraction 
with 3 × EtOAc (20 mL), and washing of the combined organic phase with H2O (20 
mL) and brine (20 mL), the organic phase was dried over MgSO4, filtered, and the 
solvent was evaporated in vacuo. The desired product was obtained by column 
chromatography (1:1 CH2Cl2:Pet) as a yellow solid (124.7 mg, 87%, Rf =0.06); mp 
82.5-88.2 °C; δH NMR (400 MHz, CDCl3): 0.97 (3H, t, J 7.4, H15), 1.39-1.49 (2H, m, 
H14), 1.66-1.72 (2H, m, H13), 4.21 (2H, t, J 6.8, H12), 6.36 (1H, d, J 16.0, H10), 7.03 
(1H, d, J 8.7, H5), 7.42-7.46 (3H, m, H8, H9, H4ʹ), 7.62-7.71 (5H, m, H3, H2ʹ, H3ʹ, 
H5ʹ, H6ʹ), 7.94 (1H, d, J 15.6, H7), 8.01 (1H, d, J 2.1, H2), 13.09 (1H, s, OH); δC NMR 
(100 MHz, CDCl3): 13.9, 19.3, 30.9, 64.6, 116.8, 119.5, 119.6, 120.0, 125.6, 
129.0(2×C), 129.2(2×C), 130.5, 131.4, 134.4, 134.9, 143.3, 146.5, 165.3, 167.2, 193.5; 
HRMS (ESI m/z): Calcd. for [C22H22O4+H]+ 351.15909, found 351.16099. 
8.6 Chapter 5 Experimental 
8.6.1 Flavonol Succinamic Acid Synthesis 
N-(4-Methoxyphenyl) acetamide 22598, 648 
To a round bottom flask, 4-anisidine 222 (6.036 g, 49 mmol) was 
dissolved in CH2Cl2 (20mL). Acetic anhydride (5 mL, 53 mmol) 
was added slowly over 1 hour, and the solution stirred at rt for 1 
hour. The solution was poured into hexane (60 mL) and stirred for 1 hour. The resultant 
precipitate was collected by filtration, and washed with cold hexane, to give the desired 
acetamide as a pale shimmery-purple solid (7.93 g, 98%, Rf =0.56 (EtOAc)); mp 129.6-
130.5 °C (lit. 129-130 °C)648; δH NMR (270 MHz, CDCl3): 2.11 (3H, s, COCH3), 3.76 
(3H, s, OCH3), 6.80-6.83 (2H, m, H3), 7.34-7.38 (2H, m, H2), 7.56 (1H, br s, NH).  
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N-(3-acetyl-4-hydroxy-phenyl)-acetamide (acetophenone acetamide) 22498 
To a round bottom flask, N-(4-methoxyphenyl)acetamide 225 
(1.00 g, 6.04 mmol), acetyl chloride (1.25 mL, 17.6 mmol), and 
CH2Cl2 (20 mL) were added. To this solution, AlCl3 (2.75 g, 
20.6 mmol) was added in portions over 1 hour, and the solution refluxed for 5 hours. 
The mixture was then cooled for 16 hours with stirring, and cold H2O added. The 
solution was extracted with 3 × CH2Cl2, the organic phase dried over MgSO4, and 
solvent evaporated. Recrystallisation by EtOH gave the desired product as a pale green 
solid (476.4 mg, 41%, Rf =0.10 (2:1 Pet:EtOAc)); mp 169.0-171.3 °C; δH NMR (270 
MHz, CDCl3): 2.16 (3H, s, H8ʹ), 2.58 (3H, s, H1), 6.91 (1H, d, J 8.9, H3ʹ), 7.26 (1H, br 
s, NH), 7.29-7.34 (1H, m, H4ʹ), 8.15 (1H, d, J 2.3, H6ʹ), 12.09 (1H, s, OH).  
3,4-Dimethoxybenzaldehyde 226649 
To a round bottom flask, 3,4-dihydroxybenzaldehyde 223 (69 mg, 
0.5 mmol), K2CO3 (173 mg, 1.25 mmol), and acetone (10mL) were 
added, and a reflux condenser attached. The solution was refluxed 
for 1 hour, before the slow addition of Me2SO4 (0.142 mmol, 1.5 mmol) over an hour, 
and further reflux for an hour. The solution was then quenched with H2O. The solution 
was extracted with 3 × EtOAc, and the organic phase washed with H2O and brine. The 
organic phase was then dried over MgSO4, and solvent removed in vacuo. The desired 
product was obtained after column chromatography (2:1 Pet: EtOAc) as a pale yellow 
oil (77.0 mg, 93%, Rf = 0.39); δH NMR (270 MHz, CDCl3): 3.89 (3H, s, H6), 3.92 (3H, 
s, H5), 6.93 (1H, d, J 8.2, H3), 7.35-7.43 (2H, m, H2, H4), 9.80 (1H, s, CHO); δC NMR 
(67.5 MHz, CDCl3): 56.1, 56.2, 108.9, 110.4, 127.0, 130.2, 149.6, 154.5, 191.0; MS 
(ESI m/z): Calcd. for [C9H10O3+H]+ 167.07, found 167.07. 
3,4-Dibenzyloxybenzaldehyde 227291  
To a round bottom flask, 3,4-dihydroxybenzaldehyde 223 
(554 mg, 4.0 mmol), K2CO3 (1.328 g, 9.6 mmol) and 
EtOH (10 mL) were added. Benzyl bromide (1.048 mL, 
8.8 mmol) was added, and the solution stirred at rt for 72 
hours. Solvent was removed in vacuo, and the solid 
dissolved in CH2Cl2. The organic phase was washed with 5% NaOH solution, and dried 
over MgSO4, before evaporation of the solvent. Recrystallisation in EtOH gave the 
desired product as a pale brown solid (945.2 mg, 74%, Rf =0.76 (2:1 Pet:EtOAc)); 
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mp 95.0-96.5 °C; δH NMR (270 MHz, CDCl3): 5.21 (2H, s, H7), 5.25 (2H, s, H7), 7.00 
(1H, d, J 8.2, H5), 7.30-7.52 (12H, m, H2, H6, H9, H10, H11), 9.80 (1H, s, CHO). 
3-(3,4-dibenzyloxyphenyl)-1-(2-hydroxy-5-acetamidophenyl)prop-2-en-1-one 
(chalcone acetamide) 22862 
To a round-bottom flask, KOH 
(112 mg, 2.0 mmol) and EtOH (10 
mL) were added and stirred to dissolve 
the base. Acetophenone acetamide 224 
(96.6 mg, 0.5 mmol) was added and 
stirred, followed by the addition of 3,4-dibenzyloxybenzaldehyde 227 (159.2 mg, 0.5 
mmol). The solution was then stirred at 40 °C for 16 hours, and the solvent was 
removed. The dry red powder was acidified with 1M HCl, and extracted with 3 × 
EtOAc (20 mL). The organic solution was transferred to a separating funnel, then 
washed with H2O (20 mL) and brine (20 mL), and dried over MgSO4 and filtered. The 
desired product was obtained by recrystallisation (1:1 THF:Pet) as a bright yellow, 
fluffy solid (194.9 mg, 79%, Rf =0.28 (EtOAc)); mp 202.6- 204.7 °C; δH NMR (270 
MHz, CDCl3): 2.18 (3H, br s, H11ʹ), 5.20 (4H, br s, H7), 6.90-6.96 (2H, br s, H5, H3ʹ), 
7.13 (1H, br s, H2), 7.23-7.46 (14H, br m, H4ʹ, H8ʹ, H9ʹ, H6, H9, H10, H11), 7.76-7.81 
(1H, br m, H6ʹ), 8.28 (1H, br s, NH), 12.74 (1H, br s, OH); δC NMR (67.5 MHz, 
CDCl3): 24.5, 71.0, 71.6, 114.3, 115.1, 118.0, 118.9, 119.7, 121.6, 123.8, 127.3, 127.6, 
128.0, 128.1, 128.7, 129.1, 136.6, 136.9, 146.0, 149.0, 151.9, 160.6, 168.5, 193.5; 
HRMS (ESI m/z): Calcd. for [C31H27NO5+H]+ 494.19620, found 494.19625. 
Dimethyldioxirane (DMDO) 234588 
Water (250 mL), acetone (190 mL) and NaHCO3 (58 g, were vigorously stirred 
in a 1L round bottomed flask at rt. Oxone (120 g) was then added in three 
portions over 20 minutes. Stirring was continued for 20 minutes at which time a 
vacuum of 80-100 torr was applied, and the distillate was collected in a cold trap (-
78 °C). The trapped solution was dried (K2CO3), filtered, and collected to yield DMDO 
at a concentration of approximately 0.1 M in acetone, as determined by 1H NMR 
titration with thioanisole.  
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6-acetamido-2-(3ʹ,4ʹ-bis(benzyloxy)phenyl)-3-hydroxy-4H-chromen-4-one 
(flavonol acetamide) 23862  
Chalcone acetamide 228 (121.9 mg, 0.25 
mmol) was dissolved in EtOH in a round 
bottom flask, and cooled to 0 °C. NaOH 
solution (5%, 2mL), was added and 
stirred for 10 minutes. H2O2 solution 
(15% in H2O, 2 mL) was added, and the 
solution stirred at 0 °C for two hours. The reaction was then stirred for 16 hours at rt, 
and carefully neutralised using 0.1M HCl. The resultant precipitate was collected by 
filtration, and dried under vacuum to give the desired flavonol as a pale yellow solid 
(114.7 mg, 91%); mp 228.6-230.2 °C (lit. 229-230 °C)62; δH NMR (270 MHz, CDCl3): 
2.22 (3H, br s, H10), 5.25 (4H, br s, H7ʹ), 6.89 (1H, v br s, NH), 7.03 (1H, d, J 8.2, 
H5ʹ), 7.27-7.51 (11H, m, H8, H6ʹ, H2ʹ, H9ʹ, H10ʹc, H10ʹd, H11ʹ), 7.67 (1H, br s, OH), 
7.80-7.95 (3H, m, H5, H10ʹa, H10ʹb), 8.24 (1H, br d, J 7.7, H7); δC NMR (67.5 MHz, 
CDCl3): 24.6, 71.0, 71.6, 114.0, 114.2, 114.5, 119.0, 120.7, 122.1, 124.0, 126.7, 127.3, 
127.6, 128.1, 128.6, 128.7, 135.0, 136.7, 137.1, 137.6, 145.4, 148.6. 150.8, 151.9, 
168.7, 172.7; MS (ESI m/z): Calcd. for [C31H25NO6+H]+ 508.17, found 508.17. 
8.6.2 Flavonol tBu Acrylate Synthesis 
(E)-tert-butyl 3-(2-(3ʹ,4ʹ-bis(benzyloxy)phenyl)-3-hydroxy-4-oxo-4H-chromen-6-
yl)acrylate (flavonol tBu acrylate) 243 
Impure chalcone tBu acrylate 245 
(approximately 1.1 g, synthesised 
from 1.95 mmol acetophenone 
202) was dissolved in EtOH, and 
cooled to 0 °C. To the solution, 
5% NaOH was added (10 mL), 
and then 15% H2O2 in H2O (10 mL). The solution was then stirred for 16 hours at room 
temperature, neutralised (1.0 M HCl), transferred to a separating funnel and extracted 
(3 × EtOAc). The organic phase was washed (H2O and brine, 20 mL each), then dried 
over MgSO4 and filtered, and the solvent evaporated in vacuo. Purification by column 
chromatography (4:1 CH2Cl2:Pet) isolated the desired flavonol in 43% from the 
acetophenone (479.4 mg, 0.83 mmol, Rf =0.06); δH NMR (270 MHz, CDCl3): 1.55 (9H, 
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s, H13), 5.22 (m, 4H, H7ʹ), 6.43 (1H, d, J 16.1, H10), 6.99 (1H, d, J 8.4, H9), 7.28-7.51 
(12H, m, H2ʹ, H5ʹ, H9ʹ, H10ʹ & H11ʹ), 7.63 (1H, d, J 8.4, H5), 7.74-7.87 (3H, m, H7, 
H8 & H6ʹ), 8.29 (1H, br s, OH); δC NMR (67.5 MHz, CDCl3):28.3, 70.9, 71.6, 81.0, 
114.0, 114.5, 119.0, 120.9, 121.7, 122.1, 123.8, 125.4, 127.3, 127.6, 128.1, 128.6, 
128.7, 131.3, 132.1, 136.7, 137.1, 138.1, 141.6, 145.4, 148.6, 150.9, 155.8, 166.0, 
172.8; HRMS (ESI m/z): Calcd. for [C36H32O7+H]+ 577.22263, found 577.22465. 
8.6.3 Flavonol Propanoic Acid Synthesis 
Butyl 3-(3-acetyl-4-hydroxyphenyl)propanoate (acetophenone nBu ester) 250 
Acetophenone nBu acrylate 201 (156.7 mg, 0.60 
mmol) was added to a round bottom flask with 
Pd/C (20 mg), MeOH (5mL) and toluene (3 mL). 
A hydrogen-filled gas bladder was equipped, and the solution stirred for 16 hours at 
room temperature. The solution was then filtered through celite, and the solvent 
removed to give the desired product as a brown oil (158.3 mg,100 %, Rf =0.72 (2:1 Pet: 
EtOAc)); δH NMR (270 MHz, CDCl3): 0.88 (3H, t, J 7.4, H13ʹ), 1.22-1.37 (2H, m, 
H12ʹ), 1.49-1.60 (2H, m, H11ʹ), 2.58-2.61 (5H, m, H8ʹ & H2), 2.88 (2H, t, J 7.6, H7ʹ), 
4.03 (2H, t, J 6.6, H10ʹ), 6.87 (1H, d, J 6.6, H3ʹ), 7.27-7.31 (1H, m, H4ʹ), 7.53 (1H, d, 
J 2.3, H6ʹ), 12.10 (1H, s, OH); δC NMR (67.5 MHz, CDCl3): 13.8, 19.2, 26.7, 30.1, 
30.7, 36.1, 64.5, 118.5, 119.5, 130.2, 131.0, 136.8, 161.0, 172.8, 204.5; HRMS (ESI 
m/z): Calcd. for [C15H20O4+H]+ 265.14344, found 265.14317. 
(E)-3-(3-(3-(3,4-bis(benzyloxy)phenyl)acryloyl)-4-hydroxyphenyl)propanoic acid 
(chalcone propanoic acid) 251 
To a round bottom flask, KOH 
(67.3 mg, 1.20 mmol) and EtOH (10 
mL) were added and stirred to 
dissolve the base. Acetophenone 
nBu ester 250 (90.0 mg, 0.34 mmol) 
was added and stirred, followed by the addition of benzaldehyde 227 (106 mg, 0.34 
mmol). The solution was stirred for 16 hours, after which time the solvent was removed 
in vacuo. The solution was acidified with 1.0 M HCl (20 mL), and extracted with 3 × 
EtOAc (20 mL). The organic phase was then washed with H2O (20 mL) and brine 
(20 mL), and then dried (MgSO4) and filtered. Evaporation of the solvent in vacuo, 
followed by column chromatography (2:1 Pet: EtOAc) gave the desired chalcone as a 
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bright yellow solid (82.3 mg, 48%, Rf =0.06 (2:1 Pet:EtOAc)); mp 130-132.3 °C; δH 
NMR (270 MHz, CDCl3): 2.64 (2H, t, J 7.5, H8ʹ), 2.92 (2H, t, J 7.4, H7ʹ), 5.19 (2H, s, 
H10), 5.21 (2H, s, H10), 6.88-6.94 (2H, m, H3ʹ & H6), 7.20-7.48 (15H, m, H4ʹ, H6ʹ, 
H5, H9, H12, H13, H14, OH), 7.62-7.81 (2H, m, H2 & H3); δC NMR (67.5 MHz, 
CDCl3): 30.0, 35.9, 71.0, 71.6, 114.2, 114.6, 118.0, 118.9, 120.0, 124.1, 127.3, 127.5, 
128.1, 128.7. 129.0, 130.3, 136.4, 136.6, 137.0, 145.7, 149.0, 151.8, 162.2, 178.6, 
193.5; HRMS (ESI m/z): Calcd. for [C32H28O6+H]+ 509.19587, found 509.19314.  
8.6.4 Enalapril Derivative Synthesis: Strategy A 
Pro-OBn 259620  
Benzyl alcohol (3.0 mL) and SOCl2 (0.5 mL) were added to an 
RBF at 0 °C. L-Proline 261 (228 mg, 2.0 mmol) was then added, 
and the solution stirred for 48 hours whilst warming to room 
temperature. HCl was removed in vacuo, and ether added until 
the solution became opaque. The RBF was cooled on ice, and the white crystalline 
material was filtered, washed with cold ether, and dried on vacuum to give the desired 
protected proline as a white solid (382.9 mg, 95%, Rf = 0.0(3:1 EtOAc:Pet)); mp 125.1-
128.5 °C; δH NMR (270 MHz, CDCl3): 1.98-2.15 (3H, m, H2, H3a), 2.32-2.42 (1H, m, 
H3b), 3.52 (2H, br s, H1), 4.49 (1H, br s, H4), 5.13-5.26 (2H, m, H5), 7.33 (5H, br s, 
H6, H7, H8), 9.10 (1H, br s, NH), 10.74 (1H, br s, NH). 
Pyr-Pro-OBn 257621 
Pro-OBn 259 (300 mg, 1.46 mmol), pyruvic acid 260 (0.114 
mL, 1.60 mmol), EDCI (425.7 mg, 2.22 mmol) and HOBt (40.5 
mg, 0.30 mmol) were stirred in CH2Cl2 for 16 hours. Additional 
CH2Cl2 was added, and the organic washed with brine and H2O, 
and dried over MgSO4. Filtration and removal of the solvent in 
vacuo, followed by column chromatography (2:1 Pet: EtOAc) gave the desired 
compound as an off-white solid (193.1 mg, 48%, Rf =0.37(30% EtOAc/Pet)); mp 43.8-
47.4°C (lit.43-47 °C)621; δH NMR (270 MHz, CDCl3): 1.69-2.31 (4H, m, H2 & H3), 
2.35 (2H, s, H9), 2.42 (1H, s, H9) 3.50-3.83 (2H, m, H1), 4.52-4.56 (0.33H, m, H4), 
4.88-4.93 (0.66H, m, H4), 5.07-5.23 (2H, m, H5), 7.33 (5H, br s, H6, H7 & H8).  
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Fmoc-Lys(Boc)-OBn 263622 
Fmoc-Lys(Boc)-OH 262 (393.6 mg, 0.84 
mmol) and NEt3 (0.156 mL, 1.12 mmol) 
were added to an RBF and stirred in 
EtOAc. Benzyl bromide (0.124 mL, 1.04 
mmol) was added, and the reaction stirred 
for 5 hours at 78 °C. Solvent was 
evaporated in vacuo, H2O added (20 mL), 
and the solution acidified to neutral pH using 0.1M HCl. The compound was transferred 
to a separating funnel, extracted (3 × EtOAc, 20 mL) and washed (H2O, brine, 20 mL of 
each), and the organic phase dried over MgSO4 and filtered. The solvent was removed 
under reduced pressure, and purified by column chromatography (1:2 EtOAc:Pet), to 
give the tri-protected lysine as a clear oil (469.0 mg, 100%, Rf =0.86); δH NMR (270 
MHz, CDCl3): 1.15-1.42 (13H, m, H9, H5, H4), 1.65-1.85 (2H, m, H3), 3.04 (2H, br s, 
H6), 4.17-4.23 (1H, m, H2), 4.32-4.56 (4H, m, H14, H15, H7), 5.09-5.18 (2H, m, H10), 
5.47 (1H, br s, NH), 7.25-7.40 (9H, m, H11, H12, H13, H15, H17, H18), 7.58-7.60 (2H, 
m, H16), 7.74-7.78 (3H, m, H19, NH). 
Lys(Boc)-OBn 258624 
Fmoc-Lys(Boc)-OBn 263 (469.0 mg, 
0.84 mmol), was dissolved in 20% 
piperidine in DMF (8mL), and stirred for 2 
hours at rt. The solvent was removed in 
vacuo, the solid redissolved in CH2Cl2 (20 mL), transferred to a separating funnel, 
washed with H2O (20 mL), and the organic phase dried over MgSO4 and filtered. 
Solvent removal in vacuo, followed by column chromatography (3% MeOH in CHCl3), 
gave the desired product as a clear oil (224.8 mg, 80%, Rf =0.12); δH NMR (270 MHz, 
CDCl3): 1.23-1.35 (11H, m, H9, H4), 1.51-1.74 (2H, m, H5), 1.80 (2H, br s, NH2), 2.11 
(2H, br s, H3), 3.02-3.08 (2H, m, H6), 3.50 (1H, br s, H2), 4.53 (1H, br s, H7), 5.13 
(2H, s, H10), 7.31 (5H, s, H11, H12, H13); δC NMR (67.5 MHz, CDCl3): 22.8, 28.5, 
34.3, 40.3, 54.4, 66.7, 79.1, 120.0, 128.4, 128.5, 128.7, 135.7, 156.1, 175.7; MS (ESI 
m/z): Calcd. for [C18H28N2O4+H]+ 337.21, found 337.21. 
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8.6.5 Enalapril Derivative Synthesis: Strategy B 
Bromoacetyl-Pro-OBn 267650 
Pro-OBn 259 (300 mg, 1.46 mmol), bromoacetic acid 268 
(223 mg, 1.59 mmol), HOBt (40.5 mg, 0.3 mmol), EDCI 
(425.7 mg, 2.22 mmol) and CH2Cl2 were stirred overnight in 
an RBF. The solution was transferred to a separating funnel, 
additional CH2Cl2 was added (20 mL), and the solution was 
washed twice with brine (20 mL). The organic phase was separated, dried (MgSO4) and 
filtered, and solvent evaporated in vacuo. Purification by column chromatography (2:1 
Pet:EtOAc) gave the desired compound as a clear oil (228.6 mg, 48%, Rf= 0.18); δH 
NMR (270 MHz, CDCl3): 1.92-2.08 (3H, m, H2 & H3a), 2.11-2.26 (1H, m, H3b), 3.55-
3.72 (2H, m, H1), 4.04 (2H, m, H9), 4.52-4.59 (1H, m, H4), 5.09-5.18 (2H, m, H5), 
7.28-7.37 (5H, m, H6, H7 & H8); δC NMR (67.5 MHz, CDCl3): 22.4, 24.9, 29.1, 31.4, 
41.9, 47.2, 59.4, 67.0, 128.2, 128.4, 128.7, 135.6, 165.2, 171.6; MS (ESI m/z): Calcd. 
for [C14H6BrNO3+H]+ 326.04, found 326.04. 
BnO-Pro-COCH2-Lys(Boc)-OBn 266 
To a round bottom flask, Lys(Boc)-OBn 
258 (52.6 mg, 0.16 mmol) was added and 
dissolved in DMF (5 mL), and the solution 
cooled to 0 °C. To this cooled solution, 
NaH (3.8 mg, 0.16 mmol) was added and 
stirred for 1 hour. Bromoacetyl-Pro-OBn 
267 (51.0 mg, 0.16 mmol) was added, and 
the solution warmed to room temperature 
with stirring for 16 hours. The solvent was 
evaporated in vacuo, CH2Cl2 added (20 mL) and the solution filtered. The solvent was 
removed in vacuo to afford the desired compound as a pale yellow oil (61.7 mg, 68%, 
Rf =0.05); δH NMR (270 MHz, CDCl3): 1.34-1.41 (13H, m, H4, H5, H9), 1.62-1.72 
(2H, m, H3),1.84-2.00 (3H, m, H4ʹ, H5ʹa), 2.07-2.20 (1H, m, H5ʹb), 3.01-3.09 (2H, m, 
H6), 3.23-3.69 (5H, m, H1ʹ, H3ʹ, H2), 4.46-4.58 (1H, m, H6ʹ), 5.09-5.16 (4H, m, H8ʹ, 
H1ʺ), 7.29-7.34 (10H, m, H10ʹ, H11ʹ, H12ʹ, H3ʺ, H4ʺ, H5ʺ); δC NMR (67.5 MHz, 
CDCl3): 24.7, 25.0, 28.5(3×C), 32.3, 40.3, 46.1, 46.7, 47.2, 49.2, 59.0, 60.8, 66.8, 67.0, 
79.1, 127.1, 127.6, 128.1, 128.2, 128.3, 128.4, 128.6, 128.6, 128.7, 128.7, 135.7, 135.8, 
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162.4, 169.4, 171.9, 172.2; HRMS (ESI m/z): Calcd. for [C32H43N3O7+H]+ 582.31738, 
found 582.31753. 
BnO-Pro-COCH2-Lys-OBn 265 
BnO-Pro-COCH2-Lys(Boc)-OBn 266 120.0 mg, 
0.206 mmol) was stirred in 20% TFA in CH2Cl2 
(6 mL) for two hours. Then, 2×CH2Cl2 (10 mL), 
toluene (10 mL), and CHCl3 (10 mL) were added 
and then evaporated in vacuo to remove unwanted 
side products and give the desired amine as a pale 
yellow oil (99.2 mg, quant., Rf =0.00 (3:1 
EtOAc:Pet); δH NMR (270 MHz, CDCl3): 1.59-
2.34 (10H, m, H3, H4, H5, H4ʹ, H5ʹ), 2.89-2.97 
(2H, m, H6), 3.25-3.74 (4H, m, H1ʹ & H3ʹ), 4.03 (1H, br s, H2), 4.51 (1H, br s, H6ʹ), 
4.99-5.25 (4H, m, H8ʹ & H1˝), 7.30 (10H, br s, H10ʹ, H11ʹ, H12ʹ, H3˝, H4˝ & H5˝), 
7.79 ppm (1H, br s, NH), 9.63 (2H, br s, NH2); HRMS (ESI m/z): Calcd. for 
[C27H35N3O5+H]+ 482.26495, found 482.26334. 
8.7 Chapter Six Experimental 
8.7.1 Flavonol-Dipeptides 
3ʹ,4ʹ-Dibenzyloxyflavonol 281291, 626 
To a solution of ethanol (8 mL) and 1,4-dioxane 
(4 mL) was added 2ʹ-hydroxyacetophenone 72 
(280 μL, 2.32 mmol) and 3,4-
dibenzyloxybenzaldehyde 227 (728 mg, 2.29 
mmol). KOH solution (40%, 2 mL) was then 
added dropwise, and the reaction stirred for five 
days. The solution was diluted with CH2Cl2 (20 mL), transferred to a separating funnel 
and the organic washed with H2O (20 mL), dried (MgSO4), and filtered. The solvent 
was evaporated in vacuo, and the residue dissolved in 1,4-dioxane (8 mL) and ethanol 
(20 mL). NaOH was added as a 2 M solution (6 mL), and the reaction mixture cooled to 
0 °C. Hydrogen peroxide (30%, 2 mL) was then added dropwise, and the reaction 
stirred at 0 °C for 2hrs. The reaction was left to stir overnight at rt, and then acidified 
with 2 M HCl. The resultant suspension was filtered, and washed with ethanol (20 mL). 
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Recrystallisation from hot EtOAc gave the desired flavonol as a pale yellow, fibrous 
solid (541.2 mg, 53%, Rf =0.63 (2:1 Pet:EtOAc)); mp 148.5-151.8 °C (lit. 145.8-146.8 
°C)626; δH NMR (400 MHz, CDCl3): 5.21-5.26 (4H, m, H7ʹ), 6.97 (1H, br s, OH), 7.05 
(1H, d, J 8.7, H2ʹ), 7.30-7.53 (12H, m, H5ʹ, H6ʹ, H9ʹ, H10ʹ, H11ʹ), 7.68 (1H, td, J 7.8, 
J 1.4, H6), 7.84 (1H, dd, J 8.5, J 1.8, H8), 7.93 (1H, d, J 2, H7), 8.22 (1H, dd, J 8.0, 
J 1.4, H5); δC NMR (100 MHz, CDCl3): 71.0, 71.6, 114.2, 114.6, 118.2, 122.1, 124.5, 
125.5, 127.3(2×C), 127.6(2×C), 128.1(2×C), 128.6(2×C), 128.7(2×C), 133.5, 136.8, 
137.2, 137.9, 145.0, 146.7, 150.8, 155.3, 173.2; MS (ESI m/z): Calcd. for 
[C29H22O5+H]+ 451.15, found 451.15.  
Fmoc-Ala-Pro-OBn 287651 
Fmoc-Ala-OH 283 (155.7 mg, 0.50 mmol), EDCI 
(191.7 mg, 1.0 mmol), HOBt (15.3 mg, 0.1 mmol) and 
CH2Cl2 (10 mL) were stirred in a round bottom flask 
under N2 for 10 minute, before addition of Pro-OBn 
259 (100 mg, 0.49 mmol). The solution was stirred at 
room temperature for 16 hours, then CH2Cl2 added (20 
mL), the solution transferred to a separating funnel, 
and the organic phase washed with 0.1 M HCl (20 
mL), H2O (20 mL) and brine (2×20 mL). The organic phase was dried over MgSO4, 
filtered, and solvent removed in vacuo. Purification by column chromatography (2:1 
Pet:EtOAc) isolated the dipeptide as a viscous oil (131.1 mg, 54%, Rf =0.22); δH NMR 
(400 MHz, CDCl3): 1.36 (3H, d, J 6.4, H3ʹ), 1.90-2.10 (3H, m, H3, H4a), 2.20-2.24 
(1H, m, H4b), 3.60-3.69 (2H, m, H2), 4.21-4.35 (3H, m, H5, H2ʹ, H3ʺ), 4.53-4.62 (2H, 
m, H3ʺ), 5.11-5.23 (2H, dd, J 17.0, J 8.4, H7), 5.88 (1H, br s, NH), 7.31-7.76 (13H, m, 
H9, H10, H11, H5ʺ, H6ʺ, H7ʺ, H8ʺ); δC NMR (67.5 MHz, CDCl3): 18.4, 25.0, 29.0, 
46.9, 47.2, 48.4, 59.0, 67.1, 120.0(2×C), 125.3(2×C), 127.1(2×C), 127.8(2×C), 
128.3(2×C), 128.4(4×C), 128.7(2×C), 135.6, 141.4, 144.0, 155.8, 171.4, 172.7; MS 
(ESI m/z): Calcd. for [C30H30N2O5+H]+ 499.22, found 499.22.  
Fmoc-Lys(Boc)-Pro-OBn 288 
Fmoc-Lys(Boc)-OH 284 (237.3 mg, 0.50 mmol), EDCI (191.7 mg, 1.0 mmol), HOBt 
(15.3 mg, 0.1 mmol) and CH2Cl2 (10 mL) were stirred in an RBF under N2 for 10 
minutes, before addition of Pro-OBn 259 (100 mg, 0.49 mmol). The solution was 
stirred at room temperature for 16 hours, then CH2Cl2 added (20 mL), the solution 
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transferred to a separating funnel, and 
the organic phase washed with 0.1 M 
HCl (20 mL), H2O (20 mL) and brine 
(2×20 mL). The organic phase was 
dried over MgSO4, filtered, and solvent 
removed in vacuo. Purification by 
column chromatography (2:1 
Pet:EtOAc) isolated the dipeptide as a 
viscous oil (206.1 mg, 63%, Rf =0.22 (2% MeOH/CHCl3)); δH NMR (400 MHz, 
CDCl3): 1.25-1.42 (13H, m, H4ʹ, H5ʹ, H9ʹ), 1.63-2.21 (5H, m, H3, H2ʹ, NH), 2.97-3.19 
(2H, m, H4), 3.45-3.71 (2H, m, H6ʹ), 4.18-4.81 (6H, m, H3ʹ, H5, H2ʹ, H2ʺ), 5.10-5.23 
(2H, m, H7), 5.68 (1H, br s, H3ʺ), 7.25-7.76 (14H, m, H9, H10, H11, H5ʺ, H6ʺ, H7ʺ, 
H8ʺ, NH); HRMS (ESI m/z): Calcd. for [C24H33N3O7+H]+ 476.23913, found 476.24002.  
Fmoc-Gln-Pro-OBn 289 
Fmoc-Gln-OH 285 (368.4 mg, 1.0 mmol), EDCI 
(383.4 mg, 2.0 mmol), HOBt (30.6 mg, 0.2 mmol) 
and CH2Cl2 (10 mL) were stirred in a round 
bottom flask under N2 for 10 minute, before 
addition of Pro-OBn 259 (200 mg, 0.98 mmol). 
The solution was stirred at room temperature for 
16 hours, then CH2Cl2 added, the solution 
transferred to a separating funnel, and the organic 
phase washed with 0.1 M HCl (20 mL), H2O (20 mL) and 2×brine (20 mL). The 
organic phase was dried over MgSO4, filtered, and solvent removed in vacuo. 
Purification by column chromatography (2:1 Pet:EtOAc) isolated the dipeptide as a 
viscous oil (298.6 mg, 46%, Rf =0.02 (3% MeOH/CHCl3)); δH NMR (270 MHz, 
CDCl3): 1.86-2.68 (8H, m, H3, H4, H3ʹ, H4ʹ), 3.68 (2H, br s, NH2), 4.14-4.64 (4H, m, 
H2, H5, C2ʹ), 5.07-5.21 (2H, m, H7), 6.03-6.27 (3H, m, H2ʹ, H3ʹ), 7.26-7.96 (13H, m, 
H9, H10, H11, H5ʺ, H6ʺ, H7ʺ, H8ʺ), 9.60 (1H, br s, NH); δC NMR (67.5 MHz, CDCl3): 
25.1, 28.6, 29.3, 30.9, 47.3, 51.5, 53.7, 59.2, 63.0, 67.1, 119.2, 120.1, 125.1, 125.2, 
126.0, 127.1(2×C), 127.3(2×C), 127.8(2×C), 128.6(2×C), 128.8(2×C), 136.7, 141.4, 
143.8, 156.4, 164.7, 170.6, 172.0; HRMS (ESI m/z): Calcd. for [C32H33N3O6+H]+ 
556.24421, found 556.24413.  
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Fmoc-Glu(OtBu)-Pro-OBn 290 
Fmoc-Glu(OtBu)-OH 286 (425.5 mg, 1.0 
mmol), EDCI (383.4 mg, 2.0 mmol), HOBt 
(30.6 mg, 0.2 mmol) and CH2Cl2 (10 mL) were 
stirred in a round bottom flask under N2 for 10 
minute, before addition of Pro-OBn 259 (200 
mg, 0.98 mmol). The solution was stirred at 
room temperature for 16 hours, then CH2Cl2 
added, the solution transferred to a separating 
funnel, and the organic phase washed with 0.1 M HCl (20 mL), H2O (20 mL) and 
2×brine (20 mL). The organic phase was dried (MgSO4), filtered, and solvent removed 
in vacuo. Purification by column chromatography (5% MeOH/CHCl3) isolated the 
dipeptide as a viscous oil (327.6 mg, 55%, Rf =0.53 (5% MeOH/CHCl3)); δH NMR (270 
MHz, CDCl3): 1.46 (9H, br s, H7ʹ), 1.75-2.41 (8H, m, H3, H4, H3ʹ, H4ʹ), 3.67-3.73 
(2H, m, H2), 4.16-4.21 (1H, br s, NH), 4.31-4.34 (2H, H5, H2ʹ), 4.58-4.65 (2H, m, 
H2ʺ), 5.10-5.22 (2H, m, H7), 5.90 (1H, br s, H3ʺ), 7.22-7.74 (13H, m, H9, H10, H11, 
H5ʺ, H6ʺ, H7ʺ, H8ʺ); δC NMR (100 MHz, CDCl3): 25.0, 27.9, 28.2, 29.1, 30.8, 47.3, 
50.7, 51.7, 59.1, 67.0, 80.6, 120.1, 125.3, 127.2(2×C), 127.8, 128.3(2×C), 128.4, 
128.7(2×C), 135.7, 141.4, 143.9, 156.3, 170.8, 171.6, 172.3; 25.0, 27.9, 28.2, 29.1, 
30.8, 47.3, 50.7, 51.7, 59.1, 67.0, 80.6, 120.1, 125.3, 127.2(2×C), 127.6(4×C), 
127.8(2×C), 128.3(2×C), 128.4(2×C), 128.7(4×C), 135.7, 141.4, 143.9, 156.3, 170.8, 
171.6, 172.3; HRMS (ESI m/z): Calcd. for [C36H40N2O7+H]+ 613.29083, found 
613.28880.  
Fmoc-Ala-Pro-OH 291 
Fmoc-Ala-Pro-OBn 287 (248.4 mg, 0.498 mmol) was added to a 
solution of Pd/C (25 mg) in MeOH (10 mL) under N2. A 
hydrogen (H2) balloon was added, and the reaction was stirred 
for 16 hours at room temperature. The solution was then filtered 
through a celite plug, and purification by column 
chromatography (5% MeOH/ CHCl3) isolated the deprotected 
dipeptide as a viscous oil (186.8 mg, 92%, Rf =0.02 
(3%MeOH/CHCl3)); δH NMR (270 MHz, CDCl3): 1.34 (3H, d, J 
6.4, H3ʹ), 1.95-2.07 (4H, m, H3, H4), 3.58-3.67 (2H, m, H2), 4.14-4.57 (5H, m, H5, 
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H2ʹ, H2ʺ, NH), 6.24 (1H, br s, H3ʺ), 7.24-7.74 (11H, m, H5ʺ, H6ʺ, H7ʺ, H8ʺ); δC NMR 
(67.5 MHz, CDCl3): 18.4, 25.0, 29.0, 46.9, 47.2, 48.4, 59.0, 120.0(2×C), 125.3(2×C), 
127.1(2×C), 128.3, 128.4(2×C), 128.7(2×C), 141.4, 144.0, 155.8, 171.4, 172.7; HRMS 
(ESI m/z): Calcd. for [C23H24N2O5+H]+ 409.17635, found 409.17553.  
Fmoc-Lys(Boc)-Pro-OH 292 
Fmoc-Lys(Boc)-Pro-OBn 288 (192.9 mg, 0.288 mmol) 
was added to a solution of Pd/C (41 mg) in MeOH 
(10 mL) under N2. A hydrogen (H2) balloon was added, 
and the reaction was stirred for 16 hours at room 
temperature. The solution was then filtered through a 
celite plug, and purification by column chromatography 
(5% MeOH/ CHCl3) isolated the deprotected dipeptide 
as a viscous oil (96.0 mg, 59%, Rf =0.02(5% MeOH/ 
CHCl3); δH NMR (270 MHz, CDCl3): 1.40-2.19 (18H, m, H3, H2ʹ, H4ʹ, H5ʹ, H9ʹ, NH), 
2.92-3.14 (2H, m, H4), 3.60-3.76 (2H, m, H6ʹ), 4.12-4.55 (6H, m, H5, H2ʹ, H3ʹ, H2ʺ), 
6.19 (1H, br s, H3ʺ), 6.86-7.72 (9H, m, H5ʺ, H6ʺ, H7ʺ, H8ʺ, NH); δC NMR (67.5 MHz, 
CDCl3):; HRMS (ESI m/z): Calcd. for [C31H39N3O7+H]+ 565.27825, found 565.28167.  
Fmoc-Gln-Pro-OH 293 
Fmoc-Gln-Pro-OBn 289 (198.6 mg, 0.537 mmol) was added 
to a solution of Pd/C (30 mg) in MeOH (10 mL) under N2. A 
hydrogen (H2) balloon was added, and the reaction was 
stirred for 16 hours at room temperature. The solution was 
then filtered through a celite plug, and purification by 
column chromatography (5% MeOH/ CHCl3) isolated the 
deprotected dipeptide as a viscous oil (127.1 mg, 50%, 
Rf =0.05(5% MeOH/ CHCl3)); δH NMR (270 MHz, CDCl3): 
1.72-2.41 (10H, m, H3, H4, H3ʹ, H4ʹ, NH2), 3.62-3.73 (2H, m, H2), 4.10-4.58 (5H, m, 
H2ʹ, H3ʹ, H2ʺ), 5.65 (1H, br s, NH), 6.64-6.76(1H, m, H3ʺ), 7.18-7.71 (8H, m, H5ʺ, 
H6ʺ, H7ʺ, H8ʺ); δC NMR (67.5 MHz, CDCl3): 25.1, 28.6, 29.3, 30.9, 47.3, 51.5, 53.7, 
59.2, 67.1, 119.2, 120.1, 125.1, 125.2, 126.0, 127.3, 127.8 (2×C), 128.6(2×C), 141.4, 
143.8, 156.4, 164.7, 170.6, 175.0; HRMS (ESI m/z): Calcd. for [C25H27N3O6+H]+ 
466.19726, found 466.19990.  
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Fmoc-Glu(OtBu)-Pro-OH 294 
Fmoc-Glu(OtBu)-Pro-OBn 290 (304.7 mg, 0.537 mmol) 
was added to a solution of Pd/C (30 mg) in MeOH 
(10 mL) under N2. A hydrogen (H2) balloon was added, 
and the reaction was stirred for 16 hours at room 
temperature. The solution was then filtered through a 
celite plug, and purification by column chromatography 
(5% MeOH/ CHCl3) isolated the deprotected dipeptide as 
a viscous oil (204.5 mg, 79%, Rf =0.04 (5% MeOH/ 
CHCl3)); δH NMR (270 MHz, CDCl3): 1.42 (9H, s, H7ʹ), 1.83-2.44 (8H, m, H3, H4, 
H3ʹ, H4ʹ), 3.75 (2H, m, H2), 4.16-4.62 (5H, m, H5, H2ʹ, H2ʺ, NH) 6.19 (1H, m, H3ʺ), 
7.24-7.74 (8H, m, H5ʺ, H6ʺ, H7ʺ, H8ʺ), 10.82 (1H, br s, COOH); δC NMR (67.5 MHz, 
CDCl3): 25.0, 27.9, 28.2, 29.1, 30.8, 47.3, 50.7, 51.7, 59.1, 80.6, 120.1, 125.3, 
127.2(2×C), 127.6(2×C), 127.8(2×C), 128.3, 128.7(4×C), 141.4, 143.9, 156.3, 170.8, 
171.6, 172.3; HRMS (ESI m/z): Calcd. for [C29H34N2O7+H]+ 523.24388, found 
523.24476. 
2-(3,4-bis(benzyloxy)phenyl)-4-oxo-4H-chromen-3-yl 2-acetamidoacetate 296 
In a round bottom flask, 3ʹ,4ʹ-dibenzyloxyflavonol 
281 (100 mg, 0.22 mmol), EDCI (71.4 mg, 0.32 
mmol), HOBt (4.2 mg, 0.032 mmol) and DMAP (4 
mg, 0.032 mmol) in CH2Cl2 (10 mL) were added. 
The solution was stirred for 10 minutes, and then 
N-acetylglycine 295 (30 mg, 0.22 mmol) was 
added. The solution was stirred at room 
temperature for 16 hours, CH2Cl2 (20 mL) was 
added, and the solution transferred to a separating funnel. The organic phase was 
washed (H2O and brine, 20 mL of each), dried (MgSO4), filtered, and the solvent 
removed in vacuo. Recrystallisation in EtOH provided the compound as a pale yellow 
amorphous solid (88.2 mg, 72%, Rf =0.05 (2:1 Pet:EtOAc)); δH NMR (400 MHz, 
CDCl3): 2.04 (3H, s, H12), 3.46-3.47 (2H, d, J 4.8, H10), 5.24 (4H, br s, H1ʺ), 6.04 
(1H, br s, NH), 7.05 (1H, d, J 8.0, H2ʹ), 7.31-7.51 (14H, m, H6, H8, H5ʹ, H6ʹ, H3ʺ, H4ʺ, 
H5ʺ), 7.69-7.73 (1H, m, H7), 8.21 (1H, dd, J 8.0, J 1.6, H5); δC NMR (100 MHz, 
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CDCl3): 23.0, 41.5, 71.0, 71.6,114.2, 114.8, 118.2, 120.7, 122.1, 123.1, 124.5, 125.5, 
126.1, 127.3(2×C), 127.4(2×C), 127.6(2×C), 128.7(2×C), 128.8, 133.5, 134.1, 136.5, 
137.9, 145.0, 148.8, 152.1, 156.2, 167.9, 171.7, 173.2 ; HRMS (ESI m/z): Calcd. for 
[C33H27NO7+H]+ 550.18603, found 550.18467.  
2-(3,4-bis(benzyloxy)phenyl)-4-oxo-4H-chromen-3-yl 1-(2-((((9H-fluoren-9-
yl)methoxy)carbonyl)amino)propanoyl)pyrrolidine-2-carboxylate (Fmoc-Ala-Pro-
diOBn-flavonol) 297 
Fmoc-Ala-Pro-OH 291 (186.8 mg, 0.46 mmol), 
3ʹ,4ʹ-dibenzyloxyflavonol 281 (225.3 mg, 0.50 
mmol), EDCI.HCl (157.7 mg, 0.82 mmol), 
DMAP (10 mg, 0.08 mmol) and CH2Cl2 
(10 mL) were added to a round bottomed flask, 
and stirred at rt for 16 hrs. The solution was 
diluted with CH2Cl2 (20 mL), transferred to a 
separating funnel, and the organic phase 
washed with H2O (3×20 mL) and brine (1×20 
mL), and dried (MgSO4) and filtered. 
Following purification by column 
chromatography (2:1 Pet:EtOAc), the desired compound was isolated as a pale yellow 
amorphous solid (172.4 mg, 45%, Rf =0.03); δH NMR (400 MHz, CDCl3): 1.22 (3H, m, 
H15), 1.70-2.71 (4H, m, H11, H12), 3.67-3.72 (2H, m, H13), 4.19-4.90 (4H, m, H10, 
H14, H16 & H17), 5.24-5.33 (4H, br s, H1ʺ), 7.03-7.94 (25H, m, H6, H7, H8, H2ʹ, H5ʹ, 
H6ʹ, H3ʺ, H4ʺ, H5ʺ, H18, H19, H20, H21, NH), 8.20 (1H, d, J 5.1, H5); δC NMR (100 
MHz, CDCl3): 18.4, 25.0, 29.0, 46.9, 47.2, 48.4, 59.0, 71.0, 71.6, 114.2, 114.8, 118.2, 
120.0(2×C), 120.7, 122.1, 123.1, 124.5, 125.3(2×C), 125.5, 126.1, 127.1(2×C), 
127.3(2×C), 127.4(2×C), 127.6(2×C), 128.7(2×C), 128.3, 128.4(2×C), 128.7(2×C), 
128.8, 133.5, 134.1, 136.5, 137.9, 141.4, 144.0, 145.0, 148.8, 152.1, 155.8, 156.2, 
171.4, 172.7, 173.2; HRMS (ESI m/z): Calcd. for [C52H44N2O9+H]+ 841.31196, found 
841.31330.  
2-(3,4-bis(benzyloxy)phenyl)-4-oxo-4H-chromen-3-yl 1-(2-((((9H-fluoren-9-
yl)methoxy)carbonyl)amino)-6-((tert-butoxycarbonyl)amino)hexanoyl)pyrrolidine-
2-carboxylate (Fmoc-Lys(Boc)-Pro-diOBn-flavonol) 298 
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Fmoc-Lys(Boc)-Pro-OH 290 (188.3 mg, 0.333 mmol), 3ʹ,4ʹ-dibenzyloxyflavonol 281 
(153.2 mg, 0.34 mmol), EDCI.HCl (115.0mg, 0.60 mmol), DMAP (6.7 mg, 0.06 mmol) 
and CH2Cl2 (10 mL) were added to a round bottomed flask, and stirred at rt for 16 hrs. 
The solution was diluted with CH2Cl2 (20 mL), the solution transferred to a separating 
funnel, and the organic phase washed with 
H2O (3×20 mL) and brine (1×20 mL), dried 
(MgSO4) and filtered. Following purification 
by column chromatography (2:1 Pet:EtOAc), 
the desired compound was isolated as a pale 
yellow amorphous solid (223.0 mg, 70%, Rf 
=0.04); δH NMR (270 MHz, CDCl3): 1.40-
2.08 (16H, m, H12a, H15, H16, H17 & 
H21), 2.17-2.63 (3H, m, H11, H12b), 2.96-
3.42 (4H, m, H18 & H13), 4.08-4.89 (4H, m, 
H10, H14, H22, H23), 5.22-5.42 (4H, m, 
H1ʺ), 6.60-6.63 (1H, m, H2ʹ), 7.21-7.84 
(25H, m, H6, H7, H8, H24, H25, H26, H27, H5ʹ, H6ʹ, H3ʺ, H4ʺ, H5ʺ, 2×NH), 8.11 (1H, 
d, J 7.8, H5); δC NMR (67.5 MHz, CDCl3): 18.1, 22.0, 24.9, 27.9(3×C), 31.6, 40.0, 
45.0, 47.3, 52.6, 57.0, 59.0, 66.5, 70.5, 70.9, 77.6, 114.0, 114.2, 118.5, 120.0(2×C), 
122.3, 123.0, 123.2, 124.8, 125.4 (2×C), 127.2 (2×C), 127.6 (3×C), 127.8 (3×C), 127.9 
(2×C), 128.0 (2×C), 128.4 (3×C), 128.5 (3×C), 133.1, 134.3, 137.2, 137.7, 141.3, 
144.3, 148.8, 151.9, 155.4, 155.9, 156.2, 165.9, 169.8, 171.3; HRMS (ESI m/z): Calcd. 
for [C60H59N3O11+H]+ 998.42224, found 998.42071.  
2-(3,4-bis(benzyloxy)phenyl)-4-oxo-4H-chromen-3-yl 1-(2-((((9H-fluoren-9-
yl)methoxy)carbonyl)amino)-5-amino-5-oxopentanoyl)pyrrolidine-2-carboxylate 
(Fmoc-Gln-Pro-diOBn-flavonol) 299 
Fmoc-Gln-Pro-OH 293 (127.1 mg, 0.27 mmol), 
3ʹ,4ʹ-dibenzyloxyflavonol 281 (126.1 mg, 0.28 
mmol), EDCI.HCl (93.9 mg, 0.49 mmol), 
DMAP (5.6 mg, 0.05 mmol) and CH2Cl2 (10 
mL) were added to a round bottomed flask, and 
stirred at rt for 16 hrs. The solution was diluted 
with CH2Cl2 (10 mL), transferred to a 
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separating funnel, and the organic phase washed with H2O (3×20 mL) and brine (1×20 
mL), and then dried (MgSO4) and filtered. Following purification by column 
chromatography (2:1 Pet:EtOAc), the desired compound was isolated as a pale yellow 
amorphous solid (116.2 mg, 48%, Rf =0.04); δH NMR (270 MHz, CDCl3): 1.83-2.64 
(8H, m, H11, H12, H15 & H16), 3.75-4.08 (4H, m, H13 & NH2), 4.19-4.87 (4H, m, 
H10, H14, H22, H23), 5.34 (4H, m, H1ʺ), 7.08 (1H, d, J 8.6, H2ʹ), 7.29-7.76 (24H, m, 
H6, H7, H8, H5ʹ, H6ʹ, H3ʺ, H4ʺ, H5ʺ & NH), 8.18 (1H, d, J 7.6, H5); δC NMR (67.5 
MHz, CDCl3): 25.1, 28.6, 29.3, 30.9, 47.3, 51.5, 53.7, 59.2, 67.1, 70.9, 71.6, 114.0, 
114.8, 118.2, 119.2, 120.1, 123.1, 123.4, 125.1, 125.2, 125.4, 126.0, 127.8 (2×C), 
127.3(3×C), 127.6(3×C), 127.8, 127.9, 128.1, 128.6(3×C), 128.7(3×C), 133.0, 134.1, 
136.6, 137.2, 141.4, 143.8, 144.0, 148.8, 152.0, 155.5, 156.4, 164.7, 170.6, 171.8, 
175.0; HRMS (ESI m/z): Calcd. for [C54H47N3O10+H]+ 898.33342, found 898.33259. 
(S)-2-(3,4-dihydroxyphenyl)-4-oxo-4H-chromen-3-yl 1-((S)-2-((((9H-fluoren-9-
yl)methoxy)carbonyl)amino)propanoyl)pyrrolidine-2-carboxylate (Flavonol-Pro-
Ala-Fmoc) 301 
Fmoc-Ala-Pro-diOBn-flavonol 297 (172.0 mg, 
0.205 mmol) was stirred with Pd/C (20 mg), in 
1,4-dioxane (7 mL) and EtOH (3 mL), under 
H2 gas for 16 hrs at rt. The solution was then 
filtered through a celite plug, and the solvent 
removed in vacuo to provide the deprotected 
product as a dark green solid (135.4 mg, quant., 
Rf =0.04 (5% MeOH in CHCl3); δH NMR (270 
MHz, CDCl3): 1.19 (3H, m, H15), 1.96-2.70 
(6H, m, H11, H12 & 2×OH), 3.64-3.73 (2H, m, H13), 4.06-4.86 (4H, m, H10, H14, 
H16 & H17), 7.00-7.75 (15H, m, H6, H7, H8, H2ʹ, H5ʹ, H6ʹ, H18, H19, H20, H21, 
NH), 8.17 (1H, d, J 5.1, H5); δC NMR (67.5 MHz, CDCl3): 22.8, 25.0, 29.8, 45.5, 47.2, 
48.5, 50.8, 59.4, 67.3, 115.8, 116.8, 118.2, 120.1(2×C), 120.7, 120.9, 123.4, 125.0, 
125.2(2×C), 125.8(2×C), 127.0, 127.2(2×C), 127.8(2×C), 132.1, 133.9, 141.4(2×C), 
143.8(2×C), 143.9, 155.5, 156.2, 157.3, 172.0; HRMS (ESI m/z): Calcd. for 
[C38H32N2O9-H]- 659.20350, found 659.20139. 
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(S)-2-(3,4-dihydroxyphenyl)-4-oxo-4H-chromen-3-yl 1-((S)-2-((((9H-fluoren-9-
yl)methoxy)carbonyl)amino)-6-((tert-butoxycarbonyl)amino)hexanoyl)pyrrolidine-
2-carboxylate (Flavonol-Pro-Lys(Boc)-Fmoc) 302 
Fmoc-Lys(Boc)-Pro-diOBn-flavonol 298 
(223.0 mg, 0.22 mmol) was stirred with Pd/C 
(25 mg), in 1,4-dioxane (9 mL) and EtOH 
(4 mL), under H2 gas for 16 hrs at rt. The 
solution was then filtered through a celite 
plug, and the solvent removed in vacuo to 
provide the deprotected product as a dark 
green solid (179.9 mg, quant., Rf =0.03 (5% 
MeOH in CHCl3); δH NMR (270 MHz, 
CDCl3): 1.20-1.52(16H, m, H12a, H15, H16, 
H17 & H21), 2.12-3.02 (3H, m, H11, H12b), 3.53-4.88 (10H, m, H18, H13, H10, H14, 
H22, H23 & 2×OH), 6.60-6.63 (1H, m, H2ʹ), 7.01-7.73 (15H, m, H6, H7, H8, H24, 
H25, H26, H27, H5ʹ, H6ʹ, 2×NH), 8.17 (1H, d, J 7.8, H5); δC NMR (67.5 MHz, CDCl3): 
18.2, 20.0, 22.7, 25.0, 28.5(3×C), 29.8, 39.8, 42.5, 45.4, 47.2, 50.8, 59.2, 67.3, 79.4, 
115.8, 116.8, 118.2, 120.1(2×C), 121.0, 123.5, 124.1, 125.2(2×C), 127.0(2×C), 
127.2(2×C), 127.8(2×C), 134.0, 141.4(2×C), 143.8, 143.9(2×C)148.5, 149.1, 155.5, 
156.5, 156.6, 165.8, 170.6, 172.1; HRMS (ESI m/z): Calcd. for [C46H47N3O11+H]+ 
818.32834, found 818.32804.  
(S)-2-(3,4-dihydroxyphenyl)-4-oxo-4H-chromen-3-yl 1-((S)-2-((((9H-fluoren-9-
yl)methoxy)carbonyl)amino)-5-amino-5-oxopentanoyl)pyrrolidine-2-carboxylate 
(Flavonol-Pro-Gln-Fmoc) 303 
Fmoc-Gln-Pro-diOBn-flavonol 299 (116.2 mg, 
0.13 mmol) was stirred with Pd/C (18 mg), in 
1,4-dioxane (5 mL) and EtOH (3 mL), under 
H2 gas for 16 hrs at rt. The solution was then 
filtered through a celite plug, and the solvent 
removed in vacuo to provide the deprotected 
product as a dark green solid (92.6 mg, quant., 
Rf = 0.02 (5% MeOH in CHCl3)); δH NMR 
(270 MHz, CDCl3): 1.41-2.61 (8H, m, H11, 
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H12, H15 & H16), 3.52-4.85 (10H, m, H10, H13, H14, H22, H23, NH2 & 2×OH), 7.01-
7.75 (15H, m, H6, H7, H8, H2ʹ, H5ʹ, H6ʹ, & NH), 8.18 (1H, d, J 7.7, H5); δC NMR 
(67.5 MHz, CDCl3): 13.5, 14.2, 18.3, 18.4, 22.7, 25.0, 26.0, 28.2, 29.8, 32.0, 42.5, 45.6, 
47.2, 58.4, 59.2, 67.2, 118.3, 119.9(2×C), 120.1(2×C), 123.4, 124.1, 125.2, 125.8, 
127.0(2×C), 127.2(2×C), 127.9(2×C), 134.1, 140.6, 141.4, 143.8, 149.1, 155.5, 156.6, 
164.8, 171.3, 172.0; HRMS (ESI m/z): Calcd. for [C40H35N3O10+H]+ 718.23652, found 
718.24062.  
8.7.2 Flavonol-Tripeptides 
Flavonol-diOBn-Pro-Pro-Ile-Cbz 307 
 To a round bottom flask, 3ʹ,4ʹ-
dibenzyloxyflavonol 281 (180.2 mg, 0.40 mmol), 
Cbz-Ile-Pro-Pro-OH 275 (160.8 mg, 0.35 mmol), 
EDCI (138.0 mg, 0.72 mmol), DMAP (8.8 mg, 
0.072 mmol) and CH2Cl2 (10 mL) were added. 
The solution was stirred at room temperature for 
16 hours, CH2Cl2 (20 mL) added, and the solution 
transferred to a separating funnel. The organic 
phase was washed with 2×H2O (20 mL), and brine 
(20 mL), and then dried (MgSO4) and filtered. The 
solvent was removed in vacuo, and purification by 
column chromatography (5% MeOH in CHCl3) 
provided the flavonol-tripeptide as a yellow oil 
(303.0 mg, 97%, Rf =0.30); δH NMR (270 MHz, CDCl3): 0.83-1.02 (6H, m, H27, H29), 
1.54-2.68 (11H, m, H11, H12, H15, H16, H26, H28), 3.55-3.87 (4H, m, H13, H17), 
4.27-4.90 (3H, m, H10, H14, H19), 5.01-5.48 (6H, m, H21 & H1ʺ), 7.03 (1H, d, J 8.6, 
H2ʹ), 7.19-7.68 (21H, m, H6, H7, H8, H23, H24, H25, H5ʹ, H6ʹ, H3ʺ, H4ʺ, H5ʺ & NH), 
8.17 (1H, dd, J 8.0, J 1.6, H5); δC NMR (67.5 MHz, CDCl3): 11.2, 15.4, 24.7, 24.8, 
25.1, 28.2, 29.3, 38.0, 46.9, 47.7, 56.8, 58.1, 58.8, 66.9, 70.9, 71.2, 114.0, 114.5, 118.1, 
122.4, 123.2, 123.4, 125.2, 125.9, 127.2(2×C), 127.5(2×C), 127.9, 128.1(2×C), 128.2, 
128.5(3×C), 128.6(3×C), 128.7(2×C), 133.2, 134.0, 136.5, 136.7, 137.3, 148.7, 151.7, 
155.5, 156.4, 170.1, 170.3, 171.0, 171.9; HRMS (ESI m/z): Calcd. for 
[C53H53N3O10+H]+ 892.38037, found 892.38442. 
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Flavonol-diOBn-Pro-Pro-Val-Cbz 308 
 To a round bottom flask, 3ʹ,4ʹ-
dibenzyloxyflavonol 281 (180.2 mg, 0.40 mmol), 
Cbz-Val-Pro-Pro-OH 276 (155.9 mg, 0.35 mmol), 
EDCI (138.0 mg, 0.72 mmol), DMAP (8.8 mg, 
0.072 mmol) and CH2Cl2 (10 mL) were added. 
The solution was stirred at room temperature for 
16 hours, then CH2Cl2 (20 mL) added and the 
solution transferred to a separating funnel. The 
organic phase was washed with 2×H2O (20 mL), 
and brine (20 mL), and then dried (MgSO4) and 
filtered. The solvent was removed in vacuo, and 
purification by column chromatography (5% 
MeOH in CHCl3) provided the flavonol-tripeptide 
as a yellow oil (249.6 mg, 81%, Rf =0.33); δH NMR (270 MHz, CDCl3): 0.91 (3H, d, J 
4.3, H27), 1.02 (3H, d, J 3.0, H28), 1.82-2.36 (8H, m, H11, H12, H15, H16), 2.69 (1H, 
br s, C26), 3.53-3.83 (4H, m, H13 & H17), 4.29-4.89 (3H, m, H10, H14 & H19), 5.04-
5.51 (6H, m, H21, H1ʺ), 7.03 (1H, d, J 5.7, H2ʹ), 7.28-7.68 (21H, m, H6, H7, H8, H23, 
H24, H25, H5ʹ, H6ʹ, H3ʺ, H4ʺ, H5ʺ & NH), 8.18 (1H, d, J 5.1, H5); δC NMR (67.5 
MHz, CDCl3): 17.8, 19.5, 24.9, 25.1, 28.1, 29.2, 31.4, 46.8, 47.6, 57.6, 58.0, 58.8, 66.9, 
70.9, 71.2, 114.0, 114.6, 118.1, 122.4, 123.2, 123.4, 125.2, 125.9, 127.2(2×C), 
127.5(2×C), 127.7, 128.1(2×C), 128.1, 128.2, 128.65(3×C), 128.6(3×C), 128.7(2×C), 
133.2, 134.0, 136.5, 136.7, 137.3, 148.7, 151.7, 155.5, 156.5, 170.3, 170.6, 171.9; 
HRMS (ESI m/z): Calcd. for [C52H51N3O10+H]+ 878.36472, found 878.36626. 
Flavonol-Pro-Pro-Ile-OH 309 
Flavonol-diOBn-Pro-Pro-Ile-Cbz 307 (303.0 mg, 0.34 
mmol) was stirred with Pd/C (30 mg) in EtOH (7 mL) and 
1,4-dioxane (3 mL) at rt for 16 hours. The solution was then 
filtered through a celite plug, and the solvent removed in 
vacuo, and purification by column chromatography (5% 
MeOH in CHCl3) provided the deprotected flavonol-
tripeptide as a dark green solid (196.2 mg, quant., Rf =0.15); 
δH NMR (270 MHz, CDCl3): 0.83-1.23 (6H, m, H27, H29), 
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1.40-2.59 (13H, m, H11, H12, H15, H16, H26, H28 & 2×OH), 3.67-3.86 (4H, m, H13 
& H17), 4.26-4.98 (3H, m, H10, H14, H19), 7.03 (1H, br s, H2ʹ), 7.19-7.68 (6H, m, H6, 
H7, H8, H5ʹ, H6ʹ & NH2), 8.15 (1H, br s, H5); δC NMR (67.5 MHz, CDCl3): 11.1, 15.4, 
24.6, 24.8, 25.0, 28.1, 29.2, 38.0, 47.0, 47.7, 54.8, 56.7, 58.1, 114.0, 114.5, 118.1, 
122.4, 123.2, 123.4, 125.9, 127.9, 128.2, 133.1, 133.9, 145.7, 146.0, 155.5, 170.1, 
170.3, 171.0, 171.9; HRMS (ESI m/z): Calcd. for [C31H35N3O8+H]+ 578.24969, found 
578.24969. 
Flavonol-Pro-Pro-Val-OH 310 
Flavonol-diOBn-Pro-Pro-Val-Cbz 308 (249.6 mg 0.28 
mmol) was stirred with Pd/C (30 mg) in EtOH (7 mL) and 
1,4-dioxane (3 mL) at rt for 16 hours. The solution was then 
filtered through a celite plug, and the solvent removed in 
vacuo, and purification by column chromatography (5% 
MeOH in CHCl3) provided the deprotected flavonol-
tripeptide as a dark green solid (157.8 mg, quant., Rf =0.14); 
δH NMR (270 MHz, CDCl3): 0.91-1.22 (6H, br m, H27 & 
H28), 1.62-2.59 (9H, m, H11, H12, H15, H16, H26), 3.36-
3.85 (6H, m, H13, H17 & NH2), 4.65-4. 59 (3H, m, H10, H14 & H19), 6.95-8.18 (7H, 
m, H5, H6, H7, H8, H2ʹ, H5ʹ & H6ʹ); δC NMR (67.5 MHz, CDCl3): 17.8, 19.5, 24.9, 
25.1, 28.1, 29.2, 31.4, 46.8, 47.6, 57.6, 58.0, 58.8, 114.0, 114.6, 118.1, 122.4, 123.2, 
123.4, 125.9, 127.7, 128.1, 133.2, 134.0, 148.7, 151.7, 155.5, 156.5, 170.3, 170.6, 
171.9; HRMS (ESI m/z): Calcd. for [C30H33N3O8+H]+ 564.23400, found 564.23319. 
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Appendix B: 
Cytotoxicity LC50 Results for 2ʹ-
Hydroxychalcones 
Cytotoxicity evaluations were conducted on 13 functionalised 2ʹ-
hydroxychalcone compounds. These evaluations were performed by Dr Sunil 
Ratnayake, on both Human Embryonic Kidney (HEK) cells, and (HepG2) cells. Each 
compound was tested at concentrations between 1-80 μ/mL in triplicate, alongside both 
positive (Triton (10% v/v)) and negative controls (no compound added). From his 
results, Dr Ratnayake also determined the LC50 values of the compounds and produced 
the graphs within this Appendix. These graphs are a visual interpretation of the 
percentage of dead cells versus the concentration of the compound tested.  
Note that sample S8 is not included in these results as it was not a compound 
from our project. 
B.1. Structures of 2ʹ-Hydroxychalcones Analysed 
Reaction # Sample # Compound # Structure 
127 S1 66 
 
148 S2 74 
 
144 S3 76 
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Reaction # Sample # Compound # Structure 
152 S4 78 
 
162 S5 80 
 
154 S6 117 
 
155 S7 118 
 
158 S9 120 
 
170 S10 121 
 
178 S11 106 
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Reaction # Sample # Compound # Structure 
176 S12 101 
 
177 S13 102 
 
179 S14 104 
 
 
B.2 Graphs of LC50 Values for 2ʹ-Hydroxychalcone 
Compounds S1-S7 and S9-S14 
 
 
0
0.05
0.1
0.15
0.2
0.25
0.3
0.35
0.4
0.45
Control
(-ve)
1 μg/ml 2 μg/ml 4 μg/ml 10 μg/ml20 μg/ml40 μg/ml80 μg/ml
127A-A(S1)
148A-A(S2)
144A-A(S3)
152A-B(S4)
 272 
 
 
 
 
 
 
0
0.05
0.1
0.15
0.2
0.25
0.3
0.35
0.4
Control
(-ve)
1 μg/ml 2 μg/ml 4 μg/ml 10 μg/ml20 μg/ml40 μg/ml80 μg/ml
162A-A(S5)
154A-A(S6)
155A-A(S7)
0
0.05
0.1
0.15
0.2
0.25
0.3
Control
(-ve)
1 μg/ml 2 μg/ml 4 μg/ml 10
μg/ml
20
μg/ml
40
μg/ml
80
μg/ml
158A-A(S9)
170A-B(S10)
178A-A(S11)
176A-A(S12)
 273 
 
 
 
 
0
0.05
0.1
0.15
0.2
0.25
0.3
Control
(-ve)
1 μg/ml 2 μg/ml 4 μg/ml 10
μg/ml
20
μg/ml
40
μg/ml
80
μg/ml
177A-A(S13)
179A-B(S14)
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
Control
(-ve)
1 μg/ml 2 μg/ml 4 μg/ml 10 μg/ml20 μg/ml40 μg/ml80 μg/ml
127A-A(S1)
148A-A(S2)
144A-A(S3)
152A-B(S4)
 274 
 
 
 
 
 
 
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
Control
(-ve)
1 μg/ml 2 μg/ml 4 μg/ml 10 μg/ml20 μg/ml40 μg/ml80 μg/ml
162A-A(S5)
154A-A(S6)
155A-A(S7)
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
Control (-
ve)
1 μg/ml 2 μg/ml 4 μg/ml 10 μg/ml 20 μg/ml 40 μg/ml 80 μg/ml
158A-A(S9)
170A-B(S10)
178A-A(S11)
176A-A(S12)
LC
50
  
S5- >80 μg/ml 
S6- 28 μg/ml 
S7- >80 μg/ml 
LC
50
  
S9- 70μg/ml 
S10- >80 μg/ml 
S11- 18μg/ml 
S12- 14 μg/ml 
